Toxicology Research Laboratory

UIC The University of Illinois at Chicago

Department of Pharmacology (M/C 868) 1940 W. Taylor St. Chicago, Illinois 60612-7353

20100915172

Task Order No.: UIC-18A UIC/TRL Study No.: 193

Title Page

Volume 1 of 2

Study Report for Task Order No. UIC-18A

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

Sponsor: US Army Medical Materiel Development Activity

Test Article: WR242511 Tartrate

Contract No.: DAMD17-92-C-2001

Study Director

Barry S. Levine, D.Sc., D.A.B.T.

In-Life Phase Completed On

March 07, 1996

Performing Laboratory

TOXICOLOGY RESEARCH LABORATORY (TRL)

University of Illinois at Chicago (UIC) Department of Pharmacology 1940 W. Taylor St. Chicago, IL 60612-7353

The views, opinions, and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy, or decision, unless so designated by other documentation.

0	5			57
			\Box	T
1	LL	10	i.	U

REPORT	DOCUMENTATIO	N PAGE			Form Approved OMB No. 0704-0188		
1a. REPORT SECURITY CLASSIFICATION		1b. RESTRICTIVE	MARKINGS				
2a. SECURITY CLASSIFICATION AUTHORITY Unclassified		3. DISTRIBUTION	/AVAILABILITY (OF REPORT			
2b. DECLASSIFICATION / DOWNGRADING SCHE	DULE	Unlimited -					
4. PERFORMING ORGANIZATION REPORT NUM	BER(S)	5. MONITORING ORGANIZATION REPORT NUMBER(S)					
UIC-18A (UIC/TRL Study No. 193)		5. MONTORING ORGANIZATION REPORT NOMBER(S)					
6a. NAME OF PERFORMING ORGANIZATION	6b. OFFICE SYMBOL (If applicable)	7a. NAME OF M	ONITORING ORGA	ANIZATION	V		
Toxicology Research Laboratory	(ii applicable)	U.S. Army	Medical Mater	iel Devel	lopment Activity		
University of Illinois at Chicago 6c. ADDRESS (City, State, and ZIP Code)		7b. ADDRESS (Ci	tv. State, and ZIP	Code)			
Department of Pharmacology (M/C 86	8)	ATTN: MCMR					
1940 W. Taylor Street		Fort Detri					
Chicago, IL 60612-7353			MD 21702-50				
8a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical	8b. OFFICE SYMBOL (If applicable)	9. PROCUREMEN	T INSTRUMENT II	DENTIFICA'	TION NUMBER		
Materiel Development Activity	MCMR-UMP	DAMD17-92-C	-2001				
8c. ADDRESS (City, State, and ZIP Code)		10. SOURCE OF	_				
Fort Detrick		PROGRAM ELEMENT NO.	PROJECT NO.	TASK NO.	WORK UNIT ACCESSION NO.		
Frederick, MD 21702-5009		63807A	30463807	∞	073		
12. PERSONAL AUTHOR(S) Levine, B.S., Brown, A.P., and Morrissey, R.L. (PAI) 13a. TYPE OF REPORT 13b. TIME COVERED 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT							
Study FROM_	14. DATE OF REPO	ORT (Year, Month	1, Day)	S. PAGE COUNT			
16. SUPPLEMENTARY NOTATION				-			
17. COSATI CODES	18. SUBJECT TERMS (Continue on revers	se if necessary ar	nd identify	by block number)		
FIELD GROUP SUB-GROUP							
	_						
19. ABSTRACT (Continue on reverse if necessa	ry and identify by block n	umber)	-				
capsule. A thirteen week recovery period was studied were 0, 0.1, 0.3 and 1.0 mg base/kg/c in toxicity to RBCs, lungs and platelets and dogs were ≈ 7 - 8 months old and weighed. In the present investigation, the primary tox weight gain were seen in mid and high dose and was accompanied by clinical signs of cychematopoiesis and bone marrow hyperplasia period in the mid and high dose animals, pre in mid and high dose animals consisting of alvand basophilic granular material in the alvectinium were seen. However, histopathologic the end of the 13 week recovery period, treat as to be considered biologically insignifican observed effect level (NOEL) of WR24251	19. ABSTRACT (Continue on reverse if necessary and identify by block number) This study evaluated the toxicity of WR242511 in male and female beagle dogs following thirteen weeks of daily oral administration by gelatin capsule. A thirteen week recovery period was included for all groups. WR242511 tartrate is being developed as an anticyanide agent. Dose levels studied were 0, 0.1, 0.3 and 1.0 mg base/kg/day and were based on a one month toxicity study in beagle dogs in which 1.0 mg base/kg/day resulted in toxicity to RBCs, lungs and platelets and a no-observed effect level (NOEL) of 0.1 mg base/kg/day was seen (UIC/TRL Study No. 134). The dogs were ≈ 7 - 8 months old and weighed 10.3 - 13.6 kg (males) and 7.4 - 11.3 kg (females) at dosing initiation. In the present investigation, the primary toxic effects of WR242511 tartrate were seen in the lungs, RBCs and platelets. Mild reductions in body weight gain were seen in mid and high dose animals. Methemoglobin, the desired pharmacologic effect, was produced in a dose-dependent fashion and was accompanied by clinical signs of cyanosis (blue gums, tongue and sclera). Mild anemia as supported by reticulocytosis, secondary splenic hematopoiesis and bone marrow hyperplasia occurred primarily in high dose animals. Significant thrombocytopenia was seen during the treatment period in the mid and high dose animals, presumably in response to the anemic state. Administration of WR242511 resulted in pulmonary lesions in mid and high dose animals consisting of alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material in the alveoli. Minimal, but statistically significant changes in clinical chemistry parameters suggestive of liver injury were seen. However, histopathologic evidence of liver injury was not observed, suggesting that WR242511 is marginally hepatotoxic. By the end of the 13 week recovery period, treatment-related effects had resolved except for residual pulmonary lesions that were of						
20. DISTRIBUTION AVAILABILITY OF ABSTRAC		21. ABSTRACT SE Unclassifi		ICATION			
22a. NAME OF RESPONSIBLE INDIVIDUAL	the one orang	22b. TELEPHONE	(Include Area Cod				
Barry S. Levine		(312) 996–	5543		N/A		

Task Order No.: UIC-18A UIC/TRL Study No.: 193

STATEMENT OF COMPLIANCE

DRAFT

Study No. 193 entitled "Thirteen Week Oral Toxicity Study of WR242511 with a Thirteen Week Recovery Period in Dogs" was conducted in compliance with the Good Laboratory Practices regulations as published in 21 CFR 58, 40 CFR 160 and 40 CFR 792 in all material aspects.

The protocol for this study was approved by the UIC Animal Care Committee.

Signature		
Study Director		
Barry S. Levine, D.Sc., D.A.B	.T.	Date

OUALITY ASSURANCE STATEMENT

STUDY TITLE: THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511
WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

STUDY NUMBER: 193

STUDY DIRECTOR: BARRY S. LEVINE

INITIATION DATE: 7/3/95

This study has been divided into a series of phases. Using a random sampling approach, Quality Assurance personnel monitors each of these phases over a series of studies. Procedures, equipment, documentation, etc., are examined in order to assure that the study is performed in accordance with the Good Laboratory Practice regulations of the Food and Drug Administration and the Environmental Protection Agency to assure that the study is conducted according to the protocol.

The following are the inspection dates, phases inspected, and report dates of QA inspections of the study.

INSPECT ON 7/5/95, TO STUDY DIR 7/5/95, TO MGMT 7/5/95 PHASES: PROTOCOL REVIEW

INSPECT ON 8/17/95, TO STUDY DIR 8/17/95, TO MGMT 8/18/95
PHASES: ANIMAL RECEIPT, PHYSICAL EXAMINATION, BODY WEIGHT AND
IMPLANTATION OF ID MICROCHIP

INSPECT ON 9/6/95, TO STUDY DIR 9/6/95, TO MGMT 9/7/95 PHASES: TEST ARTICLE PREPARATION

INSPECT ON 12/5/95, TO STUDY DIR 12/7/95, TO MGMT 12/13/95 PHASES: ANIMAL IDENTIFICATION, ORAL DOSING, AND OPHTHALMIC EXAMINATION

INSPECT ON 4/8-9/96, TO STUDY DIR 4/9/96, TO MGMT 4/9/96 PHASES: RAW DATA AND DRAFT REPORT FROM ANALYTICAL LAB

INSPECT ON 4/23-26/96, TO STUDY DIR 4/26/96, TO MGMT 5/30/96 PHASES: RAW DATA

INSPECT ON 5/21-22/96, TO STUDY DIR 5/22/96, TO MGMT 5/30/96 PHASES: PATHOLOGY DRAFT REPORT

INSPECT ON 5/31-6/3/96, TO STUDY DIR 6/3/96, TO MGMT 6/6/96 PHASES: DRAFT REPORT

Ronald Schnewheek

QUALITY ASSURANCE

6/6/96 DATE

Page 3

Task Order No.: UIC-18A UIC/TRL Study No.: 193

Signature Page



THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

TRL Chemical No.: 1720614

Sponsor: US Army Medical Materiel

Development Activity

Fort Detrick

Frederick, MD 21702-5014

Sponsor

Representative: George J. Schieferstein, Ph.D.

Testing Facility: TOXICOLOGY RESEARCH LABORATORY (TRL)

University of Illinois at Chicago (UIC)

Department of Pharmacology

1940 W. Taylor St. Chicago, IL 60612-7353

Barry S. Levine, D.Sc., D.A.B.T. Date Study Director

Study Initiation: July 3, 1995

Dosing Initiation: September 6, 1995

In-Life Completion: March 7, 1996

Task Order No.: UIC-18A

UIC/TRL Study No.: 193



TABLE OF CONTENTS

VOLUME 1

TITLE PAGE		1
STATEMENT	OF COMPLIANCE	2
QUALITY AS	SSURANCE STATEMENT	3
SIGNATURE	PAGE	4
TABLE OF C	ONTENTS	5
1.	SUMMARY	7
2.	INTRODUCTION	7
3.	MATERIALS AND METHODS	8
	3.1 Test Article 3.2 Animals	8
4.	RESULTS	14
	4.1 Mortality/Clinical Signs 4.2 Body Weights 4.3 Food Consumption 4.4 Clinical Pathology 4.5 Electrocardiography 4.6 Ophthalmology 4.7 Organ Weights 4.8 Pathology	14 14 15 15 17 17
5.	DISCUSSION/CONCLUSION	18
6.	PERSONNEL	21
7	ARCHIVES	21

DRAFT

Contract No.: DAMD17-92-C-2001

Task Order No.: UIC-18A UIC/TRL Study No.: 193

TABLE OF CONTENTS (contd.)

LIST OF TABLES

1 2 3 4 5 6 7 8 9	Summary of Toxic Responses Summary of Clinical Signs Summary of Body Weights Summary of Weight Gains Summary of Daily Mean Food Consumption Summary of Clinical Chemistry Tests Summary of Hematology Tests Summary of Urinalysis Tests Organ Weight Summary (% Brain Weight) Summary of Microscopic Lesions	131
	FIGURES	
1 2	Summary of Male Body Weights	136 137
	APPENDICES	
A B C D E F	Analytical Chemistry Report Clinical Pathology Methodology Individual Observations (Clinical Signs) Individual Body Weights and Body Weight Gains Individual Food Consumption Data Individual Clinical Chemistry Data	B-1 C-1 D-1 E-1
	VOLUME 2	
	APPENDICES (contd.)	
G H I J K L M	Individual Hematology Data Individual Urinalysis Data Cardiology Report Ophthalmology Report Individual Organ Weights Pathology Report Protocol and Protocol Amendments Study Deviations	H-1 I-1 J-1 K-1 L-1 M-1

Task Order No.: UIC-18A UIC/TRL Study No.: 193

DRAFT

SUMMARY

This study evaluated the toxicity of WR242511 in male and female beagle dogs following thirteen weeks of daily oral administration by gelatin capsule. A thirteen week recovery period was included for all groups. WR242511 tartrate is being developed as an anticyanide agent. Dose levels studied were 0, 0.1, 0.3 and 1.0 mg base/kg/day and were based on a one month toxicity study in beagle dogs in which 1.0 mg base/kg/day resulted in toxicity to RBCs, lungs and platelets and a no-observed effect level (NOEL) of 0.1 mg base/kg/day was seen (UIC/TRL Study No. 134). The dogs were ≈ 7 - 8 months old and weighed 10.3 - 13.6 kg (males) and 7.4 - 11.3 kg (females) at dosing initiation.

In the present investigation, the primary toxic effects of WR242511 tartrate were seen in the lungs, RBCs and platelets. Mild reductions in body weight gain were seen in mid and high dose animals. Methemoglobin, the desired pharmacologic effect, was produced in a dose-dependent fashion and was accompanied by clinical signs of cyanosis (blue gums, tongue and sclera). Mild anemia as supported by reticulocytosis, secondary splenic hematopoiesis and bone marrow hyperplasia occurred primarily in high dose animals. Significant thrombocytopenia was seen during the treatment period in the mid and high dose animals, presumably in response to the anemic state. Administration of WR242511 resulted in pulmonary lesions in mid and high dose animals consisting of alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material in the alveoli. Minimal, but statistically significant changes in clinical chemistry parameters suggestive of liver injury were seen. However, histopathologic evidence of liver injury was not observed, suggesting that WR242511 is marginally hepatotoxic. By the end of the 13 week recovery period, treatmentrelated effects had resolved except for residual pulmonary lesions that were of such low severity as to be considered biologically insignificant. Because the aforementioned toxic responses were limited to the mid and high dose levels, the no-observed effect level (NOEL) of WR242511 tartrate was 0.1 mg base/kg/day.

2. INTRODUCTION

This study was conducted to determine the specific target organ toxicity, dose-response relationships and a potential no-adverse effect level of WR242511 tartrate in dogs following thirteen weeks of daily oral (capsule) administration. A thirteen week recovery period was included for all groups to assess the reversibility of toxic effects. WR242511 tartrate is being developed as an anticyanide agent. The study was conducted in accordance with the specifications of the Sponsor, as indicated in Task Order UIC-18A. The FDA requires the use of two animal species, one which is a non-rodent, in preclinical toxicology studies. The dog is a standard and accepted non-rodent species for regulatory toxicology studies, and was specified by the Sponsor. Oral administration is the intended clinical route and was also specified by the Sponsor. All methods and procedures were conducted in accordance with the Quality Assurance Programs of the Toxicology Research Laboratory, University of Illinois at Chicago and Pathology Associates, Intl. and designed to conform with FDA Good Laboratory Practices Regulations. No unforeseen circumstances affected the integrity of the study. Dosing was initiated on September 6, 1995 and the in-life portion was terminated on March 7, 1996.

Trask Order No.: UIC-18A

MATERIALS AND METHODS

3.1 Test Article

WR242511 tartrate (Bottle Lot No. BM 05816), a yellow powder, was provided by the Sponsor and was initially received on June 16,1993, and a second shipment was received on November 15, 1995 from Herner & Co., Rockville, MD. The chemical name of the test article is 8-[(4-Amino-1-methylbutyl)amino]5-(1-hexyloxy)-6-methoxy-4-methylquinoline DL tartrate and the base mole fraction is 0.71. It was stored at -20 to -15°C, ambient humidity and protected from light in an amber bottle. The chemical structure is shown below.

The Analytical Chemistry Report is contained in Appendix A. The test article was initially identified by GC-MS and the purity was determined by HPLC to be 99.32 \pm 0.03%. The purity was re-determined following the completion of the in-life portion of the study. At that time, the purity was 99.20 \pm 0.10%. Thus, the test article was stable under storage conditions.

WR242511 tartrate

3.2 Animals

Thirty seven male and thirty seven female Beagle dogs were obtained from Marshall Farms, North Rose, NY on August 17,1995. The animals were approximately 7 months old (dates of birth between 1/18/95 and 1/30/95) upon arrival at the UIC AAALAC-accredited animal facility. Each animal was given a facility-unique animal number upon arrival. This number was coded on a subcutaneously implanted microchip and also appeared on a cage card visible on the front of each cage. Animals were singly housed in runs, except as subsequently noted, in a temperature (65 - 84°F) and humidity (50 ± 20%) controlled room with a 12 hour light/12 hour dark cycle. Eight dogs were housed two/run (within sex) during the quarantine/pretest period, but were singly housed prior to initiation of the dosing phase. The run size, typically at least 15 square feet, was adequate to house dogs at the upper weight range as described in the Guide for the Care

Task Order No.: UIC-18A UIC/TRL Study No.: 193

DRAFT

and Use of Laboratory Animals, DHHS (NIH) No. 86.23. All runs were cleaned and bedding was replaced daily. The runs were sanitized once every two weeks.

Certified Canine Diet No. 5007 (PMI Feeds Inc., St. Louis, MO), approximately 400 g on a daily basis (exactly 400 g on days when food consumption was measured), and tap water ad libitum from an automatic watering system in which the room distribution lines were flushed daily were provided from arrival until termination. The water was untreated with additional chlorine or HCl. The food was removed for an overnight fast ($\approx 16 - 20$ hours) prior to blood collection for clinical pathology, overnight urine collection, and/or scheduled sacrifice. There were no known contaminants in the feed or water which were expected to influence the study. The results of the most current comprehensive chemical analyses of Chicago water are documented in files maintained by Quality Assurance.

The animals were quarantined for three weeks. During that time, the animals were observed daily for signs of illness and all unusual observations were reported to the Study Director or Clinical Veterinarian. Body weights and preliminary physical examinations were done upon arrival at the animal facility. Each dog was lightly sprayed with Para Pyrethrin Mist upon arrival for fleas, lice, and ticks. All dogs were previously vaccinated by the animal supplier against canine distemper, infectious canine hepatitis, oral papilloma, leptospirosis, parainfluenza, parvo and rabies. Blood samples were collected within three days of arrival for quarantine clinical chemistry and hematology tests, and fecal samples were collected for internal parasites examinations. Animals were examined during quarantine and approved for use by the Clinical Veterinarian prior to being placed on test. Quarantine release was documented on the Clinical Veterinarian Log by the veterinarian prior to study initiation.

3.3 Experimental Design

Near the end of the quarantine/pretest period, 32 animals of each sex were selected for study on the basis of quarantine data including body weight, food consumption, clinical pathology, electrocardiograms, and ophthalmology examinations. These animals were randomized within sex into the groups shown in the following table using a restricted randomized procedure stratified by body weight. No litter mates were included in the same dose group, except for a half litter mate male (recovery) and female (non-recovery) in treatment group 4. Following allocation to treatment groups, the animals were randomly assigned to one of six animal rooms used for this study.

Treatment Group	Dose Level (mg base/kg/day)	Number of Males	Number of Females
1	0	4 + 4°	4 + 4°
2	0.1	$4 + 4^{\circ}$	4 + 4*
3	0.3	4 + 4°	4 + 4*
4	1.0	4 + 4*	4 + 4*

^{*}Recovery Animals

Task Order No.: UIC-18A UIC/TRL Study No.: 193

Dose levels were selected in consultation with the sponsor based upon the results of an earlier four week oral toxicity study in the dog (UIC/TRL Study No. 134). Dose levels refer to the base.

Four animals/sex/dose were necropsied in week 14 after 91 or 92 days of dosing. All remaining animals were held for a thirteen week recovery period, at which time they were necropsied. The number of animals/sex/group was necessary for adequate statistical analysis.

Following treatment group allocation, the animal's number appeared on a card visible on the front of each run. The run card additionally contained the study number, test article identification, treatment group number, sex and dose level. Run cards were color-coded as a function of treatment group.

The test article was administered once daily by gelatin capsule starting with day 1 for 91 or 92 days. All animals received an empty gelatin capsule for at least 3 days during week -1 to acclimate them to the procedure. The specific quantity of the test article (weighed to the nearest 0.1 mg) was adjusted for purity and the base mole fraction, and was based on each animal's most recent body weight (twice weekly in weeks 1 - 4 and weekly thereafter). The control animals received empty gelatin capsules. The animals were dosed up to and including the day prior to scheduled necropsy except for the recovery animals, which were dosed for 91 days. The dogs weighed 10.3 - 13.6 kg (males) and 7.4 - 11.3 kg (females) on day -5 and were approximately 7 - 8 months old at initiation of treatment.

Non-fasted body weights were recorded on days -9 and -5, twice weekly during the first four study weeks, weekly thereafter during the remainder of treatment and during the recovery period. Fasted weights were collected at scheduled termination. Clinical signs were recorded once daily, approximately 1 - 2 hours after dosing. The general behavior, posture, locomotion, breathing pattern and coat were observed for all animals. The animals were also observed immediately prior to dosing and in the afternoon for moribundity/mortality. During the recovery period, clinical signs were recorded once daily in the morning and moribundity/mortality checks were conducted in the morning and afternoon. Physical examinations (clinical observations) which included examination of eyes and all orifices were conducted on day -9, on day 1 prior to dosing, and once weekly thereafter. Food consumption was measured for all animals over an approximate 24 hour period once weekly commencing with week -2. All dogs were examined by indirect ophthalmoscopy prior to study initiation (week -2) and during week 13, and in week 26 for the recovery animals. The eyes were dilated with 1% atropine sulfate prior to the examination.

Hematology and clinical chemistry parameters were measured following an overnight fast in weeks -3, -1, 4, 8, and 13. Hematology and clinical chemistry tests were also performed for the recovery animals in weeks 18 and 26. The overnight fasted animals

Task Order No.: UIC-18A UIC/TRL Study No.: 193

DRAFT

were unanesthetized and sufficient blood was collected from the jugular vein to measure the following parameters. The samples were processed in the same random order as collected. Water was available ad libitum during all fasting periods. Clinical pathology methodology is contained in Appendix 2.

Clinical Chemistry

Alanine aminotransferase (ALT)

Albumin/globulin ratio (calc.)

Alkaline phosphatase

Aspartate aminotransferase (AST)

Calcium Chloride

Cholesterol Creatinine

Creatine kinase (CK) Gamma glutamyl transferase (GGT) Globulin (calculated)

Glucose Haptoglobin

Lactate dehydrogenase (LDH)

Inorganic phosphorus

Potassium Sodium Total bilirubin Total protein

Triglycerides

Urea nitrogen (BUN)

Hematology

Activated partial

thromboplastin time (APTT)

*Erythrocyte count and morphology Heinz bodies Hematocrit Hemoglobin

Leukocyte count, total

and differential

Mean corpuscular hemoglobin (MCH)

Mean corpuscular hemoglobin

concentration (MCHC)

Mean corpuscular volume (MCV)

^bMethemoglobin Platelet count Prothrombin time Reticulocyte count

*Includes nucleated RBCs.

^bMeasured with a Co-oximeter (Instrumentation Laboratory). The assay was performed within one hour of sample collection. The specimens were kept on wet ice prior to analysis.

Urine specimens were collected in weeks -1, 4, 8 and 13, and during the recovery period in weeks 18 and 26 following an overnight fast. During the overnight fasting period, the animals were placed in a metabolism cage for urine collection. Water was available ad libitum during all fasting periods. The following parameters were measured.

Task Order No.: UIC-18A UIC/TRL Study No.: 193

Urinalysis Parameters

DRAFT

Qualitative

Bilirubin Glucose

Ketones Occult Blood

Leukocytes

Color

Specific Gravity

Microscopic examination of spun sediment

ECG tracings were collected from all dogs during the pretest period and in week 13, and in week 26 for the recovery animals. The following leads were measured: I, II, III, aV_R , aV_L , and aV_F . Analysis included heart rate, the duration of the P wave, and PR, QRS and QT intervals. All recordings had a sensitivity of 1 mV/cm and a recording rate of 50 mm/sec. The recordings were made with the animal in the standard position of right lateral recumbency. In order to obtain all of the ECG's within a few days at each time point, the recordings were collected throughout the day during the baseline and recovery periods, but were performed in week 13 in the afternoon, at least 2 hours after dosing.

Nitrite

Protein

Urobilinogen

pΗ

Four animals/dose/sex were killed and necropsied in random order over a two consecutive day period (days 92 and 93). The remaining recovery animals were killed and necropsied in random order at the onset of week 27, after a thirteen week recovery period. This was accomplished by sodium pentobarbital anesthesia and exsanguination. An extensive necropsy was performed under the direction and supervision of the pathologist. Terminal body weights were collected prior to routine sacrifice.

The necropsy procedure was a thorough and systematic examination and dissection of the animal viscera and carcass to include the external surface, all orifices, the cranial cavity, external surface of the brain, cross section of the spinal cord, the nasal cavity and nasal turbinates, thoracic, abdominal and pelvic cavities and their viscera, and cervical tissues and organs. The following tissues and organs were collected and fixed in 10% neutral buffered formalin (NBF), except for the eyes which were fixed in 2.5% phosphate buffered glutaraldehyde.

Task Order No.: UIC-18A UIC/TRL Study No.: 193

*Adrenal glands Aorta (thoracic)

*Brain (fore-, mid-, and hind-)

Cecum Colon Diaphragm Duodenum Esophagus

Eyes and optic nerve

Gallbladder Gross lesions *Heart

Ileum Jejunum *Kidneys

*Liver (with gallbladder

drained) Lungs/Bronchi

Lymph node (submandibular

and mesenteric) Mammary gland

Muscle (skeletal)

*Ovaries Pancreas **Pituitary** Prostate

Rib with marrow

Salivary gland (mandibular)

Sciatic Nerve

Spinal cord (cervical, thoracic)

*Spleen Stomach *Testes Thymus

*Thyroid gland with parathyroids

Tongue Tonsil Trachea Ureter

Urinary bladder

Uterus

The above tissues from all dogs sacrificed at scheduled necropsy in week 14 were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Those tissues/organs for which treatment-related lesions were observed were examined microscopically for all recovery animals.

Myeloid:erythroid (M:E) ratios were determined from a rib bone marrow smear for all animals at the week 14 necropsy. Because treatment-related changes were seen at the end of the dosing period, M:E ratios were also determined for the recovery animals.

3.4 Statistical Analyses

For each sex, Analysis of Variance tests were conducted on body weight, weekly body weight gain, total body weight gains, ECG measurements, hematology, clinical chemistry, urinary specific gravity and pH, and organ weight data. Organ weight analyses included weights relative to brain weights. If a significant F ratio was obtained (p < 0.05), Dunnett's test was used for pair-wise comparisons with the concurrent control group. Food consumption data were analyzed by the Kruskal-Wallis test. If a significant effect was obtained (p ≤ 0.05), the Mann-Whitney U test was used for pair-wise comparisons

^{*}Weighed at scheduled necropsy. Paired organs were weighed as a unit.

Task Order No.: UIC-18A UIC/TRL Study No.: 193

D

with the concurrent control group. All statistical analyses procedures compared treated to control animals at each time point. Data were not corrected for baseline values, except that body weight analysis included absolute values, weekly changes and total weight changes.

4. RESULTS

4.1 Mortality/Clinical Signs

The summaries of clinical signs are presented in Table 2. Individual clinical signs and daily incidence of clinical signs are contained in Appendix C.

No animals died during the study. Treatment related signs of cyanosis were observed as blue gums, blue sclera, and blue tongue. During the treatment period, blue tongue was observed in 2/8 males and 2/8 females in the low dose group, 7/8 males and 8/8 females in the mid dose group, and all animals in the high dose group. This was first seen in high dose animals in week 1, whereas blue tongue was initially observed in mid and low dose animals in the 3rd and 6th weeks respectively. Animals in the low and mid dose groups had blue tongues that were mild in severity (easily seen blue color) while animals in the high dose group had blue tongues that were mild to severe (intense, harsh blue-purple color) in discoloration. Animals in the high dose group also demonstrated blue sclera and blue gums during the treatment period.

During the recovery period, signs of cyanosis were not seen in the low and mid dose animals except for one male dog in the mid dose group on days 96 - 97. Clinical signs of cyanosis were still present in the high dose group during the recovery period up to day 131 (week 19).

4.2 Body Weights

Summaries of body weights are presented in Tables 3.1 - 3.6. Summaries of weight gains are presented in Tables 4.1 - 4.8. Summaries of male and female body weights are also graphically depicted in Figures 1 and 2. Individual body weights and weight gains are contained in Appendix D.

During the treatment and recovery periods, high dose females and mid and high dose males tended to have lower body weights than the corresponding vehicle control group, although these differences were not statistically significant. Statistically significant reductions in weight gains were seen during the latter half of week 1 in mid and high dose females. By the end of the treatment period, body weight loss was evident in mid and high dose males and females, which was statistically significant in mid dose males and high dose females. Body weight gains during the recovery period were similar

Task Order No.: UIC-18A UIC/TRL Study No.: 193

among the control and treatment groups.

DRAFT

4.3 Food Consumption

Summaries of daily food consumption are in Tables 5.1 - 5.4. Individual food consumption data are shown in Appendix E.

Food intake was significantly decreased on days 14 and 21 in high dose males. Although similar reductions occurred in high dose females, the decreases were not significant. Food consumption was apparently not affected thereafter in these animals, nor was it altered in the lower dose groups.

4.4 Clinical Pathology

Summaries of clinical chemistry tests are presented in Tables 6.1 - 6.44. Individual clinical chemistry data are in Appendix F. Summaries of hematological tests are presented in Tables 7.1 - 7.40 and individual hematology data are in Appendix G. Individual urinalysis data are contained in Appendix H.

Clinical Chemistry

Clinical chemistry alterations in drug-treated male and female dogs were suggestive of treatment-related hepatic effects. In week 4, serum albumin content and the A/G ratio were decreased in high dose males and females; however, total protein levels were unaffected (Tables 6.5 - 6.12). Serum haptoglobin content was increased 203% and 297% in high dose male and female dogs, respectively, in week 4 (Tables 6.43 and 6.44). The occurrence of increased levels of haptoglobin, which is synthesized by hepatocytes, is indicative of an inflammatory response, i.e., an acute phase reaction. Serum albumin, haptoglobin, and the A/G ratio in WR242511-treated dogs in week 8 and thereafter were similar to control animal values. In high dose males, increases in serum activity of AST and serum triglyceride concentration occurred in weeks 8 and 13 (Tables 6.3 and 6.21). In week 13, serum activity of AST was increased 33% in high dose females (Table 6.4). Serum activity of LDH was elevated 51% and 78% in high dose male and female dogs, respectively, in week 4 (Tables 6.23 and 6.24). Serum LDH activity was normal in week 8 and thereafter in female dogs. Activity of LDH were increased 69% in high dose males in week 8 and but was similar to control animal values thereafter. All of these changes suggest the presence of mild hepatocellular injury.

In week 4, serum total bilirubin concentrations were elevated slightly in mid and high dose male but not female dogs (50% and 43% elevations, respectively) (Table 6.13). Serum total bilirubin concentrations were still slightly elevated (36%) in mid dose male dogs in week 8, but were similar to control animals thereafter. These changes may suggest mild hepatobiliary dysfunction in these animals, or more likely relate to excessive amounts of hemoglobin undergoing degradation, i.e., secondary to hemolytic anemia (see following hematology section).

Task Order No.: UIC-18A UIC/TRL Study No.: 193

0)

Biologically significant changes in clinical chemistry parameters were not observed in drug-treated male or female dogs during the recovery period (weeks 18 and 26).

Hematology

Methemoglobinemia, the desired pharmacologic effect of WR242511, was observed in male and female dogs exposed to WR242511 (Tables 7.19 and 7.20). During the treatment period, methemoglobin occurred in a dose-dependent fashion in male and female dogs and averaged 2%, 7% and 23% in the low, mid and high dose groups, respectively. During the recovery period, levels of methemoglobin in WR242511-exposed dogs did not differ from control animals.

Both male and female dogs administered WR242511 had changes in erythrocyte parameters during the treatment period indicative of mild anemia. In week 4, RBC counts were decreased in high dose male and female dogs and hemoglobin concentration was decreased in high dose males and mid and high dose females (Tables 7.1 - 7.4). RBC counts and hemoglobin were also decreased in week 8 in mid dose males. Although RBCs from high dose males in week 4 were hypochromic, macrocytosis and a corresponding increase in MCH were seen (Tables 7.7, 7.9, and 7.11). MCV was increased in week 4 and MCH was decreased in week 8 in high dose females and MCHC was decreased slightly in weeks 4 and 8 in mid and high dose females (Tables 7.8, 7.10, and 7.12). As a result of the mild anemia, compensatory increases in reticulocyte counts were seen in week 4 in mid and high dose males and in week 8 in high dose males (Table 7.13). High dose females also had increased reticulocyte counts throughout the treatment period. Compensatory increases in nucleated RBCs were also observed in high dose males and females in week 4 (Tables 7.15 and 7.16). Slight polychromasia (typically due to increased numbers of degenerating RBCs) was observed periodically during the treatment period in high dose animals (Appendix G). During the recovery period, RBC hematologic parameters in drug-treated male and female dogs were similar to control animal values.

Total leukocyte counts in high dose females were increased 35% and 59% in weeks 8 and 13, respectively, and this was essentially due to elevated mature neutrophil counts of 36%, 43% and 77% in weeks 4, 8 and 13, respectively (Tables 7.28 and 7.30). The only significant change in leukocyte counts observed in drug-treated male dogs was a slight increase in monocyte counts in weeks 4 and 13 in the high dose group (Table 7.35). Hematologic parameters in drug-treated dogs were similar to control animal values during the recovery period.

Administration of WR242511 resulted in significant thrombocytopenia during the treatment period in male and female dogs in both the mid and high dose groups (Tables 7.21 and 7.22). Thrombocytopenia was most severe in week 4 (platelet counts were decreased 51 - 66%), but improved thereafter. Platelet counts in WR242511-treated male

Task Order No.: UIC-18A UIC/TRL Study No.: 193

and female dogs were similar to control animal values during the recovery period.

No other changes in clinical pathology parameters were considered to be related to WR242511 treatment. Sporadic increases and decreases were seen, but were considered to be biologically insignificant. This included minimal alterations in PT and/or APTT in WR242511-treated animals.

Urinalysis

There were no treatment-related changes in urinalysis parameters.

4.5 Electrocardiography

The Cardiology Report is contained in Appendix I.

There were no electrocardiographic changes which were considered to be treatment-related.

4.6 Ophthalmology

The Ophthalmology Report is contained in Appendix J.

There were no treatment-related ophthalmic changes.

4.7 Organ Weights

Organ weight summaries expressed as % brain weight values are in Table 9. Individual organ weight data are contained in Appendix K.

Organ weights were not affected by test article treatment.

4.8 Pathology

The Pathology Report is contained in Appendix L. A summary of microscopic lesions is shown in Table 10.

At necropsy in week 14, multiple white foci were observed in lungs from animals in the high dose group. Wet tissue review of unperfused lung revealed that they failed to collapse normally in 3/4 males and 2/4 females in the high dose group. Also, enlarged bronchial lymph nodes were observed in high dose males and mid and high dose females. These gross necropsy observations were supported histologically as mid and high dose dogs demonstrated lung lesions (alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material) and

Task Order No.: UIC-18A UIC/TRL Study No.: 193

bronchial lymph node lesions (macrophage accumulation). Accumulation of alveolar macrophages was characterized by the presence of numerous macrophages in the lumen of the affected alveoli. Macrophages were relatively large with a small nucleus and copious vacuolated cytoplasm. Chronic perivascular inflammation consisted of infiltration of lymphocytes around small vessels, and was generally found in or near collections of alveolar macrophages. Chronic interstitial inflammation was generally associated with more severe cases of alveolar macrophage accumulation. Basophilic granular material denoted the presence of fine basophilic granular material in the lumen of the alveoli.

Mid and high dose animals necropsied in week 14 also demonstrated bone marrow hyperplasia and splenic erythropoiesis. Bone marrow hyperplasia was characterized by an increased number of hematopoietic cells and a reduced proportion of large vacuoles that were interpreted as fat cells. Erythropoiesis in spleen was characterized by the presence of colonies of deeply basophilic erythrocyte precursor cells in the splenic parenchyma. The bone marrow hyperplasia was primarily erythroid in nature, as a decrease in the M:E (myeloid:erythroid) ratio of the rib bone marrow was seen. Administration of WR242511 at 0.1 mg base/kg/day did not result in clinically significant treatment-related effects.

The lung lesions seen in week 14 had essentially resolved by the end of the 13 week recovery period. The residual effects in the mid and high dose groups after the 13 week recovery period were of such minimal severity that they were not considered to be clinically significant. Treatment-related effects observed in week 14 in the spleen, bone marrow, and bronchial lymph nodes had also resolved by the end of the 13 week recovery period.

No other microscopic changes were considered to be related to WR242511 treatment.

DISCUSSION/CONCLUSION

This study evaluated the toxicity of WR242511 tartrate in Beagle dogs following thirteen weeks of daily oral administration by gelatin capsule. The dose levels were 0, 0.1, 0.3 and 1.0 mg base/kg/day. A thirteen week recovery period was included for all groups. The results are summarized in Table 1. No animals died during the study. Biologically significant clinical signs of cyanosis, characterized by blue gums, sclera and/or tongue, were seen in all WR242511 treatment groups and occurred in a dose-dependent fashion. During the recovery period, signs of cyanosis were not seen in the low and mid dose animals except for one male dog in the mid dose group on days 96 - 97. Clinical signs of cyanosis were still present in the high dose group during the recovery period up to day 131 (week 19). No treatment-related ophthalmic or ECG changes were observed during the study.

During the treatment and recovery periods, high dose females and mid and high dose males tended to have lower body weights than the corresponding vehicle control group, although these

Task Order No.: UIC-18A UIC/TRL Study No.: 193

differences were not statistically significant. Food intake was only marginally affected in high dose animals. By the end of the treatment period, body weight loss was evident in mid and high dose males and females. Body weight gains during the recovery period were similar among the control and treatment groups.

Changes in clinical chemistry parameters during the treatment period in male and female dogs administered WR242511 suggested mild treatment-related hepatic effects. Decreased serum albumin and A/G ratio and increased serum activity of AST were seen in high dose male and female dogs. Serum triglyceride concentration and LDH activity were also elevated in high dose males. Serum haptoglobin content was increased in high dose male and female dogs which is suggestive of the presence of an inflammatory event, i.e., an acute phase reaction. These alterations suggest the presence of mild hepatocellular injury in male and female dogs. However, accompanying histopathologic evidence of hepatic injury were not seen, suggesting that WR242511 was marginally hepatotoxic. Clinical chemistry parameters in animals given WR242511 did not differ from control animal values during the 13 week recovery period.

Mid and high dose male and female dogs had changes in erythrocyte parameters during the 13 week treatment period indicative of mild anemia. These changes included decreased RBC counts and decreased hemoglobin concentration in mid and high dose animals. The anemia may have been hemolytic in origin as elevated serum total bilirubin concentrations, indicative of excessive hemoglobin degradation, were seen in mid and high dose males. As a result of the mild anemia, compensatory increases in reticulocyte counts and nucleated RBCs were observed. The anemia was accompanied by secondary histologic changes including splenic erythropoiesis in mid and high dose females and bone marrow hyperplasia in mid and high dose animals. The increased M:E ratio of the bone marrow indicated that the hyperplasia was primarily erythroid in nature and likely a physiologic response to the anemia. These data suggest that hemolysis may have played a role in the development of the anemia, although hemosiderosis was not seen microscopically in the liver, spleen and or bone marrow. During the recovery period, RBC parameters in animals given WR242511 did not differ from control animal values.

Exposure to WR242511 resulted in significant thrombocytopenia during the entire treatment period in male and female dogs in both the mid and high dose groups. This was apparently in response to the mild drug-induced anemia. Thrombocytopenia was most severe in week 4, but improved thereafter. Platelet counts in WR242511-treated animals were similar to control animal values during the recovery period.

Methemoglobinemia, the desired pharmacologic effect of WR242511, was observed in male and female dogs during the treatment period and occurred in a dose-dependent fashion. The production of methemoglobin indicates an oxidant nature of the drug, which supports the mild anemia as being hemolytic in origin. During the recovery period, levels of methemoglobin in WR242511-exposed dogs did not differ from control animals.

Task Order No.: UIC-18A UIC/TRL Study No.: 193

D)

Lungs from several high dose animals failed to deflate normally in the week 14 necropsy, suggesting the presence of edema. Histopathologic evaluation indicated that animals in the mid and high dose group had developed pulmonary lesions by the end of the treatment period. These lesions were characterized by alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material in the alveoli. The severity and incidence of these lesions was greater in the high dose group. Chronic interstitial inflammation was generally associated with more severe cases of alveolar macrophage accumulation. However, accumulation of alveolar macrophages was not always associated with interstitial changes that were detectable by light microscopy. A possible mechanism for the pulmonary lesions could be subtle changes or injury to the capillary endothelium and/or alveolar type I pneumocytes resulting in chronic hemorrhage and edema. These events could produce the alveolar interstitial changes as a secondary response. Although specific staining was not performed, the basophilic granular material observed in the alveoli is consistent with the presence of bacterial growth, which is a frequently encountered complication of pulmonary edema. This lesion was observed in 3/4 high dose females and 1/4 high dose males. High dose females had elevated mature neutophil counts during the treatment period, which is consistent with the presence of a bacterial infection. The pulmonary lesions seen in week 14 had essentially resolved by the end of the 13 week recovery period and the residual effects were of such minimal severity that they were considered to be clinically insignificant.

In summary, the primary toxic effects of WR242511 tartrate were seen in the lungs, RBCs and platelets. Mild reductions in body weight gain were in the mid and high dose animals. Methemoglobin, the desired pharmacologic effect, was produced in a dose-dependent fashion and was accompanied by clinical signs of cyanosis (blue gums, tongue and sclera). Mild anemia as supported by reticulocytosis, secondary splenic hematopoiesis and bone marrow hyperplasia occurred primarily in high dose animals. Significant thrombocytopenia was seen during the treatment period in the mid and high dose animals, presumably in response to the anemic state, Administration of WR242511 resulted in pulmonary lesions in mid and high dose animals consisting of alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material in the alveoli. Minimal, but statistically significant changes in clinical chemistry parameters suggestive of liver injury were seen. However, histopathologic evidence of liver injury was not observed, suggesting that WR242511 is marginally hepatotoxic. By the end of the 13 week recovery period, treatment-related effects had resolved except for residual pulmonary lesions that were of such low severity as to be considered biologically insignificant. Because the aforementioned toxic responses were limited to the mid and high dose levels, the no-observed effect level (NOEL) of WR242511 tartrate was 0.1 mg base/kg/day.

DRAFT

Contract No.: DAMD17-92-C-2001

Task Order No.: UIC-18A UIC/TRL Study No.: 193

6. PERSONNEL

Study Director Pathologist

Clinical Veterinarian Ophthalmologist

Cardiologist

Clinical Laboratory Chemistry Specialist Tox. Lab Supervisor Lead Technician

Quality Assurance

Barry S. Levine, D.Sc., D.A.B.T.

Robert L. Morrissey, D.V.M., Ph.D., D.A.C.V.P.

Terry Hewett, D.V.M., D.A.C.L.A.M. Samuel J. Vainisi, D.V.M., D.A.C.V.O.

Robert L. Hamlin, D.V.M., Ph.D., D.A.C.V.I.M.

Maria Lang, A.H.T., C.V.T. Thomas Tolhurst, B.S. Soudabeh Soura, B.S. Teresa O'Neill, B.S. Ronald Schoenbeck

Report preparation was assisted by Soudabeh Soura, B.S., , Teresa O'Neill, B.S., Mukesh Pitroda, B.A., and Alan P. Brown, Ph.D.

7. ARCHIVES

The raw data, specimens, test article reserves, and final report are archived at the Toxicology Research Laboratory (TRL), University of Illinois at Chicago (UIC), Department of Pharmacology, 1940 W. Taylor St., Chicago, IL 60612-7353.

Contract No.: DAMID17-922C-2001
Task Order No.: UIC-18A
UIC/TRL Study No.: 193

Table 1 THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

Summary of Toxic Responses

Dose (mg base/kg/day)	0	0.1	0.3	1.0
Dogs/Sex	4 + 4*	4 + 4*	4 + 4*	4 + 4*
Deaths	0	0	WE	ME
Body Weight Gain	-	NE	1	1
Food Consumption	-	NE	NE	↓ (M)
Clinical Signs	-	Blue Tongue (2M/2F)	Blue Tongue (7M/8F)	Blue Gums (5M/6F) Blue Sclera (2M/3F) Blue Tongue (8M/8F)
Clinical Chemistry ^b	-	NE	† TBILI (M)	† AST † LDH ‡ ALB † HAPT † TBILI (M) ‡ A/G † TRIG (M)
Hematology		† METHGB (?)	† METHGB † RETICS (M) ‡ RBC (M) ‡ PLT ‡ HGB ‡ MCHC (F)	METHGB RBC (F/M?) HGB (F/M?) MCV NRBC MCHC NRBC WBC (F) RETICS PLT
Urinalysis		NE	NE NE	NE
Electrocardiography	-	NE	NE NE	NE
Ophthalmology		NE	NE	NE
Organ Weights		NE	NE	NE
Histopathology ⁴		NE	LUNG - Accumulation, alveolar macrophage (1M/2F) - Chronic, perivascular inflammation (1M/2F) - Chronic, interstitial inflammation (1M/1F) BRONCHIAL LYMPH NODE - Macrophage accumulation (1F) BONE MARROW - Hyperplasia (4M/2F) SPLEEN - Erythropoiesis (2F)	LUNG - Accumulation, alveolar macrophage (4M/4F) - Chronic, perivascular inflammation (4M/4F) - Chronic, interstitial inflammation (3M/4F) - Basophilic granular material (1M/3F) BRONCHIAL LYMPH NODE - Macrophage accumulation (2M/3F) BONE MARROW - Hyperplasia (4M/4F) - 1 M/E Ratio SPLEEN - Erythropoiesis (2F)

RECOVERY PERIOD: During the recovery period, clinical signs of cyanosis were generally not seen except in high dose animals. Treatment-related effects on body weights, food intake, and clinical pathology parameters were not seen. Histopathology changes seen in week 14 generally resolved by the end of the recovery period.

CONCLUSIONS: The primary toxic effects of WR242511 tartrate were seen in the lungs, RBCs and platelets. Mild reductions in body weight gain was seen in the mid and high dose animals. Methemoglobin, the desired pharmacologic effect, was produced in a dose-dependent fashion and was accompanied by clinical signs of cyanosis (blue gums, tongue and sclera). Mild anemia as supported by reticulocytosis, secondary splenic hematopoiesis and bone marrow hyperplasia occurred primarily in high dose animals. Significant thrombocytopenia was seen during the treatment period in the mid and high dose animals, presumably in response to the anemic state. WR242511 resulted in pulmonary lesions in mid and high dose animals consisting of alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material in the alveoli. Minimal, but statistically significant changes in clinical chemistry parameters suggestive of liver injury were seen. However, histopathologic evidence of liver injury was not observed, suggesting that WR242511 is marginally hepatotoxic. By the end of the 13 week recovery period, treatment-related effects had resolved except for residual pulmonary lesions that were of such low severity as to be considered biologically insignificant. Because the aforementioned toxic responses were limited to the mid and high dose levels, the no-observed effect level (NOEL) of WR242511 tartrate was 0.1 mg base/kg/day.

[&]quot;Recovery animals

^{*}AST = aspartate aminotransferase, ALB = albumin, A/G = albumin/globulin ratio, HAPT = haptoglobin, TRIG = triglycerides, LDH = lactate dehydrogenase, TBIL1 = total bilirubin.

[&]quot;METHGB = methemoglobin, RBC = ervthrocytes, HGB = hemoglobin, MCH = mean corpuscular hemoglobin, MCV = mean corpuscular volume. MCHC = mean corpuscular hemoglobin concentration, RETIC = reticulocytes, PLT = platelets, WBC = leukocytes, MNEUT = mature neutrophils, NRBC = nucleated red blood cells.

^{*}Week 14 necropsy

NE = No effect

^{? =} Marginal change

Task Order No.: UIC-18A UIC/TRL Study No.: 193

Table 2

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

Summary of Clinical Signs (Males)

Treatment Period

	* **	The second secon		
DOSE: (mg base/kg/day) GROUP:	0 I-M	0.1 2-M	0.3 3-M	1.0 4-M
Scheduled Sacrifice	4	4	4	4
Blue Gums	0	0	0	5 (22,26-28,31-39,41,55,58-59,63-64,85-86)
Blue Sclera	0	0	0	2 (51,83-85,87,89)
Blue Tongue	0	2 (38-46,50,55- 57,59,61)	7 (15-17,19-53,55-62,65,74- 75,80-84,89-90,92)	8 (4-93)
Total Number of Animals	ec	8	8	

Recovery Period

DOSE: (mg base/kg/day)	*	0.1	0.3	1.0
GROUP:	M-1	2-M	3-M	4-M
Scheduled Sacrifice	4	4	4	4
Blue Gums	0	0	d)	2 (94)
Blue Sclera	0	0	0	1 (94)
Blue Tongue	0	0	1 (96-97)	4 (94-113,118,124,129,131)
Total Number of Animals	80	8	8	8
			The second secon	

B

*Number(s) in parentheses indicate the day(s) the adverse sign was observed

Task Order No.: UIC-18A UIC/TRL Study No.: 193

Table 2 (contd.)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

Summary of Clinical Signs (Females)

Treatment Period

DOSE: (mg base/kg/day) 0	0	0.1	0.3 3-F	1.0 4-F
SIGONIC:				
Scheduled Sacrifice	4	4	4	4
Blue Gums	0	0	0	6 (16-36,38-42,44-45,48,50-68,70-72, 76-90,93)
Blue Sclera	0	0	0	3 (37,50-64,70-72,83-84,86-91)
Blue Tongue	0	2 (39,41)	8 (18,22,24-26,28-63,65-79, 81-82,92)	8 (6-93)
Total Number of Animals	8	8	8	∞

Recovery Period

DOSE: (mg base/kg/day) 0 GROUP: 1-F	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
Scheduled Sacrifice	4	4	4	4
Blue Gums	0	0	0	2 (94)
Blue Tongue	0	0	0	4 (94-99,101,103,105-116,118)
Total Number of Animals	8	8	8	8

BAF

*Number(s) in parentheses indicate the day(s) the adverse sign was observed

Table 3.1

THIRTEEN WEEK ORAL TOXICITY STUDY OF THE WEEK ORAL TOXICITY STUDY OR TOXICITY STUDY OF THE WEEK ORAL TOXICITY STUDY OR TOXICITY STUDY OR

			TCDCO V DICE	LDRIOD	IN DOOL	, 	
			SUMMARY	OF BODY	WEIGHTS	(Kilograms)	
	STUDY:	193	Treatment	Period	SEX:	MALE	
F	PERIOD	DOSE: GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day
	DAY -5	MEAN S.D. N	11.4 1.13 8	11.5 0.61 8	11.4 0.74 8	11.3 0.74 8	
Ε	DAY 3	MEAN S.D. N	11.5 1.15 8	11.5 0.56 8	11.4 0.96 8	11.4 0.79 8	
ε	DAY 7	MEAN S.D. N	11.6 1.12 8	11.6 0.66 8	11.4 0.99 8	11.4 0.78 8	
ţ	DAY 10	MEAN S.D. N	11.7 1.06 8	11.6 D.62 8	11.6 0.96 8	11.4 0.75 8	
Į.	DAY 14	MEAN S.D. N	11.5 1.07 8	11.6 0.66 8	11.4 1.00 8	11.2 0.75 8	
Ţ	DAY 17	MEAN S.D. N	11.7 1.17 8	11.6 0.70 8	11.5 1.12 8	11.2 0.76 8	
	DAY 21	MEAN S.D. N	11.7 1.17 8	11.7 D.69 8	11.6 1.D9 8	11.1 D.71 8	
	DAY 24	MEAN S.D. N	11.7 1.22 8	11.6 0.65 8	11.5 1.08 8	11.0 0.68 8	
ı	DAY 28	MEAN S.D. N	11.8 1.28 8	11.7 0.67 8	11.5 1.03 8	11.0 0.67 8	
1	DAY 34	MEAN S.D. N	11.7 1.20 8	11.6 0.84 8	11.3 1.21 8	10.8 0.73 8	

Table 3.2

DRAFT THIRTEEN WEEK ORAL TOXICITY STUDY WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF BODY WEIGHTS (Kilograms) Treatment Period STUDY: 193 SEX: MALE 1.0 mg base/kg/day DOSE: 0 0.3 0.1 PERIOD GROUP: 1-M 2-M. 3-M 4-M MEAN DAY 41 11.6 11.5 11.2 10.8 S.D. 1.20 0.75 0.72 1.12 N 8 8 8 8 MEAN 11.9 DAY 48 11.6 11.2 11.0 S.D. 1.29 1.00 1.26 0.70 8 8 8 8 DAY 54 MEAN 11.9 11.7 11.3 11.0 S.D. 1.15 1.08 1.31 0.70 8 8 8 8 DAY 62 MEAN 11.9 11.7 11.1 11.0 S.D. 1.26 0.97 1.38 0.73 8 8 **DAY 69** MEAN 12.1 12.0 11.2 11.1 S.D. 1.30 0.99 1.45 0.83 8 N 8 8 8 MEAN **DAY 76** 12.0 11.8 11.0 11.0 S.D. 1.41 1.02 1.49 0.80 8 8 8 8 DAY 83 MEAN 12.0 11.0 12.0 11.1 S.D. 1.37 0.99 1.61 0.88 8 8 8 8 DAY 90 MEAN 12.0 11.9 10.7 10.9 S.D. 1.43 0.96 1.52 0.84

Analysis of Variance using DUNNETT'S Procedure

8

8

8

8

Table 3.3



		SUMMARY	OF BODY	WEIGHTS	(Kilograms)	
STUDY: 1	93	Treatment	Period	SEX:	FEMALE	
PERIOD	DOSE: GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	mg base/kg/day
DAY -5	MEAN S.D. N	9.8 0.84 8		9.8 0.89 8	9.8 0.89 8	
DAY 3	MEAN S.D. N	9.9 0.89 8	9.7 1.33 8	9.8 1.02 8	9.6 0.80 8	
DAY 7	MEAN S.D. N	10.0 0.86 8	9.7 1.38 8	9.8 1.01 8	9.4 0.73 8	
DAY 10	MEAN S.D. N	10.0 0.90 8	9.9 1.40 8	9.9 1.14 8	9.4 0.83 8	
DAY 14	MEAN S.D. N	10.0 0.79 8	9.8 1.41 8	9.8 1.12 8	9.2 0.89 8	
DAY 17	MEAN S.D. N	10.0 0.86 8	9.8 1.45 8	9.8 1.24 8	9.2 0.98 8	
DAY 21	MEAN S.D. N	10.2 0.79 8	9.9 1.48 8	9.8 1.20 8	9.2 0.82 8	
DAY 24	MEAN S.D. N	10.0 0.76 8	9.8 1.53 8	9.7 1.15 8	9.1 0.79 8	
DAY 28	MEAN S.D. N	10.0 0.84 8	9.8 1.67 8	9.8 1.19 8	9.1 0.76 8	
DAY 34	MEAN S.D. N	10.0 0.81 8	9.7 1.46 8	9.7 1.31 8	9.0 0.66 8	

Table 3.4

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF BODY WEIGHTS (Kilograms) Treatment Period STUDY: 193 SEX: FEMALE 0.1 0.3 1.0 mg base/kg/day DOSE: n 1-F PERIOD GROUP: 2-F 3-F 4-F 10.0 9.8 9.6 9.0 DAY 41 MEAN S.D. 0.87 1.51 1.30 0.69 8 8 N 8 8 9.1 DAY 48 MEAN 10.2 10.1 9.7 0.72 S.D. 0.82 1.40 1.35 8 9.3 DAY 54 MEAN 10.3 10.1 9.8 0.89 0.74 S.D. 1.52 1.33 8 8 8 8 9.7 9.1 DAY 62 MEAN 10.1 10.2 0.69 S.D. 0.97 1.62 1.33 N 8 8 8 8 9.8 MEAN 10.1 9.1 **DAY 69** 10.3 S.D. 0.96 1.60 1.34 0.82 8 8 N 8 8 9.8 9.1 DAY 76 MEAN 10.2 10.2 0.79 S.D. 0.88 1.53 1.35 8 8 8 8 MEAN 10.2 10.3 9.8 9.1 DAY 83 S.D. 0.90 1.53 1.38 0.78 9.8 9.1 DAY 90 MEAN 10.3 10.3 1.01 0.79 S.D. 1.48 1.48 N 8 8 8 8

Table 3.5

RECOVERY PERIOD IN DOGS

SUMMARY OF BODY WEIGHTS (Kilograms)

		SUMMARY	OF BODY	WEIGHTS	(Kilograms)	
 STUDY:				SEX:		•••••
PERIOD	DOSE: GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day
DAY 97	MEAN S.D.	12.2 1.78	11.8 0.37	10.9 1.90 4	10.8	
	N ·	4	4	4	4	
DAY 104	MEAN S.D. N		0.38	1.96	11.1 1.00 4	
DAY 111	MEAN S.D.	12.2 1.78	0.37	1.80	10.8	
	N	4	4	4	4	
DAY 119	MEAN S.D. N	12.5 2.20 4	12.1 0.24 4	11.1 2.35 4	11.1 1.23 4	
DAY 125	MEAN S.D.	12.4 2.25	12.0 0.29	11.1 2.03	11.2 1.17	
	N	4	4	4	4	
DAY 133	MEAN S.D. N	12.6 2.22 4	12.1 0.17 4	11.2 2.09 4	11.3 1.32 4	
DAY 139	MEAN S.D. N		12.1	11.2 2.11	11.2 1.35 4	
DAY 146	MEAN S.D. N		11.9 0.19	11.1	11.1	
DAY 153	MEAN S.D. N		11.7	11.1	11.2	
DAY 160	MEAN S.D. N		11.9	11.3	11.4	
DAY 167	MEAN S.D. N	12.6 2.75				
DAY 174	MEAN S.D. N	13.0 2.71	12.1 0.38 4	11.5 2.30 4	11.8 1.30 4	
DAY 181	MEAN S.D.	13.1 2.54	12.1 0.38	11.5	11.9 1.47	

Table 3.6

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF BODY WEIGHTS (Kilograms) Recovery Period STUDY: 193 SEX: FEMALE 1.0 mg base/kg/day DOSE: n 0.1 0.3 1-F 4-F PERIOD GROUP: 2-F 3-F 9.3 10.1 10.3 MEAN 8.8 **DAY 97** S.D. 1.09 1.53 1.47 0.64 N **DAY 104** MEAN 10.3 10-5 9.5 9.1 S.D. 0.99 1.55 1.37 0.66 **DAY 111** MEAN 10.3 10.3 9.3 9.0 S.D. 0.74 1.26 1.67 1.51 9.3 MEAN 10.5 10.4 9.6 **DAY 119** S.D. 1.21 1.61 1.41 0.90 N 4 9.1 MEAN 10.4 9.5 **DAY 125** 10.4 1.40 S.D. 1.39 1.57 0.87 N 4 MEAN 10.6 9.7 9.3 **DAY 133** 10.7 S.D. 1.51 0.83 1.48 1.44 N-4 **DAY 139** MEAN 10.6 10.7 9.6 9.3 S.D. 1.36 1.48 1.66 0.96 4 **DAY 146** MEAN 10.5 10.6 9.4 9.2 S.D. 1.36 1.53 1.61 0.89 9.2 9.5 **DAY 153** MEAN 10.6 10.6 S.D. 1.33 1.55 1.61 0.88 9.6 9.4 MEAN 10.9 10.8 **DAY 160** 1.70 1.06 S.D. 1.38 1.66 4 10.9 9.6 MEAN 9.7 **DAY 167** 11.1 S.D. 1.63 1.57 1.22 1.44 N 4 9.7 MEAN 10.0 **DAY 174** 11.1 11.0 1.12 S.D. 1.42 1.53 1.59 9.9 9.9 **DAY 181** MEAN 11.0 11.0 S.D. 1.52 1.55 1.54 1.20

Analysis of Variance using DUNNETT'S Procedure

N

Table 4.1



		SUMMARY	Y OF WEIGH	HT GAINS	G (Kilograms)	
STU	DY: 193	Treatment	Period	SEX:	MALE	
PERIOD ²	DOSE: GROUP:	0 1-M		0.3 3-M	1.0 4-M	mg base/kg/day
DAY 3	· MEAN S.D. N	0.1 0.24 8	0.19	0.0 0.31 8	0.1 0.28 8	
DAY 7	MEAN S.D. N	0.1 0.11 8	0.22	0.0 0.16 8	0.0 0.13 8	
DAY 10	MEAN S.D. N	D.2 0.27 8	0.17	0.1 0.13 8	0.D 0.22 8	
DAY 14	MEAN S.D. N	-0.2 0.23 8	0.17	-0.1 0.28 8	-0.3 0.17 8	
DAY 17	MEAN S.D. N	0.2 0.28 8	0.1 0.18	0.0 0.21 8	0.0 0.11 8	
DAY 21	MEAN S.D. N	0.0 0.25 8	0.14	0.1 0.13 8	0.0 0.12 8	
DAY 24	MEAN S.D. N	-0.1 0.10 8	0.09	-0.1 0.15 8	-0.1 0.12 8	
DAY 28	MEAN S.D. N	0.2 0.10 8	0.24	0.1 0.17 8	0.0 0.16 8	•
DAY 34	MEAN S.D. N	-0.1 0.17 8	0.27	-0.2 0.24 8	-0.2 0.17 8	
DAY 41	MEAN S.D. N	-0.1 0.14 8	0.16	-0.1 0.18 8	0.0 0.11 8	

 $^{^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period

baseline is day -5

Table 4.2

		SUMMARY	OF WEIGHT	GAINS	5 (Kilograms)	
 STUDY: 1	93	Treatment	Period	SEX:	MALE	
 PERIOD ^a	DOSE: GROUP:	0 1-m	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day
DAY 48	MEAN S.D. N	0.3 0.21 8	0.1 0.50 8	0.0 0.21 8	0.2 0.27 8	
DAY 54	MEAN S.D. N	0.0 0.32 8	0.1 0.18 8	0.1 0.17 8	0.1 0.30 8	
DAY 62	MEAN S.D. N	0.0 0.15 8	-0.1 0.33 8	-0.2 0.19 8	0.0 0.09 8	
DAY 69	MEAN S.D. N	0.1 .0.13 8	0.3 0.20 8	0.1 0.21 8	0.1 0.14 8	
DAY 76	MEAN S.D. N	0.0 0.19 8	-0.1 0.24 8	-0.2 0.18 8	-0.1 0.09 8	
0AY 83	MEAN S.O. N	0.0 0.22 8	0.1 0.20 8	0.0 0.17 8	0.0 0.19 8	·
0AY 90	MEAN S.D. N	0.0 0.17 8	-0.1 0.14 8	-0.4 0.64 8	-0.1 0.16 8	
TOTAL GAIN	MEAN S.D. N	0.6 0.72 8	0.4 0.71 8	-0.7* 1.48 8	-0.4 0.52 8	

^{*} P less than .05

 $^{^{\}mathrm{d}}\mathrm{Weight}$ gains compared to the previous period

Table 4.3



200000000000000000000000000000000000000							
			SUMMARY	OF WEIGHT	GAINS	(Kilograms)	
••••	STUDY:	193	Treatment	Period	SEX:	FEMALE	
	PERIOD a	DOSE: GROUP:	0 1-F	°0.1 2-F	0.3 3-F	1.0 4-F	mg base/kg/day
				- · · · · · · · · · · · · · · · · · · ·	J (
	L						
	DAY 3 b	MEAN	0.1	-0.1	0.0	-0.2	
		S.D.	0.24	0.19	0.16	0.19	
		N	8	8	8	8	
	DAY 7	MEAN	0.1	0.0	-0.1*	-0.2*	
	DAT	S.D.	0.13	0.15	0.11	0.13	
		N.	8				
		N	0	8	8	8	
	DAY 10	MEAN	0.0	0.2	0.2	D.0	
		S.O.	0.15	0.16	0.26	0.20	•
		N	8	8	8	8	
	04V 1/	MEAN	0.0	0.1	0.1		
	OAY 14	MEAN	0.0	-0.1	-0.1	-0.2	
		S.D.	0.17	0.14	0.20	0.17	
		N	8	8	8	8	
	OAY 17	MEAN	0.0	0.0	0.0	0.0	
		S.O.	0.23	0.21	0.22	0.39	
		N	8	8	8	8	
	04						
	DAY 21	MEAN	0.2	0.1	0.0	-0.1	
		S.O.	0.14	0.25	0.19	0.40	
		N	8	8	8	8	
	0AY 24	MEAN	-0.2	-0.2	-0.1	-0.1	
		S.D.	0.15	0.33	0.20	0.21	
		N	8	8	8	8	
	DAY 28	MEAN	0.0	0.0	0.1	0.0	
	DA1 20	S.D.	0.24	0.22	0.16	0.19	
		N	8	8	8	8	
		N	0	0	0	0	
	DAY 34	MEAN	0.0	-0.1	-0.2	-0.1	
		S.D.	0.15	0.29	0.23	0.19	
		N	8	8	8	8	
	OAY 41	MEAN	0.1	0.1	-0.1	0.0	
	VAL 41	S.D.	0.16	0.14	0.15	0.09	
		N	8	8	8	8	
			0	0	0	0	

P less than .D5

^aWeight gains compared to the previous period

bBaseline is day -5

Table 4.4



		SUMMAR	OF WEIG	HT GAINS	S (Kilograms)	
 STUDY:	193	Treatment	Period	SEX:	FEMALE	
PERIOD ^a	DOSE: GROUP:	0 1-F	. 0.1 2-F	0.3 3-F	1.0 4-F	mg base/kg/day
DAY 48	MEAN S.D. N	0.1 0.15 8	0.3 0.28 8	0.1 0.19 8	0.1 0.14 8	
DAY 54	MEAN S.O. N	0.1 0.33 8	0.1 0.23 8	0.1 0.13 8	0.1 0.18 8	
DAY 62	MEAN S.D. N	-0.2 0.20 8	0.0 0.28 8	-0.1 0.12 8	-0.1 0.18 8	,
DAY 69	MEAN S.D. N	0.1 0.23 8	0.1 0.15 8	0.1 0.15 8	-0.1 0.21 8	
DAY 76	MEAN S.D. N	0.1 0.17 8	-0.1 0.21 8	0.0 0.20 8	0.0 0.23 8	
OAY 83	MEAN S.O. N	0.1 0.09 8	0.0 0.21 8	0.0 0.14 8	0.0 0.20 8	
DAY 90	MEAN S.D. N	0.0 0.25 8	0.1 0.27 8	0.0 0.16 8	0.0 0.07 8	is .
TOTAL GAIN	MEAN S.O. N	0.5 0.46 8	0.6 0.69 8	-0.1 0.77 8	-0.7* 0.63 8	

^{*} P less than .05

 $^{^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period

Table 4.5



	S	UMMARY	OF WEIGHT	GAINS	S (Kilograms)	•	
 STUDY: 19	3	Recovery	Period	SEX:	MALE		
	DOSE: GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day	
 							• • • • • • • • • • • • • • • • • • • •
DAY 97 ^b	MEAN S.D. N	-0.1 0.22 4	-0.1 0.13 4	0.0 0.14 4	-0.1 0.26 4	•	141
DAY 104	MEAN S.D. N	0.3 0.06 4	0.3 0.27 4	0.3 0.10 4	0.3 0.21 4		
DAY 111	MEAN S.D. N	-0.3 0.17 4	-0_4 0.22 4	-0.3 0.34 4	-0.3 0.19 4	,	
DAY 119	MEAN S.D. N	0.3 0.43 4	0.3 0.21 4	0.3 0.57 4	0.3 0.32 4		
DAY 125	MEAN S.D. N	-0.1 0.20 4	-0.1 0.12 4	0.0 0.33 4	0.1 0.24 4		
DAY 133	MEAN S.D. N	0.2 0.14 4	0.1 0.13 4	0.1 0.17 4	0.2 0.17 4		
DAY 139	MEAN S.D. N	0.1 0.10 4	0.0 0.08 4	0.0 0.13 4	-0.1 0.22 4	•	
DAY 146	MEAN S.D. N	-0.2 0.15 4	-0.2 0.13 4	-0.1 0.10 4	-0.2 0.13 4		
DAY 153	MEAN S.D. N	0.1 0.26 4	-0.2 0.28 4	0.1 0.19 4	0.2 0.10 4		
DAY 160	MEAN S.D. N	0.0 0.31 4	0.1 0.21 4	0.2 0.22 4	0.2 0.21 4		

Analysis of Variance using DUNNETT'S Procedure

^aWeight gains compared to the previous period

Baseline is day 90

Table 4.6 .



		SUMMARY	OF WEIGHT	GAINS	5 (Kilograms)	
STUDY:	193	Recovery	Period	SEX:	MALE	
PERIOD a	DOSE: GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day
OAY 167	MEAN S.O. N	0.1 .0.10 4	0.0 0.23 4	-0.1 0.22 4	0.1 0.05 4	
DAY 174	MEAN S.D. N	0.4 0.13 4	0.2 0.14 4	0.3 0.19 4	0.3 0.29 4	
DAY 181	MEAN S.D. N	0.1 0.27 4	0.1 0.15 4	0.0 0.25 4	0.1 0.39 4	·
TOTAL GAIN	MEAN S.O. N	0.8 0.71 4	0.3 0.57 4	0.6 0.33 4	0.9 1.12 4	

Analysis of Variance using OUNNETT'S Procedure

 $^{{}^{\}rm a}{\rm Weight}$ gains compared to the previous period

Table 4.7



		SUMMARY OF	WEIGHT	GAIN	5 (Kilograms)	
STUDY:	193	Recovery Period	1	SEX:	FEMALE	
		•				me has distil
a	DOSE:	0 1-F	0.1 2-F		1.U 4-F	mg base/kg/day
PERIOD	GROUP:	1°F	Z*F	3-F	4-1	
DAY 97 b	MEAN	-0.1	-0.2	-0.1	-0.1	
	S.D.	0.19	0.13	0.05	0.13	
	N	4	- 4	4	4	
DAY 104	MEAN	0.2	0.1	0.2	0.4	
	S.D.	0.21	0.10	0.14	0.10	
	N	4	4	4	4	
DAY 111	MEAN	0.0	-0.2	-0.3	-0.2	
DA1 111	S.D.	0.29	0.22	0.19	0.10	
	N	4	4	4	4	
	.,	•	•	,	•	
DAY 119	MEAN	0.2	0.2	0.4	0.3	
	S.D.	0.13	0.22	0.13	0.22	
	N	4	4	4	4	
DAY 125	MEAN	-0.1	0.0	-0.2	-0.1	
DAT 123	S.D.	0.22	0.05	0.06	0.05	
	N.	4	4	4	4	
		•	•	•	·	
DAY 133	MEAN	0.2	0.2	0.2	0.1	
	S.D.	0.10	0.19	0.16	0.29	
	N	4	4	4	4	
470						
0AY 139	MEAN S.D.	-0.1 0.29	0.1	-0.1 0.25	0.1	
	N.	4	0.22	4	0.13	
	N	4	4	-	4	
DAY 146	MEAN	-0.1	-0.1	-0.1	-0.1	
	S.O.	0.15	0.17	0.22	0.21	
	N	4	4	4	4	
200 457	145 411	0.0		0.0	0.0	
DAY 153	MEAN	0.2	0.0	0.0	0.0	
	S.D.	0.10	0.14	0.13	0.22	
	N	4	4	4	4	
DAY 160	MEAN	0.3	0.2	0.1	0.2	
	S.O.	0.06	0.24	0.14	0.19	
	N	4	4	4	4	

Analysis of Variance using DUNNETT'S Procedure

 $^{^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period

baseline is day 90



		SUMMARY	OF WEIGHT	GAINS	G (Kilograms)	
STUDY:	193	Recovery	Period	SEX:	FEMALE	•
PERIOD a	DOSE: GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	mg base/kg/day
DAY 167	MEAN S.D. N	0.2 0.15 4	0.0 0.05 4	0.2 0.13 4	0.2 0.18 4	
DAY 174	MEAN S.D. N	0.0 0.18 4	0.2 0.17 4	0.3 0.15 4	0.2 0.13 4	
DAY 181	MEAN S.D. N	-0.2 0.17 4	-0.1 0.10 4	-0.1 0.22 4	0.2 0.15 4	
TOTAL GAIN	MEAN S.D. N	0.8 0.84 4	0.5 0.14 4	0.4 0.33 4	1.1 0.68 4	

Analysis of Variance using DUNNETT'S Procedure

^aWeight gains compared to the previous period

Table 5.1

DRAFT

SUMMARY OF DAILY MEAN FOOD CONSUMPTION (Grams)

	SUMMARY	OF DAILY	MEAN	FOOD COL	NSUMPTION	(Grams)
STU	JDY: 193	Treatment F	eriod	SEX:	MALE	
PERIOD	DOSE: GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 m 4-M	g base/kg/day
	INTAKE (g) S.D. N		293			
DAY -4	INTAKE (g) S.D. N	349 53.8 8	292 63.6 8	348 55.4 8	349 73.7 8	
DAY 7	INTAKE (g) S.D. N	384 33.0 8	347 62.3 8	327 65.1 8	322 84.3 8	
DAY 14	INTAKE (g) S.D. N	365 52.6 8	356 49.3 8	310 82.1 8	264* 84.0 8	
DAY 21	INTAKE (g) S.D. N	397 5.2 8	400 0.7 8	381 40.1 8	109.4	
DAY 25	INTAKE (g) S.D. N	365 61.7 8	362 53.4 8	82.8	115.7	
DAY 35	INTAKE (g) S.D. N	393 12.7 8	400 0.0 8	51.9	125.3	
DAY 42	INTAKE (g) S.D. N	391 26.2 8	395 13.8 8	2.1	363 52.9 8	
DAY 49	INTAKE (g) S.D. N	352 72.0 8	400 0.0 8	64.3	388 32.9 8	
DAY 51	INTAKE (g) S.D. N	377 39.0 8	364 67.0 8	38.6	373 69.8 8	
DAY 54	INTAKE (g) S.D. N	364 47.7 8	361 53.6 8	29.9	8.2	
DAY 63	INTAKE (g) S.D. N	360 62.8 8	391 19.6 8	91.4	40.8	
DAY 70	INTAKE (g) S.D. N	379 59.4 8	382 49.9 8	57.1	68.2	
DAY 77	INTAKE (g) S.D. N	355 113.6 8	400 0.0 8	30.7	26.2	
DAY 84	INTAKE (g) S.D. N	396 10.3 8	391 26.5 8	0.0	0.0	
DAY 91	INTAKE (g) S.D. N	380 56.9 8	400 0.0 8	0.0	0.0	

^{*} P less than .05 Statistical Analysis by Kruskal-Wallis test and Mann-Whitney U test

Table 5.2

DRAFT

SUMMARY OF DAILY MEAN FOOD CONSUMPTION (Grams) Treatment Period STUDY: 193 SEX: FEMALE 1.0 mg base/kg/day 0 0.1 0.3 DOSE: PERIOD GROUP: 1-F 2-F 3-F 4-F 292 274 309 270 INTAKE (g) DAY -8 S.D. 55.6 89.0 59.6 86.6 INTAKE (g) 310 307 329 268 DAY -4 100.6 S.D. 63.9 60.7 84.7 8 8 INTAKE (g) 313 306 275 196 DAY 7 1DD.0 83.5 73.7 93.4 S.D. 8 8 282 DAY 14 INTAKE (g) 310 332 205 100.9 72.1 89.6 118.0 S.D. 8 N 8 8 8 350 INTAKE (g) 345 345 286 DAY 21 65.9 S.D. 53.6 83.0 84.1 8 8 8 8 INTAKE (g) 330 311 319 272 DAY 25 66.7 79.8 109.1 115.7 S.D. 8 8 8 8 INTAKE (g) DAY 35 329 332 318 321 S.D. 77.9 75.1 92.9 84.0 8 8 8 8 DAY 42 INTAKE (g) 330 363 373 351 62.8 56.4 40.2 52.4 S.D. 8 302 DAY 49 INTAKE (g) 300 309 315 97.7 S.D. 123.8 117.2 104.5 8 8 8 8 317 DAY 51 INTAKE (g) 315 312 332 S.D. 122.2 83.6 88.3 79.4 8 8 8 8 347 DAY 54 INTAKE (g) 332 343 322 119.4 59.7 52.3 S.D. 61.3 N 8 8 335 341 292 DAY 63 INTAKE (g) 316 94.6 71.9 92.8 111.4 S.D. N 8 8 8 INTAKE (g) 351 338 **DAY 70** 328 300 123.0 87.9 63.9 89.0 S.D. 8 8 8 345 373 373 370 **DAY 77** INTAKE (g) S.D. 82.7 57.2 72.1 38.7 8 8 8 DAY 84 INTAKE (g) 375 385 379 368 48.0 33.6 S.D. 3D₋7 65.1 8 8 8 INTAKE (g) 330 375 **DAY 91** 381 335 28.2 86.3 S.D. 77.8

Statistical Analysis by Kruskal-Wallis test and Mann-Whitney U test $Page\ 40$

8

8



SUMMARY OF DAILY MEAN FOOD CONSUMPTION (Grams) STUDY: 193 Recovery Period SEX: MALE DOSE: 0.1 0.3 1.0 mg base/kg/day 1-M PERIOD GROUP: 2-M 3-M 4-M 388 400 **DAY 98** INTAKE (g) 380 400 S.D. 24.0 39.5 0.0 0.0 N 4 4 4 354 INTAKE (g) 400 400 400 **DAY 105** S.D. 91.5 0.0 0.0 0.0 4 4 4 4 INTAKE (g) 400 400 400 400 **DAY 112** S.D. 0.0 0.0 0.0 N 4 4 4 4 **DAY 119** INTAKE (g) 400 400 400 400 0.0 0.0 S.D. 0.0 0.0 N 4 4 4 **DAY 126** INTAKE (g) 400 400 400 400 0.0 S.D. 0.0 0.0 0.0 4 INTAKE (g) 400 **DAY 133** 400 400 400 S.D. 0.0 0.0 0.0 0.0 4 4 4 4 400 386 **DAY 140** INTAKE (g) 400 400 S.D. 0.0 0.0 29.0 0.0 N 4 4 4 4 INTAKE (g) **DAY 147** 400 400 400 400 S.D. 0.0 0.0 0.0 0.0 N 4 4 4 4 400 400 **DAY 154** INTAKE (g) 400 400 S.D. 0.0 0.0 0.0 0.0 4 **DAY 161** INTAKE (g) 400 390 400 400 S.D. 0.0 19.5 0.0 0.0 4 4 4 4 INTAKE (g) 390 400 400 400 **DAY 168** S.D. 0.0 0.0 21.0 0.0 4 4 4 4 DAY 175 INTAKE (g) 349 400 400 353 S.D. 0.0 0.0 93.5 103.0 N 4 INTAKE (g) 354 361 400 **DAY 182** 400 79.0 56.3 0.0 S.D. 0.0 4

Statistical Analysis by Kruskal-Wallis test and Mann-Whitney U test

Table 5.4

DRAFT

SUM	MARY	OF	DAILY	MEAN	FOOD	CONSUMPTION	(Grams)

	SUMMARY	OF DAILY	MEAN	FOOD COL	NSUMPTIO	N (Grams)
 STUDY	7: 193	Recovery Per	iod	SEX:	FEMALE	
	DOSE:	0	0.1	0.3	1.0	mg base/kg/day
PERIOD	CDOLID.	1_5	2-5	7.5	/- E	
DAY OR	INTAKE (g)	310	285	363	359	
DA1 90	S.D.	310 104.3	86.6	74.0	68.1	
	N N	4	4	4	4	
DAY 105	INTAKE (g)	345 63.9	318	336	400	
	S.D.	63.9	125.4	128.0	0.0	
	N	4	4	4	*	
OAY 112	INTAKE (g)	304	334	361	400	
	S.D.	304 166.4	334 83.8	361 78.5	400	
	N	4	4	4	4	
		750	700	7/0	400	
DAY 119	INTAKE (g)	358 68.4	309 108.9	362 77.0	400	
	S.D. N	4	4	4	0.0	
			7	7		
DAY 126	INTAKE (g) S.D. N	362	319	396 9.0	400	
	S.D.	45.3	319 66.6	9.0	0.0	
	N	4	4	4	4	
DAY 177	INTAKE (a)	75/	321	400	400	
DAT 133	S.D.	58.4	92.4	0.0	0.0	
	INTAKE (g) S.D. N	4	4		4	
OAY 140	INTAKE (g)	270 45.1 4	329			
	s.D.	45.1	99.9			
	N	4	4	4	4	
DAY 147	INTAKE (g)	400	359	400	400	
DAI 141	S.D.	0.0	82.5			
	N	0.0	4		4	
5.W 454		7700				
DAY 154	INTAKE (g)	329	385	400		
	S.D. N	99.0	30.5	0.0		
					7	
DAY 161	INTAKE (g)	352 62.5 4	338	400	400	*
	s.O.	62.5	82.8	0.0	0.0	
	N	4	4	4	4	
DAY 168	INTAKE (a)	305	3/.8	400	354	
DA1 100	S.D.	121.5	104.0	0.0	87.5	
	N	4	4	4	4	
Note: 944		10% 20				
0AY 175	INTAKE (g)	265	292			
	S.D. N	95.1 4	128.9		34.5	
	T .	4	4	4	. 4	
DAY 182	INTAKE (g)	262	278	400	359	
7	S.D.	111.5	83.8			
	N	4	4	4	4	

Statistical Analysis by Kruskal-Wallis test and Mann-Whitney U test



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Alanine Aminotransferase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: ALT UNITS: IU/L

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-M	: 0 mg base/	'kg/day						
MEAN	42	25	33	37	39	39	36	
SD	12.3	2.6	5.3	8.3	7.5	9.4	6.4	
N	8	8	8	8	8	4	4	
Group: 2-M	: 0.1 mg bas	se/kg/day						
MEAN	38	29	34	37	37	41	41	
SD	11.3	4.9	8.5	7.9	7.9	8.4	3.9	
N	8	8	8	8	8	4	4	
		•						
Group: 3-M	: 0.3 mg bas	e/kg/day						
MEAN	43	29	32	35	36	39	45	
SD	19.4	8.9	11.2		11.4	24.9	19.1	
N	8	8	8	8	8	4	4	
Group: 4-M	: 1.0 mg bas	se/kg/day						
MEAN	35	27	28	34	34	35	40	
SD	6.4		4.1	4.4	5.0	4.4	8.4	
N	8	8	8	8	8	4	4	
14	•	-	_		_	•	-	

Table 6.2

SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Alanine Aminotransferase

STUDY ID: UIC-18A

.....

STUDY NO: 193

SEX: FEMALE

ABBR: ALT

UNITS: IU/L

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F:	0 mg base/	kg/day						
MEAN	33	29	32	- 33	35	33	31	
SD	4.5	3.8	8.3	8.9	12.4	4.2	6.6	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg base	e/kg/day						
MEAN	32	29	31	32	31	27	30	
SD	5.4	3.4	3.6	4.2	4.9	7.5	3.2	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg base	e/kg/day						
MEAN	26	24*	26	29	29	25	35	
SD	6.0	5.0	8.8	6.3	3.3	2.8	6.0	
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg base	e/kg/day						
MEAN	30	26	27	27	31	28	27	
SD	5.7	2.9	4.8	3.7	6.6	6.2	5.0	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

Table 6.3

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Aspartate Aminotransferase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193

ABBR: AST

UNITS: IU/L

 PERIOD(s):	Hook -3							
	week -J	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-M:	0 mg base/k	g/day						
MEAN	33	33	37	33	33	34	40	
SD	3.3	6.5	12.0	6.5	4.2	4.9	6.5	
N	8	8	8	8	8	4	4	
Group: 2-M:	0.1 mg base	e/kg/day						
MEAN	32	38	37	36	37	37	42	
SD	5.0	18.7	8.5	8.7	5.1	9.5	10.2	
N	8	8	8	8	8	4	4	
Group: 3-M:	0.3 mg base	e/kg/day						
MEAN	33	31	38	41	41	33	42	
SD	5.0	4.3	6.1	10.6	8.8	7.4	10.2	47
N	8	8	8	8	8	4	4	
Group: 4-M:	1.0 mg base	e/kg/day						
MEAN	34	35	47	52*	43*	36	39	
SD	6.1	6.1	9.5	11.6	8.1	7.9	7.1	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

Table 6.4

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Aspartate Aminotransferase

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: AST

UNITS: IU/L

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-F	: 0 mg base/	kg/day						
MEAN	36	• 33	39	39	40	36	38	
SD	7.2	5.5	8.2	15.4	9.6	12.1	6.8	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg bas	e/kg/day						
MEAN	30	30	32	33	40	24	33	
SD	8.4	7.4	6.6	6.6	4.6	4.1	4.4	
N	8	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg bas	e/kg/day						
MEAN	29	32	39	37	39	41	48	
SD	9.5	6.7	9.8	11.0	7.4	6.9	9.5	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day						
MEAN	30	30	46	42	53*	28	35	
SD	8.3	4.9	8.9	5.0	6.2	3.9	6.7	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Total Protein

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: TP UNITS: g/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-M:	0 mg base/	kg/day						
MEAN	6.4	5.7	5.9	6.2	6.0	6.3	6.6	
SD	0.26	0.28	0.31	0.34	0.37	0.24	0.15	
N	8	8	8	8	8	4	4	
Group: 2-M:	0.1 mg bas	e/kg/day						
MEAN	6.3	5.7	6.0	6.0	6.1	6.2	6.4	
SD	0.24	0.28	0.49	0.27	0.35	0.38	0.21	
N	8	8	8	8	8	4	4	
Group: 3-M:	0.3 mg bas	e/kg/day						
	6.2		5.9	6.2	6.0	6.2	6.5	
SD	0.27	0.23	0.40	0.21	0.33	0.53	0.23	
N	8	8	8	8	8	4	4	
Group: 4-M:	1.0 mg bas	e/kg/day						
MEAN	6.3	5.7	5.8	6.3	6.2	6.5	6.7	
SD	0.28	0.23	0.44	0.37	0.29	0.10	0.31	
N	8	8	8	8	8	4	4	

Table 6.6

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Total Protein

STUDY ID: UIC-18A

STUDY NO: 193

ABBR: TP

SEX: FEMALE

UNITS: g/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F	: 0 mg base/k	g/day						
MEAN	6.0	5.7	6.0	5.9	6.2	6.2	6.6	
SD	0.45	0.36	0.33	0.29	0.31	0.24	0.38	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg base	e/kg/day						
MEAN	6.3	5.8	5.9	6.0	6.3	6.4	6.6	
SD	0.35	0.31	0.46	0.41	0.27	0.13	D.42	
N	8	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg base	e/kg/day						
MEAN	6.1	5.7	5.9	5.9	6.3	6.2	6.5	
SD	0.28	0.23	0.40	0.36	0.29	0.06	0.33	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg base	e/kg/day						
MEAN	6.3	5.9	5.7	5.8	6.3	6.3	6.5	
SD	D.40	D.50	0.25	0.37	0.24	D.33	D.17	
N	8	8	8	8	8	4	4	



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Albumin

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: ALB UNITS: g/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-M :	0 mg base/	kg/day					•	
	3.2		3.2	3.3	3.2	3.3	3.6	
SD	0.18	0.14	0.12	0.09	0.14	0.13	0.13	
N	8	8	8	8	8	4	4	
Group: 2-M :	0.1 mg bas	e/kg/day						
MEAN	3.2		3.2	3.2	3.2	3.2	3.5	
SD	0.17	0.19	0.24	0.16	0.20	0.17	0.22	
N	8	8	8	8	8	4	4	
Group: 3-M :	0.3 mg bas	e/kg/day						
	3.1		3.0	3.1	3.0	3.0	3.4	
SD	0.17	0.15	0.19	0.12	0.21	0.25	0.29	
N	8	8	8	8	8	4	4	
Group: 4-M :	1.0 mg bas	e/kg/day						
	3.2		2.8*	3.1	3.1	3.1	3.6	
SD	0.17	0.12	0.19	0.12	0.20	0.17	0.25	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Albumin

STUDY ID: UIC-18A

.....

SEX: FEMALE

STUDY NO: 193 ABBR: ALB

UNITS: g/dL

 	ANNE					• • • • • • • • • • • • • • • • • • •		
PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F:	0 mg base/	kg/day	•••••					
MEAN	3.2	3.2	3.3	3.2	3.2	3.2	3.5	
SD	0.19	0.11	0.15	0.16	0.13		0.05	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg bas	e/kg/day						
MEAN	3.3		3.3	3.3	3.3	3.3	3.4	
SD	0.14	0.24	0.19	0.24	0.16	0.10	0.13	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg bas	e/kg/day						
MEAN	3.2	3.0	3.2	3.2	3.1	3.1	3.5	
SD	0.20		0.15					
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg bas	e/kg/day						
	3.3	3.2	2.9*	3.1	3.2	3.1	3.4	
SO	0.20		0.16		0.10	0.14		
N	8	8	8	8	8	4	4	
N	0	0	0	0	0	4	**	

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF DRAFT TO THIRTEEN WEEK ORAL TOXICITY STUDY OF DRAFT TO THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Globulin

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: GLOB

UNITS: g/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-M:	0 mg base/	kg/day	******	_				
	3.2		2.7	- 3.0	2.9	3.1	3.0	
SD	0.21	0.23	0.29	0.32	0.27	0.24	0.10	
N	8	8	8	8	8	4	4	
Group: 2-M:	0.1 mg bas	e/kg/day						
MEAN	3.1	2.5	2.8	2.8	2.9	3.0	2.8	
SD	0.12	0.13	0.29	0.14	0.20	0.40	0.10	
N	8	8	8	8	8	4	4	
Group: 3-M :	0.3 mg bas	e/kg/day						
	3.1		2.8	3.1	3.0	3.2	3.1	
SD	0.30		0.27			0.29	0.08	
N	8	8	8	8	8	4	4	
Group: 4-M:	1.0 mg bas	e/kg/day						
	3.2	2.5	3.0	3.1	3.1	3.4	3.1	
SD	0.24		0.30			0.14		
N	8	8	8	8	8	4	4	
• •	_	_	_	_	_			



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Globulin

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: GLOB UNITS: g/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F:	0 mg base/	kg/day						
MEAN	2.9	2.5	2.7	2.7	3.0	3.1	3.1	
SD	0.32	0.30	0.23	0.23	0.32	0.29	0.34	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg bas	e/kg/day						
MEAN	3.0	2.6	2.7	2.7	3.1	3.2	3.2	
SD	0.26	0.24	0.33	0.23	0.16	0.13	0.37	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg bas	e/kg/day						
· ·	3.0		2.7	2.7	3.2	3.1	3.0	
SD	0.33	0.17	0.28	0.25	0.17	0.13	0.40	
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg bas	e/kg/day						
	3.0		2.8	2.7	3.1	3.2	3.0	
	0.28		0.25					
N	8	8	8	8	8	4	4	
5.5	_		_		_			



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: A/G Ratio

STUDY ID: UIC-18A

STUDY NO: 193

ABBR: A/G

UNITS: -

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-M	: 0 mg base/i	cg/day						
MEAN	1.00	1.22	1.21	1.10	1.11	1.07	1.23	
SD	0.091	0.116	0.144	0.121	0.097	0.100	0.063	
N	8	8	8	8	8	4	4	
Group: 2-M	: 0.1 mg base	e/kg/day						
MEAN	1.03	1.26	1.16	1.13	1.13	1.09	1.25	
SD	0.052	0.074	0.090	0.049	0.071	0.186	0.102	
N	8	8	8	8	8	4	4	
Group: 3-M	0.3 mg base	e/kg/day						
MEAN	1.04	1.24	1.09	1.02	1.02	0.93	1.10	
SD	0.145	0.121	0.094	0.052	0.091	0.035	0.119	
N	8	8	8	8	8	4	4	
Group: 4-M :	: 1.0 mg base	e/kg/day						
MEAN	1.00	1.25	0.95*	1.01	1.00	0.91	1.17	
SD	0.098	0.060	0.071	0.088	0.095	0.081	0.093	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

Table 6.12



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: A/G Ratio

STUDY ID: UIC-18A

SEX: FEMALE

UNITS: -

STUDY NO: 193 ABBR: A/G ----

					• • • • • • • • • • • •			
PERIOD(s)	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-	: 0 mg base/	kg/day						
MEAN	1.10	1.25	1.21	1.20	1.07	1.04	1.12	
SD	0.101	0.128	0.082	0.110	0.131	0.145	0.113	
N	8	8	8	8	8	4	4	
Group: 2-	: 0.1 mg bas	e/kg/day						
MEAN	1.11	1.24	1.24	1.21	1.08	1.04	1.06	
SD	0.077	0.159	0.123	0.086	0.056	0.062	0.119	
N	8	8	8	8	8	4	4	
Group: 3-	: 0.3 mg bas	e/kg/day						
MEAN	1.09		1.18	1.21	0.98	1.02	1.20	
SD	0.171	0.102	0.100	0.106	0.050	0.102	0.193	
N	8	8	8	8	8	4	4	
Group: 4-1	: 1.0 mg bas	e/kg/day						
MEAN	1.13	1.18	1.06*	1.15	1.03	1.00	1.14	
SD	0.097	0.130	0.129	0.128	0.116	0.152	0.068	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Total Bilirubin

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: TBILI

UNITS: mg/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-M:		The second secon						
MEAN	0.18	0.13	0.14	0.14	0.15	0.16	0.18	
SD	0.021	0.020	0.021	0.016	0.022	0.010	0.030	
N	8	8	8	8	8	4	4	
Group: 2-M :	0.1 mg bas	e/kg/day						
MEAN	0.17	0.12	0.16	0.16	0.14	0.18	0.19	
SD	0.026	0.015	0.025	0.029	0.019	0.019	0.010	
N	8	8	8	8	8	4	4	
Group: 3-M :	: 0.3 mg bas	e/kg/day						
MEAN	0.19	0.14	0.21*	0.19*	0.17	0.17	0.22	
SD	0.036	0.029	0.042	0.044	0.040	0.033	0.057	
N	8	8	8	8	8	4	4	
Group: 4-M :	: 1.0 mg bas	se/kg/day						
MEAN	0.17	0.13	0.20*	0.15	0.15	0.16	0.15	
SD	0.021	0.015	0.038	0.027	0.023	0.053	0.022	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Total Bilirubin

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: TBILI UNITS: mg/dL

 PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F	: 0 mg base/	kg/day						
MEAN	0.16	0.15	0.19	0.20	0.18	0.15	0.21	
SD	0.041	0.016	0.024	0.060	0.012	0.022	0.040	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg bas	e/kg/day						
MEAN	0.16	0.15	0.18	0.20	0.17	0.18	0.22	
SD	0.024	0.016	0.031	0.029	0.015	0.039	0.025	
N	8	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg bas	e/kg/day						
MEAN	0.14	0.13	0.20	0.17	0.16	0.15	0.18	
SD	0.029	0.016	0.045	0.045	0.043	0.047	0.060	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day						
MEAN	0.15	0.15	0.22	0.16	0.17	0.13	0.17	
SD	0.017	0.027	0.065	0.037	0.034	0.022	0.029	
N	8	8	8	8	8	4	4	



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Alkaline Phosphatase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: ALKP UNITS: IU/L

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-M :	0 mg base/	kg/day						
MEAN	138	120	123	114	92	86	82	
SD	33.5	27.7	29.4	29.1	26.2	15.6	22.6	
N	8	8	8	8	8	4	4	
Group: 2-M:	0.1 mg bas	e/kg/day						
MEAN	143	126	114	100	84	77	77	
SD	58.9	48.7	39.0	32.5	24.5	31.7	30.0	
N	8 .	8	8	8	8	4	4	
Group: 3-M:	0.3 mg bas	e/kg/day						
MEAN	108	96	90	93	78	84	89	
SD	26.6	22.4	18.7	20.3	18.1	30.3	24.0	
N	8	8	8	8	8	4	4	
Group: 4-M :	1.0 mg bas	e/kg/day						
MEAN	126	110	98	98	86	85	102	
SD	43.0	39.4	21.7	27.5	28.4	25.9	47.8	
N	8	8	8	8	8	4	4	



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Alkaline Phosphatase

STUDY ID: UIC-18A

.....

STUDY NO: 193 ABBR: ALKP SEX: FEMALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PRO	PROCEDURE
--	-----------

_								
PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F	0 mg base/	kg/day						
MEAN	120	107	108	103	93	83	77	
SD	18.3	15.6	19.9		23.6	10.4	5.3	
N	8	8	8	8	8	4	4	
Group: 2-F	0.1 mg bas	e/kg/day						
MEAN	106	98	86	77*	72	77	77	
SD	21.0	19.5	17.0	15.2	21.6	32.9	23.3	
N	8	8	8	8	8	4	4	
Group: 3-F	0.3 mg bas	e/kg/day						
MEAN	117	101	93	86	77	95	99	
SD	52.0	39.6	28.2	21.3	14.1	33.0	19.4	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day						
MEAN	93	84	90	77*	74	93	114	
SD	19.4	18.4	24.3	11.6	15.0	35.5	36.2	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

Table 6.17

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A

STUDY NO: 193 ABBR: GGT

SEX: MALE

UNITS: IU/L

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-M	: 0 mg base/	kg/day						
MEAN	3	3	3	5	6	6	6	
SD	1.6	1.7	1.7	1.3	0.7	0.6	1.7	
N	8	8	8	8	8	4	4	
Group: 2-M	: 0.1 mg bas	e/kg/day						
MEAN	3	3	3	4	6	6	5	
SD	1.7	1.5	1.1	0.8	0.7	1.0	1.2	
N	8	8	8	8	8	4	4	
Group: 3-M	: 0.3 mg bas	e/kg/day						
MEAN	3	3	4	4	6	6	6	
SD	1.9	1.6	1.6	1.2	0.9	0.5	1.4	
N	8	8	8	8	8	4	4	
Group: 4-M	: 1.0 mg bas	e/kg/day						
MEAN	3 III	4	4	3	7	5	4	
SD	1.9	3.0	1.6	1.7	1.4	1.0	2.9	
N	8	8	8	8	8	4	4	
44	0	0	0	U	0	-		



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: GGT UNITS: IU/L

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F:	0 mg base/	kg/day						
MEAN	2	3	3	4	6	3	6	
SD	1.4	1.0	1.7	1.4	1.8	2.6	4.5	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg bas	e/kg/day						
MEAN	2	3	4	4	7	5	6	
SD	1.4	1.0	0.9	1.5	1.3	1.3	0.5	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg bas	e/kg/day						
MEAN	3	3	4	4	7	6	6	
SD	1.4	1.3	1.2	1.1	1.0	0.8	4.0	
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg bas	e/kg/day						
MEAN	3	3	3	4	7	4	6	
SD	1.7	1.4	1.5	0.9	1.5	1.7	1.0	
N	8	8	8	8	8	4	4	



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Cholesterol

STUDY ID: UIC-18A

SEX: MALE

UNITS: mg/dL

STUDY NO: 193

ABBR: CHOL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Cours 1-M	0 mg baca	ka/day	•••••					
•			160	17/	15/	177	162	
SD								
N	8	8	8	8	8	4	4	
Group: 2-M:	0.1 mg bas	e/kg/day						
	193	150	158	152	147	149	141	
N	8	8	8	8	8	4	4	
Groups 3-M s	0.3 mg bas	e/kg/day						
	_		165	17/	155	156	1/0	
===								
N	8	8	8	8	8	4	4	
Group: 4-M :	1.0 mg bas	se/kg/day						
			173	171	169	195	177	
N	8	8	8	8	8	4	4	
	Group: 1-M: MEAN SD N Group: 2-M: MEAN SD N Group: 3-M: MEAN SD N Group: 4-M: MEAN SD	Group: 1-M: 0 mg base/ MEAN 215 SD 17.7 N 8 Group: 2-M: 0.1 mg bas MEAN 193 SD 34.4 N 8 Group: 3-M: 0.3 mg bas MEAN 198 SD 22.9 N 8 Group: 4-M: 1.0 mg bas MEAN 210 SD 31.3	Group: 1-M : 0 mg base/kg/day MEAN 215 160 SD 17.7 19.9 N 8 8 Group: 2-M : 0.1 mg base/kg/day MEAN 193 150 SD 34.4 21.0 N 8 8 Group: 3-M : 0.3 mg base/kg/day MEAN 198 151 SD 22.9 18.8 N 8 Group: 4-M : 1.0 mg base/kg/day MEAN 210 167 SD 31.3 25.6	Group: 1-M: 0 mg base/kg/day MEAN 215 160 169 SD 17.7 19.9 21.5 N 8 8 8 Group: 2-M: 0.1 mg base/kg/day MEAN 193 150 158 SD 34.4 21.0 29.5 N 8 8 8 Group: 3-M: 0.3 mg base/kg/day MEAN 198 151 165 SD 22.9 18.8 25.5 N 8 8 8 Group: 4-M: 1.0 mg base/kg/day MEAN 210 167 173 SD 31.3 25.6 30.0	Group: 1-M: 0 mg base/kg/day MEAN 215 160 169 174 SD 17.7 19.9 21.5 19.0 N 8 8 8 8 Group: 2-M: 0.1 mg base/kg/day MEAN 193 150 158 152 SD 34.4 21.0 29.5 30.9 N 8 8 8 8 Group: 3-M: 0.3 mg base/kg/day MEAN 198 151 165 174 SD 22.9 18.8 25.5 30.1 N 8 8 8 8 Group: 4-M: 1.0 mg base/kg/day MEAN 210 167 173 171 SD 31.3 25.6 30.0 28.1	Group: 1-M : 0 mg base/kg/day MEAN 215 160 169 174 154 SD 17.7 19.9 21.5 19.0 18.9 N 8 8 8 8 8 Group: 2-M : 0.1 mg base/kg/day MEAN 193 150 158 152 147 SD 34.4 21.0 29.5 30.9 26.3 N 8 8 8 8 8 Group: 3-M : 0.3 mg base/kg/day MEAN 198 151 165 174 155 SD 22.9 18.8 25.5 30.1 19.9 N 8 8 8 8 8 Group: 4-M : 1.0 mg base/kg/day MEAN 210 167 173 171 169 SD 31.3 25.6 30.0 28.1 31.5	Group: 1-M: 0 mg base/kg/day MEAN 215 160 169 174 154 173 SD 17.7 19.9 21.5 19.0 18.9 16.1 N 8 8 8 8 8 8 4 Group: 2-M: 0.1 mg base/kg/day MEAN 193 150 158 152 147 149 SD 34.4 21.0 29.5 30.9 26.3 28.9 N 8 8 8 8 8 4 Group: 3-M: 0.3 mg base/kg/day MEAN 198 151 165 174 155 156 SD 22.9 18.8 25.5 30.1 19.9 17.1 N 8 8 8 8 8 8 4 Group: 4-M: 1.0 mg base/kg/day MEAN 210 167 173 171 169 195 SD 31.3 25.6 30.0 28.1 31.5 64.6	Group: 1-M : 0 mg base/kg/day MEAN 215 160 169 174 154 173 162 SD 17.7 19.9 21.5 19.0 18.9 16.1 15.5 N 8 8 8 8 8 8 4 4 Group: 2-M : 0.1 mg base/kg/day MEAN 193 150 158 152 147 149 141 SD 34.4 21.0 29.5 30.9 26.3 28.9 15.2 N 8 8 8 8 8 4 4 4 Group: 3-M : 0.3 mg base/kg/day MEAN 198 151 165 174 155 156 149 SD 22.9 18.8 25.5 30.1 19.9 17.1 11.4 N 8 8 8 8 8 8 4 4 4 Group: 4-M : 1.0 mg base/kg/day MEAN 210 167 173 171 169 195 177 SD 31.3 25.6 30.0 28.1 31.5 64.6 53.9



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Cholesterol

STUDY ID: UIC-18A

Group: 4-F : 1.0 mg base/kg/day

MEAN

SD

N

186 159

24.8 19.2 8 8

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

STUDY NO: 193

SEX: FEMALE

ABBR: CHOL

UNITS: mg/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F:	0 mg base/	kg/day						
MEAN	193	168	185	171	189	188	192	
SD	25.1	31.3	34.6	30.1	35.7	40.2	79.9	
N	8	8	8	8	8	4	4	
Group: 2-F :	0.1 mg bas	e/kg/day						
MEAN	202	164	173	167	185	222	184	
SD	26.7	14.8	19.8	26.0	14.5	34.3	18.7	
N	8	8	8	8	8	4	4	
Group: 3-F :	0.3 mg bas	e/kg/day						
MEAN	198	167	177	175	183	194	141	
SD	28.9	23.6	34.4	29.4	17.6	37.6	27.7	
N	8	8	8	8	8	4	4	

162 158 27.2 43.7

8

8

185

29.8

213

51.2

177

50.7

8



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Triglycerides

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: TRIG UNITS: mg/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-M :	0 mg base/	kg/day						
MEAN	43	44	33	38	37	32	34	
SD	6.9	9.8	7.5	6.6	4.4	4.1	2.6	
N	8	8	8	8	8	4	4	
Group: 2-M:	0.1 mg bas	e/kg/day						
MEAN	36	38	36	33	34	28	29	
SD	6.4	5.4	7.1	6.2	6.1	5.0	7.5	
N	8	8	8	8	8	4	4	
Group: 3-M:	0.3 mg bas	e/kg/day						
MEAN	39	39	37	38	36	39	38	
SD	7.2	8.8	9.0	12.4		17.3	4.5	
N	8	8	8	8	8	4	4	
Group: 4-M:	1.0 mg bas	e/kg/day						
MEAN	39	38	41	50*	48*	36	30	
SD	5.6	5.9	5.3	11.7	15.4	3.7	3.6	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Triglycerides

STUDY ID: UIC-18A

SEX: FEMALE

UNITS: mg/dL

STUDY NO: 193 ABBR: TRIG LA. FEMALE

 	ANALYS	SIS OF VARIA	NCE FOLLOWE	D BY DONNE	IT'S PROCEDU	JRE		
PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-F	: 0 mg base/	kg/day						
	43		45	43	44	40	34	
SD	6.0	11.0	8.9	9.4	6.9	13.0	5.3	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg bas	e/kg/day						
MEAN	39		40	33	39	38	30	
SD	10.8	12.5	9.4	9.8	8.5	12.5	6.1	
N	8	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg bas	e/kg/day						
	39		40	41	45	47	26	
SD	7.8	6.6	8.1	7.4	8.9	11.2	8.6	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day						
	41		57	49	54	37	37	
	4.7	8.1	12.8	15.8	11.1			
N	8	8	8	8	8	4	4	



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: LDH

UNITS: IU/L

PERIO)(s): Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group	: 1-M : 0 mg base	e/kg/day						
MEAN	36	44	47	- 39	39	53	50	
SD	14.1	14.1	16.1	10.8	15.5	10.3	12.3	
N	8	8	8	8	8	4	4	
Group	: 2-M : 0.1 mg ba	ise/kg/day						
MEAN	35	44	37	36	36	45	51	
SD	12.8	23.3	8.8	16.4	18.7	9.9	18.7	
N	8	8	8	8	8	4	4	
Group	: 3-M : 0.3 mg ba	se/kg/day						
MEAN	40		42	42	32	47	57	
SD	10.1	8.9	14.3	13.9	10.9	9.1	20.6	
N	8	8	8	8	8	4	4	
Group	: 4-M : 1.0 mg ba	ise/kg/day						
MEAN	39		71*	66*	43	46	56	
SD	14.9	16.7	25.4	31.1	12.0	6.8	19.4	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

Table 6.24

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: LDH

UNITS: IU/L

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F	: 0 mg base/	kg/day					•	
MEAN	48	47	72	53	43	52	40	
SD	14.5	13.4	35.8	32.6	20.6	13.1	14.0	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg bas	e/kg/day						
MEAN	46	38	39	41	45	53	47	
SD	11.7	12.5	7.4	13.4	28.1	37.1	20.7	
N	8	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg bas	e/kg/day						
MEAN	48	49	47	37	40	51	42	
SD	28.7	30.7	18.7	9.6	16.9	36.1	12.0	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day						
MEAN	44	64	128*	50	72	75	51	
SD	17.2	46.7	57.1	18.4	31.6	40.7	10.6	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Creatine Kinase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: CK

UNITS: IU/L

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-M	: 0 mg base/	kg/day						
MEAN	225	233	269	211	155	145	149	
SD	65.8	90.7	272.5	70.1	45.0	24.2	30.5	
N	8	8	8	8	8	4	4	
Group: 2-M	: 0.1 mg bas	e/kg/day						
MEAN	199	300	178	181	282	125	199	
SD	50.5	265.3	66.8	59.9	322.5	32.3	94.6	
N	8	8	8	8	8	4	4	
Group: 3-M	: 0.3 mg bas	e/kg/day						
MEAN	231	181	187	236	149	134	253	
SD	54.0	52.4	71.0	87.1	35.4	21.6	35.6	
N	8	8	8	8	8	4	4	
Group: 4-M	: 1.0 mg bas	e/kg/day						
MEAN	224	249	260	217	169	218	232	
SD	73.2	105.3	154.0	74.2	40.0	121.4	88.1	
N	8	8	8	8	8	4	4	

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Creatine Kinase

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: CK UNITS: IU/L

 PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F	0 mg base/k	g/day						• • • • • • • • • • • • • • • • • • • •
MEAN	265	153	183	147	183	134	189	
SD	221.3	34.8	44.8	64.9	140.6	61.3	21.0	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg base	e/kg/day						
MEAN	230	163	151	163	236	119	164	
SD	152.2	49.4	66.4	77.6	189.1	37.9	61.6	
N	8	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg base	e/kg/day						
MEAN	181	178	146	146	116	148	209	
SD	64.7	80.9	67.0	41.5	25.8	66.6	102.1	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg base	e/kg/day						
MEAN	171	175	209	140	167	169	200	
SD	36.1	51.2	119.6	27.1	69.0	56.6	82.6	
N	8	8	8	8	8	4	4	

Table 6.27

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: BUN

UNITS: mg/dL

 PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	• • • • • • • • • • • • • • • • • • • •
 Group: 1-M :	0 mg base/	'kg/day				• • • • • • • • •		
MEAN	10.8		13.2	13.5	14.1	16.0	13.8	
SD	2.83	2.55	2.29	2.90	2.02	3.05	1.91	
N	8	8	8	8	8	4	4	
Group: 2-M :	0.1 mg bas	se/kg/day						
MEAN	11.7	11.5	13.0	13.3	17.2	16.0	15.6	
SD	1.55	2.91	1.62	2.86	3.39	1.75	2.57	
N	8	8	8	8	8	4	4	
Group: 3-M :	0.3 mg bas	se/kg/day						
MEAN	12.5	12.0	14.2	15.4	16.0	15.3	13.9	
SD	2.48	4.01	3.17	3.76	2.57	1.84	2.02	
N	8	8	8	8	8	4	4	
Group: 4-M :	1.0 mg bas	se/kg/day						
•	11.7		13.5	15.0	16.3	17.5	14.8	
SD	2.32		2.76	1.49				
N	8	8	8	8	8	4	4	

Table 6.28

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: BUN

UNITS: mg/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-F	0 mg base/	kg/day						
MEAN	12.9		15.4	15.9	18.3	15.2	16.9	
SD	2.30	3.89	4.06	3.50	3.78	4.25	4.26	
N	8	8	8	8	8	4	4	
Group: 2-F	0.1 mg bas	e/kg/day						
V.*	13.2		14.7	14.1	16.2	15.7	15.8	
SD	2.33	3.67	2.36	2.83	3.64	4.80	3.51	
N	8	8	8	8	8	4	4	
Group: 3-F : 0.3 mg base/kg/day								
MEAN		10.7	13.1	14.9	17.5	12.6	12.5	
SD	1.30		2.76			2.09	1.59	
N	8	8	8	8	8	4	4	
Group: 4-F	1.0 mg bas	e/kg/day						
MEAN		11.6	13.6	15.3	16.6	14.0	17.5	
SD	2.85		2.97	2.79		1.90		
N	8	8	8	8	8	4	4	



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Creatinine

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: CREAT

UNITS: mg/dL

PE	RIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Gr	oup: 1-M:	0 mg base/	kg/day						
ME,	AN	0.76	0.72	0.75	0.78	0.79	0.84	0.85	
	SD	0.066	0.029	0.054	0.055	0.043	0.044	0.075	
	N	8	8	8	8	8	4	4	
Gr	oup: 2-M:	0.1 mg bas	e/kg/day						
MEA		0.70	0.72	0.74	0.78	0.80	0.83	0.81	
	SD	0.085	0.090	0.072	0.075	0.068	0.090	0.088	
	N	8.	8	8	8	8	4	4	
Gr	oup: 3-M:	0.3 mg bas	e/kg/day						
ME	AN	0.77	0.72	0.76	0.75	0.77	0.76	0.81	
	SD	0.045	0.062	0.072	0.057	0.093	0.114	0.125	
	N	8	8	8	8	8	4	4	
Gr	oup: 4-M:	1.0 mg bas	e/kg/day						
ME		0.72		0.74	0.80	0.79	0.85	0.80	
	SD	0.090		0.060	0.085	0.067	0.085	0.133	
	N	8	8	8	8	8	4	4	



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Creatinine

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: CREAT

UNITS: mg/dL

PER	10D(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Gro	up: 1-F : 0	mg base/	kg/day						
MEA	N	0.77	0.78	0.81	0.78	0.83	0.79	0.83	
S		0.057	0.049	0.072	0.087	0.059	0.058	0.088	
1	N	8	8	8	8	8	4	4	
Gro	up: 2-F : 0).1 mg bas	e/kg/day						
MEA	-	0.82	0.80	0.80	0.80	0.87	0.81	0.87	
S		0.078	0.099	0.098	0.085	0.060	0.054	0.045	
	N	8	8	8	8	8	4	4	
Gro	up: 3-F : 0	.3 mg bas	e/kg/day						
MEA	N.	0.68	0.70	0.74	0.71	0.75	0.63*	0.73	
S		0.090	0.076	0.100	0.083	0.101	0.022	0.111	
J	N	8	8	8 ,	8	8	4	4	
Gro	up: 4-F: 1	.0 mg bas	e/kg/day						
MEA	•	0.76		0.76	0.75	0.90	0.69	0.71	
			0.073	0.069	0.085	0.070	0.096	0.059	
7	N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Sodium

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: NA

UNITS: mEq/L

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-M	: 0 mg base/	kg/day			********			
MEAN	147	145	146	146	147	147	148	
SD	1.4	1.7	1.0	0.9	. 1.2	1.0	1.7	
N	8	8	8	8	8	4	4	
Group: 2-M	: 0.1 mg bas	e/kg/day						
MEAN	146	146	144	144	146	147	147	
SD	0.8	1.4	1.6	1.8	1.3	2.1	1.3	
N	8	8	8	8	8	4	4	
Group: 3-M	: 0.3 mg bas	e/kg/day						
MEAN	147	146	146	147	146	147	147	
SD	1.7	1.3	1.3	1.4	2.2	3.6	2.2	
N	8	8	8	8	8	4	4	
Group: 4-M	: 1.0 mg bas	e/kg/day						
MEAN	146	146	145	146	146	148	148	
SD	1.9	1.6	2.0	1.8	2.5	1.5	1.4	
N	8	8	8	8	8	4	4	

Table 6.32

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Sodium

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: NA UNITS: mEq/L

PERIOD	(s): Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group:	1-F : 0 mg base,	/kg/day						
MEAN	146	147	146	145	147	145	145	
SD	0.9	2.0	1.4	1.0	1.2	0.0	0.0	
N	8	8	8	8	8	4	4	
Group:	2-F : 0.1 mg bas	se/kg/day						
MEAN	147	148	146	145	147	146	145	
SD	1.3	1.4	1.5	0.9	1.1	1.3	1.8	
N	8	8	8	8	8	4	4	
Group:	3-F : 0.3 mg bas	se/kg/day						
MEAN	146		145	145	147	146	145	
SD	1.0	0.6	1.0	0.7	2.2	1.7	1.0	
N	8	8	8	8	8	4	4	
Group:	4-F : 1.0 mg bas	se/kg/day						
MEAN	146		146	145	147	145	144	
SD	1.1	1.6	1.1	1.6		1.6	1.4	
N	8	8	8	8	8	4	4	

Table 6.33

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Potassium

STUDY ID: UIC-18A

SEX: MALE

UNITS: mEq/L

STUDY NO: 193 ABBR: K

 PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-M	: 0 mg base/	kg/day						
MEAN	4.55	4.50	4.44	4.49	4.44	4.55	4.40	
SD	0.165	0.237	0.272	0.283	0.106	0.103	0.115	
N	8	8	8	8	8	4	4	
Group: 2-M	: 0.1 mg bas	e/kg/day						
MEAN	4.50	4.54	4.28	4.43	4.43	4.36	4.34	
SD	0.262	0.452	0.169			0.345	0.147	
N	8	8	8	8	8	4	4	
Group: 3-M	: 0.3 mg bas	e/kg/day						
MEAN		4.39	4.17	4.35	4.26	4.59	4.22	
SD	0.262	0.244	0.155	0.208	0.242	0.121	0.121	
N	8	8	8	8	8	4	4	
Group: 4-M	: 1.0 mg bas	e/kg/day						
MEAN	4.51		4.33	4.48	4.46	4.74	4.40	
SD	0.208			0.147				
N	8	8	8	8	8	4	4	
**	_	_	_	_	_			



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Potassium

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193

UNITS: mEq/L

ABBR: K

PERIOD(s	:): Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1	I-F : 0 mg base/	'kg/day					
MEAN	4.36	4.35	4.60	4.42	4.50	4.50	4.28
SD	0.188	0.253	0.256	0.217	0.206	0.146	0.196
N	8	8	8	8	8	4	4
Group: 2	2-F : 0.1 mg bas	e/kg/day					
MEAN	4.55	4.24	4.56	4.39	4.52	4.50	4.43
SD	0.163	0.145	0.149	0.147	0.217	0.242	0.111
N	8	8	8	8	8	4	4
Group: 3	S-F : 0.3 mg bas	e/kg/day					
MEAN	4.42	4.32	4.40	4.31	4.25	4.42	4.11
SD	0.347	0.259	0.151	0.183	0.253	0.229	0.192
N	8	8	8	8	8	4	4
Group: 4	-F : 1.0 mg bas	e/kg/day					
MEAN	4.37	4.39	4.51	4.28	4.46	4.37	4.07
SD	0.173	0.237	0.183	0.120	0.207	0.163	0.297
N	8	8	8	8	8	4	4

Table 6.35

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Chloride

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: CL

UNITS: mEq/L

 Week 26	Week 18	Week 13	Week 8	Week 4	Week -1	Week -3	PERIOD(s):
					cg/day	0 mg base/k	Group: 1-M
114	113	113	111	112	109	114	MEAN
2.0	1.6	2.1	1.4	2.8	2.1	1.2	SD
4	4	8	8	8	8	8	N
					e/kg/day	: 0.1 mg base	Group: 2-M
116	114	113	110	111	109	114	MEAN
1.7	1.0	1.5	1.6	2.3	2.4	1.6	SD
4	4	8	8	8	8	8	N
					e/kg/day	: 0.3 mg base	Group: 3-M
116	114	114	112	111	109	114	MEAN
1.3	1.8	2.4	1.7	2.5	2.1	3.2	SD
4	4	. 8	8	8	8	8	N
					e/kg/day	: 1.0 mg base	Group: 4-M
116	115	113	111	112	106	112	MEAN
4.3	1.3	1.7	1.4	2.5	2.4	1.9	SD
4	4	8	8	8	8	8	N
1.7 4 116 1.3 4	1.0 4 114 1.8 4 115 1.3	1.5 8 114 2.4 8	1.6 8 112 1.7 8	2.3 8 111 2.5 8	109 2.4 8 e/kg/day 109 2.1 8 e/kg/day 106 2.4	114 1.6 8 : 0.3 mg base 114 3.2 8 : 1.0 mg base 112 1.9	MEAN SD N Group: 3-M MEAN SD N Group: 4-M MEAN SD



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Chloride

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: CL

UNITS: mEq/L

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-F	: 0 mg base/	kg/day						
MEAN	112	108	109	111	113	109	114	
SD	1.9	1.5	2.4	2.1	1.8	1.3	3.0	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg base	e/kg/day						
MEAN	109	109	108	109	113	110	113	
SD	2.8	2.1	2.0	2.0	1.9	1.3	1.4	
N	8.	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg base	e/kg/day						
MEAN	108*	108	109	111	114	112	114	
SD	3.1	1.6	3.9	2.3	1.9	1.9	1.2	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg base	e/kg/day						
MEAN	111	108	110	109	114	110	114	
SD	3.5	1.6	2.6	1.9	1.8	0.8	1.4	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

Table 6.37

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Calcium

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: CA

UNITS: mg/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-M:	0 mg base/	kg/day						
MEAN	10.3	10.2	10.1	10.1	10.4	10.7	9.9	
SD	0.34	0.23	0.23	0.23	0.23	0.21	0.24	
N	8	8	8	8	8	4	4	
Group: 2-M:	0.1 mg bas	e/kg/day						
MEAN	10.3	10.4	10.1	9.8	10.4	10.4	9.7	
SD	0.26	0.27	0.20	0.32	0.27	0.29	0.21	
N	8	8	8	8	8	4	4	
Group: 3-M:	0.3 mg bas	e/kg/day						
MEAN		10.2	10.1	9.9	10.1	10.3	9.5	
SD	0.32	0.26	0.31	0.36	0.41	0.71	0.52	
N	8	8	8	8	8	4	4	
Group: 4-M :	1.0 mg bas	e/kg/day						
MEAN	10.3		10.0	10.1	10.4	10.5	9.9	
SO	0.22		0.21	0.21		0.43		
N	8	8	8	8	8	4	4	

SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Calcium

STUDY NO: 193

UNITS: mg/dL

ABBR: CA

 PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F:	0 mg base/	kg/day						
MEAN	11.2	10.3	10.4	10.0	10.6	9.9	10.1	
SD	0.57	0.31	0.19	0.23	0.32	0.33	0.17	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg bas	e/kg/day						
MEAN	10.8	10.3	10.2	10.0	10.8	9.9	10.0	
SD	0.21	0.23	0.31	0.23	0.26	0.14	0.26	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg bas	e/kg/day						
MEAN	10.8		10.1	9.8	10.7	9.3*	9.8	
SD	0.24	0.31	0.24	0.42	0.33	0.25	0.17	
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg bas	e/kg/day						
MEAN	11.2	10.3	9.8*	9.8	10.6	9.5	9.9	
SD	0.57	0.37	0.16	0.27	0.17	0.15	0.14	
N	8	8	. 8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Inorganic Phosphorus

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: IP

UNITS: mg/dL

1	PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
(Group: 1-M :	0 mg base/k	g/day						
1	MEAN	5.7	5.9	6.0	5.8	5.3	4.9	4.1	
	SD	0.38	0.50	0.47	0.58	0.65	0.41	0.39	
	N	8	8	8	8	8	4	4	
(Group: 2-M :	0.1 mg base	/kg/day						
		5.7		5.9	5.3	5.2	4.9	4.2	
	SD	0.29	0.73	0.72	0.74	0.55	0.48	0.33	
	N	8	8	8	8	8	4	4	
	Group: 3-M :	0.3 mg base	/kg/day						
1	MEAN	5.3	5.6	5.3	5.1	4.6	4.8	3.5	
	SD	0.40	0.33	0.44	0.56	0.71	0.50	0.95	
	N	8	8	8	8	8	4	4	
(Group: 4-M :	1.0 mg base	e/kg/day						
	•	5.5		5.4	5.3	5.5	4.9	4.0	
	SD	0.52	0.24	0.41	0.76	0.36	0.79	0.13	
	N	8	8	8	. 8	8	4	4	



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Inorganic Phosphorus

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: IP UNITS: mg/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-F:	0 mg base/	'kg/day						
MEAN	6.0	5.3	5.6	5.0	5.7	4.2	4.1	
SD	1.04	0.49	0.88	0.78	0.78	0.69	0.51	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg bas	se/kg/day						
MEAN	5.7	4.7	5.5	4.6	5.4	4.5	3.6	
SD	0.66	0.61	0.56	0.48	0.64	0.82	0.40	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg bas	se/kg/day						
MEAN		5.1	5.1	4.9	5.5	4.1	3.8	
SD	0.67	0.42	0.45	0.44	0.52	0.56	0.78	
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg bas	e/kg/day						
•	6.2		5.1	5.1	5.7	4.1	4.3	
SD	0.41		0.39				0.42	
N	8	8	8	8	8	4	4	



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Glucose

STUDY ID: UIC-18A

STUDY NO: 193 ABBR: GLU

UNITS: mg/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-M :	0 mg base/	kg/day			• • • • • • • • • • • • • • • • • • • •			
MEAN	107	108	105	102	106	108	101	
SD	9.3	8.7	8.1	5.8	12.5	8.5	8.2	
N	8	8	8	8	8	4	4	
Group: 2-M :	: 0.1 mg bas	e/kg/day						
MEAN	107	114	111	106	115	107	99	
SD	10.0	6.7	5.8	6.4	8.0	4.1	1.3	
N	8	8	8	8	8	4	4	
Group: 3-M :	: 0.3 mg bas	e/kg/day						
MEAN	105	107	106	102	109	107	111	
SD	9.3	6.5	6.1	6.6	7.4	5.1	13.3	
N	8	8	8	8	8	4	4	
Group: 4-M :	: 1.0 mg bas	e/kg/day						
MEAN	104	102	104	101	103	111	102	
SD	7.1	7.8	10.4	10.6	6.7	16.3	9.4	
N	8	8	8	8	8	4	4	
	Group: 1-M: MEAN SD N Group: 2-M: MEAN SD N Group: 3-M: MEAN SD N Group: 4-M: MEAN	Group: 1-M : 0 mg base/ MEAN 107 SD 9.3 N 8 Group: 2-M : 0.1 mg bas MEAN 107 SD 10.0 N 8 Group: 3-M : 0.3 mg bas MEAN 105 SD 9.3 N 8 Group: 4-M : 1.0 mg bas MEAN 104 SD 7.1	Group: 1-M : 0 mg base/kg/day MEAN 107 108 SD 9.3 8.7 N 8 8 Group: 2-M : 0.1 mg base/kg/day MEAN 107 114 SD 10.0 6.7 N 8 8 Group: 3-M : 0.3 mg base/kg/day MEAN 105 107 SD 9.3 6.5 N 8 8 Group: 4-M : 1.0 mg base/kg/day MEAN 104 102 SD 7.1 7.8	Group: 1-M : 0 mg base/kg/day MEAN 107 108 105 SD 9.3 8.7 8.1 N 8 8 8 Group: 2-M : 0.1 mg base/kg/day MEAN 107 114 111 SD 10.0 6.7 5.8 N 8 8 8 Group: 3-M : 0.3 mg base/kg/day MEAN 105 107 106 SD 9.3 6.5 6.1 N 8 8 8 Group: 4-M : 1.0 mg base/kg/day MEAN 104 102 104 SD 7.1 7.8 10.4	Group: 1-M : 0 mg base/kg/day MEAN	Group: 1-M : 0 mg base/kg/day MEAN	Group: 1-M : 0 mg base/kg/day MEAN	Group: 1-M : 0 mg base/kg/day MEAN 107 108 105 102 106 108 101 SD 9.3 8.7 8.1 5.8 12.5 8.5 8.2 N 8 8 8 8 8 8 4 4 4 Group: 2-M : 0.1 mg base/kg/day MEAN 107 114 111 106 115 107 99 SD 10.0 6.7 5.8 6.4 8.0 4.1 1.3 N 8 8 8 8 8 8 4 4 4 Group: 3-M : 0.3 mg base/kg/day MEAN 105 107 106 102 109 107 111 SD 9.3 6.5 6.1 6.6 7.4 5.1 13.3 N 8 8 8 8 8 8 4 4 Group: 4-M : 1.0 mg base/kg/day MEAN 104 105 107 106 102 109 107 111 SD 9.3 6.5 6.1 6.6 7.4 5.1 13.3 N 8 8 8 8 8 8 4 4 4



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Glucose

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: GLU

UNITS: mg/dL

PERIOD	(s): Wee	ek -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group:	1-F : 0 mg	base/	kg/day						
MEAN		112	106	102	102	112	100	101	
SD		6.1	7.8	9.0	3.2	7.8	4.0	7.5	
N		8	8	8	8	8	4	4	
Group:	2-F : 0.1	mg bas	e/kg/day						
MEAN		117	106	102	100	110	99	101	
SD		13.7	10.2	7.0	6.1	9.4	4.3	3.5	
N		8	8	8	8	8	4	4	
Group:	3-F : 0.3	mg base	e/kg/day						
MEAN		113	104	101	100	106	108*	111	
SD		9.3	8.9	9.9	11.5	8.8	4.1	8.1	
N		8	8	8	8	8	4	4	
Group:	4-F : 1.0	mg base	e/kg/day						
MEAN		118	104	96	99	104	101	116*	
SD		12.8	9.9	7.7	9.0	6.2	5.3	5.3	
N		8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Haptoglobin

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: HAPT

UNITS: mg/dL

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-M	: 0 mg base/	kg/day						
MEAN	50.8	80.8	60.6	65.8	57.9	103.6	65.9	
SD	27.65	29.97	43.32	42.13	39.61	27.40	53.61	
N	7	7	7	5	4	3	3	
Group: 2-M	: 0.1 mg base	e/kg/day						
MEAN	42.0	69.7	66.1	66.1	50.1	55.5	68.7	
SD	39.18	32.24	50.55	41.42	32.43	40.83	10.61	
N	8 .	7	8	5	7	3	2	
Group: 3-M	: 0.3 mg bas	e/kg/day						
	44.1	86.1	83.1	78.5	64.6	73.6	41.5	
SD	21.17	22.34	43.10	37.88	19.09	31.29	21.62	
N	7	6	8	7	5	4	3	
Group: 4-M	: 1.0 mg bas	e/kg/day						
	40.2	70.1	183.6*	60.1	68.8	97.8	87.2	
SD	28.85	30.68	71.58	38.91	31.06	8.64	45.86	
N	8	7	8	8	8	3	3	
	Group: 1-M MEAN SD N Group: 2-M MEAN SD N Group: 3-M MEAN SD N Group: 4-M MEAN SD	Group: 1-M: 0 mg base/MEAN 50.8 SD 27.65 N 7 Group: 2-M: 0.1 mg base/MEAN 42.0 SD 39.18 N 8 Group: 3-M: 0.3 mg base/MEAN 44.1 SD 21.17 N 7 Group: 4-M: 1.0 mg base/MEAN 40.2 SD 28.85	Group: 1-M : 0 mg base/kg/day MEAN 50.8 80.8 SD 27.65 29.97 N 7 7 Group: 2-M : 0.1 mg base/kg/day MEAN 42.0 69.7 SD 39.18 32.24 N 8 7 Group: 3-M : 0.3 mg base/kg/day MEAN 44.1 86.1 SD 21.17 22.34 N 7 6 Group: 4-M : 1.0 mg base/kg/day MEAN 40.2 70.1 SD 28.85 30.68	Group: 1-M: 0 mg base/kg/day MEAN 50.8 80.8 60.6 SD 27.65 29.97 43.32 N 7 7 7 Group: 2-M: 0.1 mg base/kg/day MEAN 42.0 69.7 66.1 SD 39.18 32.24 50.55 N 8 7 8 Group: 3-M: 0.3 mg base/kg/day MEAN 44.1 86.1 83.1 SD 21.17 22.34 43.10 N 7 6 8 Group: 4-M: 1.0 mg base/kg/day MEAN 40.2 70.1 183.6* SD 28.85 30.68 71.58	Group: 1-M : 0 mg base/kg/day MEAN 50.8 80.8 60.6 65.8 SD 27.65 29.97 43.32 42.13 N 7 7 7 5 Group: 2-M : 0.1 mg base/kg/day MEAN 42.0 69.7 66.1 66.1 SD 39.18 32.24 50.55 41.42 N 8 7 8 5 Group: 3-M : 0.3 mg base/kg/day MEAN 44.1 86.1 83.1 78.5 SD 21.17 22.34 43.10 37.88 N 7 6 8 7 Group: 4-M : 1.0 mg base/kg/day MEAN 40.2 70.1 183.6* 60.1 SD 28.85 30.68 71.58 38.91	Group: 1-M : 0 mg base/kg/day MEAN 50.8 80.8 60.6 65.8 57.9 SD 27.65 29.97 43.32 42.13 39.61 N 7 7 7 5 4 Group: 2-M : 0.1 mg base/kg/day MEAN 42.0 69.7 66.1 66.1 50.1 SD 39.18 32.24 50.55 41.42 32.43 N 8 7 8 5 7 Group: 3-M : 0.3 mg base/kg/day MEAN 44.1 86.1 83.1 78.5 64.6 SD 21.17 22.34 43.10 37.88 19.09 N 7 6 8 7 5 Group: 4-M : 1.0 mg base/kg/day MEAN 40.2 70.1 183.6* 60.1 68.8 SD 28.85 30.68 71.58 38.91 31.06	Group: 1-M : 0 mg base/kg/day MEAN 50.8 80.8 60.6 65.8 57.9 103.6 SD 27.65 29.97 43.32 42.13 39.61 27.40 N 7 7 7 5 4 3 Group: 2-M : 0.1 mg base/kg/day MEAN 42.0 69.7 66.1 66.1 50.1 55.5 SD 39.18 32.24 50.55 41.42 32.43 40.83 N 8 7 8 5 7 3 Group: 3-M : 0.3 mg base/kg/day MEAN 44.1 86.1 83.1 78.5 64.6 73.6 SD 21.17 22.34 43.10 37.88 19.09 31.29 N 7 6 8 7 5 4 Group: 4-M : 1.0 mg base/kg/day MEAN 40.2 70.1 183.6* 60.1 68.8 97.8 SD 28.85 30.68 71.58 38.91 31.06 8.64	Group: 1-M: 0 mg base/kg/day MEAN 50.8 80.8 60.6 65.8 57.9 103.6 65.9 SD 27.65 29.97 43.32 42.13 39.61 27.40 53.61 N 7 7 7 5 4 3 3 Group: 2-M: 0.1 mg base/kg/day MEAN 42.0 69.7 66.1 66.1 50.1 55.5 68.7 SD 39.18 32.24 50.55 41.42 32.43 40.83 10.61 N 8 7 8 5 7 3 2 Group: 3-M: 0.3 mg base/kg/day MEAN 44.1 86.1 83.1 78.5 64.6 73.6 41.5 SD 21.17 22.34 43.10 37.88 19.09 31.29 21.62 N 7 6 8 7 5 4 3 Group: 4-M: 1.0 mg base/kg/day MEAN 40.2 70.1 183.6* 60.1 68.8 97.8 87.2 SD 28.85 30.68 71.58 38.91 31.06 8.64 45.86

^{*-}Significant Difference from Control P < .05



SUMMARY OF CLINICAL CHEMISTRY TESTS TEST: Haptoglobin

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: HAPT

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

Charles to another the control of	PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	Group: 1-F	: 0 mg base/	kg/day						
	MEAN	39.0	46.7	46.0	76.5	36.5	48.1	36.2	
	SD	3.82	37.48	38.77	48.88	8.70	28.99	6.01	
	N	2	4	3	3	4	2	2	
	Group: 2-F	: 0.1 mg bas	e/kg/day						
	MEAN	32.8	45.2	71.8	40.0	43.8	62.1	25.5	
	SD	21.71	39.75	84.64	31.04	25.09	4.17	NA	
	N	5	6	3	2	3	2	1	
	Group: 3-F	: 0.3 mg bas	e/kg/day						
	MEAN	48.8	52.6	74.3	44.7	52.8	55.7	41.3	
	SD	22.29	17.41	35.43	32.04	32.16	38.29	NA	
	N	7	6	6	5	6	3	1	
	Group: 4-F	: 1.0 mg bas	e/kg/day						
	MEAN	28.1	31.7	182.4*	57.1	63.0	105.5	18.6	
	SD	8.43	16.64	77.86	23.03	36.74	NA	NA	
	N	6	7	8	7	5	1	1	

*-Significant Difference from Control P < .05

NA-Not Applicable

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS TEST: Erythrocytes

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193 ABBR: RBC

UNITS: 10^6/mm^3

 PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-M	0 mg base/	kg/day						
MEAN	6.85	6.50	6.49	6.92	6.62	6.73	6.96	
SD	0.452	0.360	0.383	0.177	0.262	0.470	0.359	
. N	8	8	8	8	8	4	4	
Group: 2-M	: 0.1 mg bas	e/kg/day						
MEAN	6.63	6.50	6.69	6.79	6.79	6.93	7.02	
SD	0.299	0.241	0.518	0.353	0.405	0.349	0.192	
N	8	8	8	8	8	. 4	4	
Group: 3-M	0.3 mg bas	e/kg/day						
MEAN	6.72	6.33	6.42	6.30*	6.51	6.82	7.04	
SD	0.498	0.278	0.534	0.595	0.735	1.122	0.812	
N	8	8	8	8	8	4	4	
Group: 4-M	: 1.0 mg bas	e/kg/day						
MEAN	6.44	6.48	5.89	6.77	6.47	6.91	6.95	
SD	0.605	0.458	0.514	0.359	0.469	0.354	0.628	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

Table 7.2



SUMMARY OF HEMATOLOGY TESTS TEST: Erythrocytes

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: RBC

UNITS: 10^6/mm^3

ANALYSIS	OF	VARIANCE	FOLLOWED.	RY	DUNNETT'S	PROCEDURE

 PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-F:	0 mg base/	kg/day						
MEAN	6.57	6.23	6.84	6.56	6.50	6.65	6.49	
SD	0.387	0.343	0.600	0.690	0.300	0.270	0.353	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg bas	e/kg/day						
MEAN	6.87		6.67	6.51	7.01	7.12	7.22	
SD	0.255	0.485	0.445	0.543	0.646	0.414	0.313	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg bas	e/kg/day						
MEAN	6.52	6.37	6.30	6.33	6.44	6.33	6.98	
SD	0.354	0.482	0.634	0.401	0.599	0.794	0.596	
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg bas	e/kg/day						
	6.70		6.11*	6.61	6.94	6.37	6.56	
SD	0.395	0.543	0.200	0.399	0.318	0.601	0.540	
N	8	8	8	8	8	4	4	
**								

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Hemoglobin

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193 ABBR: HGB

UNITS: g/dL

 PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-M :	0 mg base/	kg/day					•••••	
MEAN	16.5	15.7	15.6	16.7	16.2	16.3	16.5	
SD	0.98	0.75	0.78	0.53	0.90	1.15	0.82	
N	8	8	8	8	8	4	4	
Group: 2-M:	0.1 mg bas	e/kg/day						
MEAN	16.0	15.7	15.9	16.4	16.6	16.6	16.9	
SD	1.03	0.73	1.32	1.25	1.19	1.10	0.68	
N	8	8	8	8	8	4	4	
Group: 3-M:	0.3 mg bas	e/kg/day						
MEAN	16.2	15.3	15.6	15.3*	15.7	15.7	16.4	
SD	1.25	0.71	1.08	1.05	1.66	2.36	1.69	
N	8	8	8	8	8	4	4	
Group: 4-M:	1.0 mg bas	e/kg/day						
MEAN	15.8	15.8	14.7	16.6	16.0	16.8	16.8	
SD	1.00	0.61	1.07	0.68	1.11	0.74	1.41	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Hemoglobin

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: HGB

UNITS: g/dL

 PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-F	: 0 mg base/	kg/day						
MEAN	16.3	15.4	16.9	16.3	16.0	16.3	16.0	
SD	1.06	0.79	1.37	1.64	0.91	0.57	1.09	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg bas	e/kg/day						
MEAN	16.7		16.2	16.1	16.9	17.0	17.3	
SD	0.73	1.04	1.08	1.34	1.57	0.76	0.62	
N	8	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg bas	e/kg/day						
MEAN	15.6	15.2	15.3*	15.4	15.4	14.7	16.4	
SD	0.64	0.80	1.21	1.01	1.40	1.58	1.27	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day						
MEAN	16.4	16.5	15.2*	15.8	16.6	15.3	15.5	
SD	0.85	1.28	0.67	1.00	1.18	1.43	1.55	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Hematocrit

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193 ABBR: HCT

UNITS: %

	PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
•••••									• • • • • • • • • • • • • • • • • • • •
	Group: 1-M:	0 mg base/	kg/day						
	MEAN	47.8	45.3	45.2	48.0	46.3	47.0	48.3	
	SD	3.10	2.27	2.64	1.84	2.29	3.41	2.97	
	N	8	8	8	8	8	4	4	
	Group: 2-M:	0.1 mg base	e/kg/day						
	MEAN	45.7		45.9	48.1	47.0	47.6	48.4	
	SD	2.89	2.37	3.99	6.43	3.60	3.25	2.06	
	N	8	8	8	. 8	8	4	4	
	Group: 3-M:	0.3 mg base	e/kg/day						
	MEAN	46.9	44.3	45.3	44.9	45.0	45.9	47.3	
	SD	3.49	2.66	3.38	3.04	4.70	6.77	4.82	
	N	8	8	8	8	8	4	4	
	Group: 4-M:	1.0 mg base	e/kg/day						
	MEAN	45.6		43.5	48.8	46.0	49.8	48.7	
	SD	3.11		3.06	1.31	3.37	2.38	3.76	
	N	8	8	8	8	8	4	4	

Table 7.6



SUMMARY OF HEMATOLOGY TESTS TEST: Hematocrit

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: HCT UNITS: %

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
 Group: 1-F :	0 mg base/	kg/day	**********	********			
MEAN	46.6	43.9	48.2	46.0	46.6	47.8	46.5
SD	3.21	2.10	3.97	4.60	2.62	1.88	2.95
N	8	8	8	8	8	4	4
Group: 2-F:	0.1 mg bas	e/kg/day					
MEAN	47.9	46.9	46.6	45.6	49.5	49.4	50.4
SD	1.36	3.31	3.08	3.72	4.48	1.78	1.39
N	8 .	8	8	8	8	4	4
Group: 3-F:	0.3 mg bas	e/kg/day					
MEAN	45.2	43.9	44.4	44.6	45.3	42.9	47.4
SD	1.78	2.48	3.35	2.82	4.49	4.48	3.41
N	8	8	8	8	8	4	4
Group: 4-F:	1.0 mg bas	e/kg/day					
MEAN	47.2		44.7	45.9	49.1	45.3	45.2
SD	2.56	3.85	1.92	3.54	3.28	4.15	4.13
N	8	8	8	8	8	4	4



THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS TEST: Mean Corpuscular Volume

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193 ABBR: MCV

UNITS: fL

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-M :	0 mg base/	kg/day						
MEAN	69.8	69.8	69.6	69.3	69.9	69.9	69.5	
SD	1.75	1.57	1.36	1.51	1.79	2.34	2.12	
N	8	8	8	8	8	4	4	
Group: 2-M:	0.1 mg bas	e/kg/day						
MEAN	69.0	68.8	68.6	70.7	69.1	68.7	69.0	
SD	2.09	2.41	2.20	6.11	2.12	1.96	1.86	
N	8	8	8	8	8	4	4	
Group: 3-M:	0.3 mg bas	e/kg/day						
MEAN	69.8	69.9	70.7	71.6	69.2	67.3	67.3	
SD	2.38	2.37	2.34	5.37	2.22	1.77	1.54	
N	8	8	8	8	8	4	4	
Group: 4-M:	1.0 mg bas	e/kg/day						
MEAN	71.0	71.2	73.9*	72.1	71.1	72.1	70.2	
SD	2.10	2.28	2.29	2.29	2.19	0.54	0.96	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Mean Corpuscular Volume

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: MCV

UNITS: fL

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-F	0 mg base/	kg/day						
MEAN	70.8	70.5	70.6	70.1	71.6	71.9	71.6	
SD	1.49	1.54	1.47	1.53	1.39	1.96	1.90	
N	8	8	8	8	8	4	4	
Group: 2-F	0.1 mg base	e/kg/day						
MEAN	69.7		70.0	70.1	70.6	69.4	69.9	
SD	1.41	1.19	1.55	1.52	1.43		2.17	
N	8	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg base	e/kg/day						
MEAN	69.3	68.9	70.6	70.4	70.3	68.0	68.0	
SD	1.26	1.31	2.04	1.89	2.36	2.34	2.21	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg base	e/kg/day						
MEAN	70.6	70.1	73.1*	69.5	70.6	71.1	69.0	
SD	1.35	1.34	1.79			1.48	1.70	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

Table 7.9



SUMMARY OF HEMATOLOGY TESTS TEST: Mean Corpuscular Hemo.

STUDY ID: UIC-18

SEX: MALE

UNITS: pg

STUDY NO: 193 ABBR: MCH

	PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26		
	Group: 1-M:	0 mg base/								
	MEAN	24.1	24.2	24.0	24.2	24.5	24.2	23.8		
	SD	0.65	0.45	0.64	0.39	0.74	0.70	0.13		
	N	8	8	8	8	8	4	4		
	Group: 2-M :	0.1 mg bas	e/kg/day							
	MEAN	24.2	24.2	23.8	24.1	24.4	24.0	24.0		
	SD	0.64	0.86	0.78	0.79	0.72	0.77	0.58		
	N	8	8	8	8	8	4	4		
	Group: 3-M :	0.3 mg bas	e/kg/day							
	MEAN	24.1	24.2	24.3	24.4	24.2	23.1*	23.4		
	SD	0.73		0.56	0.88	0.43	0.44	0.35		
	N	8	8	8	8	8	4	4		
	Group: 4-M:	1.0 mg bas	e/kg/day							
	MEAN	24.6	24.5	25.0*	24.5	24.7	24.4	24.2		
	SD	0.86		0.73	0.68	0.67	0.24	0.19		
		8	8	8	8	8	4	4		
	N	0	0	0	0	0	**	-		

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Mean Corpuscular Hemo.

STUDY ID: UIC-18

STUDY NO: 193 ABBR: MCH

UNITS: pg

PERIOD(s)	: WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-	F : 0 mg base/	kg/day						
MEAN	24.8		24.7	24.8	24.5	24.5	24.6	
SD	0.36	0.57	0.50	0.33	0.54	0.43	0.54	
N	8	8	8	8	8	4	4	
Group: 2-	F : 0.1 mg bas	e/kg/day						
MEAN	24.4		24.3	24.6	24.2	23.9	24.0	
SD	0.64	0.45	0.36	0.35	0.49	0.54	0.56	
N	8	8	8	8	8	4	4	
Group: 3-	F : 0.3 mg bas	e/kg/day						
MEAN	24.0		24.4	24.3	23.9	23.3	23.5	
SD	0.51	0.59	0.61	0.69	0.67	0.68	0.66	
N	8	8	8	8	8	4	4	
Group: 4-	F : 1.0 mg bas	e/kg/day						
MEAN	24.6		24.9	23.9*	23.9	24.0	23.6	
SD	0.81	0.57	0.74	0.86	0.93	0.70	0.87	
N	8	8	8	8	8	4	4	

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Mean Corpus. Hemo. Conc.

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193 ABBR: MCHC

UNITS: g/dL

PERIOD	(s): WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group:	1-M : 0 mg base	/kg/day			• • • • • • • • • • • • • • • • • • • •			
MEAN		34.7	34.5	34.9	35.0	34.6	34.2	
SD	0.29	0.44	0.52	0.33	0.59	0.18	0.92	
N	8	8	8	8	8	4	4	
Group:	2-M : 0.1 mg ba	se/kg/day						
MEAN	35.0		34.7	34.3	35.4	34.9	34.8	
SD	0.53	0.53	0.44	2.05	0.30	0.44	0.28	
N	8	8	8	8	8	4	4	
Group:	3-M : 0.3 mg ba	se/kg/day						
MEAN	34.5	34.6	34.5	34.2	34.9	34.2	34.8	
SD	0.41	0.72	0.70	1.35	0.78	0.25	0.49	
N	8	8	8	8	8	4	4	
Group:	4-M : 1.0 mg ba	se/kg/day						
MEAN	34.6		33.8*	34.0	34.7	33.8*	34.4	
SD	0.45	0.35	0.31	0.68	0.38	0.47	0.30	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

Table 7.12



SUMMARY OF HEMATOLOGY TESTS TEST: Mean Corpus. Hemo. Conc.

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: MCHC

UNITS: g/dL

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-F:								
MEAN	35.0	35.1	35.0	35.4	34.3	34.2	34.4	
SD	0.43	0.37	0.46	0.59	0.51	0.33	0.46	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg bas	e/kg/day						
MEAN	34.9	34.8	34.8	35.2	34.2	34.5	34.3	
SD	0.85	0.65	0.47	0.60	0.52	0.55	0.49	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg bas	e/kg/day						
MEAN	34.6		34.5*	34.6*	34.0	34.3	34.6	
SD	0.58	0.43	0.39	0.40	0.50	0.37	0.35	
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg bas	e/kg/day						
MEAN	34.8		34.0*	34.4*	33.9	33.7	34.3	
SD	0.71		0.32					
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Reticulocytes

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193
ABBR: RETICS

UNITS: % RBCs

PE	?(a)001s	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Gro	oup: 1-M : 0	mg base/	kg/day				••••••		
ME	N.	0.3	0.3	0.4	0.6	0.4	0.4	0.6	
	SD	0.13	0.13	0.21	0.42	0.15	0.22	0.40	
	N	8	8	8	8	8	4	4	
Gro	oup: 2-M : 0	.1 mg base	e/kg/day						
MEA	N	0.3	0.4	0.5	0.5	0.6	0.2	0.2	
5	D	0.24	0.18	0.25	0.35	0.38	0.13	0.13	
	N	8 .	8	8	8	8	4	4	
Gro	oup: 3-M : 0	.3 mg base	e/kg/day						
MEA	N.	0.3	0.3	0.9*	0.8	0.6	0.5	0.4	
5	D	0.25	0.23	0.38	0.32	0.19	0.31	0.28	
	N	8	8	8	8	8	4	4	
Gro	oup: 4-M : 1	.0 mg base	e/kg/day						
MEA	N.	0.3	0.5	1.3*	1.3*	0.8	0.4	0.3	
9	SD .	0.18	0.24	0.36	0.31	0.43	0.16	0.10	
	N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Reticulocytes

STUDY ID: UIC-18

STUDY NO: 193 ABBR: RETICS

SEX: FEMALE

UNITS: % RBCs

ANALYSIS OF VARIA	NCE FOLLOWED	BY DUNNETT'	S PROCEDURE
-------------------	--------------	-------------	-------------

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-F:	0 mg base/	kg/day			• • • • • • • • • • • • • • • • • • • •			
		0.4	0.4		0.4	0.3	0.2	
SD	0.13	0.28	0.16	0.20	0.30	0.10	0.10	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg bas	e/kg/day						
	0.3		0.4	0.4	0.3	0.4	0.6	
SD	0.27	0.17	0.21	0.21	0.20	0.10	0.33	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg bas	e/kg/day						
MEAN			0.6	0.7	0.5	0.4	0.4	
SD	0.18	0.22	0.18	0.34	0.19	0.45	0.13	
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg bas	e/kg/day						
	0.2		1.6*	1.1*	1.3*	0.5	0.4	
SD		0.19	0.63		0.54	0.25	0.39	
N	8	8	8	8	8	4	4	
	_							

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS TEST: Nucleated Red Cells

STUDY ID: UIC-18

STUDY NO: 193 ABBR: NRBC

UNITS: COUNT

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERI	DD(s): WE	EK -3 W	/EEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Grou	o: 1-M : 0 m	g base/kg/	'day						
MEAN		0	0	0	0	0	0	0	
SD		0.4	0.4	0.0	0.0	0.0	0.0	0.0	
N		8	8	8	8	8	4	4	
Grou	o: 2-M : 0.1	mg base/k	g/day						
MEAN		0	0	0	0	0	0	0	
SD		0.7	0.0	0.0	0.0	0.0	0.0	0.0	
N		8	8	8	8	8	4	4	
Grou	o: 3-M : 0.3	mg base/k	g/day						
MEAN		0	0	0	0	0	0	0	
SD		0.0	0.0	0.4	0.0	0.4	0.0	0.0	
N		8	8	8	8	8	4	4	
Grou	o: 4-M : 1.0	mg base/k	g/day						
MEAN		0	0	1*	0	0	0	0	
SD		0.0	0.4	0.9	0.4	0.0	0.0	0.0	
		8	7	8	8	8	4	4	
N		0	,	0	O	0		-	

WBC corrected for NRBC = or > 10 *-Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Nucleated Red Cells

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: NRBC

UNITS: COUNT

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-F	: 0 mg base/	kg/day						
MEAN	0	0	0	0	0	0	0	
SD	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg bas	e/kg/day						
MEAN	0	0	0	0	0	0	0	
SD	0.0	0.0	0.0	0.0	0.4	0.0	0.0	
N	8	8	7	8	8	4	4	
Group: 3-F	: 0.3 mg bas	e/kg/day						
MEAN	0	0	0	0	0	0	0	
SD	0.0	0.0	0.0	0.0	0.0	0.0	0.5	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day						
MEAN	0	0	7*	0	1	0	0	
SD	0.0	0.0	9.6	0.0	0.9	0.0	0.0	
N	8	8	8	8	8	4	4	

WBC corrected for NRBC = or > 10

*-Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Heinz Bodies

STUDY ID: UIC-18 STUDY NO: 193 ABBR: HEINZ BOD. SEX: MALE

UNITS: % RBCs

	ANALYSIS	S OF	VARIANCE	FOLLOWED	BY DU	NNETT'S	PROCE	OURE
PERIOD(s): WE								

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-M	: 0 mg base/	kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.00	0.00	0.00	0.04	0.00	0.00	0.00	
N	8	8	8	8	8	4	4	
Group: 2-M	: 0.1 mg bas	e/kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.00	0.00	0.00	0.00	0.00	0.05	0.05	
N	8	8	8	8	8	4	4	
Group: 3-M	: 0.3 mg bas	e/kg/day						
MEAN		0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.00	0.00	0.00	0.04	0.04	0.00	0.00	
N	8	8	8	8	8	4	4	
Group: 4-M	: 1.0 mg bas	e/kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
N	8	8	8	8	8	4	4	



SUMMARY OF HEMATOLOGY TESTS TEST: Heinz Bodies

STUDY ID: UIC-18 STUDY NO: 193 SEX: FEMALE

STUDY NO: 193
ABBR: HEINZ BOD.

UNITS: % RBCs

ANALYSIS O	F VARIANCE	FOLLOWED	BY	DUNNETT'S	PROCEDURE
------------	------------	----------	----	-----------	-----------

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-F	: 0 mg base/	kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.1	0.1	
SD	0.00	0.00	0.04	0.04	0.07	0.06	0.10	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg bas	e/kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.00	0.00	0.00	0.05	0.00	0.00	0.05	
N	8	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg bas	e/kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	D.0	0.8	
SD	0.00	0.00	0.00	0.04	0.04	0.00	1.55	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.00	0.00	0.00	0.05	0.07	0.00	0.00	
N	8	8	8	8	8	4	4	

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: % Methemoglobin

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193 ABBR: % METHGB

UNITS: % HGBs

PERIOD (s): WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group:	1-M : 0 mg base/	kg/day						
MEAN	1.4	1.3	1.4	0.9	0.5	0.6	0.7	
SD	1.12	0.98	1.03	0.41	0.17	0.17	0.12	
N	8	8	8	8	8	4	4	
Group:	2-M : 0.1 mg bas	e/kg/day		4				
MEAN	1.6	1.5	2.9	1.8	1.7	0.5	0.7	
SD	0.85		0.95	0.26	0.51	0.14	0.06	
N	8	8	8	8	8	4	4	
Group:	3-M : 0.3 mg bas	e/kg/day						
MEAN	1.3	1.2	9.5*	6.2*	6.3*	0.6	0.8	
SD	0.68	0.62	1.54	1.29	1.37	0.14	0.17	
N	8	8	8	8	8	4	4	
Group:	4-M : 1.0 mg bas	e/kg/day						
MEAN	0.9	1.1	27.5*	21.5*	20.1*	1.1	0.7	
SD	0.66	0.82	4.03	5.26	5.02	0.56	0.08	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF HEMATOLOGY TESTS TEST: % Methemoglobin

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: % METHGB

UNITS: % HGBs

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-F	: 0 mg base/	kg/day						
MEAN	1.2	0.9	0.7	0.7	0.6	0.7	0.7	
SD	1.12	0.58	0.33	0.10	0.18	0.17	0.13	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg bas	e/kg/day						
MEAN	0.7		2.5	1.9	2.6	0.7	0.6	
SD	0.51	0.81	0.57	0.37	1.21	0.10	0.10	
N	8	8	8	8	8	4	4	
	-							
Group: 3-F	: 0.3 mg base	e/kg/day						
	1.1		8.5*	6.8*	7.0*	0.6	0.7	
SD	0.73	0.70	1.79	1.71	1.73	0.00	0.10	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg base	e/kg/day						
MEAN	0.9	1.0	26.3*	21.2*	21.9*	0.8	0.8	
SD	0.73	0.39	4.68	4.27	4.07	0.10	0.10	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF HEMATOLOGY TESTS TEST: Platelets

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193 ABBR: PLT

UNITS: 10^3/mm^3

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-M :	0 mg base/	kg/day						
MEAN	277	213	217	217	200	227	215	
SD	35.8	26.9	28.4	40.4	46.5	26.2	33.4	
N	8	8	8	8	8	4	4	
Group: 2-M :	0.1 mg bas	e/kg/day						
MEAN	352*	272*	219	188	203	237	231	
SD	63.4	46.5	51.0	59.4	44.2	27.7	34.4	
N	8	8	8	8	8	4	4	
Group: 3-M :	0.3 mg bas	e/kg/day						
MEAN	255	202	95*	135*	134*	230	221	
SD	92.7	39.6	14.6	27.5	40.7	17.5	38.8	
N	8	8	8	8	8	4	4	
Group: 4-M :	1.0 mg bas	e/kg/day						
MEAN	323	249	73*	143*	160	286	210	
SD	26.1	24.2	20.2	27.4	34.4	58.0	41.2	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Platelets

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: PLT

UNITS: 10^3/mm^3

 PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-F:	0 mg base/	kg/day						
MEAN	276	261	233	234	223	227	229	
SD	43.5	57.5	16.7	44.3	45.8	30.6	48.6	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg bas	e/kg/day						
MEAN	298	260	187	227	223	282	321	
SD	28.1	27.9	53.3	32.5	53.8	18.4	48.0	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg bas	e/kg/day	1					
MEAN	260	232	114*	158*	151	276	257	
SD	60.8	64.0	62.4	59.4	61.4	85.5	84.3	
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg bas	e/kg/day						
MEAN	282	267	106*	162	226	289	253	
SD	51.9		31.0	90.8	117.8	67.7	64.9	
N	8	8	8	8	8	4	4	
	110		_	_	_			

^{*-}Significant Difference from Control P < .05

DRAFT

SUMMARY OF HEMATOLOGY TESTS TEST: Prothrombin Time

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193 ABBR: PT

UNITS: sec

PERI	00(s): WEEK -	3 WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Grou	p: 1-M : 0 mg ba	se/kg/day						
MEAN	8.	4 8.4	8.5	8.5	9.3	8.5	8.3	
SD	0.5	9 0.53	0.53	0.60	0.98	0.56	0.49	
N	1	8 8	8	8	8	4	4	
Grou	p: 2-M : 0.1 mg	base/kg/day						
MEAN	8.3	3 8.2	8.3	8.5	8.3*	8.3	8.0	
SD	0.2	4 0.26	0.29	0.19	0.21	0.10	0.13	
N	ł	8 8	8	8	8	4	4	
Grou	p: 3-M : 0.3 mg	base/kg/day						
MEAN		3 8.1	8.4	8.2	8.7	8.2	7.9	
SD	0.2	B 0.24	0.61	0.33	0.91	0.10	0.12	
N		8 8	8	8	8	4	4	
Grou	p: 4-M : 1.0 mg	base/kg/day						
MEAN	_		8.2	8.3	8.1*	8.6	8.1	
SD		6 0.39	0.73	0.38	0.34	0.55	0.54	
N		8 8		8	8	4	4	

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Prothrombin Time

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: PT

UNITS: sec

PEI	(100(s): W	EEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
					•••••			
Gro	oup: 1-F: 0 f	ng base/kg	/day					
MEA	N	8.2	8.2	8.2	8.3	8.2	8.3	8.0
	SD	0.21	0.27	0.21	0.30	0.20	0.24	0.39
	N	8	8	8	8	8	4	4
Gro	oup: 2-F : 0.	1 mg base/	kg/day					
MEA	N.	8.2	8.3	8.3	8.5	8.3	8.2	8.1
	SD	0.14	0.32	0.23	0.14	0.20	0.26	0.19
	N	8	8	8	8	8	4	4
Gro	oup: 3-F : 0.	3 mg base/	kg/day					
ME	N.	8.2	8.2	8.1	8.2	8.2	8.3	8.0
	SD	0.23	0.28	0.14	0.18	0.13	0.13	0.28
	N	8	8	8	8	8	4	4
Gre	oup: 4-F : 1.0	0 mg base/	kg/day					
MEA	AN	8.2	8.2	8.0*	8.2	8.1	8.2	7.8
	SD	0.20	0.21	0.21	0.22	0.23	0.35	0.17
•	N	8	8	8	8	8	4	4
	t.a	•	0	0	0	J	-	

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Act. Partial Thrombo. Time

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193 ABBR: APTT

UNITS: sec

The second secon								
 PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-M :	0 mg base/	kg/day						• • • • • • • • •
MEAN	10.8	10.3	9.8	10.2	9.1	9.8	9.7	
SD	0.94	0.70	0.65	0.79	0.80	0.44	0.68	
N	8	8	8	8	8	4	4	
Group: 2-M :	0.1 mg bas	e/kg/day						
MEAN	10.4	10.0	9.7	10.2	9.9	9.4	9.6	
SD	0.95	0.80	0.73	0.74	0.87	0.30	0.29	
N	8	8	8	8	8	4	4	
Group: 3-M :	0.3 mg bas	e/kg/day						
MEAN	10.4	10.3	9.6	10.2	9.5	9.5	9.7	
SD	0.26	0.49	0.77	0.49	0.93	0.80	0.41	
N	8	8	8	8	8	4	4	
Group: 4-M:	1.0 mg bas	e/kg/day						
MEAN	11.5	11.2	10.5	11.1	10.6*	10.3	11.1*	
SD	1.16	1.48	1.07	1.24	0.82	0.79	0.84	
N	8	8	8	8	8	4	4	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF HEMATOLOGY TESTS TEST: Act. Partial Thrombo. Time

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: APTT UNITS: sec

 PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-F:	0 mg base/	kg/day			******			
MEAN	10.7		9.9	10.2	9.6	9.9	10.2	
SD	0.83		0.21	0.59	0.79	0.93	0.54	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg bas	e/kg/day						
MEAN	10.5	10.0	10.0	10.0	9.8	9.5	10.0	
SD	0.43	0.72	0.63	0.51	0.49	0.53	0.31	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg bas	e/kg/day						
MEAN	10.5	9.8	9.8	9.9	9.7	10.4	10.2	
SD	0.55	0.72	0.36	0.37	0.65	0.38	0.32	
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg bas	e/kg/day						
MEAN	10.5		10.0	9.6	9.5	9.9	10.0	
SD	0.43	0.41	0.45	0.27	0.47	0.28	0.22	
N	8	8	8	8	8	4	4	

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Leukocytes

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193 ABBR: WBC

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-M :	0 mg base/	kg/day						
MEAN	7.1	9.3	8.9	8.4	8.9	7.9	7.7	
SD	1.11	2.31	1.54	2.09	2.38	1.40	1.00	
N	8	8	8	8	8	4	4	
Group: 2-M :	0.1 mg bas	e/kg/day						
MEAN	6.8	9.1	8.2	7.5	8.1	7.8	8.2	
SD	0.67	1.87	0.84		1.06	1.19	0.51	
N	8	. 8	8	8	8	4	4	
Group: 3-M :	0.3 mg bas	e/kg/day						
	7.0	9.5	10.1	8.8	8.7	6.4	6.2	
SD	1.35	2.50	3.02	2.28	1.66	1.02		
N	8	8	8	8	8	4	4	
Group: 4-M:	1.0 mg bas	e/kg/day						
MEAN	7.6	9.7	10.8	12.2	12.5	7.9	9.0	
SD	1.49	2.52	2.61	6.22	5.15	2.79	3.20	
N	8	8	8	8	8	4	4	



SUMMARY OF HEMATOLOGY TESTS TEST: Leukocytes

STUDY ID: UIC-18

. SEX: FEMALE

STUDY NO: 193 ABBR: WBC

UNITS: 10^3/mm^3

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 	0 //							
	0 mg base/							
MEAN	8.1	8.4	8.7	- 8.9	8.7	8.8	7.5	
SD		2.15	2.02	1.04	1.55	0.38	1.51	
N	8	8	8	8	8	4	4	
Group: 2-F	0.1 mg bas	e/kg/day						
MEAN	6.3	8.0	8.2	8.2	8.3	6.5*	7.8	
SD	1.14	1.52	1.63	1.52	2.76	1.06	1.44	
N	8	8	8	8	8	4	4	
Group: 3-F	0.3 mg bas	e/kg/day						
MEAN	7.7	8.9	8.8	8.4	8.4	6.9	7.1	
SD	2.40	1.51	1.60	1.02	1.15	0.40	0.45	
N	8	8	. 8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day						
MEAN	6.7	8.6	11.2	12.0*	13.8*	8.3	8.1	
SD	1.42	1.35	2.92	3.19	3.79	1.98	1.97	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF HEMATOLOGY TESTS TEST: M. Neutrophils

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193
ABBR: M. Neutrop

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

	PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
***************************************	Group: 1-M	0 mg base/	'kg/day						
		4.0		6.2	5.9	6.1	5.4	5.3	
	SD	0.87	1.72	1.29	1.84	2.35	0.76	0.41	
	N	8	8	8	8	8	4	4	
	Group: 2-M	0.1 mg bas	se/kg/day						
	MEAN	3.7		5.2	4.8	5.3	5.4	5.5	
	SD	0.46	2.10	0.68	1.04	0.89			
	N	8	8	8	8	8	4	4	
	Group: 3-M	: 0.3 mg bas	e/kg/day						
		3.5		6.7	6.1	6.0	4.4	4.1	
	SD	0.67	1.86	2.42	1.75	1.48	0.88	0.96	
	N	8	8	8	8	8	4	4	
	Group: 4-M	1.0 mg bas	se/kg/day						
	MEAN	4.0	6.3	6.6	8.6	8.9	5.2	6.0	
	SD	0.94	2.15	1.81	4.65	3.96	2.48	2.24	
	N	8	8	8	8	8	4	4	



SUMMARY OF HEMATOLOGY TESTS TEST: M. Neutrophils

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: M. Neutrop

UNITS: 10^3/mm^3

ANALYSIS C)F	VARIANCE	FOLLOWED	BY	DUNNETT'S	PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-F	0 mg base/	kg/day					•	
MEAN	5.2	4.7	5.9	6.3	5.6	5.6	4.6	
SD	2.26	2.46	1.23	1.22	1.17	0.48	1.21	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg bas	e/kg/day						
MEAN	3.7	5.0	5.0	5.5	5.1	3.9	4.8	
SD	0.97	1.69	1.54	1.47	2.09		0.77	
N	8	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg bas	e/kg/day						
	4.3		5.7	5.4	5.0	4.0	4.8	
SD	1.96	1.30	1.24	1.31	1.51	0.79	0.45	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day						
MEAN	3.8		8.0*	9.0*	9.9*	5.6	5.2	
SD	0.45	1.29	2.47	2.67	2.86		1.80	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05



SUMMARY OF HEMATOLOGY TESTS TEST: I. Neutrophils

STUDY IO: UIC-18

SEX: MALE

STUDY NO: 193 ABBR: I. Neutrop

UNITS: 10^3/mm^3

ANALYSIS OF	VARIANCE	FOLLOWED	BY	DUNNETT'S	PROCEDURE
-------------	----------	----------	----	------------------	-----------

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 Group: 1-M :	0 mg base/	kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.5	
SD	0.00	0.04	0.04	0.00	0.00	0.00	0.95	
N	8	8	8	8	8	4	4	
Group: 2-M :	0.1 mg bas	e/kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.00	0.00	0.00	0.00	0.04	0.00	0.00	
N	8	8	8	8	8	4	4	
Group: 3-M :	0.3 mg bas	e/kg/day						
MEAN	0.0	0.0	0.1	0.0	0.0	0.0	0.0	
SO	0.04	0.00	0.09	0.04	0.00	0.00	0.00	
N	8	8	8	8	8	4	4	
Group: 4-M :	1.0 mg bas	e/kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.00	0.07	0.04	0.07	0.00	0.00	0.00	
N	8	8	8	8	8	4	4	



SUMMARY OF HEMATOLOGY TESTS TEST: I. Neutrophils

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: I. Neutrop

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK 4	WEEK -3	WEEK -1	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-F	: 0 mg base/	kg/day						
MEAN	0.0	0.0	0.5	0.0	0.0	0.0	0.0	
SD	0.00	0.00	1.52	0.00	0.04	0.00	0.00	
N	8	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg bas	e/kg/day						
MEAN	0.1	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.14	0.00	0.04	0.00	0.04	0.00	0.00	
N	8	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg base	e/kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.05	0.00	0.00	0.00	0.00	0.00	0.00	
N	8	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day						
MEAN	0.1	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.11	0.04	0.00	0.07	0.00	0.00	0.00	
N	8	8	8	8	8	4	4	

DRAFT

SUMMARY OF HEMATOLOGY TESTS TEST: Lymphocytes

STUDY ID: UIC-18 STUDY NO: 193 ABBR: Lymphocyte SEX: MALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

	PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
 	Group: 1-M :	0 mg base/	kg/day						
	MEAN	2.3	2.6	2.1	2.0	2.2	2.0	1.5	
	SD	0.81	1.03	0.83	0.61			1.06	
,	N	8	8	8	8	8	4	4	
	Group: 2-M:	0.1 mg bas	e/kg/day						
	MEAN	2.3	2.1	2.2	2.2	2.2	1.8	2.0	
	SD	0.35	0.65	0.63	0.38	0.35	0.21	0.39	
	N	8	8	8	8	8	4	4	
	Group: 3-M :	0.3 mg bas	e/kg/day						
	MEAN	2.5	2.2	2.5	2.0	2.1	1.4	1.9	
	SD	0.90	0.89	0.49	0.63			0.71	
	N	8	8	8	8	8	4	4	
	Group: 4-M :	: 1.0 mg bas	e/kg/day						
	MEAN	2.9	2.7	3.0	2.5	2.5	2.1	2.4	
	SD	0.99	1.15	1.24	0.79			0.53	
	N	8	8	8	8	8	4	4	
	2.7								



SUMMARY OF HEMATOLOGY TESTS TEST: Lymphocytes

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: Lymphocyte

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PE	RIOD(s):	WEEK 4	WEEK -3	WEEK -1	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Gr	oup: 1-F : (mg base/	cg/day						
ME	AN	2.2	2.2	2.1	2.2	2.5	2.5	2.3	
	SD	1.05	0.37	1.01	0.87	0.54	0.52	0.36	
	N	8	8	8	8	8	4	4	
Gr	oup: 2-F : (0.1 mg base	e/kg/day						
		2.4		2.3	2.2	2.7	2.3	2.6	
	SD	0.75	0.58	0.62	0.50	0.69	0.50	0.76	
	N	8	8	8	8	8	4	4	
Gr	oup: 3-F : (0.3 mg base	e/kg/day						
	•	2.6		3.0	2.5	2.7	2.5	2.1	
	SD	0.50		0.83					
	N	8	8	8	8	8	4	4	
Gr	oup: 4-F : '	1.0 mg base	e/kg/day						
ME	AN	2.4	2.2	2.4	2.3	3.0	2.2	2.5	
	SD	0.79	1.01	0.91	0.86	1.34	0.29	0.38	
	N	8	8	8	8	8	4	4	

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Monocytes

STUDY ID: UIC-18

SEX: MALE

STUDY NO: 193
ABBR: Monocytes

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-M:	0 mg base/k	kg/day					•	
MEAN	0.5	0.5	0.5.	0.2	0.3	0.3	0.3	
SD	0.19	0.30	0.21	0.13	0.16	0.22	0.06	
N	8	8	8	8	8	4	4	
Group: 2-M :	0.1 mg base	e/kg/day						
MEAN	0.4	0.4	0.5	0.3	0.3	0.2	0.4	
SD	0.16	0.30	0.27	0.20	0.19	0.13	0.16	
N	8	8	8	8	8	4	4	
Group: 3-M:	0.3 mg base	e/kg/day						
MEAN	0.4	0.4	0.5	0.2	0.4	0.3	0.1	
SD	0.24	0.18	0.35	0.12	0.22	0.15	0.08	
N	8	8	8	8	8	4	4	
Group: 4-M:	1.0 mg base	e/kg/day						
MEAN	0.4	0.4	1.0*	0.5	0.6*	0.3	0.2	
SD	0.11	0.14	0.42	0.42	0.28	0.08	0.22	
N	8	8	8	8	8	4	4	

^{*-}Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Monocytes

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: Monocytes

UNITS: 10^3/mm^3

ANALYSIS	OF	VARIANCE	FOLLOWED	BY	DUNNETT'S	PROCEDURE	

PERIOD(s):	WEEK 4	WEEK -3	WEEK -1	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-F:	0 mg base/	kg/day						
MEAN	0.3	0.6	0.8	0.2	0.3	0.3	0.2	
SO	0.14	0.31	0.68	0.12	0.14	0.17	0.10	
N	8	8	8	8	8	4	4	
Group: 2-F:	0.1 mg bas	e/kg/day						
MEAN	0.3	0.4	0.5	0.3	0.3	0.1	0.2	
SD	0.08	0.15	0.23	0.18	0.15	0.05	0.06	
N	8	8	8	8	8	4	4	
Group: 3-F:	0.3 mg bas	e/kg/day						
MEAN	0.3	0.7	0.4	0.3	0.3	0.1	0.1	
SD	0.18	0.18	0.24	0.18	0.15	0.15	0.10	
N	8	8	8	8	8	4	4	
Group: 4-F:	1.0 mg bas	e/kg/day						
MEAN	0.6	0.5	0.5	0.4	0.6	0.3	0.2	
SD	0.37	0.14	0.31	0.24	0.50	0.13	0.08	
N	8	8	8	8	8	4	4	

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS TEST: Eosinophils

STUDY ID: UIC-18

UNITS: 10^3/mm^3

STUDY NO: 193 ABBR: Eosinophil

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-M :	0 mg base/	kg/day						
MEAN	0.3	0.2	0.2	0.2	0.3	0.2	0.2	
SD	0.19	0.18	0.23	0.21	0.16	0.13	0.23	
N	8	8	8	8	8	4	4	
Group: 2-M:	0.1 mg bas	e/kg/day						
MEAN	0.4	0.2	0.3	0.3	0.2	0.5	0.3	
SD	0.32	0.16	0.20	0.18	0.15	0.13	0.22	
N	8	8	8	8	8	4	4	
	_	•	Ü		•			
Group: 3-M:	0.3 mg bas	e/kg/day						
MEAN	0.5	0.3	0.3	0.5	0.3	0.3	0.2	
SD	0.24	0.17	0.28	0.52	0.21	0.22	0.05	
N	8	8	8	8	8	4	4	
Group: 4-M:	1.0 mg bas	e/kg/day						
MEAN	0.4	0.3	0.2	0.6	0.4	0.4	0.4	
SD	0.21	0.17	0.11	0.75	0.46	0.42	0.25	
N	8	8	8	8	8	4	4	
14	_	_			0	*	•	



SUMMARY OF HEMATOLOGY TESTS TEST: Eosinophils

STUDY ID: UIC-18

SEX: FEMALE

STUDY NO: 193 ABBR: Eosinophil

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK 4	WEEK -3	WEEK -1	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-F : 0	mg base/	cg/day						
	0.3		0.3	0.2	D.3	0.5	0.4	
SD	0.34	0.15	0.23	0.16	0.18	0.29	0.28	
N	8	8	8	8	8	4	4	
Group: 2-F: 0	.1 mg base	e/kg/day						
MEAN	0.4	0.2	0.2	0.2	0.2	0.3	0.3	
SD	0.36	0.10	0.20		0.14	0.22	0.29	
N	8	8	8	8	8	4	. 4	
Group: 3-F: 0	.3 mg base	e/kg/day						
MEAN	0.2	0.3	0.2	0.3	0.3	0.3	0.2	
SD	0.14	0.17	0.15	0.19	0.22	0.17	0.15	
N	8	8	8	8	8	4	4	
Group: 4-F: 1	.0 mg base	e/kg/day						
MEAN	0.2	0.2	0.2	0.3	0.3	0.3	0.2	
SD	D.20	0.12	0.18	.0.18	0.15	0.14	0.06	
N	8	8	8	8	8	4	4	

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF HEMATOLOGY TESTS TEST: Basophils

STUDY ID: UIC-18 STUDY NO: 193 SEX: MALE

UNITS: 10^3/mm^3

ABBR: Basophils

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group: 1-M:	0 mg base/	kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
N	8	8	8	8	8	4	4	
Group: 2-M:	0.1 mg bas	e/kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	8	8	8	8	8	4	4	
N	0	0	0	0	0	•	4	
Group: 3-M:	0.3 mg bas	e/kg/day						
MEAN	0.1	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.18	0.00	0.00	0.00	0.00	0.00	0.00	
N	8	8	8	8	8	4	4	
N	Ü	Ü	J		J	7	-	
Group: 4-M:	1.0 mg bas	e/kg/day						
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
N	8	8	8	8	8	4	4	

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS TEST: Basophils

STUDY ID: UIC-18

STUDY NO: 193 ABBR: Basophils SEX: FEMALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIODO	(s): WEEK	4 WEEK -3	WEEK -1	WEEK 8	WEEK 13	WEEK 18	WEEK 26	
Group:	1-F : 0 mg ba	se/kg/day						
MEAN	0.	0.0	0.0	0.0	0.0	0.0	0.0	
SD		0.00	0.00	0.00	0.00	0.00	0.00	
N		8 8	8	8	8	4	4	
Group:	2-F : 0.1 mg	base/kg/day						
MEAN	0.	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.0	0.00	0.00	0.00	0.00	0.00	0.00	
N		8 8	8	8	8	4	4	
Group:	3-F : 0.3 mg	base/kg/day						
MEAN	0.		0.0	0.0	0.0	0.0	0.0	
SD	0.0	0.00	0.00	0.00	0.00	0.00	0.00	
N		8 8	8	8	8	4	4	
Group:	4-F : 1.0 mg	base/kg/day						
MEAN	0.	0.0	0.0	0.0	0.0	0.0	0.0	
SD	0.0	0.00	0.00	0.00	0.00	0.00	0.00	
N		8 8	8	8	8	4	4	



SUMMARY OF URINALYSIS TESTS TEST: pH

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: PH

UNITS: -

ANALYSIS	OF	VARIANCE	FOLLOWED	BY	DUNNETT'S	PROCEDURE
----------	----	----------	----------	----	-----------	-----------

 				• • • • • • • • • • •			
PERIOD(s):	Week -3	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-M:	0 mg base/	kg/day		****			
MEAN	7.5	6.8	6.4	6.4	5.8	5.0	
SD	1.07	1.16	0.52	1.30	0.96	0.00	
N	8	8	8	8	4	4	
Group: 2-M:	0.1 mg bas	e/kg/day					
MEAN	7.5	6.4	6.4	6.1	5.8	6.0	
SD	1.07	0.52	0.52	0.83	0.50	2.00	
N	8	8	8	8	4	4	
Group: 3-M :	0.3 mg bas	e/kg/day					
MEAN	7.3		6.4	6.1	5.8	5.5	
SD		0.83		0.99		0.58	
N	8	8	8	8	4	4	
Group: 4-M :	1.0 mg bas	e/kg/day					
MEAN	7.0	7.6	6.6	6.0	5.0	6.0	
SD	0.93	1.51		0.53		0.82	
N	8	8	8	8	4	4	
14	U	0	0	O	-	-	



SUMMARY OF URINALYSIS TESTS TEST: pH

STUDY ID: UIC-18A

STUDY NO: 193 ABBR: PH SEX: FEMALE

UNITS: -

 PERIOD(s):	Week -3	Week 4	Week 8	Week 13	Week 18	Week 26	
 Coorne 1-E	: 0 mg base/	ka/day					
						62.52	
MEAN	6.6	6.4	6.6	6.1	6.3	5.5	
SD	0.92	0.52	1.19	0.64	0.50	0.58	
N	8	8	8	8	4	4	
Group: 2-F	: 0.1 mg bas	e/kg/day					
MEAN	6.5	6.8	6.6	6.3	6.0	6.3	
SD		1.04		1.04			
N	8	8	8	8	4	4	
Group: 3-F	: 0.3 mg bas	e/kg/day					
MEAN	6.5	6.4	6.0	5.9	5.5	5.0	
SD	0.76	0.52	0.76	0.64	0.58	0.00	
N	8	8	8	8	4	4	
Group: 4-F	: 1.0 mg bas	e/kg/day					
MEAN	6.8		6.6	5.9	6.0	6.3	
SD	0.71	0.46	0.52	0.64	0.82	1.89	
N	8	8	8	8	4	4	

Table 8.2

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS



SUMMARY OF URINALYSIS TESTS TEST: Specific Gravity

STUDY ID: UIC-18A

STUDY NO: 193

ABBR: SG

SEX: MALE

UNITS: g/mL

PERIOD(s):	Week -3	Week 4	Week 8	Week 13	Week 18	Week 26	
Group: 1-M :	0 mg base/k	g/day					
MEAN	1.047	1.048	1.058	1.054	1.076	1.057	
SD	0.0283	0.0211	0.0275	0.0264	0.0502	0.0378	
N	8	8	8	8	4	4	
Group: 2-M :	0.1 mg base	/kg/day					
MEAN	1.055	1.058	1.072	1.050	1.056	1.069	
SD	0.0295	0.0279	0.0381	0.0283	0.0325	0.0104	
N	8	8	8	8	4	4	
Group: 3-M:	0.3 mg base	/kg/day					
MEAN	1.056	1.044	1.074	1.073	1.053	1.050	
SD	0.0258	0.0226	0.0243	0.0253	0.0319	0.0174	
N	8	8	8	8	4	4	
Group: 4-M:	1.0 mg base	/kg/day					
MEAN	1.061	1.046	1.069	1.069	1.058	1.042	
SD	0.0446	0.0300	0.0305	0.0451	0.0161	0.0171	
N	8	8	8	8	4	4	

RAFT

SUMMARY OF URINALYSIS TESTS TEST: Specific Gravity

STUDY ID: UIC-18A

STUDY NO: 193

ABBR: SG

SEX: FEMALE

UNITS: g/mL

AUAL YSTS	OF	VARIANCE	FOLL OUFD	RY	DUNNETT'S	PROCEDURE
WWWT1919	Ur	AWKTWICE	POLLOWED	D i	DOWNETT 3	PRUCEDUKE

PERIOD(s):	Week -3	Week 4	Week 8	Week 13	Week 18	Week 26	
 Group: 1-F:	0 mg base/k	g/day					
MEAN	1.045	1.060	1.075	1.060	1.050	1.058	
SD	0.0283	0.0252	0.0179	0.0225	0.0120	0.0170	
N	8	8	8	8	4	4	
Group: 2-F:	0.1 mg base	e/kg/day					
MEAN	1.055	1.054	1.075	1.069	1.053	1.051	
SD	0.0195	0.0207	0.0402	0.0277	0.0145	0.0178	
N	8	8	8	8	4	4	
Group: 3-F:	0.3 mg base	/kg/day					
MEAN	1.057		1.072	1.079	1.059	1.088	
SD	0.0134	0.0167	0.0142	0.0261	0.0182	0.0660	
N	8	8	8	8	4	4	
Group: 4-F:	1.0 mg base	/kg/day					
MEAN	1.050	1.072	1.064	1.084	1.043	1.082	
SD	0.0109	0.0157	0.0256	0.0370	0.0197	0.0635	
N	8	8	8	8	4	4	



DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

ORGAN WEIGHT SUMMARY (% BRAIN WEIGHT) STUDY: 193 TREATMENT PERIOD

STUDY: 193 SEX: MALE

ALL FATES DAYS: 92-93 ALL BALANCES ANALYSIS OF VARIANCE USING DUNNETT'S PROCEDURE

ANALISIS OF VAK	IANCE USING I	DUNNETT'S PI	ROCEDURE		
GROUP:	(1) 1-M	(2) 2-M	~ (3) 3-M	(4) 4-M	
Adrenal Glands (% BRAIN WEIG	HT)			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	_
MEAN		1.73	1.74	1.54	
SD		0.277			
N		4	4	4	
Heart (% BRAIN WEIGHT)					
MEAN	125.23	113.55	113.71	108.58	
SD	15.934	11.660	6.450	2.658	
N	4	4	4	4	
Kidneys (% BRAIN WEIGHT)					
MEAN		69.22	58.04	61.20	
SD		9.965	6.300		
N	4	4	4	4	
Liver (% BRAIN WEIGHT)					
MEAN		387.69			
SD			60.111		
N	4	4	4	4	
Spleen (% BRAIN WEIGHT)					
MEAN		40.62			
SD SD		4.397			
N	4	4	4	4	
Testes (% BRAIN WEIGHT)					
MEAN		18.67			
SD		2.541	2.234	2.384	
N	4	4	4	4	
Thyroid + Parathyroids (% BR	AIN WEIGHT)				
MEAN		1.46			
SD		0.242		0.199	
N	4	4	4	4	

⁽¹⁾⁻⁰ mg base/kg/day (2)-0.1 mg base/kg/day

^{(3)-0.3} mg base/kg/day (4)-1.0 mg base/kg/day

Table 9.1 (contd.)

OF WR245

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR212517 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

	ORGAN WEIGHT ST	UMMARY	(% BRA	IN WEIG	HT)	
STUDY: 193 SEX: FEMALE	TREATMENT P ALL FATES D. ANALYSIS OF VARIA	AYS: 92-93	ALL BAL DUNNETT'S PR	ANCES OCEDURE		
	GROUP:	(5) 1-F	(6) 2-F	(7) 3-F	(8) 4-F	
	SD	1.98	2.30 0.416 4	0.456	0.469	
			113.53 11.964 4		18.261	
	Kidneys (% BRAIN WEIGHT) MEAN SD N	52.08 3.736 4	58.01 6.424 4	55.94 6.266 4	55.00 6.453 4	
	Liver (% BRAIN WEIGHT) MEAN SD N	47.774	367.84 46.803 4	72.917	58.715	
	Ovaries (% BRAIN WEIGHT) MEAN SD N	1.50 0.544 4	2.23 1.470 4	0.835	1.39 0.363 4	
	Spleen (% BRAIN WEIGHT) MEAN SD N	41.11 11.833 4	52.77 9.496 4	59.57 14.809 4	67.34 33.161 4	

Thyroid + Parathyroids (% BRAIN WEIGHT)

MEAN

SD

N

1.28

0.150

4

(5)-0 mg base/kg/day (6)-0.1 mg base/kg/day (7)-0.3 mg base/kg/day (8)-1.0 mg base/kg/day

1.23

0.160

1.34

1.12

0.198



ORGAN WEIGHT SUMMARY (% BRAIN WEIGHT) RECOVERY PERIOD STUDY: 193 SEX: MALE ALL FATES DAYS: 183-184 ALL BALANCES ANALYSIS OF VARIANCE USING DUNNETT'S PROCEDURE - (3) (4) (1) (2) 3-M 4-M GROUP: Adrenal Glands(% BRAIN WEIGHT) MEAN 1.94 1.94 1.60 1.81 0.729 0.421 0.275 SD 0.160 Heart(% BRAIN WEIGHT) MEAN 116.15 123.15 116.30 116.94 SD 20.316 4.935 12.542 9.465 N Kidneys(% BRAIN WEIGHT) MEAN 69.07 68.71 64.73 65.96 SD 13.991 5.968 7.183 8.422 Liver(% BRAIN WEIGHT) MEAN 311.12 324.41 347.09 377.92**

21.994

43.83

11.209

20.76

4.239

1.47

0.569

22.995

46.30

4.684

16.38

4.112

1.39

0.270

20.580

50.20

30.482

18.19

0.985

1.25

0.253

24.554

49.12

5.816

17.38

5.269

1.41

0.082

4

SD

MEAN

MEAN

MEAN

SD

N

Thyroid + Parathyroids(% BRAIN WEIGHT)

SD

N

Spleen(% BRAIN WEIGHT)

Testes(% BRAIN WEIGHT)

N

(4)-1.0 mg base/kg/day

** - Significant difference P<.01

⁽¹⁾⁻⁰ mg base/kg/day

^{(2)-0.1} mg base/kg/day

^{(3)-0.3} mg base/kg/day

Table 9.2 (contd.)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WRZ42511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

ORGAN WEIGHT SUMMARY (% BRAIN WEIGHT)

STUDY: 193 SEX: FEMALE

RECOVERY PERIOD

ALL FATES DAYS: 183-184 ALL BALANCES ANALYSIS OF VARIANCE USING DUNNETT'S PROCEDURE

ANALTSIS UP VAKIA	INCE OSING I	DONNETT'S PR	KOCEDUKE		
GROUP:	(5) 1-F	(6) 2-F	- (7) 3-F	(8) 4-F	
Adrenal Glands(% BRAIN WEIGHT))				
MEAN		2.05	2.14	2.08	
SD	0.056		0.746	0.489	
N	4	4	4	4	
Heart(% BRAIN WEIGHT)			7		
MEAN	102.20	115.65	106.76	105.27	
SD	5.438	16.590	14.573	12.325	
N	4	4	4	4	
Kidneys(% BRAIN WEIGHT)					
MEAN	49.81	48.33	59.51	54.01	
SD	6.964	5.348	_	4.958	
N	4	4	4	4	
Liver(% BRAIN WEIGHT)					
MEAN	312.86			378.92	
SD	51.415	50.676	29.472	61.883	
N	4	4	4	4	
Ovaries(% BRAIN WEIGHT)					
MEAN	1.91	1.44	1.61	2.19	
SD	0.666	0.300	0.173	0.589	
N	4	4	4	4	
Spleen(% BRAIN WEIGHT)					
MEAN	44.97	43.35	40.56	45.67	
SD	3.771	12.380	5.530	14.047	
N	4	4	4	4	
Thyroid + Parathyroids(% BRAII	WEIGHT)				
MEAN	1.28	1.19	1.08	1.09	
SD	0.187	0.147	0.240	0.169	
N	4	4	4	4	

(5)-0 mg base/kg/day (6)-0.1 mg base/kg/day (7)-0.3 mg base/kg/day (8)-1.0 mg base/kg/day

Contract No.: DAMD17-92-C-2001

Task Order No.: UIC-18A UIC/TRL Study No.: 193

DRAFT

Table 10

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

Summary of Microscopic Lesions

		Week 14				Week 27					
			Dose (mg base/kg/day)								
ORGAN - lesion	Sex	0	0.1	0.3	1.0	0	0.1	0.3	1.0		
LUNG											
- Accumulation,	М	0/4 (0.00)*	0/4 (0.00)	1/4 (0.38)	4/4 (2.25)	0/4 (0.00)	0/4 (0.00)	1/4 (0.06)	1/4 (0.13)		
alveolar macrophage	F	2/4 (0.19)	2/4 (0.13)	2/4 (0.75)	4/4 (2.25)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)		
- Inflammation	М	0/4 (0.00)	0/4 (0.00)	1/4 (0.38)	4/4 (0.50)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	1/4 (0.13)		
chronic, perivascular	F	1/4 (0.06)	2/4 (0.25)	2/4 (0.50)	4/4 (0.75)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)		
- Inflammation	М	0/4 (0.00)	0/4 (0.00)	1/4 (0.13)	3/4 (0.63)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	2/4 (0.19)		
chronic, interstitium	F	1/4 (0.13)	0/4 (0.00)	1/4 (0.38)	4/4 (1.50)	0/4 (0.00)	0/4 (0.00)	1/4 (0.13)	2/4 (0.44)		
- Basophilic granular	М	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	1/4 (0.63)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)		
material	F	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	3/4 (0.94)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)		
- Inflammation	М	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)		
chronic, peribronchial	F	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	1/4 (0.06)		
LYMPH NODE, BRONCHIAL											
- Accumulation.	М	-	-		2/2 (3.00)	-	-	-			
macrophage	F	-	-	1/1 (2.00)	3/3 (3.00)			-			
BONE MARROW (RIB)											
- Hyperplasia	M	0/4 (0.00)	1/4 (0.25)	4/4 (1.75)	4/4 (2.75)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)		
SPLEEN	F	0/4 (0.00)	0/4 (0.00)	2/4 (0.50)	4/4 (1.50)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)		
- Erythropoiesis	М	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)		
	F	0/4 (0.00)	0/4 (0.00)	2/4 (0.50)	2/4 (0.75)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)		

^{*} Incidence (mean group severity score)

⁻ None examined

Figure 1

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

Summary of Male Body Weights





Figure 2

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

Summary of Female Body Weights



Mean Body Weights (kg)

APPENDIX A

Analytical Chemistry Report

UIC/TRL STUDY NUMBER 193

Identity, Purity and Stability Study of WR242511

Analysts:

Adam Negrusz

A. Karl Larsen, Jr.

Study Site:

Drug Disposition Research Laboratory

College of Pharmacy

University of Illinois at Chicago

Chicago, Illinois 60612

Sponsor:

Toxicology Research Laboratory

University of Illinois at Chicago

Chicago, Illinois 60612

Report Prepared by:

Dr. Adam Negrusz

A. Nepu.

Report Prepared:

March 12, 1996

Approved:

March 12, 1996

Dr. Eugene F. Woods, Ph.D. Soval
Laboratory Director



Part I: Identity, Purity and Stability Study of WR242511

Objective

The objective of this study was to confirm the identity, establish the purity and stability of WR242511.

Identification

GC-MS System

Gas Chromatograph:

Hewlett-Packard Series II

Mass Selective Detector:

Hewlett-Packard Model 5970

Analytical Column:

30 m x 0.25 mm ID, DB-5 with a 3 micron film thickness.

GC Parameters:

Injector temp. 250°C, oven temp. 70°C initial, 280°C final, 15°C/minute ramp, carrier gas - helium, flow rate 2

ml/minute, split ratio 10:1

Procedure

Subject sample (WR242511 tartrate) was submitted by the Toxicology Research Laboratory. The sample was dissolved in methanol to a concentration of 0.71 μ g base/ml and a 2 μ l aliquot was injected on the column. The MSD scanned from 40 amu to 400 amu at a rate of 1 scan per second.

Results - GC-MS

The mass spectrum indicates a molecular ion m/e 373 which is in agreement with the WR242511 free base molecular weight. Major fragments of WR242511 sample are m/e 84, 175, 203, 288.

Figure 1 shows the mass spectrum of the WR242511 sample.

Purity

Experimental

The subject sample (WR242511 tartrate) was supplied by the Toxicology Research Laboratory and stored at -20°C when it was not analyzed.

Description

A fine yellow powder, no obvious odor.

Spectrum

An ultraviolet spectrum (Figure 2) recorded on a Shimadzu Spectronic 200 UV spectrometer (dual beam) was obtained from a 14.2 μ g base/ml solution of WR242511 prepared in mobile phase. The sample was found with maximal absorptivity observed at 212 nm and 264 nm.

HPLC System

Solvent Delivery System:

Waters 510 Pump

Injector:

Rheodyne 7125 with 50 μ l sample loop

Analytical Column:

Spherisorb CN 5 μ , 250 mm x 4.6 mm (Alltech)

Detector:

Perkin-Elmer LC-55B UV Detector, 225 nm, 264 nm

Integrator:

Spectra-Physics SP4270 Integrator

Mobile Phase:

20% methanol, 50% acetonitrile, 30% 0.01 M ammonium formate (in water), pH 3.0 (adjusted with 88% formic

acid), flow 1.5 ml/minute

Procedure

Six solutions of WR242511 were prepared as follows. Twenty five mg of a WR242511 tartrate sample was weighed into a 25 ml volumetric flask. The sample was dissolved in and the volume brought to mark with mobile phase. A 25 μ l aliquot of each solution was immediately chromatographed at 225 nm and next at 264 nm.

Calculation of Results

Quantitations were based on the assumption of equal detector response per unit weight of all UV-absorbing components. Areas of WR242511 and other detectable components in the subject sample chromatograms were employed in the following equation to calculate the percentage of WR242511 present in the sample:

%PURITY = (area of WR242511/total area) x 100

Results



Typical chromatograms are shown in Figure 3. The subject samples were found to contain less than 1% of one UV-absorbing impurity (225 nm). At 264 nm, no visible impurities were observed. Percent purity of initial WR242511 sample was found to be 99.32%, standard deviation - 0.03%; terminal purity was $99.20\% \pm 0.10\%$. The assay results are presented in Tables 1 and 2.

DRAFT

FIGURE 1 MASS SPECTRUM OF WR242511 SAMPLE




FIGURE 2
ULTRAVIOLET SPECTRUM OF WR242511





FIGURE 3

CHROMATOGRAMS OF WR242511 SAMPLE, CONC. 0.71 MG BASE/ML, 225 NM, A - INITIAL SAMPLE, B - TERMINAL SAMPLE



A

B

Table 1
Purity Data for WR242511
Initial Sample

Solutions

Peak Identity	1	2	3	4	5	6
A	1740	1918	1908	1776	1724	1795
В	2105	1899	2317	1987	1726	1981
WR242511	563320	583535	596616	567607	560299	562946
% Purity	99.32	99.32	99.30	99.31	99.39	99.29

Mean \pm S.D. - 99.32 \pm 0.03

Table 2

Purity Data for WR242511

Terminal Sample

Solutions

Peak Identity	1	2	3	4	5	6
A	5892	5472	5547	5704	6207	5438
В	22291	21109	21573	22443	21327	18050
WR242511	3649259	3535752	3474495	3565767	3620320	3492032
% Purity	99.063	99.114	99.226	99.215	99.245	99.332

Mean \pm S.D. - 99.20 \pm 0.10

APPENDIX B CLINICAL PATHOLOGY METHODOLOGY

CLINICAL CHEMISTRY

DRAFT

Alanine Aminotransferase (ALT/GPT)

Modified Wroblewski & La Due procedure Ciba-Corning 550 Express Clinical Chemistry System Henry, R.J., Chiamori, N., Golub, O.J. and Berkman, S. Am. J. Clin. Path., <u>34</u>, 381, 1960.

Aspartate Aminotransferase

Modified Karmen procedure Ciba-Corning 550 Clinical Chemistry Stystem Bergmeyer, H.V., Scheibe, P., and Wahlefeld, A.W. Clin. Chem., <u>24</u>, 68, 1978.

Total Protein

Biuret technique Ciba-Corning 550 Express Clinical Chemistry System Kingsley, G.R. J. Biol. Chem. <u>131</u>, 197, 1939.

Albumin

Bromocresol green method Ciba-Corning 550 Express Clinical Chemistry System Doumas, B.T. and Biggs, H.G. Standard Methods of Clinical Chemistry, 7, 175, 1972.

Total Bilirubin

Modified Walters and Gerard method Ciba-Corning 550 Express Clinical Chemistry System Ertinghausen, G., Fabiny-Byrd, D.L., Tiffany, T.O., and Carey, S.J. Clin. Chem. 19, 1366, 1973.

Alkaline Phosphatase

Modified Bessey-Lowry procedure Ciba-Corning 550 Express Clinical Chemistry System Neumann, H. and Von Vreedendaal M. Clin. Chem. Acta., <u>17</u>, 183, 1967.

Gamma Glutamyl Transferase (GGT)

JFCC Methods for Gamma Glutamyl Transferase Shaw, L.M., Stromme, J.H., London, J.L., Theodorsen, L. J. Clin. Chem. Clin. Biochem. 21, 633-646, 1983.

Cholesterol

Cholesterol esterase-oxidase method Ciba-Corning 550 Express Clinical Chemistry System Rosechlow, P., et. al Z.F. Klin. Chem. V. Klin. Biochem. 12, 226, 1974.

Triglycerides

Tetrazolium salt reduction method Ciba-Corning 550 Express Clinical Chemistry System Klotzsch, S., et. al. Advances Automated Analysis, Vol. 1, Mediad Inc., Tarrytown, N.Y., p. 111, 1973.

CLINICAL CHEMISTRY (Contd.)

DRAFT

Lactate Dehydrogenase

 $L \rightarrow P$ technique

Ciba-Corning 550 Express Clinical Chemistry System Wacker, W.E.C., Ulmer, D.D., Valle, B.L. New England J Med. 225, 449, 1956.

Creatine Kinase (CK)

Modification of Szasz et al. procedure Ciba-Corning 550 Express Clinical Chemistry System Clin. Chem. 22, 650-656, 1976.

Urea Nitrogen (BUN)

Modified urease technique Ciba-Corning 550 Express Clinical Chemistry System Talke, H. and Schubert, G.E. Klin. Wchnschr. 43, 174, 1965.

Creatinine

Jaffe method Ciba-Corning 550 Express Clinical Chemistry System Larsen. K. Clin. Chem. Acta, <u>41</u>, 209, 1972

Na+, K+

Ion specific electrodes Model 614 ISE Na+/K+ Analyzer (Ciba Corning)

Chloride

Mecuric thiocyanate procedure Ciba-Corning 550 Express Clinical Chemistry System Zall, O.M., Fisher, D. and Garner, M.Q. Anal. Chem, <u>28</u>, 1065, 1956.

Calcium

Modified alizarin procedure Ciba-Corning 550 Express Clinical Chemistry System Frings, C.S., et. al. Clin. Chem., <u>16</u>, 816, 1970.

Phosphorus, Inorganic

Ammonium molybdate method Ciba-Corning 550 Express Clinical Chemistry System Fiske, C.H. and Subbarow, Y. J. Biol. Chem. <u>66</u>, 325, 1925.

Glucose

Hexokinase method Ciba-Corning 550 Express Clinical Chemistry System Bondar, J.L. and Mead, D.C. Clin. Chem. <u>20</u>, 586, 1974.

Haptoglobin

Antigen-antibody method Ciba-Corning 550 Express Clinical Chemistry System Atlantic Antibodies Test Kit

HEMATOLOGY

Erythrocyte Count

Electronic counting procedure Sysmex K1000 Hematology Analyzer DRAFT

Hemoglobin

Cyanomethemoglobin method

Sysmex K1000 Hematology Analyzer

<u>Hematocrit</u>

Indirect method; calculated value based on volume of red cells and volume of blood

Mean Corpuscular Volume (MCV)

Indirect method; calculated value based on hematocrit and red blood cell count

Mean Corpuscular Hemoglobin (MCH)

Indirect method; calculated value based on erythrocyte count and hemoglobin

Mean Corpuscular Hemoglobin Concentration (MCHC)

Indirect method; calculated value based on hematocrit and hemoglobin

Reticulocyte Count

New methylene blue staining procedure Brecher, G., Am. J. Clin. Path., 19, 895, 1949.

Platelet Count

Electronic counting procedure Sysmex K1000 Hematology Analyzer

Prothrombin Time (PT)

Electra 700 coagulation machine

Activated Partial Thromboplastin Time (APTT)

Electra 700 coagulation machine

Fibrinogen

Electra 700 coagulation machine

Leukocyte Count

Electronic counting procedure

Sysmex K1000 Hematology Analyzer

Leukocyte Differential Count

Neutrophils - Immature (bands)

Neutrophils - Mature (segs)

Monocytes

Basophils

Lymphocytes

Eosinophils

Wright stain procedure

Schalm, O.W., Jain, N.C. and Carroll, E.J. Veterinary Hematology, Color Plates Chapter, 3rd Edition, Lee and Febiger, 1975.

HEMATOLOGY (Contd.)

DRAFT

Nucleated RBCs

Wright stain procedure

Schalm, O.W., Jain, N.C. and Carroll, E.J. Veterinary Hematology, Color Plates Chapter, 3rd Edition, Lee and Febiger, 1975.

RBC Morphology

Wright stain procedure

Schalm, O.W., Jain, N.C. and Carroll, E.J. Veterinary Hematology, Color Plates Chapter, 3rd Edition, Lee and Febiger, 1975.

Heinz Bodies

Methyl violet staining technique

Methemoglobin

Co-oximeter (Instrumentation Laboratory Model 282)

<u>URINALYSIS</u>

Qualitative Measurements

DRAFT

Ketones, Protein, Glucose, Blood, Bilirubin, Urobilinogen, Nitrite, Leukocytes, pH Boehringer Mannheim Chemstrip 9 Reagent Strips

Specific Gravity

Optical temperature compensated refractometer

Microscopic Evaluation

Urinary sediment stained with kova-stain and evaluated using the Ames Atlas of Urine Sediment, Ames Co., Division Miles Laboratories, Elkhart, Indiana.

DRAFT

APPENDIX C

Individual Observations (Clinical Signs)



ABCOVERT FERTOD IN DOGS								
		INDIVI	DUAL CLIN	ICAL SIGNS				
STUDY: DAY 1-1		GROUP: DOSE:		SEX:	MALE			* * * * * * * * * * * * *
ANIMAL #	OBSERVATIONS		**********	SEVERITY	LOC	TIME	OCCUE	RRED
8656	Normal Scheduled Sacr	rifice				DAY DAY	1-DAY 92	91
8687	Normal Scheduled Sacr	ifice				DAY DAY	1-DAY 92	91
8669	Normal Scheduled Sacr	ifice				DAY DAY	1-DAY 92	91
8673	Normal Scheduled Sacr	rifice				DAY DAY	1-DAY 92	91
8667	Normal Scheduled Sacr	rifice				DAY DAY	1-DAY 183	182
8654	Normal Scheduled Sacr	rifice				DAY DAY	1-DAY 183	182
8680	Normal Scheduled Sacr	rifice				DAY DAY	1-DAY 183	182
8676	Normal Scheduled Sacr	rifice				DAY DAY	1-DAY 183	182

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INDIVIDUAL CLINICAL SIGNS

		1110141	DOAL CLIM	ICAL SIGNS				
STUDY: DAY 1-	193 DAY 184	GROUP: DOSE:	1-F 0(mg/kg)	SEX:	FEMALE			*********
ANIMAL #	OBSERVATIO	ns		SEVERITY -	LOC	TIME	E OCCUP	RRED
8721	Normal Scheduled	Sacrifice				DAY DAY	1-DAY 93	92
8712	Normal Scheduled	Sacrifice				DAY DAY	1-DAY 93	92
8710	Normal Scheduled	Sacrifice	•			DAY DAY	1-DAY 93	92
8723	Normal Scheduled	Sacrifice				DAY DAY	1-DAY 93	92
8705	Normal Scheduled	Sacrifice				DAY DAY	1-DAY 184	183
8700	Normal Scheduled	Sacrifice				DAY DAY	1-DAY 184	183
8699	Normal Normal Scheduled Vomit Seen	Sacrifice In Run				DAY DAY DAY DAY		57 7 183
8690	Normal Scheduled	Sacrifice				DAY DAY	1-DAY 184	183

DAY 1-DAY 91 DAY 92

		INDIVII	DUAL CLINI	CAL SIGNS				
STUDY: DAY 1-1	193 DAY 184	GROUP: DOSE:	2-M 0.1(mg/kg	SEX:	MALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCUR	RED
8685	Normal Scheduled Sacri	fice				DAY 1 DAY 9	-DAY	91
	Normal Scheduled Sacri	fice				DAY 1 DAY 9	-DAY	91
8686	Blue Tongue Blue Tongue Blue Tongue Blue Tongue Blue Tongue Normal Normal Normal Normal Normal Normal Scheduled Sacri	fice		1 1 1 1		DAY 1 DAY 4 DAY 5 DAY 5	88-DAY 55-DAY 51 1-DAY 16-DAY 16-DAY 51-DAY 50 50 52-DAY	49 54
8665	Normal Normal Scheduled Sacri Vomit Seen In R	fice un				DAY 1 DAY 1 DAY 1 DAY 1	L-DAY L1-DAY L83 L0	9 182
8666	Normal Normal Scheduled Sacri Vomit Seen In R	fice un				DAY 1 DAY 3 DAY 1 DAY 3	L-DAY 84-DAY 183 83	32 182
8655	Normal Scheduled Sacri	fice				DAY 1	L-DAY	182
8659	Blue Tongue Normal Normal Normal Scheduled Sacri Vomit Seen In R	fice un		1		DAY 4	5-DAY L-DAY 17-DAY 35-DAY 183	44 83

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

Normal Scheduled Sacrifice

8677

INDIVIDUAL	CLINICAL	CTCMC
TWDTATDOWT	CLINICAL	SIGNS

		TWDTATI	DOWL CLIMI	CAL SIGNS				
STUDY: DAY 1-	193 DAY 184	GROUP: DOSE:	2-F 0.1(mg/kg	SEX:	FEMALE			
ANIMAL #	OBSERVATIONS			SEVERITY -	LOC	TIME	e occur	RRED
8717	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 93	92
8703	Blue Tongue Normal Scheduled Sacri	ifice		1		DAY DAY DAY	1-DAY	92
8713	Normal Normal Scheduled Sacri Vomit Seen In B	ifice Run					1-DAY 52-DAY 93 51	
8693	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 93	92
8695	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 184	183
8709	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 184	183
8715	Blue Tongue Normal Normal Scheduled Sacri	ifice		1			1-DAY 42-DAY	
8697	Normal Scheduled Sacri	ifice				DAY DAY	1-DAY 184	183

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sciera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

DRAFT

		400			
	INDIVI	DUAL	CLINICAL	SIGNS	
STUDY: 193	GROUP:				

STUDY: 193 DAY 1-DAY 184	GROUP: DOSE:	3-M 0.3(mg/kg)	SEX:	MALE
DAI I-DAI 104	DOBE:	0.3 (mq/kq)		

ANIMAL #	OBSERVATIONS	SEVERITY LC	C TIME OCCURRED
8674	Blue Tongue Blue Tongue Blue Tongue Blue Tongue Blue Tongue Blue Tongue Normal Normal Normal Normal Normal Normal Normal Normal Normal Scheduled Sacrifice	1 1 1 1	DAY 24-DAY 28 DAY 34-DAY 50 DAY 60-DAY 62 DAY 74-DAY 75 DAY 82-DAY 84 DAY 92 DAY 1-DAY 23 DAY 29-DAY 33 DAY 51-DAY 59 DAY 63-DAY 73 DAY 76-DAY 81 DAY 85-DAY 91 DAY 93-DAY 182 DAY 183
8653	Blue Tongue Blue Tongue Normal Normal Normal Scheduled Sacrifice	1 1	DAY 30 DAY 39 DAY 1-DAY 29 DAY 31-DAY 38 DAY 40-DAY 91 DAY 92
8660	Blue Tongue Blue Tongue Normal Normal Normal Scheduled Sacrifice	1	DAY 42-DAY 43 DAY 89 DAY 1-DAY 41 DAY 44-DAY 88 DAY 90-DAY 91 DAY 92
8668	Blue Tongue	1 1 1 1 1 1	DAY 15-DAY 17 DAY 19-DAY 25 DAY 27-DAY 44 DAY 46-DAY 53 DAY 55-DAY 62 DAY 65 DAY 75 DAY 80-DAY 84

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

		RECOVE	KY PERIOD	IN DOGS				
		INDIVII	OUAL CLINI	CAL SIGNS				
STUDY: DAY 1-1	193 DAY 184	GROUP: DOSE:	3-M 0.3(mg/kg	SEX:	MALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCURR	ED
8668 (contd.)	Blue Tongue Normal Scheduled Sacr	ifice		1		DAY DAY DAY DAY DAY DAY DAY	1-DAY 14 18 26 45 54 63-DAY 66-DAY 76-DAY 85-DAY 91	64 74 79
8682	Normal Scheduled Sacr	ifice				DAY DAY	1-DAY 1:	82
8684	Blue Tongue Normal Normal Scheduled Sacr	ifice		1		DAY	46-DAY 1-DAY 4 48-DAY 92	5
8662	Blue Tongue Blue Tongue Normal Normal Scheduled Sacr	ifice		1		DAY	60-DAY 1-DAY 2 31-DAY 62-DAY	9 5 9
8688	Blue Tongue Blue Tongue Blue Tongue Diarrhea Normal Normal Normal Normal Scheduled Sacr	ifice		1 1 1		DAY DAY DAY DAY DAY DAY	96-DAY 74 1-DAY 3 38-DAY 51-DAY 75-DAY 98-DAY	97 4

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK

RECOVERY	PERTOD	TIM	DOGS		ם	Ц	u
INDIVIDUA	L CLIN	CAL	SIGNS				

STUDY: 193 DAY 1-DAY 184	GROUP: DOSE:	3-F 0.3(mg/kg)	SEX:	FEMALE

DAY 1-	DĀY 184	DOSE:	0.3 (mg/kg)	DDM: 1	D. 11 12 2	
ANIMAL #	OBSERVATIONS		S	EVERITY	LOC	TIME OCCURRED
8692	Blue Tongue Blue Tongue Blue Tongue Blue Tongue Blue Tongue Blue Tongue Normal Normal Normal Normal Normal Normal Normal Normal Normal Scheduled Sacr	ifice		1 1 1 1		DAY 28 DAY 34 DAY 34 DAY 44-DAY 49 DAY 58-DAY 60 DAY 73-DAY 75 DAY 81-DAY 82 DAY 1-DAY 27 DAY 29-DAY 33 DAY 35-DAY 43 DAY 50-DAY 57 DAY 61-DAY 72 DAY 61-DAY 72 DAY 76-DAY 80 DAY 83-DAY 92 DAY 93
8718	Blue Tongue Normal Scheduled Sacr	ifice		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		DAY 22 DAY 31-DAY 36 DAY 38-DAY 44 DAY 50 DAY 54-DAY 57 DAY 59-DAY 63 DAY 66-DAY 73 DAY 75-DAY 79 DAY 82 DAY 92 DAY 1-DAY 21 DAY 23-DAY 30 DAY 37 DAY 45-DAY 49 DAY 51-DAY 53 DAY 51-DAY 53 DAY 58 DAY 64-DAY 65 DAY 74 DAY 80-DAY 81 DAY 83-DAY 91 DAY 93

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

DRAFT

INDIVIDUAL CLINICAL SIGNS

			DUAL CLINIC			
STUDY: DAY 1-1	193 DAY 184	GROUP: DOSE:	3-F 0.3(mg/kg)	SEX:	FEMALE	
ANIMAL #	OBSERVATIONS		S	EVERITY	LOC	TIME OCCURRED
8706	Blue Tongue Blue Tongue Blue Tongue Blue Tongue Blue Tongue Normal Normal Normal Normal Normal Normal Scheduled Sacri			1 1 1 1		DAY 30 DAY 38 DAY 40-DAY 41 DAY 51-DAY 53 DAY 65-DAY 71 DAY 1-DAY 29 DAY 31-DAY 37 DAY 39 DAY 42-DAY 50 DAY 54-DAY 64 DAY 72-DAY 92 DAY 93
8714	Blue Tongue Blue Tongue - Normal Normal Normal Scheduled Sacri	ifice		1		DAY 54-DAY 56 DAY 74-DAY 75 DAY 1-DAY 53 DAY 57-DAY 73 DAY 76-DAY 92 DAY 93
8701	Blue Tongue Normal Scheduled Sacr	ifice		11111111	,	DAY 18 DAY 24-DAY 26 DAY 29-DAY 40 DAY 49-DAY 50 DAY 52-DAY 53 DAY 55-DAY 56 DAY 59-DAY 62 DAY 65 DAY 70-DAY 72 DAY 1-DAY 17 DAY 19-DAY 23 DAY 27-DAY 28 DAY 41-DAY 48 DAY 51 DAY 54 DAY 57-DAY 58 DAY 63-DAY 64 DAY 66-DAY 69 DAY 73-DAY 183 DAY 184

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

			DUAL CLINIC			
	193 DAY 184					
ANIMAL #	OBSERVATIONS		S	EVERITY	LOC	TIME OCCURRED
8702	Blue Tongue Blue Tongue Blue Tongue Normal Normal Normal Normal Scheduled Sacr			1 1 1		DAY 28-DAY 30 DAY 52-DAY 53 DAY 73-DAY 75 DAY 1-DAY 27 DAY 31-DAY 51 DAY 54-DAY 72 DAY 76-DAY 183 DAY 184
8720	Blue Tongue Blue Tongue Normal Normal Normal Scheduled Sacr	ifice		1		DAY 35-DAY 36 DAY 52-DAY 53 DAY 1-DAY 34 DAY 37-DAY 51 DAY 54-DAY 183 DAY 184
8704	Blue Tongue Normal Scheduled Sacr	ifice		111111111		DAY 28-DAY 29 DAY 31-DAY 32 DAY 35-DAY 36 DAY 38 DAY 41-DAY 45 DAY 48-DAY 53 DAY 57 DAY 59-DAY 62 DAY 1-DAY 27 DAY 30 DAY 33-DAY 34 DAY 37 DAY 37 DAY 39-DAY 40 DAY 39-DAY 47 DAY 54-DAY 56 DAY 58 DAY 63-DAY 183 DAY 184

Ubservation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sciera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)



		KECOVE	KI PERIOD	IN DOGS		
		INDIVI		ICAL SIGNS		
STUDY: DAY 1-	193 DAY 184	GROUP: DOSE:	4-M 1.0(mg/kg	SEX:	MALE	
ANIMAL #	OBSERVATIONS		•	SEVERITY	LOC	TIME OCCURRED
8661	Blue Sclera Blue Tongue Blue Tongue Blue Tongue Blue Tongue Blue Tongue Normal Scheduled Sacr			1 1 1 2 2		DAY 87 DAY 7-DAY 59 DAY 63-DAY 64 DAY 66-DAY 91 DAY 60-DAY 62 DAY 65 DAY 1-DAY 6 DAY 92
8670	Blue Gums Blue Gums Blue Tongue	ifice		1 1 1 1 1 2 2 2 2 2 2 2		DAY 34 DAY 38-DAY 39 DAY 10-DAY 36 DAY 40-DAY 56 DAY 58-DAY 67 DAY 69-DAY 73 DAY 76-DAY 79 DAY 84-DAY 90 DAY 37-DAY 39 DAY 57 DAY 68 DAY 74-DAY 75 DAY 80-DAY 83 DAY 91 DAY 1-DAY 9 DAY 92
8681	Blue Gums Blue Gums Blue Sclera Blue Sclera Blue Sclera Blue Tongue			1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		DAY 36-DAY 38 DAY 85-DAY 86 DAY 51 DAY 83-DAY 85 DAY 89 DAY 10-DAY 22 DAY 24-DAY 36 DAY 40-DAY 50 DAY 54-DAY 59 DAY 63-DAY 64 DAY 68-DAY 74

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

DRAFT

		INDIVII	OUAL CLINI	CAL SIGNS		
STUDY: DAY 1-D	193 AY 184	GROUP: DOSE:	4-M 1.0(mg/kg	SEX:	MALE	
ANIMAL # (OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED
8681 (contd.)	Blue Tongue Normal Scheduled Sacri			1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		DAY 78-DAY 83 DAY 85 DAY 37-DAY 39 DAY 51-DAY 53 DAY 60-DAY 62 DAY 65-DAY 67 DAY 75-DAY 77 DAY 84 DAY 86-DAY 91 DAY 1-DAY 9 DAY 23 DAY 92
	Blue Gums Blue Tongue Blue Tongue Blue Tongue Blue Tongue Blue Tongue Diarrhea Normal Normal Scheduled Sacri	.fice		1 1 1 2 1		DAY 41 DAY 12-DAY 26 DAY 28-DAY 89 DAY 91 DAY 90 DAY 25 DAY 1-DAY 11 DAY 27 DAY 92
	Blue Gums Blue Gums Blue Gums Blue Gums Blue Sclera Blue Tongue			111111111111111111111111111111111111111		DAY 26 DAY 36 DAY 63 DAY 94 DAY 94 DAY 4-DAY 18 DAY 20-DAY 35 DAY 37-DAY 38 DAY 41-DAY 42 DAY 44 DAY 58 DAY 63-DAY 64 DAY 74-DAY 77 DAY 85 DAY 94-DAY 99

Observation	Severity No.	Description
Blue Gums/	1	Mild (easily seen, blue color)
Blue Tongue/	2	Severe (Intense, harsh, blue-purple color)

		INDIVI	DUAL	CLINICAL	SIGNS	
STUDY:	193	GROUP:	4 - M		SEX:	MALE

STUDY: 193	GROUP: 4-M	SEX:
DAY 1-DAY 184	DOSE: $1.0 (ma/ka)$	

DAY 1-D	193 AY 184	DOSE:	1.0(mg/kg)	SEX: M	IALE	
ANIMAL #	OBSERVATIONS		SE	VERITY	LOC	TIME OCCURRED
	Blue Tongue Normal Normal Normal Scheduled Sacri	ifice		1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		DAY 102-DAY 104 DAY 36 DAY 39-DAY 40 DAY 43 DAY 45-DAY 57 DAY 59-DAY 62 DAY 65-DAY 73 DAY 78-DAY 84 DAY 86-DAY 93 DAY 1-DAY 3 DAY 19 DAY 100-DAY 101 DAY 105-DAY 182 DAY 183
	Blue Tongue Blue Tongue Blue Tongue Blue Tongue Blue Tongue Normal Normal Normal Normal Normal Normal Normal Scheduled Sacri	ifice		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		DAY 13 DAY 27-DAY 35 DAY 39-DAY 91 DAY 93 DAY 96-DAY 98 DAY 1-DAY 12 DAY 14-DAY 26 DAY 36-DAY 38 DAY 92 DAY 94-DAY 95 DAY 99-DAY 182 DAY 183
	Blue Tongue					DAY 7-DAY 9 DAY 12-DAY 35 DAY 39-DAY 44 DAY 50 DAY 52-DAY 58 DAY 60-DAY 67 DAY 69 DAY 73 DAY 75 DAY 85-DAY 90

Observation	Severity No.	Description
8lue Gums/	1	Mild (easily seen, blue color)
8lue Tongue/	2	Severe (Intense, harsh, blue-purple color)
Blue Sclera		

	RECOVERY PERIOD	IN DOGS		
	INDIVIDUAL CLINI			
STUDY: 193 DAY 1-DAY 184	GROUP: 4-M DOSE: 1.0(mg/kg	SEX: MAI	Œ	
ANIMAL # OBSERVATIONS		SEVERITY I	LOC TIME	OCCURRED
8658 (contd.) Blue Tongue Normal Normal Normal Normal Normal Normal Normal Normal Normal Scheduled Sacri		1111222222222	DAY	94-DAY 113 118 124 129 131 36-DAY 38 45-DAY 49 51 59 68 70-DAY 72 74 76-DAY 84 91-DAY 93 1-DAY 6 10-DAY 11 114-DAY 117 119-DAY 123 125-DAY 128 130 132-DAY 182
Blue Gums Blue Tongue		111111111112	DAY DAY DAY DAY DAY DAY DAY DAY DAY DAY	27-DAY 28 31-DAY 36 55 58-DAY 59 63-DAY 64 94 9-DAY 44 50-DAY 63 60-DAY 71 76-DAY 77 82-DAY 89

<u>Observation</u>	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

DRAF

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INDIVIDUAL C	INTCAL	SIGNS
--------------	--------	-------

STUDY: 193 GROUP: 4-M SEX: MALE DAY 1-DAY 184 DOSE: 1.0(mg/kg) SEVERITY LOC TIME OCCURRED ANIMAL # OBSERVATIONS DAY 59 DAY 64-DAY 65 DAY 72-DAY 75 DAY 78-DAY 81 DAY 90 DAY 92-DAY 93 DAY 1-DAY 8 DAY 104-DAY 182 DAY 183 DAY 78 Blue Tongue
Blue Tongue
Blue Tongue
Blue Tongue
Blue Tongue
Blue Tongue
Normal 222222 8652 (contd.) Normal

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

Scheduled Sacrifice Vomit Seen In Run

 		KECOVE	KI PERIOD	IN DOGS				
 INDIVIDUAL CLINICAL SIGNS								
 STUDY: DAY 1-1	193 DAY 184	GROUP: DOSE:	4-F 1.0(mg/kg	SEX:	FEMALE			
 ANIMAL #	OBSERVATIONS		~~~~~~~	SEVERITY	LOC	TIME OCCURRED		
8696	Blue Gums Blue Sclera Blue Sclera Blue Sclera Blue Sclera Blue Sclera Blue Tongue Blue Tongue Blue Tongue Blue Tongue Normal Normal Normal Scheduled Sacri	ifice		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		DAY 36 DAY 50-DAY 57 DAY 59-DAY 62 DAY 70-DAY 72 DAY 83-DAY 84 DAY 86-DAY 91 DAY 16 DAY 19-DAY 20 DAY 22-DAY 23 DAY 28-DAY 92 DAY 1-DAY 15 DAY 17-DAY 18 DAY 21 DAY 24-DAY 27 DAY 93		
8719	Blue Gums Blue Tongue Normal Normal Scheduled Sacr	ifice		1 1 1 1 2 2 2		DAY 41 DAY 7-DAY 61 DAY 63-DAY 71 DAY 73 DAY 75-DAY 78 DAY 80-DAY 92 DAY 72 DAY 74 DAY 79 DAY 1-DAY 6 DAY 62 DAY 93		
8711	Blue Tongue Blue Tongue Normal Normal Scheduled Sacr	ifice		1		DAY 7-DAY 22 DAY 24-DAY 92 DAY 1-DAY 6 DAY 23 DAY 93		
8716	Blue Gums Blue Tongue			1		DAY 34 DAY 10-DAY 13		

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

	THIRT W	EEN WEE! R242511 RECOVE	K ORAL TOXI WITH A THI RY PERIOD I	ICITY STUDY IRTEEN WEEK IN DOGS	g of	RAFT
		INDIVI	DUAL CLINIC	CAL SIGNS		
STUDY: DAY 1-I	193 DAY 184	GROUP: DOSE:	4-F 1.0(mg/kg)	SEX:	FEMALE	
ANIMAL #	OBSERVATIONS		<u> </u>	SEVERITY	LOC	TIME OCCURRED
8716 (contd.)	Blue Tongue Blue Tongue Blue Tongue Blue Tongue Normal Normal Normal Normal Normal Scheduled Sacr	ifice	·	1 1 1		DAY 16-DAY 17 DAY 19-DAY 21 DAY 24-DAY 85 DAY 87-DAY 92 DAY 1-DAY 9 DAY 14-DAY 15 DAY 18 DAY 22-DAY 23 DAY 86 DAY 93
8725	Blue Gums Blue Tongue Blue Tongue Blue Tongue Blue Tongue Normal Normal Normal Normal Normal Scheduled Sacr	ifice		1 1 1 1 1		DAY 67-DAY 68 DAY 9 DAY 29 DAY 31-DAY 94 DAY 96 DAY 1-DAY 8 DAY 10-DAY 28 DAY 30 DAY 95 DAY 97-DAY 183 DAY 184
8707	Blue Tongue Normal Normal Normal Normal Scheduled Sacr	ifice		1111111222222		DAY 9-DAY 68 DAY 73-DAY 74 DAY 76-DAY 82 DAY 85 DAY 87 DAY 89-DAY 93 DAY 95-DAY 97 DAY 99 DAY 69-DAY 72 DAY 75 DAY 83-DAY 84 DAY 86 DAY 88 DAY 1-DAY 8 DAY 94 DAY 98 DAY 100-DAY 183 DAY 184

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sciera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

	KECOVE	KI PEKIUD	IN DOGS		
	INDIVI	DUAL CLINI	CAL SIGNS	•••••	
193 DAY 184	GROUP: DOSE:	4-F 1.0(mg/kg	SEX:	FEMALE	
OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED
Blue Gums Blue Gums Blue Gums Blue Sclera Blue Sclera Blue Sclera Blue Tongue			111111111111111111111111111111111111111		DAY 68 DAY 94 DAY 37 DAY 58 DAY 63 DAY 86 DAY 6-DAY 33 DAY 78-DAY 80 DAY 85-DAY 86 DAY 90-DAY 91 DAY 95-DAY 98 DAY 101 DAY 103 DAY 105-DAY 116 DAY 118 DAY 34-DAY 77 DAY 81-DAY 84 DAY 81-DAY 89 DAY 92-DAY 94 DAY 1-DAY 5 DAY 99-DAY 100 DAY 102 DAY 104 DAY 117 DAY 119-DAY 183 DAY 184
Blue Gums Blue Sclera Blue Sclera Blue Sclera			111111111111111111111111111111111111111		DAY 16-DAY 36 DAY 38-DAY 42 DAY 44-DAY 45 DAY 48 DAY 50-DAY 68 DAY 70-DAY 72 DAY 76-DAY 90 DAY 93-DAY 94 DAY 37 DAY 56-DAY 57 DAY 63-DAY 64
	DAY 184 OBSERVATIONS Blue Gums Blue Gums Blue Gums Blue Sclera Blue Sclera Blue Sclera Blue Tongue Blue Gums	DAY 184 DOSE: OBSERVATIONS Blue Gums Blue Gums Blue Gums Blue Sclera Blue Sclera Blue Sclera Blue Tongue Blue Gums	GROUP: 4-F DOSE: 1.0 (mg/kg) OBSERVATIONS Blue Gums Blue Gums Blue Sclera Blue Sclera Blue Sclera Blue Tongue Blue Gums	193	Blue Gums Blue Sclera Blue Sclera Blue Sclera Blue Sclera Blue Sclera Blue Tongue Blue Gums

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

DRAFT

TNDT	VTDITAT.	CLINICAL	STONS
TNDT	A TO OWTH	CHIMICHI	STGMS

STUDY:	193	GROU
DAY 1-	DAY 184	DOSE

GROUP: 4-F SEX: FEMALE DOSE: 1.0 (mg/kg)

DAY 1-DAY 184 DOSE: 1.0 (mg/kg

 ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8722 (contd.)	Blue Sclera Blue Tongue Scheduled Sacrifice	111111111222222		DAY 90 DAY 7-DAY 9 DAY 12-DAY 36 DAY 39-DAY 63 DAY 65-DAY 67 DAY 69-DAY 71 DAY 73-DAY 81 DAY 85-DAY 89 DAY 91-DAY 98 DAY 113-DAY 115 DAY 37-DAY 38 DAY 64 DAY 68 DAY 72 DAY 82-DAY 84 DAY 90 DAY 1-DAY 6 DAY 10-DAY 11 DAY 99-DAY 112 DAY 116-DAY 183 DAY 184

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (Intense, harsh, blue-purple color)

 			INCIDENCE (OF	OBSER	VATIONS	3		
STUDY:	193				SEX:	MALE			
 		PERIOD	DOSE:(mg/kg) GROUP:		0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	
		DAY 1 No. Observed Normal			3 3 100%	8 8 100%	8 8 100%	8 8 100%	
		No. Observed Normal			3 3 100%	8 8 100%	8 8 100%	8 8 100%	
		No. Observed Normal			3 3 100%	8 8 100%	8 8 100%	8 8 100%	
		No. Observed Normal Blue Tongue			3 3 100%	8 8 100%	8 8 100%	8 7 88%	
		SEV 1		C		0	0	1 . 12%	
		DAY 5 No. Observed Normal Blue Tongue SEV		8	3 3 100%	8 8 100%	8 8 100%	8 7 88%	
		1		()	0	0	1 12%	
		DAY 6 No. Observed Normal Blue Tongue SEV			3 3 100%	8 8 100%	8 8 100%	8 7 88%	
		1		(0	0	1 12%	
		DAY 7 No. Observed Normal Blue Tongue SEV			3 3 100%	8 8 100%	8 8 100%	8 5 62%	
		1		()	0	0	3 38%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

TNCTDENCE	OF	OBSERVATIONS

-											
	STUDY: 193				SEX:	N	IALE				
		PERIOD	DOSE:(mg/kg) GROUP:		0 1-M		0.1 2-M		0.3 3-M		1.0 4-M
		DAY 8 No. Observed Normal Blue Tongue SEV			100%		100%		100%		62%
		1		0		0		0		3	38%
		DAY 9 No. Observed Normal Blue Tongue SEV			100%		100%		100%		50%
		1		0		0		0		4	50%
		DAY 10 No. Observed Normal Blue Tongue SEV		8	100%	8 7	88%	8	100%	8	38%
		1 Vomit Seen In	Run	0		0	12%	0		5 0	62%
		DAY 11 No. Observed Normal Blue Tongue SEV 1		8 8	100%	8 8		8 8	100%		38%
		DAY 12 No. Observed Normal Blue Tongue SEV		8	100%	8		8	100%	8	12%
		1		0		0		0		7	88%
		No. Observed Normal Blue Tongue SEV		8	100%	8	100%	8	100%	8 0	
		1		0		0		0		8	100%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

************************				. 2005			
		INCIDENCE (OF OBSER	CVATION	S		
STUDY: 193			SEX:	MALE			
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M		1.0 4-M
	No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%		12%
	1		0	0	0	7	88%
	No. Observed Normal Blue Tongue		8 8 100%	8 8 100%	8 7 88%	8	12%
	SEV 1		0	0	1 12%	7	88%
	DAY 16 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 7 88%		12%
	1		0	0	1 12%	7	88%
	No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 7 88%		12%
	1		0	0	1 12%	7	88%
	No. Observed Normal Blue Tongue		8 8 100%	8 8 100%	8 8 100%	8	12%
	SEV 1		0	0	0	7	88%
	DAY 19 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 7 88%	8 2	25%
	1		0	0	1 12%	6	75%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF RECOVERY PERIOD IN DOGS

		INCIDENCE OF	OBSER	VATIONS	3			
STUDY: 193			SEX:	MALE				
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M		0.3 3-M	222	1.0 4-M
	DAY 20 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8	88%	8	12%
	1		0	0	1	12%	7	88%
	DAY 21 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8	88%	8	12%
	1		0	0	1	12%	7	88%
	DAY 22 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 7	88%	8	12%
	1 Blue Tongue		0	0	0		1	12%
	SEV 1		0	0	1	12%	7	88%
	DAY 23 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8	88%	8 2	25%
	1		0	0	1	12%	6	75%
	DAY 24 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8	75%	8	12%
	1		0	0	2	25%	7	88%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sciera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

 					DOGD				***************************************
 			INCIDENCE OF	OBSER	VATIONS	3			
STUDY:	193			SEX:	MALE				
 		PERIOD	DDSE:(mg/kg) GROUP:	0 1-M	0.1 2-M		0.3 3-M		1.0 4-M
		DAY 25 No. Dbserved Normal Blue Tongue SEV		8 8 100%	8 8 100%	8	75%	8	12%
		1 Diarrhea SEV	•	0	0	2	25%	7	88%
		1 DAY 26		0	0	0		1	12%
		No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8	88%	8	12%
		1 Blue Tongue SEV		0	0	0		1	12%
		1		0	0	1	12%	7	88%
		DAY 27 No. Dbserved Normal Blue Gums SEV		8 8 100%	8 8 100%	8	75%		12%
		1 Blue Tongue SEV		0	0	0		1	12%
		1		0	0	2	25%	7	88%
		DAY 28 No. Dbserved Normal Blue Gums SEV		8 8 100%	8 8 100%	8	75%	8	
		1 Blue Tongue SEV		0	0	0		1	12%
		1		0	0	2	25%	8	100%
		No. Observed Normal Blue Tongue		8 8 100%	8 8 100%	8	88%	8	
		SEV 1		0	0	1	12%	8	100%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

		INCIDENCE OF	F OBSER	VATIONS	3		
STUDY: 193			SEX:	MALE			
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	
	DAY 30 No. Observed Normal Blue Tongue SEV 1		8 8 100%	8 8 100%	8 5 62% 3 38%	8 0 8 100%	
	DAY 31 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 7 88%	8 0	
	1 Blue Tongue SEV 1		0	0	0 1 12%	1 12%	
	DAY 32 No. Observed Normal Blue Gums		8 8 100%	8 8 100%	8 7 88%	8	
	SEV 1 Blue Tongue SEV 1		0	0	0 1 12%	1 12%	
	DAY 33 No. Observed Normal Blue Gums		8 8 100%	8 7 88%	8 7 88%	8 0	
	SEV 1 Blue Tongue SEV		0	0	0	1 12%	
	1 Vomit Seen In	Run	0	0 1 12%	1 12% 0	8 100% 0	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Rlue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF RECOVERY PERIOD IN DOGS

				INCIDENCE	OF (OBSER	VA:	rions				
S	TUDY:	193				SEX:	MZ	ALE				
			PERIOD	DOSE:(mg/kg) GROUP:		0 1-M		0.1 2-M		0.3 3-M		1.0 4-M
			DAY 34 No. Observed Normal Blue Gums SEV		8	100%		00%		75%	8	
			1 Blue Tongue SEV		0		0					25%
			1		0		0		2	25%	8	100%
			DAY 35 No. Observed Normal Blue Gums SEV		8	100%	8 8 1	100%	8	62%	8	
			1 Blue Tongue		0		0		0		1	12%
			SEV 1		0		0		3	38%	8	100%
			DAY 36 No. Observed Normal Blue Gums		8	100%	8 8 1	100%	8 5	62%	8	12%
			SEV 1 Blue Tongue SEV		0		0		0		3	38%
			1 2		0		0		3	38%		62% 25%
			DAY 37 No. Observed Normal Blue Gums		8	100%	8 8 1	100%	8 5	62%	8	12%
			SEV 1 Blue Tongue SEV		0		0		0		1	12%
			1 2		0		0		3	38%		50% 38%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

	INCIDEN	CE OF OBSE	RVATIONS	5		
STUDY: 193		SEX	MALE			
PERI	OOSE:(mg/kg) OO GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	
Ne B	38 o. Observed ormal lue Gums SEV	8 8 100%	8 7 88%	8 6 75%	8 1 12%	
В	1 lue Tongue SEV 1	0	0 1 12%	0 2 25%	2 25%	
	2	Ö	0	0	3 38%	
N B	o. Observed ormal lue Gums	8 8 100%	8 7 88%	8 5 62%	8	
В	SEV 1 lue Tongue	0	0	0	1 12%	
	SEV 1 2	0	1 12% 0	3 38% 0	5 62% 3 38%	
N B	40 o. Observed ormal lue Tongue SEV	8 8 100%	8 7 88%	8 6 75%	8 0	
,	1 2	0	1 12% 0	2 25%	7 88% 1 12%	
N B	41 o. Observed ormal lue Gums SEV	8 8 100%	8 7 88%	8 6 75%	8 0	
В	1 lue Tongue	0	0	0	1 12%	
	SEV 1	0	1 12%	2 25%	8 100%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sciera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



,		INCIDENCE OF	F (OBSERV	VA	TIONS				
STUDY: 193				SEX:	М	ALE				
PE	RIOD	OOSE:(mg/kg) GROUP:		0 1-M		0.1 2-M		0.3 3-M		1.0 4-M
	NY 42 No. Observed Normal Blue Tongue SEV		8	100%	8 7	88%	8 5	62%	8	
	1		0		1	12%	3	38%	8	100%
	No. Observed Normal Blue Tongue SEV		8	100%	8 7	88%	8 5	62%	8	
	1 2		0		1	12%	3	38%	7	88% 12%
	No. Observed Normal Blue Tongue SEV			100%		88%		75%	8 0	
	1		0		1	12%	2	25%	8	100%
	No. Observed Normal Blue Tongue SEV		8	100%	8	75%	8	88%	8	
	1 2		0		0	25%	1	12%	5	62% 38%
	No. Observed Normal Blue Tongue SEV			100%		88%		62%	8 0	
	1 2		0		0	12%	3	38%	5	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF THE RECOVERY PERIOD IN DOGS

	INCIDENCE	OF OBSE	RVATION	IS		
STUDY: 193		SEX	MALE			
PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	
DAY 47 No. Obser Normal 8lue Tong SEV		8 8 100%	8 8 100%	8 5 62%	8	
1 2		0	0	3 38% 0	5 62% 3 38%	
OAY 48 No. Obser Normal Blue Tong SEV		8 8 100%	8 8 100%	8 6 75%	8	
1 2		0	0	2 25% 0	5 62% 3 38%	
DAY 49 No. Obser Normal Blue Tong SEV		8 8 100%	8 8 100%	8 6 75%	8	ć
1 2		0	0	2 25% 0	5 62% 3 38%	
OAY 50 No. Obser Normal Blue Tong SEV		8 8 100%	8 7 88%	8 5 62%	8	
1 2		0	1 12% 0	3 38% 0	7 88% 1 12%	
OAY 51 No. Observ Normal Blue Scle SEV		8 8 100%	8 8 100%	8 7 88%	8 0	
1 8lue Tongo SEV	ue .	0	0	0	1 12%	
1 2		0	0	1 12% 0	5 62% 3 38%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

	INCIDENCE	OF OBSER	VATION	S		•
STUDY: 193		SEX:	MALE			
PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	
DAY 52 No. Observed Normal Blue Tongue SEV 1 2		8 8 100% 0	8 8 100%	8 7 88% 1 12% 0	8 0 6 75% 2 25%	
DAY 53 No. Observed Normal Blue Tongue SEV 1		8 8 100%	8 8 100%	8 7 88%	8 0	
DAY 54 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	2 25% 8 0	
1 2 DAY 55	_	0	0	0	7 88% 1 12%	
No. Observed Normal Blue Gums SEV		8 8 100%	8 7 88%	8 7 88%	8 0	
1 Blue Tongue SEV 1 2		0	1 12%	1 12%	1 12% 7 88% 1 12%	
DAY 56 No. Observed Normal Blue Tongue SEV		8 8 100%	8 7 88%	8 7 88%	8 0	
1 2		0	1 12% 0	1 12% 0	7 88% 1 12%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



	INCIDENCE C	OF OBSE	RVATION	S		
STUDY: 193		SEX	: MALE			
PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	
DAY 57 No. Observed Normal Blue Tongue SEV 1		8 8 100%	8 7 88% 1 12%	8 7 88% 1 12%	8 0 6 75%	
DAY 58 No. Observed Normal Blue Gums	1	8 8 100%	8 8 100%	8 7 B8%	2 25% 8 0	
SEV 1 Blue Tongue SEV 1		0	0	0 1 12%	1 12%	
DAY 59 No. Observed Normal Blue Gums SEV	ı	8 8 100%	8 7 88%	8 7 88%	8 0	
SEV 1 Blue Tongue SEV 1		0	0 1 12%	0 1 12%	1 12% 6 75%	
2		ō	0	0	3 38%	
DAY 60 No. Observed Normal Blue Tongue SEV	1	8 8 100%	8 8 100%	8 5 62%	8	
1 2		0	0	3 38% 0	5 62% 3 38%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

	INCIDENCE O	F OBSER	VATIONS	3		
STUDY: 193		SEX:	MALE			
PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	
DAY 61 No. Obser Normal Blue Tong SEV 1 2		8 8 100%	8 7 88% 1 12%	8 5 62%	8 0 5 62% 3 38%	
DAY 62 No. Obser Normal Blue Tong SEV 1		8 8 100%		8 6 75% 2 25%	8 0 5 62%	
2 DAY 63 No. Obser Normal Blue Gums SEV		0 8 8 100%	8 8 100%	8 8 100%	3 38% 8 0	
1 Blue Tong SEV 1	ue	0	0	0	2 25% 8 100%	
DAY 64 NO. Obser Normal Blue Gums SEV		8 8 100%	8 8 100%	8 8 100%	8 0	
1 Blue Tong SEV 1 2	ue	0	0 0	0 0	1 12% 7 88% 1 12%	
DAY 65 No. Obser Normal Blue Tong SEV		8 8 100%	8 8 100%	8 7 88%	8 0	
1 2		0	0	1 12%	4 50% 4 50%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

				. 2000			
		INCIDENCE O	F OBSE	RVATION	S		
STUDY: 193			SEX	MALE	•••••		
***************************************	PER100	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	
	DAY 66 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	8	
	1 2		0	0	0	6 75% 2 25%	
	DAY 67 No. Observed Normal Blue Tongue		8 8 100%	8 8 100%	8 8 100%	8	
	SEV 1 2		0	0	0	6 75% 2 25%	
	DAY 68 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	8	
	1 2		0	0	0	5 62% 3 38%	
	DAY 69 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	8 0	
	1 2		0	0	0	7 88% 1 12%	
	DAY 70 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	8	
	1 2		0	0	0	6 75% 2 25%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS STUDY: 193 SEX: MALE DOSE:(mg/kg) 0 0.1 0.3 1.0 PERIOD GROUP: 1-M 2-M 3-M 4-M DAY 71 No. Observed 8 8 8 8 8 Normal 8 100% 8 100% 8 100% 0 Blue Tongue SEV 1 0 0 0 6 75% 2 0 0 0 0 2 25%	
DOSE:(mg/kg) 0 0.1 0.3 1.0 PERIOD GROUP: 1-M 2-M 3-M 4-M DAY 71 No. Observed 8 8 8 8 Normal 8 100% 8 100% 8 100% 0 Blue Tongue SEV 1 0 0 0 0 6 75%	
PERIOD GROUP: 1-M 2-M 3-M 4-M DAY 71 No. Observed 8 8 8 8 Normal 8 100% 8 100% 8 100% 0 Blue Tongue SEV 1 0 0 0 6 75%	••••
No. Observed 8 8 8 8 8 Normal 8 100% 8 100% 0 0 Blue Tongue SEV 1 0 0 0 0 6 75%	
	••••
DAY 72 No. Observed 8 8 8 8 Normal 8 100% 8 100% 8 100% 0 8 Lue Tongue SEV	
1 0 0 0 5 62% 2 0 0 0 3 38%	
DAY 73 No. Observed 8 8 8 8 Normal 8 100% 8 100% 0 Blue Tongue SEV	
1 0 0 0 6 75% 2 0 0 0 2 25%	
DAY 74 No. Observed 8 8 8 8 Normal 8 100% 8 100% 6 75% 0 Blue Tongue SEV	
1 0 0 1 12% 5 62% 2 0 0 0 3 38% Diarrhea SEV	
1 0 0 1 12% 0	
DAY 75 No. Observed 8 8 8 8 Normal 8 100% 8 100% 6 75% 0 Blue Tongue SEV	
1 0 0 2 25% 5 62% 2 0 0 0 3 38%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

TNCTDENCE	OF	ORSERVATIONS

STUDY:	193				SEX:	M	IALE					
		PERIOD	DOSE:(mg/kg) GROUP:		0 1-M		0.1 2-M		0.3 3-M		1.0 4-M	 Name of State
		DAY 76 No. Observed Normal Blue Tongue SEV		8	100%	8		8	100%	8		•
		1 2		0		0		0			75% 25%	
		OAY 77 No. Observed Normal Blue Tongue SEV		8	100%	8	100%	8	100%	8		
		1 2		0		0		0			75% 25%	
		DAY 78 No. Observed Normal Blue Tongue SEV		8	100%	8	100%	8	100%	8 0		
		1 2 Vomit Seen In	Run	0 0 0		0 0 0		0 0		3	62% 38% 12%	
	,	DAY 79 No. Observed Normal Blue Tongue SEV			100%		100%		100%	8 0		
		1 2		0		0		0			62% 38%	
		No. Observed Normal Blue Tongue		8	100%	8	100%	8	88%	8		
		SEV 1 2		0		0		1 0	12%	4	50% 50%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



	INCIDENCE	OF OBSER	VATION	S		
STUDY: 193		SEX:	MALE			
PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	***************************************
DAY 81 No. Observ Normal Blue Tongu SEV		8 8 100%	8 8 100%	8 7 88%	8	
1 2		0	0	1 12% 0	4 50% 4 50%	
DAY 82 No. Observ Normal Blue Tongu SEV		8 8 100%	8 8 100%	8 6 75%	8 0	
1 2		0	0	2 25% 0	5 62% 3 38%	
DAY 83 No. Observ Normal Blue Sclen		8 8 100%	8 8 100%	8 6 75%	8	
SEV 1 Blue Tongu	e	0	0	0	1 12%	
SEV 1 2		0	0	2 25% 0	5 62% 3 38%	
DAY 84 No. Observ Normal Blue Scler SEV		8 8 100%	8 7 88%	8 6 75%	8	
1 Blue Tongu	e	0	0	0	1 12%	
SEV 1 2 Vomit Seer	ı In Run	0 0 0	0 0 1 12%	2 25% 0 0	5 62% 3 38% 0	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



•••••	THIR	TEEN WEEK ORAI WR242511 WITH RECOVERY PER INCIDENCE OR	A THIR	TEEN WE DOGS	EK			F	T
STUDY: 193				MALE				 	
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M		1.0 4-M		
***************************************	DAY 85 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 8 100%	8	•••••	 • • • • •	
	1 Blue Sclera SEV		0	0	0	1	12%		
	1 Blue Tongue SEV		0	0	0	1	12%		
	1		0	0	0	8	100%		
	DAY 86 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 8 100%	8			
	1 Blue Tongue SEV		0	0	0	1	12%		
	1 2		0	0	0		75% 25%		
	DAY 87 No. Observed Normal Blue Sclera SEV		8 8 100%	8 8 100%	8 8 100%	8 0			
,	1 Blue Tongue SEV		0	0	0		12%		
	1 2		0	0	0		75% 25%		
	DAY 88 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	8			
	1 2		0	0	0	6 2	75% 25%		

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

	INCIDENCE (OF OBSER	VATIONS	3		
STUDY: 193		SEX:	MALE			
PERICO	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	
DAY 89 No. Observed Normal Blue Sclera SEV		8 8 100%	8 8 100%	8 7 88%	8	
1 Blue Tongue SEV		. 0	0	0	1 12%	
1 2		0	0	1 12% 0	6 75% 2 25%	
DAY 90 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 7 88%	8	
1 2		0	0	1 12% 0	4 50% 4 50%	
DAY 91 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	8	
1 2		0	0	0	4 50% 4 50%	
DAY 92 No. Observed Scheduled Sacr Normal Blue Tongue SEV	rifice	8 4 50% 4 50%	8 4 50% 4 50%	8 4 50% 3 38%	8 4 50% 1 12%	
1 2		0	0	1 12% 0	0 3 38%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)
Blue Sclera		

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

TNCTDENCE	OF	OBSERVATIONS
I MILL I I PRIMITE PA	() 14	CIBSERVATIONS

		THETDHICH	OL	ODDER	ANTIONS	,		
STUDY: 193				SEX:	MALE			
	PER10D	DOSE:(mg/kg) GROUP:		0 1-M	0.1 2-M	0.3 3-M		1.0 4-M
	DAY 93 No. Observed Normal Blue Tongue		4	100%	4 4 100%	4 4 100%	4	
	SEV 1 2		0		0	0		25% 75%
	No. Observed Normal Blue Gums		4	100%	4 4 100%	4 100%	4	25%
	SEV 1 Blue Sclera		0		0	0	2	50%
	SEV 1 Blue Tongue		0		0	0	1	25%
	SEV 1		0		0	0	3	75%
	OAY 95 No. Observed Normal Blue Tongue SEV		4	100%	4 4 100%	4 4 100%	1	25%
	1 DAY 96		0		0	0	3	75%
	No. Observed Normal Blue Tongue SEV		4	100%	4 4 100%	4 3 75%	0	
	1		0		0	1 25%	4	100%
	DAY 97 No. Observed Normal Blue Tongue SEV		4	100%	4 100%	4 3 75%	0	
	1		0		0	1 25%	4	100%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

	THIR	TEEN WEEK ORAI WR242511 WITH RECOVERY PEI	L TOXIC A THIR RIOD IN	ITY STU TEEN WE DOGS	DDY OF	RAFT
		INCIDENCE O	F OBSER	VATIONS	3	
STUDY: 193			SEX:	MALE		
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
	DAY 98 No. Observed Normal Blue Tongue SEV 1		4 100%	4 4 100%	4 100%	4 100%
	DAY 99 No. Observed Normal Blue Tongue SEV		4 4 100%	4 4 100%	4 4 100%	4 1 25%
	1		0	0	0	3 75%
	DAY 100 No. Observed Normal Blue Tongue SEV		4 100%	4 100%	4 100%	4 2 50% 2 50%
	DAY 101 No. Observed Normal Blue Tongue SEV		4 100%	4 100%	4 100%	2 50%
	1 DAY 102		0	0	0	2 50%
	No. Observed Normal Blue Tongue SEV		4 100%	4 100%	4 4 100%	1 25%
	1		0	0	0	3 75%
	No. Observed Normal Blue Tongue		4 100%	4 100%	4 100%	1 25%

SEVERITY CODES

0

0

0

3 75%

SEV

1

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



INCIDENCE OF OBSERVATIONS

		INCIDENCE OF	OBSER	VATIONS			
STUDY: 193			SEX:	MALE			
Р	ERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M		1.0 4-M
D	AY 104 No. Observed Normal Blue Tongue SEV		4 4 100%	4 4 100%	4 4 100%	4 2	50%
	1		0	0	0	2	50%
D	AY 105 No. Observed Normal Blue Tongue SEV	*	4 4 100%	4 100%	4 4 100%		75%
	1		0	0	0	1	25%
D	AY 106 No. Observed Normal Blue Tongue SEV		4 4 100%	4 4 100%	4 4 100%	4 3	75%
	1		0	0	0	1	25%
D	AY 107 No. Observed Normal Blue Tongue SEV		4 4 100%	4 4 100%	4 4 100%		75%
	1		0	0	0	1	25%
D	AY 108 No. Observed Normal Blue Tongue SEV		4 4 100%	4 100%	4 4 100%	4 3	75%
	1		0	0	0	1	25%
D	AY 109 No. Observed Normal Blue Tongue SEV		4 4 100%	4 4 100%	4 4 100%	4 3	75%
	1		0	0	0	1	25%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



	INCIDENCE	OF OBSER	VATION	S		
STUDY: 193		SEX:	MALE			
PER I OO	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-м	1.0 4-M	
DAY 110 No. Obs Normal Blue To SEV		4 4 100%	4 4 100%	4 4 100%		
1		0	0	0	1 25%	
DAY 111 No. Obse Normal Blue Tor SEV		4 100%	4 100%	4 100%	4 3 75%	
1		0	0	0	1 25%	
DAY 112 No. Obse Normal Blue Ton SEV		4 4 100%	4 4 100%	4 4 100%	4 3 75%	
1		0	0	0	1 25%	
DAY 113 No. Obse Normal Blue Tor SEV		4 4 100%	4 4 100%	4 4 100%	4 3 75%	
1		0	0	0	1 25%	
DAY 114 No. Obse Normal	erved	4 100%	4 4 100%	4 4 100%	4 4 100%	
DAY 115 No. Obse Normal	erved	4 4 100%	4 4 100%	4 4 100%	4 4 100%	
DAY 116 No. Obse Normal	erved	4 4 100%	4 4 100%	4 4 100%	4 4 100%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sciera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



				INCIDENCE	OF	OBSER	VATIONS	3		
ST	JDY:	193				SEX:	MALE			
			PERIOD	DOSE:(mg/kg) GROUP:		0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	
			DAY 117 No. Observed Normal		4	100%	4 4 100%	4 4 100%	4 4 100%	
			DAY 118 No. Observed Normal Blue Tongue SEV			100%	4 100%	4 4 100%	4 3 75%	
			1		0		0	0	1 25%	
			No. Observed Normal		4	100%	4 4 100%	4 4 100%	4 4 100%	
			No. Observed Normal		4	100%	4 4 100%	4 4 100%	4 4 100%	
			No. Observed Normal		4	100%	4 4 100%	4 4 100%	4 4 100%	
			No. Observed Normal		4	100%	4 4 100%	4 4 100%	4 4 100%	
			DAY 123 No. Observed Normal		4	100%	4 4 100%	4 4 100%	4 100%	
			DAY 124 No. Observed Normal Blue Tongue SEV		4	100%	4 4 100%	4 4 100%	4 3 75%	
			1 DAY 125 No. Observed Normal		4 4		0 4 4 100%	0 4 4 100%	1 25% 4 4 100%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF RECOVERY PERIOD IN DOGS

			RECOVERI PER	STOD IN	DUGS			
 			INCIDENCE OF	OBSER	VATIONS	5		
 STUDY:	193			SEX:	MALE			
		PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 - 2-M	0.3 3-M	1.0 4-M	
 		DAY 126 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		DAY 128 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		DAY 129 No. Observed Normal Blue Tongue		4 4 100%	4 4 100%	4 4 100%	4 3 75%	
		SEV 1		0	0	0	1 25%	
		DAY 130 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		DAY 131 No. Observed Normal Blue Tongue SEV		4 4 100%	4 4 100%	4 4 100%	4 3 75%	
		1		0	. 0	0	1 25%	
		DAY 132 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		DAY 133						

SEVERITY CODES

No. Observed

Normal

4 100%

4 100%

4 4 100% 4 100%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF DO TO THE THIRTEEN WEEK ORAL TOXICITY STUDY OF THE THIRTEEN WEEK RECOVERY PERIOD IN DOGS

	INCIDENCE	OF OBSER	VATIONS	5		
STUDY: 193		SEX:	MALE			
PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	
DAY 134 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
DAY 135 No. Observed Normal		- 4 4 100%	4 4 100%	4 4 100%	4 4 100%	
DAY 136 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
DAY 137 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
DAY 138 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
DAY 139 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
DAY 140 No. Observed Normal		4 4 100%	4 100%	4 4 100%	4 4 100%	
DAY 141 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
DAY 142 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
DAY 143 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
DAY 144 No. Observed Normal		4 100%	4 4 100%	4 4 100%	4 4 100%	

	THIR	TEEN WEEK ORA WR242511 WITH RECOVERY PE	A THIR	TEEN WI DOGS	EEK		B	T
		INCIDENCE O	F OBSER	VATION	S		 	
STUDY: 193			SEX:	MALE			 	
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M		
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	 	
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%		
	No. Observed Normal		4 100%	4 100%	4 4 100%	4 4 100%		
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%		
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%		
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 100%		
	DAY 151 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%		
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%		
	DAY 153 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%		
	DAY 154 No. Observed Normal		4 4 100%	4 4 100%	4 100%	4 4 100%		

INCIDENCE OF OBSERVATIONS STUDY: 193 SEX: MALE DOSE: (mg/kg) 0.1 0 1.0 0.3 PERIOD GROUP: 1-M 2-M 3-M 4-M **DAY 155** No. Observed 4 4 100% 4 4 100% 4 4 100% 4 4 100% Normal **DAY 156** No. Observed 4 100% 4 100% 4 100% 4 100% Normal **DAY 157** No. Observed 4 4 1D0% 4 1DD% 4 100% 4 100% Normal DAY 158 No. Observed 4 100% 4 100% 4 100% 4 100% Normal **DAY 159** No. Observed 4 4 100% 4 100% 4 100% 4 100% Normal DAY 160 No. Observed 4 100% 4 100% 4 100% 4 100% Normal **DAY 161** 4 4 100% No. Observed 4 100% Normal DAY 162 No. Observed 4 100% 4 100% 4 100% Normal 4 100% **DAY 163** No. Observed 4 100% 4 100% 4 100% 4 100% Normal **DAY 164**

No. Observed

Normal

4 100%

4 100%

4 100%

4 100%

	THIR	TEEN WEEK ORA WR242511 WITH RECOVERY PE	L TOXIC A THIR RIOD IN	ITY S TEEN DOGS	STUDY (of D		ß	T
		INCIDENCE O	F OBSER	VATIO	ONS			 	• • • • • • • •
STUDY: 193			SEX:	MALE	3		• • • •	 ••••	
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	- 0. 3-		1.0 4-M	 	
	DAY 165 No. Observed Normal		4 4 100%	4 4 100%	4 4 100	% 4 4 1	00%		
	DAY 166 No. Observed Normal		4 4 100%	4 4 100%	4 100	% 4 1	00%		
	DAY 167 No. Observed Normal		4 4 100%	4 4 100%	4 100	x 4 1	00%		
	No. Observed Normal		4 4 100%	4 4 100%	4 100	4 4 4 1	00%		
	No. Observed Normal		4 4 100%	4 4 100%	4 100	4 4 4 1	00%		
	No. Observed Normal		4 4 100%	4 4 100%	4 100	4 4 1	00%		
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100	4 4 1	00%		
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100	4 4 1	00%		
	DAY 173 No. Observed Normal		4 4 100%	4 4 100%	4 100	4 4 4 1	00%		
	DAY 174 No. Observed Normal		4 4 100%	4 4 100%	4 4 100	4 4 4 1	00%		

				INCIDENCE OF	7	OBSERV	VA	TIONS						
STUD	Υ:	193				SEX:	M	IALE						
			PERIOD	DOSE:(mg/kg) GROUP:		0 1-M		0.1 ⁻ 2-M		0.3 3-M		1.0 4-M	 	2000
			DAY 175 No. Observed Normal		4	100%	4	100%	4	100%	4	100%		
*			DAY 176 No. Observed Normal		4	100%	4		44	100%	4	100%		
			DAY 177 No. Observed Normal		4	100%	44	100%	44	100%	4	100%		
			DAY 178 No. Observed Normal		4	100%	4	100%	4	100%	4	100%		
			DAY 179 No. Observed Normal		4	100%	44	100%	44	100%	4	100%		
			DAY 180 No. Observed Normal		4	100%	4	100%	4	100%	4	100%		
			DAY 181 No. Observed Normal		4	100%	4	100%	44	100%	4	100%		
			DAY 182 No. Observed Normal		4	100%	4	100%	4	100%	4	100%		
			DAY 183 No. Observed Scheduled Sacr	ifice	4	100%	4	100%	44	100%	4	100%		
			DAY 184 No. Observed		0		0		0		0			

THIRTEEN WEEK ORAL TOXICITY STUDY OF NO RECOVERY PERIOD IN DOGS

 			INCIDENCE	OF (OBSI	ERVATION	S		
STUDY:	193			S	EX:	FEMALE			
 		PERIOD	OOSE:(mg/kg) GROUP:		0 1-F	0.1 2-F	- 0.3 3-F		1.0 4-F
		DAY 1 No. Observed Normal			100%	8 8 100%	8 8 100%		100%
		DAY 2 No. Observed Normal			100%	8 8 100%	8 8 100%		100%
		DAY 3 No. Observed Normal			100%	8 8 100%	8 8 100%		100%
		No. Observed Normal			100%	8 8 100%	8 8 100%		100%
		OAY 5 No. Observed Normal			100%	8 8 100%	8 8 100%		100%
		DAY 6 No. Observed Normal Blue Tongue		8 8	100%	8 8 100%	8 8 100%	8	88%
		SEV 1		0		0	0	1	12%
		DAY 7 No. Observed Normal Blue Tongue		8 8	100%	8 8 100%	8 8 100%	8 4	50%
		SEV 1		0		0	0	4	50%
		OAY 8 No. Observed Normal Blue Tongue		8 8	100%	8 8 100%	8 8 100%	8 4	50%
		SEV 1		0		0	0	4	50%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



	INCIDENCE O	F OBSER	NOITAV	S		
STUDY: 193		SEX: F	EMALE			
PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1. 4-	0 F
DAY 9 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	8 2 25 6 75	
DAY 10 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	8 3 38	%
DAY 11 No. Observed Normal Blue Tongue SEV		8 8 100%	0 8 8 100%	8 8 100%	8 3 38	
1 DAY 12		0	0	0	5 62	%
No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	8 2 25	%
1		0	0	0	6 75	%
DAY 13 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	8 2 25	%
1		0	0	0	6 75	%
DAY 14 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 8 100%	8 3 38	%
1		0	0	0	5 62	2%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

INCIDENCE OF OBSERVATIONS	15	TTON	TAV	ER	ORS	OF	7	ENC	CID	I
---------------------------	----	------	-----	----	-----	----	---	-----	-----	---

		INCIDENCE OF	OBSE	RVATION	5		
STUDY: 193	••••••	•	SEX:	FEMALE		• • • • • • •	
	PERIOD	DOSE:(mg/kg) GROUP:	0 1 • F	0.1 2-F	0.3 3-F	1.0 4-F	
	DAY 15 No. Observed Normal Blue Tongue SEV 1		8 8 100%	8 8 100%	8 8 100%	8 3 38% 5 62%	
	DAY 16 No. Observed Normal Blue Gums	-	8 8 100%	8 8 100%	8 8 100%	8 1 12%	
	SEV 1 Blue Tongue SEV		0	0	0	1 12%	
	1 DAY 17		0	0	0	7 88%	S
	No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 8 100%	8 2 25%	
	1 Blue Tongue SEV		0	0	0	1 12%	
	DAY 18 No. Observed		0	0	0	6 75%	;
	Normal Blue Gums SEV		8 8 100%	8 8 100%	8 7 88%	8 3 38%	\$
	1 Blue Tongue SEV		0	0	0	1 12%	
	1 DAY 19 No. Observed		8	0	1 12%	5 62%	•
	Normal Blue Gums SEV		8 100%	8 100%	8 100%	1 123	6
	1 Blue Tongue SEV		0	0	0	1 129	
	1		0	0	0	7 887	4

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

		KECOVEKI PE	KIOD IN	DOGS			
		INCIDENCE OF	OBSER	VATIONS	3		
STUDY: 193			SEX: F	EMALE	•••••		••••••••••
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 - 2-F	0.3 3-F		1.0 4-F
	DAY 20 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 8 100%	8	12%
	1 Blue Tongue		0	0	0	1	12%
	SEV 1		0	0	0	7	88%
	No. Observed Normal Blue Gums		8 8 100%	8 8 100%	8 8 100%	8 2	25%
	SEV 1 Blue Tongue		0	0	0	1	12%
	SEV 1		0	0	0	6	75%
	DAY 22 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 7 88%	8 2	25%
	1 8lue Tongue SEV		0	0	0	1	12%
	1		0	0	1 12%	6	75%
	DAY 23 No. Observed Normal 8lue Gums SEV		8 8 100%	8 8 100%	8 8 100%	8	38%
	1 8lue Tongue SEV		0	0	0		12%
	, 1		0	0	0	5	62%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

••••	RECOVERY PI	ERIOD IN	1 DOGS			
	INCIDENCE (OF OBSER	RVATIONS	3		
STUDY: 193	**********************	SEX: F	EMALE	••••••	••••••	
PERI	DOSE:(mg/kg) OD GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	
No Bl	. Observed rmal ue Gums	8 8 100%	8 8 100%	8 7 88%	8 2 25%	
ві	EV 1 ue Tongue	0	0	0	1 12%	
	EV 1	0	0	1 12%	6 75%	
No Bl	. Observed rmal ue Gums	8 8 100%	8 8 100%	8 7 88%	8 2 25%	
Bl	EV 1 ue Tongue	0	0	0	1 12%	
	1	0	0	1 12%	6 75%	
No Bl	o. Observed ormal ue Gums	8 8 100%	8 8 100%	8 7 88%	8 2 25%	
ві	EV 1 ue Tongue	0	0	0	1 12%	
	1	0	0	1 12%	6 75%	
No BI	27 o. Observed ormal ue Gums SEV	8 8 100%	8 8 100%	8 8 100%	8 2 25%	
ВІ	sev 1 Lue Tongue SEV	0	0	0	1 12%	
	1	0	0	0	6 75%	

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

	TOCOADKI E	EKIOD	IN DOGS			
	INCIDENCE	OF OBS	ERVATION	S		
STUDY: 193		SEX:	FEMALE	• • • • • • • • •		•••••••••••••••
PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	
DAY 28 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 5 62%	8 1 12%	•••••••••••••••••••••••••••••••••••••••
1 Blue Tongue SEV		0	0	0	1 12%	
1		0	0	3 38%	7 88%	
DAY 29 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 5 62%	8	
1 Blue Tongue SEV		0	0	0	1 12%	
1		0	0	3 38%	8 100%	
DAY 30 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 5 62%	8 1 12%	
1 Blue Tongue SEV		0	0	0	1 12%	
1		0	0	3 38%	7 88%	
DAY 31 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 5 62%	8	
1 Blue Tongue		0	0	0	1 12%	
SEV 1		0	0	3 38%	8 100%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF RECOVERY PERIOD IN DOGS

******		I BRITOD II	A DOGS	L) 00 0	_
	INCIDENCE	OF OBSE	RVATION	S	•••••••	
STUDY: 193		SEX:	FEMALE			
PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	
Normal Blue Go SEV 1	ums	8 8 100%	8 8 100%	8 5 62%	8 0 1 12%	
Blue To SEV 1	ongue	0	0	3 38%	8 100%	
DAY 33 No. Obs Normal Blue G SEV		8 8 100%	8 8 100%	8 6 75%	8	
SEV 1 Blue To SEV	ongue	0	0 -	0 2 25%	1 12%	
DAY 34 No. Ob Normal Blue G		8 8 100%	8 8 100%	8 5 62%	8 0	
SEV 1 Blue T SEV		0	0	0	2 25%	
1 2		0	0	3 38% 0	7 88% 1 12%	
DAY 35 No. Ob Normal Blue G SEV		8 8 100%	8 8 100%	8 4 50%	8	
1 Blue T SEV	fongue	0	0	0	1 12%	
1 2	ja .	0	0	4 50% 0	7 88% 1 12%	

Observation	Severity No.	Description
Blue Gums/	1	Mild (easily seen, blue color)
Blue Tongue/	2	Severe (intense, harsh, blue-purple color)

 			RECOVERY P	ERIOD II	DOGS	ا ننا نا		الما	0 00 00 0
			INCIDENCE	OF OBSE	RVATION	s	•••••		
 STUDY:	193		**********	SEX: I	FEMALE			• • • •	• • • • • • • • • • • • • • • •
 		PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	9	0.3 3-F		1.0 4-F
		DAY 36 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8	50%	8	•••••••••••••••••••••••••••••••••••••••
		1 Blue Tongue SEV		0	0	0		2	25%
		1 2		0	0	0	50%		88% 12%
		DAY 37 No. Observed Normal Blue Sclera		8 8 100%	8 8 100%	8 7	88%	8	
		SEV 1 Blue Tongue SEV		0	0	0		2	25%
		1 2		0	0	1	12%		75% 25%
		No. Observed Normal Blue Gums		8 8 100%	8 8 100%	8 4	50%	8	
		SEV 1 Blue Tongue SEV		0	0	0		1	12%
		1 2		0 .	0	0	50%		75% 25%
		DAY 39 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8	75%	8	
		1 Blue Tongue SEV		0	0	0		1	12%
		-		-		_		_	

SEVERITY CODES

0

1 2

2 25%

1 12%

7 88%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

	INCIDENCE	OF OBSE	RVATION	S		
STUDY: 193		SEX: I	FEMALE	`		
PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	- 0.3 3-F	1.0 4-F	
DAY 40 No. Obser Normal Blue Gums SEV		8 8 100%	8 8 100%	8 5 62%	8	
1 Blue Tong SEV	ue	0	0	0	1 12%	
1 2		0	0	3 38% 0	7 88% 1 12%	
DAY 41 No. Obser Normal Blue Gums SEV		8 8 100%	8 7 88%	8 5 62%	8	
1 Blue Tong	ue	0	0	0	2 25%	
1 2		0	1 12% 0	3 38% 0	7 88% 1 12%	
DAY 42 No. Obser Normal Blue Gums SEV	ved	8 8 100%	8 8 100%	8 6 75%	8	
1 Blue Tong SEV	ue	0	0	0	1 12%	
1 2		0	0	2 25% 0	7 88% 1 12%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Rive Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

		THCIDENCE	OF OBSE.	RVATION	5		
STUDY: 193			SEX:	FEMALE			
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F		1.0 4-F
	DAY 43						
	No. Observed		8	8	8	8	
	Normal		8 100%	8 100%	6 75%	0	
	Blue Tongue						
	SEV			4.0		_	
	1		0	0	2 25%		88%
	2		0	0	0	1	12%
	DAY 44						
	No. Observed		8	8	8	8	
	Normal		8 100%	8 100%	5 62%	0	
	Blue Gums						
	SEV						
	1		0	0	0	1	12%
	Blue Tongue						
	SEV		•	_		~	000
	1		0	0	3 38%		88%
	2		0	0	0	- 1	12%
	DAY 45						
	No. Observed		8	8	8	8	
	Normal		8 100%	8 100%	6 75%	0	
	Blue Gums						
	SEV						
	1		0	0	0	1	12%
	Blue Tongue						
	SEV				0.050		0.00
	1		0	0	2 25%		88%
	2		0	0	0	1	12%
	DAY 46						
	No. Observed		8	8	8	8	
	Normal		8 100%	8 100%	7 88%	0	
	Blue Tongue						
	SEV						
	1		0	0	1 12%		88%
	2		0	0	0	1	12%
	DAY 47						
	No. Observed		8	8	8	8	
	Normal		8 100%	8 100%	7 88%	0	
	Blue Tongue		0 100%	0 100%	, 557	•	
	SEV						
	1		0	0	1 12%	7	88%
	2		ő	Ō	0	1	12%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

•••••	INCIDENCE (OF C	BSI	ERVATIONS	5				
STUDY: 193		SE	Χ:	FEMALE					
PERIOD	DOSE:(mg/kg) GROUP:		0 1-F	0.1 2-F		0.3 3-F		1.0 4-F	
DAY 48 No. Observed Normal	•	8	00%	8 8 100%	8	75%	8		••••
Blue Gums SEV			00%			13%			
1 Blue Tongue SEV		0		0	D		1	12%	
1 2		0		0	2	25%		88% 12%	
		Ü		· ·	U		•	12.4	
DAY 49 No. Observed		8		8	8		8		
Normal Blue Tongue SEV		8 1	00%	8 100%	5	62%	0		
1 2		0		0	3	38%		88% 12%	
OAY 50									
No. Observed Normal Blue Gums		8 8 1	00%	8 8 100%	5	62%	8		
SEV 1 Blue Sclera		0		0	0		1	12%	
SEV 1 Blue Tongue		0		0	0		1	12%	
SEV		0		0	7	704	7	88%	
1 2		0		0	0	38%		12%	
DAY 51 No. Observed		8		8	8		8		
Normal Blue Gums			00%	7 88%		75%	0		
SEV 1 Blue Sclera		0		0	0		1	12%	
SEV 1 Blue Tongue		0		0	0		1	12%	
SEV 1	*	0		0	2	25%	7	88%	
2 Vomit Seen I	n Run	0		0 1 12%	0	23%		12%	

Observation	Severity No.	<u>Oescription</u>
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

 			MECOVERT I	ביונים	.00 .	LIN DOGS				
 			INCIDENCE	OF	OBSE	ERVATIONS	S			
STUDY:	193			S	EX:	FEMALE				••••••• _{••} •••• _{••}
 		PERIOD	DOSE:(mg/kg) GROUP:		0 1-F	0.1 2-F		0.3 3-F		1.0 4-F
		DAY 52 No. Observed Normal Blue Gums SEV		8	100%	8 8 100%	8 3	38%	8 0	•
		1 Blue Sclera SEV 1 Blue Tongue		0		0	0			12%
v		SEV 1 2		0)	0	5	62%	7	88% 12%
		No. Observed Normal Blue Gums		8	3 100%	8 8 100%	8	38%	8	
		SEV 1 Blue Sclera SEV		C)	0	0		1	12%
		1 Blue Tongue SEV		0)	0	0		1	12%
		4				0	-	424	7	999

SEVERITY CODES

0

2

5 62% 0

7 88%

1 12%

Observation	Severity No.	Description
Blue Gums/	1	Mild (easily seen, blue color)
Blue Tongue/	2	Severe (intense, harsh, blue-purple color)

		INCIDENCE OF	OBSE	ERVATIONS	5			
STUDY: 193		• • • • • • • • • • • • • • • • • • • •	SEX:	FEMALE				
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 ⁻ 2•F		0.3 3-F	1.0 4-F	
	DAY 54 No. Observed Normal Blue Gums SEV 1 Blue Sclera		8 8 100%	8 8 100%	8 6 7			
	SEV 1 Blue Tongue		0	0	0	1	1 12%	
	SEV 1 2		0	0	2 0		7 88% 1 12%	
	No. Observed Normal Blue Gums		8 8 100%	8 8 100%	8 5		3	
	SEV 1 Blue Sclera		0	0	0		1 12%	
	SEV 1 Blue Tongue		0	0	0	,	1 12%	
	SEV 1 2		0	0	3 3		7 88% 1 12%	
	DAY 56 No. Observed Normal Blue Gums		8 8 100%	8 8 100%	8 5		8	
	SEV 1 Blue Sclera SEV		0	0	0	•	1 12%	
	1 Blue Tongue SEV		0	0	0		2 25%	
	1 2		0	0	3		7 88% 1 12%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

	INCIDENCE	OF OBSE	RVATION	S		
STUDY: 193		SEX: 1	FEMALE			
PERIOD	DOSE:(mg/kg) GROUP:	0 1- F			1.0 4-F	
DAY 57 No. Observ Normal Blue Gums SEV	ed	8 8 100%	8 8 100%	8 6 75%	8	
1 Blue Scler SEV	a	0	0	0	1 12%	
1 Blue Tongu SEV	e	0	0	0	2 25%	
1 2		0	0	2 25% 0	7 88% 1 12%	
DAY 58 No. Observ Normal Blue Gums	ed	8 7 88%	8 8 100%	8 7 88%	8	
SEV 1 Blue Scler SEV	a	0	0	0	1 12%	
1 Blue Tongu SEV	e	0	0	0	1 12%	
1 2 Vomit Seen	ı în Run	0 0 1 12%	0 0 0	1 12% 0 0	7 88% 1 12% 0	
DAY 59 No. Observ Normal Blue Gums	red	8 8 100%	8 8 100%	8 4 50%	8	
SEV 1 Blue Scler SEV	a	0	0	0	1 12%	
SEV 1 Blue Tongu SEV	e	0	0	0	1 12%	
1 2		0	0	4 50% 0	7 88% 1 12%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF RECOVERY PERIOD IN DOGS

		INCIDENCE OF	OBS	ERVATIONS				
STUDY: 193			SEX:	FEMALE				
		DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F		0.3 3-F		1.0 4-F
	DAY 60 No. Observed Normal Blue Gums SEV		8 8 100%				8	
	1 Blue Sclera SEV		0	0				12%
	1 Blue Tongue SEV		0	0	0			12%
	1 2		0	0	0	50%		88%
	DAY 61 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 5	62%	8	
	1 Blue Sciera SEV		0	0	0		1	12%
	1 Blue Tongue SEV		0	0	0		1	12%
	1 2		0	0	0	38%		88% 12%
	DAY 62 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 5	62%	8	12%
	1 Blue Sclera SEV		0	0	0		1	12%
	1 Blue Tongue SEV		0	0	0		1	12%
	1 2		0	0	3	38%		75% 12%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF RECOVERY PERIOD IN DOGS

		KBCOVBKI IBI	CTOD III	DOGD			
		INCIDENCE OF	OBSER	VATIONS	}		
STUDY: 193			SEX: F	EMALE			
	PERIOD	DOSE:(mg/kg), GROUP:	0 1-F	0.1 - 2-F	0.3 3-F		1.0 4-F
	DAY 63						
	No. Observed		8	8	8	8	
	Normal		8 100%	8 100%	7 88%	0	
	Blue Gums		0 100%	0 100%			
	SEV						
	1		0	0	0	1	12%
	Blue Sclera		•	· ·	0	•	TEA
	SEV						
	1		0	0	0	2	25%
	Blue Tongue		•	•		-	
	SEV						
	1		0	0	1 12%	7	88%
	2		0	0	0		12%
	DAY 64						
	No. Observed		8	8	8	8	
	Normal		8 100%	8 100%	8 100%	0	
	Blue Gums						
	SEV		_				
	1		0	0	0	1	12%
	Blue Sclera						
	SEV 1						4.004
			0	0	0	1	12%
	Blue Tongue SEV						
	1		0	•		,	THE W
	2		0	0	0	0	75% 25%
	2		U	U	U	2	23%
	DAY 65						
•	No. Observed		8	8	8	8	
	Normal		8 100%	8 100%	6 75%	0	
	Blue Gums						
	SEV						
	1		0	0	0	1	12%
	Blue Tongue						
	SEV	•					
	1		0	0	2 25%	7	88%
	2		0	0	0	1	12%

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



		RECOVERY P	ERIOD IN	1 DOGS				
		INCIDENCE	OF OBSER	RVATION	S			
STUDY: 193	• • • • • • • • • • • • • • • • • • • •		SEX: F					
	PER I OD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F		0.3 3-F	1.0 4-F	
	DAY 66 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 6	75% 0		
	1 Blue Tongue SEV		- 0	0	0	1	12%	
	1 2		0	0	0		88% 12%	
,	DAY 67 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8	75% C		
	1 Blue Tongue SEV		0	0	0	2	25%	
	1 2		0	0	0		88% 12%	
	DAY 68 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8	75% 0		
	1 Blue Tongue SEV		0	0	0		38%	
	1 2		0	0	0		75% 2 25%	
	DAY 69 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8	75% (
	1		0	0	2	25%	75%	

SEVERITY CODES

0

0

2 25%

2

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK

	RECOVERY PERIOD IN DOGS						
		INCIDENCE O	F OBSE	RVATIONS	S		
STUDY: 193			SEX: 1	FEMALE			
	PER1OD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	- 0.3 3-F	1.0 4-F	
	DAY 70 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 5 62%	8	
	1 Blue Sclera SEV		0	0	0	1 12%	
	1 Blue Tongue SEV		0	0	0	1 12%	
	1 2		0	0	3 38% 0	6 75% 2 25%	
	DAY 71 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 5 62%	8	
	1 Blue Sclera SEV		0	0	0	1 12%	
	1 Blue Tongue SEV		0	0	0	1 12%	
	1 2		0	0	3 38% 0	6 75% 2 25%	
	DAY 72 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 6 75%	8	
	1 Blue Sclera SEV	,	0	0	0	1 12%	
	1 Blue Tongue SEV		0	0	0	1 12%	
			0	0	2 25%	4 50%	

SEVERITY CODES

0

2

0

2 25% 0 4 50% 4 50%

<u>Observation</u>	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)
Rive Sciena		

THIRTEEN WEEK ORAL TOXICITY STUDY OF RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

		INCIDENCE OF	(JESE.	KVF	LITON	S					
STUDY: 193		••••••	SE	EX:	FEM	IALE				•••••••	*****	• • • • • • • • •
	PERIOD	DOSE:(mg/kg) GROUP:		0 1-F		0.1 2-F	-	0.3 3-F		1.0 4-F		
	DAY 73 No. Observed Normal Blue Tongue SEV		8	100%	8		8 5	62%	8	• • • • • • • •		
	1 2		0				3	38%		88% 12%		
	DAY 74 No. Observed Normal Blue Tongue SEV 1 2		0	100%	0	100%	3	62%		75%		
	DAY 75 No. Observed Normal Blue Tongue		8 8	100%	8	100%	8 4	50%	8 0	25%		
	SEV 1 2		0		0			50%		75% 25%		
	DAY 76 No. Observed Normal Blue Gums SEV		8	100%	8	100%	8 7	88%	8			
	1 Blue Tongue SEV		0							12%		
	1 2		0		0		1	12%		88% 12%		
	DAY 77 No. Observed Normal		8	100%	8	100%	8 7	88%	8			
	Blue Gums SEV 1 Blue Tongue		0		0		0		1	12%		
	SEV 1 2		0		0		1 0	12%		88% 12%		

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



			INCIDENCE	OF OB	SERVA'	TIONS			
 STUDY:	193			SEX	: FEM	ALE .			
		PERIOD	DOSE:(mg/kg) GROUP:	1-	0 F	0.1 2-F	0.3 3-F	1.0 4-F	
•		DAY 78 No. Observed Normal Blue Gums SEV		8 8 100	8	8	88%	8	
		1 Blue Tongue SEV		0	0	0)	1 127	K
		1		0	0	1	12%	8 100%	%
		DAY 79 No. Observed Normal Blue Gums		8 8 100	% 8 °	8 100% 7	88%	8	
		SEV 1 Blue Tongue SEV		0	0	0)	1 125	%
		1 2		0	0	1	12%	7 885 1 125	
		DAY 80 No. Observed Normal Blue Gums SEV		8 8 100	8 % 8		3 3 100%	8 0	
		1 Blue Tongue SEV		0	0	0)	1 12	X
		1		0	0	0)	8 100	%
		DAY 81 No. Observed Normal Blue Gums SEV		8 8 100	8 % 8	100% 7	88%	8 0	
		1 Blue Tongue SEV		0	0	O)	1 12	X
		1 2		0	0	1	12%	7 885 1 125	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

********************		INCIDENCE	OF OBSI	ERVATIONS	S		
STUDY: 193			SEX:	FEMALE			
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	
	DAY 82 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 6 75%	8	
	1 Blue Tongue SEV		0	0	0	1 12%	
	1 2		0	0	2 25% 0	6 75% 2 25%	
	DAY 83 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 8 100%	8 0	
	1 Blue Sclera SEV		0	0	0	1 12%	
	1 Blue Tongue SEV		0	0	0	1 12%	
	1 2		0	0	0	5 62% 3 38%	
	DAY 84 No. Observed Normal Blue Gums SEV		8 8 100%	8 8 100%	8 8 100%	8	
	1 Blue Sclera SEV		0	0	0	1 12%	
	1 Blue Tongue SEV		0	0	0	1 12%	
	1 2		0	0	0	5 62% 3 38%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

DRAFT

	INCIDENCE	OF OBS	
STUDY: 193			FEMALE

3			S	EX:	FEN	ALE	••••					
	PERIOD	DOSE:(mg/kg) GROUP:		1-F		2-F	٠		0.3 3-F		1.0 4-F	
	DAY 85 No. Observed Normal Blue Gums SEV		8		8			8 1	100%	8		
	1 Blue Tongue SEV		0		0		(0		1	12%	
	1		0		0		(0		8	100%	
	No. Observed Normal Blue Gums SEV		8	100%	8	100%		8 1	100%	8	12%	
	1 Blue Sclera		0		0		(0		1	12%	
	SEV 1 Blue Tongue SEV		0		0		1	0		2	25%	
	1 2		0		0			0			75% 12%	
	DAY 87 No. Observed Normal Blue Gums		8	100%	8	100%		8 6	100%	8		
	SEV 1 Blue Sclera		0		0		1	0		1	12%	
	SEV 1 Blue Tongue		0		0		ı	0		1	12%	
	SEV 1 2		0		0			0		1	88% 12%	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



INCIDENCE OF OBSERVATIONS

STUDY: 193			S	EX:	FEN	MALE					
	PER100	DOSE:(mg/kg) GROUP:		0 1-F		0.1 2-F	-	0.3 3-F		1.0 4-F	
	DAY 88				• • • • •						
	No. Observed		8		8		8		8		
	Normal					100%	8	100%	0		
	Blue Gums										
	SEV										
	1		0		0		0		1	12%	
	Blue Sclera										
	SEV										
	1		0		0		0		1	12%	
	Blue Tongue										
	SEV										
	1		0		0		0			75%	
	2		0		0		0		2	25%	
	DAY 89										
	No. Observed		0				0		8		
	Normal			100%		100%			0		
	Blue Gums		0	100%	٥	100%	0	100%	U		
	SEV										
	1		n		n		0		1	12%	
	Blue Sclera				•		•				
	SEV										
	1		0		0		0		1	12%	
	Blue Tongue										
	SEV										
	1		0		0		0			88%	
	2		0		0		0		1	12%	
	DAY 00										
	DAY 90 No. Observed				0		8		8		
	Normal		8	100%		100%		100%	0		
	Blue Gums		0	100%	٥	100%	0	100%	U		
	SEV										
	1		n		n	i	0		1	12%	
	Blue Sclera		0							14.70	
	SEV										
	1		0		0		0		2	25%	
	Blue Tongue										
	SEV						_		7	88%	
	1		0		9		0			12%	
	2		0		()	0		-	16/4	

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



		RECOVERY PE	RIOD II	N DOGS			
		INCIDENCE O	F OBSE	RVATION	S		
STUDY: 193			SEX: 1	FEMALE			
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	- 0.3 3-F	1.0 4-F	
	DAY 91 No. Observed Normal Blue Sclera SEV		8 8 100%	8 8 100%	8 8 100%	8 0	
	1 Blue Tongue SEV		- 0	0	0	1 12%	
	1		0	0	0	8 100%	
	DAY 92 No. Observed Normal Blue Tongue SEV		8 8 100%	8 8 100%	8 7 88%	8	
	1 2		0	0	1 12% 0	7 88% 1 12%	
	DAY 93 No. Observed Scheduled Sacr Normal Blue Gums SEV	ifice	8 4 50% 4 50%	8 4 50% 4 50%	8 4 50% 4 50%	8 4 50% 0	
	1 Blue Tongue SEV		0	0	0	1 12%	
	1 2		0	0	0	3 38% 1 12%	
	DAY 94 No. Observed Normal Blue Gums SEV		4 4 100%	4 100%	4 4 100%	4 1 25%	
			-	-	_		

SEVERITY CODES

0

0

0

2 50% 1 25%

Blue Tongue SEV

2

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)



THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK

		RECOVERY PE	RIOD IN	DOGS			
		INCIDENCE O	F OBSER	VATION	S		
STUDY: 193		••••••••••••	SEX: F	'EMALE			
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	
	DAY 95 No. Observed Normal Blue Tongue SEV		4 4 100%	4 4 100%	4 4 100%	4 1 25%	,
	1		0	0	0	3 75%	
	DAY 96 No. Observed Normal Blue Tongue SEV		4 100%	4 4 100%	4 100%	4	
	1		0	0	0	4 100%	
	DAY 97 No. Observed Normal Blue Tongue SEV		4 100%	4 4 100%	4 4 100%	4 1 25%	
	1		0	0	0	3 75%	
	DAY 98 No. Observed Normal Blue Tongue SEV 1		4 100%	4 4 100%	4 100%	4 2 50% 2 50%	
	DAY 99						
	No. Observed Normal Blue Tongue SEV		4 100%	4 4 100%	4 4 100%	3 75%	
	1		0	0	0	1 25%	
	DAY 100						
	No. Observed Normal		4 100%	4 4 100%	4 4 100%	4 100%	

SEVERITY CODES

Observation	Severity No.	<u>Description</u>
Blue Gums/	1	Mild (easily seen, blue color)
Blue Tongue/ Blue Sclera	2	Severe (intense, harsh, blue-purple color)

	THIR	TEEN WEEK ORA WR242511 WITH RECOVERY PE	A THIF	TEEN W	UDY OF EEK		AFT	
•••••••		INCIDENCE O	F OBSER	RVATION	S			
STUDY: 193			SEX: F	EMALE				
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	- 0.3 3-F	1.0 4-F		
	DAY 101 No. Observed Normal Blue Tongue SEV		4 4 100%	4 4 100%	4 4 100%	4 3 75%		••
	1		0	0	0	1 25%		
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%		
	DAY 103 No. Observed Normal Blue Tongue SEV		4 4 100%	4 4 100%	4 4 100%	4 3 75%		
	1		0	0	0	1 25%		
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%		
	DAY 105 No. Observed Normal Blue Tongue SEV 1		4 4 100%	4 100%	4 100%	4 3 75%		
	DAY 106		U	0	U	1 23/1		
	No. Observed Normal Blue Tongue SEV		4 100%	4 4 100%	4 4 100%	4 3 75%		
	1		0	0	0	1 25%		
	OAY 107 No. Observed Normal Blue Tongue		4 4 100%	4 100%	4 4 100%	4 3 75%		

SEVERITY CODES

0

1 25%

SEV

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

TMOTDENCE	OT	ODGEDITA MITORG
TMCTDEMCE	UF	OBSERVATIONS

		THOTDENCE OF	1	CDSE	TIC A T	SITON				
STUDY: 193			S	EX:	FEI	MALE				
	PERIOD	DOSE:(mg/kg) GROUP:		0 1-F		0.1 2-F		0.3 3-F		1.0 4-F
	DAY 108									
	No. Observed		4		4		4		4	
	Normal		4	100%	4	100%	4	100%	3	75%
	Blue Tongue									
	SEV									
	1		0		0		0		1	25%
	0.1V 100									
	DAY 109 No. Observed		,		,		,		,	
	Normal		4	100%	4	100%	4	100%	4	75%
	Blue Tongue		4	100%	-	100%	4	100%	_	13%
	SEV									
	1		0		0		0		1	25%
	DAY 110									
	No. Observed		4		4		4		4	-
	Normal		4	100%	4	100%	4	100%	5	75%
	Blue Tongue SEV									
	1		0		0		0		1	25%
	,		O				U			23%
	DAY 111									
	No. Observed		4		4		4		4	
	Normal		4	100%	4	100%	4	100%	3	75%
	Blue Tongue									
	SEV						•			254
	1		0		0		0		1	25%
	DAY 112									
	No. Observed		4		4		4		4	
	Normal			100%		100%	4	100%	3	75%
	Blue Tongue									
	SEV									
	1		0		0		0		1	25%
	DAY 113									
	No. Observed		4		4		4		4	
	Normal		4	100%	4	100%	4	100%	2	50%
	Blue Tongue									
	SEV						_		-	F04
	1		0		C)	0		2	50%

Observation	Severity No.	Description
Blue Gums/	. 1	Mild (easily seen, blue color)
Blue Tongue/	2	Severe (intense, harsh, blue-purple color)
Blue Sclera		



 			INCIDENCE OF	F	OBSE	RV	ATIONS	•			
 STUDY:	193		***************************************		EX:						
 		PERIOD	DOSE:(mg/kg) GROUP:		0 1-F		0.1 2-F		0.3 3-F		1.0 4-f
		DAY 114 No. Observed Normal Blue Tongue SEV		4	100%	4	100%	4	100%	4 2	50%
		1		0		0	1	0		2	50%
		OAY 115 No. Observed Normal Blue Tongue SEV		4	100%	4	100%	4	100%	4 2	50%
		1		0		0	1	0		2	50%
		OAY 116 No. Observed Normal Blue Tongue SEV		4	100%	4	100%	4	100%		75%
		1		0		0)	0		1	25%
		DAY 117 No. Observed Normal		4	100%	4	100%	4	100%	4	100%
		No. Observed Normal Blue Tongue SEV			100%	4	100%	4 4	100%		75% 25%
		1 OAY 119 No. Observed Normal		0 4 4	100%	4	100%	4	100%	4	100%

Observation	Severity No.	<u>Description</u>
Blue Gums/ Blue Tongue/	1 2	Mild (easily seen, blue color) Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF D A F TWO RECOVERY PERIOD IN DOGS

		INCIDENCE	OF OBSER	VATIONS		
STUDY: 193			SEX: F	EMALE		
,	PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
	DAY 120 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%
	DAY 121 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%
	DAY 122 No. Observed Normal		4 100%	4 100%	4 100%	4 100%
	DAY 123 No. Observed Normal		4 100%	4 100%	4 100%	4 100%
	DAY 124 No. Observed Normal		4 100%	4 4 100%	4 100%	4 4 100%
	DAY 125 No. Observed Normal		4 100%	4 4 100%	4 100%	4 100%
	DAY 126 No. Observed Normal		4 100%	4 4 100%	4 100%	4 100%
	DAY 127 No. Observed Normal		4 100%	4 4 100%	4 100%	4 4 100%
	DAY 128 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%
	DAY 129 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%

DRAFT

 			INCIDENCE	OF OBSI	ERVATION	S		
STUDY:	193			SEX:	FEMALE			
		PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	
		DAY 130 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		DAY 135 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		No. Observed Normal		4 4 100%	4 4 100%	4 100%	4 4 100%	
		No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	

DRAFT

			INCIDENCE	OF OBSE	RVATION	S		
STUDY:	193			SEX:	FEMALE			
		PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	
		DAY 141 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		DAY 142 No. Observed Normal		- 4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		DAY 143 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		DAY 144 No. Observed Normal		4 4 100%	4 100%	4 4 100%	4 4 100%	
		DAY 145 No. Observed Normal		4 4 100%	4 4 100%	4 100%	4 4 100%	
		DAY 146 No. Observed Normal		4 4 100%	4 4 100%	4 100%	4 4 100%	
		DAY 147 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		DAY 148 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	
		DAY 149 No. Observed Normal		4 4 100%	4 100%	4 100%	4 4 100%	
		DAY 150 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%	

THIRTEEN WEEK ORAL TOXICITY STUDY OF STATE OF ST

		INCIDENCE OF	OBS	ERVATIONS		
STUDY: 193		(SEX:	FEMALE		
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
	DAY 151 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 100%
	DAY 153 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%
	DAY 154 No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 4 100%
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 100%
	No. Observed Normal		4 100%	4 100%	4 4 100%	4 100%
	No. Observed		4 4 100%	4 4 100%	4 4 100%	4 100%
	DAY 158 No. Observed Normal		4 4 100%	4 100%	4 4 100%	4 100%
	DAY 159 No. Observed Normal		4 4 100%	4 100%	4 100%	4 100%
	No. Observed Normal		4 4 100%	4 4 100%	4 4 100%	4 100%

 			INCIDENCE (OF	OBSI	ERVA	TIONS	3			
STUDY:	193			S	EX:	FEM	ALE				
 		PERIOD	DOSE:(mg/kg) GROUP:		0 1- F		0.1 2-F		0.3 3-F		1.0 4-F
		DAY 161 No. Observed Normal			100%	4	100%	4	100%	44	100%
		No. Observed Normal			100%	4	100%	4	100%	4	100%
		DAY 163 No. Observed Normal			100%	4	100%	4	100%	4	100%
		No. Observed Normal			100%	4	100%	4	100%		100%
		DAY 165 No. Observed Normal			100%	4	100%	4	100%		100%
		No. Observed Normal		4	100%	4	100%	4	100%	4	100%
		DAY 167 No. Observed Normal			100%	4	100%	4	100%		100%
		No. Observed Normal			100%	4	100%	4	100%	4	100%
		No. Observed Normal		4	100%	4	100%	4	100%	4	100%
		No. Observed		4	100%		100%	4	100%		100%

DRAFT

TNCTDENCE	OF	OBSERVATIONS
TIME TIME NEW	() H.	OBSERVATIONS

		THCIDENCE	OF OBSI	ERVATION	S	
STUDY: 193			SEX:	FEMALE		
	PERIOD	OOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
	DAY 171 No. Observed		4	,	,	4
	Normal		4 100%	4 100%	4 100%	4 100%
	DAY 172 No. Observed		4	4	4	4
	Normal		4 100%	4 100%	4 100%	4 100%
	OAY 173 No. Observed		4	4	4	4
	Normal		4 100%	4 100%	4 100%	4 100%
	No. Observed		4	4	4	4
	Normal DAY 175		4 100%	4 100%	4 100%	4 100%
	No. Observed		4 100%	4 4 100%	4 100%	4 4 100%
	OAY 176		4 100%	4 100%	7 100%	7 10011
	No. Observed Normal		4 4 100%	4 100%	4 100%	4 4 100%
	DAY 177					
	No. Observed Normal		4 100%	4 100%	4 100%	4 100%
	DAY 178 No. Observed		4	4	4	4
	Normal		4 100%	4 100%	4 100%	4 100%
	DAY 179 No. Observed		4	4	4	4
	Normal		4 100%	4 100%	4 100%	4 100%
	No. Observed		4	4	4	4
	Normal		4 100%	4 100%	4 100%	4 100%
	DAY 181 No. Observed		4	4	4	4
	Normal		4 100%	4 100%	4 100%	4 100%

DRAFT

***************************************		INCIDENCE	OF OBSI	ERVATION	1S		
STUDY: 1	L93		SEX:	FEMALE			
	PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	
	DAY 182 No. Observed Normai		4 4 100%	4 4 100%	4 4 100%	4 4 100%	•
	DAY 183 No. Observed Normat		4 4 100%	4 4 100%	4 100%	4 4 100%	
	DAY 184 No. Observed Scheduled Sac	rifice	4 4 100%	4 4 100%	4 4 100%	4 100%	

APPENDIX D

Individual Body Weights and Body Weight Gains



				IN	DIVID	UAL BO	DY WE	IGHTS	(Kilogram	s)			
ST	UDY: 1	93		GR DO		1-M 0(mg/k	a)	SE	X: MA	LE			
ANIMAL #	DAY -5	DAY 3	DAY 7		DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
				4					_				
8656	10.3	10.1	10.3	10.5	10.4	10.1	10.4	10.3	10.4	10.4	10.2	10.6	
8687	10.8	10.9	11.0	11.7	11.4	11.5	11.7	11.5	11.8	11.6	11.6	11.8	
8669	11.8	11.8	12.1	12.1	11.5	12.2	12.4	12.3	12.4	12.5	12.3	12.9	
8673	11.8	12.1	12.1	12.5	12.2	12.3	12.0	12.1	12.3	11.9	12.0	12.1	
8667	10.0	10.4	10.5	10.5	10.5	10.6	10.7	10.5	10.5	10.5	10.6	10.6	
8654	10.9	10.7	10.7	10.8	10.6	10.9	10.5	10.4	10.6	10.5	10.3	10.4	
8680	11.6	12.0	12.1	12.1	12.2	12.4	12.4	12.3	12.5	12.4	12.2	12.7	
8676	13.6	13.6	13.6	13.5	13.5	13.7	13.8	13.8	14.1	13.8	13.7	14.0	
MEAN	11.4	11.5	11.6	11.7	11.5	11.7	11.7	11.7	11.8	11.7	11.6	11.9	
S.D.	1.13	1.15	1.12	1.06	1.07	1.17	1.17	1.22	1.28	1.20	1.20	1.29	
N	8	8	8	8	8	8	8	8	8	8	8	8	
					:	Data Unav	ailable						

DRAFT

		IN	DIVID	JAL BO	DY WE	IGHTS	(Kilograms)	
STUDY: 193		GR DO:	OUP: 1 SE: 0	-M (mg/k	g)	SE	X: MALE	
	ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	
	-/-/	40.0	40.7	40.7	40.7	40.0	40.	
	8656	10.9	10.7	10.6	10.7	10.9	10.8	
	8687	11.5	11.6	11.6	11.6	11.3	11.3	
	8669	12.4	12.3	12.4	12.3	12.6	12.7	
	8673	12.3	12.3	12.4	12.4	12.4	12.0	
	8667	11.1	11.0	11.3	11.1	11.2	11.2	
	8654	10.5	10.4	10.6	10.3	10.2	10.1	
	8680	12.7	12.9	13.1.	13.4	13.1	13.2	
	8676	14.0	14-2	14.4	14.5	14.4	14.5	
	MEAN	11.9	11.9	12.1	12.0	12.0	12.0	
	S.D.	1.15	1.26	1.30	1.41	1.37	1.43	
	N	8	8	8	8	8	8	
			: 1	Data Unava	ailable			



				IN	DIVID	JAL BO	DY WE	IGHTS	(Kilogram	s)		
ST	UDY: 1	93	,			2-M 0.1(mg	/ka)	SE	X: MA	LE		
ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14		DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
				40.4			44 .					
8685	10.4	10.5	10.5	10.6	10.7	10.4	10.6	10.5	10.6	10.1	10.2	10.5
8679					••			• •				
8663	11.5	11.7	11.9	12.0	11.8	12.0	12.1	12.0	12.0	12.1	12.0	12.2
8686	11.9	11.7	11.4	11.8	11.5	11.7	11.5	11.2	11.8	11.5	11.2	10.1
8665	10.7	10.8	10.8	10.8	10.7	10.9	10.9	10.9	10.9	10.9	11.0	11.2
8666	11.6	11.5	11.7	11.6	11.6	11.7	11.7	11.6	11.8	11.4	11.5	11.7
8655	11.8	11.8	11.7	11.8	11.8	11.7	11.9	11.7	11.7	11.9	11.9	12.1
8659	12.0	11.7	11.9	11.8	11.9	12.0	12.2	12.0	11.8	11.9	11.7	12.1
8677	12.0	12.2	12.6	12.5	12.7	12.7	12.7	12.5	12.8	12.9	12.7	13.2
MEAN	11.5	11.5	11.6	11.6	11.6	11.6	11.7	11.6	11.7	11.6	11.5	11.6
S.D.	0.61	0.56	0.66	0.62	0.66	0.70	0.69	0.65	0.67	0.84	0.75	1.00
N	8	8	8	8	8	8	8	8	8	8	8	8
	: Data Unavailable											



			IN	DIVID	JAL BO	DY WE	IGHTS	(Kilograms)	 	
 STUDY:	193		GR DO	OUP: 2 SE: 0	2-M).1 (mg	/ka)	SI	EX: MALE		
	cient course	ANIMAL #	DAY 54		DAY 69	DAY 76	DAY 83	DAY 90	 	
 		0/05	10 /	10.1	10.7	10.7	10 /	10 /		
		8685 8679	10.4	10.1	10.3	10.3	10.4	10.4		
		8663	12.5	12.4	12.6	12.5	12.6	12.6		
		8686	10.3	11.0	11.1	11.3	11.3	11.2		
		8665	11.1	11.1	11.3	10.7	11.3	11.4		
		8666	11.8	11.6	12.0	11.7	11.7	11.8		
		8655	12.0	11.7	12.4	12.2	12.2	12.0		
		8659	12.4	12.4	12.5	12.4	12.5	12.2		
		8677	13.4	13.2	13.4	13.4	13.6	13.6		
		MEAN	11.7	11.7	12.0	11.8	12.0	11.9		
		S.D.	1.08	0.97	0.99	1.02	0.99	0.96		
		N	. 8	8	8	8	8	8		
				:	Data Unav	ailable				



	INDIVIDUAL BODY WEIGHTS (Kilograms)													
-	ST	JDY: 1	93				3-M 0.3(mg	/ka)	SE	SEX: MALE				
	ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 1D	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
-	8674 8653	10.3	9.8 11.8	9.7 11.5	9.9 11.6	10.1	10.2	10.4	10.5	10.8	10.7	10.7	10.8	
	8660 8668	11.7	11.8	11.8 12.6	11.9 12.7	11.9 12.8	11.9 12.9	11.9 13.0	12.0 12.8	11.9 12.7	12.0 12.7	12.0 12.4	12.0 12.5	
	8682 8684 8662	10.8 10.6 11.6	10.4 10.9 11.8	10.4 11.1 11.7	10.6 11.1 12.1	10.2 10.9 11.5	9.8 11.1 11.5	10.1 11.2 11.5	9.8 11.2 11.4	10.0 11.1 11.5	9.4 11.0 11.1	9.3 11.1 10.8	9.2 11.3 10.6	
	8688	12.2	12.4	12.5	12.5	12.6	12.9	13.1	12.9	13.1	13.1	12.7	13.1	
	MEAN S.D. N	11.4 D.74 8	11.4 D.96 8	11.4 D.99 8	11.6 0.96 8	11.4 1.DD 8	11.5 1.12 8	11.6 1.09 8	11.5 1.08 8	11.5 1.03 8	11.3 1.21 8	11.2 1.12 8	11.2 1.26 8	
							Data Unav	a i labia						



		IN	DIVIDU	JAL BO	DY WE	IGHTS	(Kilograms)	
STUDY: 193			OUP: 3		/ka)	SE	X: MALE	
	ANIMAL #				DAY 76	DAY 83	DAY 90	
	04.14	10.0	10.7	10.0	10.0	44.0	10.7	
	8674 8653	10.8 10.3	10.7 10.0	10.8 9.6	10.8 9.2	11.0 8.9	10.6 8.8	
	8660	12.1	11.9	12.2	12.1	12.1	12.0	
	8668	12.4	12.3	12.5	12.1	12.1	10.2	
	8682	9.2	9.2	9.3	9.1	9.0	9.0	
	8684	11.2	11.1	11.2	11.3	11.4	11.3	
	8662	10.9	10.4	10.6	10.3	10.4	10.4	
	8688	13.4	13.5	13.5	13.4	13.6	13.4	
	MEAN	11.3	11.1	11.2	11.0	11.1	10.7	
	S.D.	1.31	1.38	1.45	1.49	1.61	1.52	
	N	8	8	8	8	8	8	

--: Data Unavailable



				IN	DIVID	JAL BO	DY WE	IGHTS	(Kilogram	s)			
ST	UDY: 1	93		GR DO		1-M 1.0(mg	/kg)	SE	X: MA	LE			
ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
9441	11.0	10.6	10.9	10.8	10.7	10.8	10.8	10.6	10.6	10.3	10.2	10.3	
8661 8670	10.6	10.6	10.5	10.7	10.3	10.3	10.3	10.3	10.3	10.1	10.1	10.2	
8681	11.6	12.0	12.0	12.2	11.8	12.0	11.8	11.8	12.1	11.8	11.8	12.0	
8664	12.0	12.2	12.2	12.3	11.9	11.9	11.7	11.5	11.3	10.9	10.7	11.2	
8675	10.3	10.5	10.4	10.6	10.4	10.4	10.5	10.3	10.5	10.2	10.3	10.6	
8683	10.9	11.3	11.4	11.0	10.9	10.8	10.9	10.9	10.9	10.9	11.0	11.5	
8658	11.5	11.3	11.4	11.3	10.9	10.8	10.8	10.6	10.6	10.4	10.3	10.3	
8652	12.5	12.5	12.5	12.3	12.3	12.2	12.3	12.0	11.9	12.0	11.9	11.6	
MEAN	11.3	11.4	11.4	11.4	11.2	11.2	11.1	11.0	11.0	10.8	10.8	11.0	
S.D.	0.74	0.79	0.78	0.75	0.75	0.76	0.71	0.68	0.67	0.73	0.72	0.70	
N	8	8	8	8	8	8	8	8	8	8	8	8	
					:	Data Unav	ailable						

THIRTEEN WEEK ORAL TOXICITY STUDY OF RECOVERY PERIOD IN DOGS

 			IND	IVIDU	AL BO	DY WEI	GHTS ((Kilograms)		
 STUDY:	193		GRC DOS	UP: 4 E: 1	.0 (mg	/kg)	SE	X: MALE		
		ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	 	
 			40.3	40 (40.4	40.5	40.5	40. /		
		8661	10.7	10.6	10.6	10.5	10.5	10.4		
		8670	10.3	10.3	10.3	10.2	9.8	9.8		
		8681	12.0	12.1	12.4	12.1	12.0	12.0		
		8664	11.2	11.3	11.2	11.1	11.2	11.3		
		8675	10.1	10.0	10.0	9.9	10.0	10.0		
		8683	11.4	11.3	11.5	11.5	11.7	11.3		
		8658	10.7	10.7	10.8	10.6	10.5	10.6		
		8652	11.9	11.8	12.0	11.9	12.0	11.9		
		MEAN	11.0	11.0	11.1	11.0	11.0	10.9		
		S.D.	0.70	0.73	0.83	0.80	0.88	0.84		
		N	8	8	8	8	8	8		
				: D	ata Unava	ilable				



INDIVIDUAL BODY WEIGHTS (Kilograms)													
				TIV.	DIATD	JAT BO	DY WE.	IGHTS	(Kilograms	5)			
STUDY: 193 GROUP: 1-F SEX: FEMALE													
				DO	SE: 0	(mg/k)	a)						
ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10		DAY 17		DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
						*********						• • • • • • • • • • •	
8721	8.5	8.7	8.7	8.8	8.8	8.7	9.0	8.9	8.7	8.5	8.6	8.7	
8712	9.6	9.4	9.5	9.3	9.5	9.8	9.9	9.5	9.3	9.4	9.3	9.7	
8710	10.0	10.0	10.3	10.5	10.6	10.4	10.6	10.4	10.6	10.6	10.7	10.9	
8723	10.8	10.9	10.8	10.7	10.6	10.8	11.0	10.7	10.7	10.7	11.1	11.1	
8705	8.6	8.7	8.9	8.8	8.9	8.7	9.0	9.0	8.9	9.2	9.3	9.5	
8700	10.1	10.0	10.2	10.2	10.1	9.9 -	10.2	9.8	10.3	10.2	10.1	10.2	
8699	10.4	10.5	10.5	10.7	10.4	10.7	10.9	10.8	10.6	10.6	10.6	10.8	
8690	10.3	10.9	11.0	11.0	10.8	10.7	10.6	10.5	10.5	10-4	10.6	10.5	
MEAN	9.8	9.9	10.0	10.0	10.0	10.0	10.2	10.0	10.0	10.0	10.0	10.2	
S.D.	0.84	0.89	0.86	0.90	0.79	0.86	0.79	0.76	0.84	0.81	0.87	0.82	
N	8	8	8	8	8	8	8	8	8	8	8	8	
					:	Data Unava	ilable						

DRAFT

		IN	DIVID	JAL BO	DY WE:	IGHTS	(Kilograms)	+	
STUDY: 193		GRO		-F (mg/k	a)	SE	X: FEMAI	Æ	
	ANIMAL #		DAY 62	DAY 69	DAY 76	DAY 83	DAY 90		
	0.704	0.7	0.5						
	8721	8.7	8.5	8.4	8.8	8.8	8.9		
	8712	10.2	9.9	10.2	10.3	10.3	10.2		
	8710	11.3	11.0	11.2	11.1	11.3	11.2		
	8723	10.7	10.9	10.5	10.6	10.7	11.2		
	8705	9.3	8.8	9.0	9.0	9.1	8.8		
	8700	10.0	9.9	10.0	9.9	9.9	9.7		
	8699	10.9	10.8	10.7	10.9	10.8	11.0		
	8690	10.9	10.7	10.9	10.9	11.0	11.0		
	MEAN	10.3	10.1	10.1	10.2	10.2	10.3		
	S.D.	0.89	0.97	0.96	0.88	0.90	1.01		
	N	8	8	8	8	8	8		
			:	Data Unav	ailable				



				IN	DIVID	UAL BO	DY WE	IGHTS	(Kilogram	s)			
 ST	UDY: 1	93			OUP: :	2-F 0.1(mg	/ka)	SE	EX: FE	MALE			
ANIMAL #	DAY -5	DAY 3	DAY 7			DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
8717	7.4	7.3	7.4	7.4	7.4	7.1	7.5	6.9	6.6	7.1	7.1	7.9	
8703	9.6	9.7	9.7	10.0	9-8	9.8	10.1	9.5	9.8	9-4	9.5	9.5	
8713	10.5	10.4	10.3	10.7	10.5	10.7	10.7	10.7	10.9	10.6	10.4	10.6	
8693	11.3	11.0	11.0	11.2	11.1	11.3	11.4	11.1	11.4	11.1	11.3	11.7	
8695	8.3	8.3	8.2	8.4	8.3	8.6	8.2	8.5	8.5	8.6	8.7	8.8	
8709	9.5	9.4	9.3	9.5	9.1	9.2	9.3	9.4	9.2	9.2	9.2	9.4	
8715	10.3	10.1	10.3	10.6	10.6	10.4	10.6	10.3	10.3	10.2	10.4	10.9	
8697	10.9	11.2	11.5	11.4	11.4	11.3	11.6	11.6	11.6	11.6	11.8	11.8	
MEAN	9.7	9.7	9.7	9.9	9.8	9.8	9.9	9.8	9.8	9.7	9.8	10.1	
S.D.	1.33	1.33	1.38	1.40	1.41	1.45	1.48	1.53	1.67	1.46	1.51	1.40	
N	8	8	8	8	8	8	8	8	8	8	8	8	
					:	Data Unav	ailable						

		IN	DIVID	JAL BO	DY WE	IGHTS	(Kilograms)		
STUDY: 193	ANIMAL #	DO:	OUP: 2 SE: (DAY 62	2-F 0.1 (mg DAY 69	/kg) DAY 76		EX: FEMA	ALE	
	8717 8703 8713 8693 8695 8709 8715 8697 MEAN S.D. N	7.6 9.6 11.0 11.7 8.7 9.7 10.8 12.0 10.1 1.52 8	7.9 9.4 11.0 12.0 8.6 9.3 10.8 12.4 10.2 1.62 8	8.2 9.3 11.2 12.2 8.7 9.3 11.0 12.3 10.3 1.60 8	8.3 9.2 11.2 11.8 8.8 9.3 10.7 12.5 10.2 1.53 8	8.3 9.3 10.8 11.9 8.7 9.6 10.8 12.6	8.7 8.9 11.2 11.9 8.9 9.7 10.8 12.5		

				IN	DIVID	UAL BO	DY WE	IGHTS	(Kilogram	s)			
ST	UDY: 1	93				3-F 0.3(mg	/kg)	SE	X: FE	MALE			,
ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
			0.5	0.5		7.0			0.4	7.0	7.0		
8692	8.7	8.6	8.5 9.2	8.5 9.4	8.3 9.5	7.9 9.8	8.1	8.0 9.9	8.1 10.2	7.9 9.7	7.9 9.7	8.0	
8718 8706	9. 3 10.4	9.2 10.7	10.7	10.7	10.5	10.5	10.6	10.6	10.2	10.6	10.6	9.9 10.6	
8714	11.1	11.2	11.2	11.8	11.5	11.5	11.7	11.2	11.2	11.3	11.3	11.6	
8701	9.0	8.9	8.9	9.1	9.0	9.0	9.1	8.8	8.9	8.8	8.6	8.9	
8702	9.2	9.0	8.9	8.9	8.7	8.5	8.5	8.5	8.4	7.9	7.9	7.8	
8720	10.3	10.3	10.3	10.1	10.4	10.3	10.3	10.4	10.3	10.4	10.0	10.4	
8704	10.7	10.8	10.5	10.9	10.7	10.9	10.5	10.4	10.7	10.6	10.6	10.5	
MEAN	9.8	9.8	9.8	9.9	9.8	9.8	9.8	9.7	9.8	9.7	9.6	9.7	
S.D.	0.89	1.02	1.01	1.14	1.12	1.24	1.20	1.15	1.19	1.31	1.30	1.35	
N	8	8	8	8	8	8	8	8	8	8	8	8	
						Data linav	ailable						

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	DI NE.	LGIIID	(Kitogi ams)	
STUDY: 193		DO	SE: (3-F 3.3(mg	/kg)		X: FEMALE	
	ANIMAL #	DAY 54	DAY 62	DAT 69	DAY 76	DAY 83	DAY 90	
						• • • • • • • • • • • • • • • • • • • •		
	8692	8.1	8.0	8.1	8.3	8.2	8.3	
	8718	10.2	10.1	10.0	9.9	9.6	9.7	
	8706	10.7	10.3	10.5	10.2	10.3	10.2	
	8714	11.8	11.7	11.7	12.0	12.0	12.2	
	8701	9.1	9.0	9.1	9.0	9.1	8.9	
	8702	8.0	7.8	7.9	7.9	7.8	7.6	
	8720	10.4	10.4	10.6	10.4	10.3	10.4	
	8704	10.4	10.3	10.7	10.7	10.8	10.9	
	MEAN	9.8	9.7	9.8	9.8	9.8	9.8	
	S.D.	1.33	1.33	1.34	1.35	1.38	1.48	
	N	8	8	8	8	8	8	
			:	Data Unav	ailable			



				IN	DIVID	JAL BO	DY WE	IGHTS	(Kilogram	s)			_
ST	UDY: 1	93				1-F L.0(mg	/ka)	SE	X: FE	MALE			-
ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14		DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
0/0/		0.5	0 /	0.7	0.7	0.7	0 /	0 /				. 7	•
8696	8.6	8.5	8.4	8.3	8.3	8.3	8.4	8.4	8.2	8.2	8.2	8.3	
8719	9.3	9.4	9.4	9.5	9.4	9.3	9.5	8.9	9.3	9.3	9.2	9.2	
8711	10.4	10.1	9.8	10.0	9.7	10.6	9.6	9.6	9.5	9.1	9.1	9.3	
8716	10.4	10.3	10.2	10.3	10.1	9.8	10.0	9.9	9.8	9.6	9.8	10.0	
8725	8.5	8.3	8.3	8.0	7.5	7.4	7.5	7.5	7.6	7.8	7.8	7.8	
8707	9.7	9.7	9.4	9.5	9.1	9.3	9.2	9.2	9.3	9.1	9.1	9.4	
8689	10.3	10.0	9.9	10.0	9.9	9.7	9.6	9.6	9.6	9.6	9.6	9.6	
8722	10.9	10.4	10.1	9.8	9.7	9.4	9.5	9.4	9.3	9.4	9.5	9.4	
MEAN	9.8	9.6	9.4	9.4	9.2	9.2	9.2	9.1	9.1	9.0	9.0	9.1	
S.D.	0.89	0.80	0.73	0.83	0.89	0.98	0.82	0.79	0.76	0.66	0.69	0.72	
N	8	8	8	8	8	8	8	8	8	8	8	8	
					*	Data linav	ailahla						

DRAFT

			IN	DIVIDU	AL BO	DY WE	GHTS	(Kilograms)		
 STUDY:	193	ANIMAL #	DO:	OUP: 4 SE: 1 DAY 62	.0 (mg	/kg)		X: FEMA	ALE	
 		ANIPAL #	DA1 34	DAT OZ	DAI 09	DAI 70	DAI 03	DA-1 70		 Laboration of the Contract of
		8696	8.3	8.3	8.1	8.4	8.4	8.3		
		8719	9.7	9.4	9.1	8.9	9.2	9.1		
		8711	9.6	9.4	9.6	9.8	9.8	9.7		
		8716	10.0	10.1	10.3	10.1	10.2	10.3		
		8725	7.9	8.0	7.9	7.8	7.8	7.8		
		8707	9.4	9.0	8.7	9.0	9.2	9.2		
		8689	9.7	9.6	9.7	9.9	9.6	9.5		
		8722	9.4	9.2	9.2	9.0	8.8	8.8		
		MEAN	9.3	9.1	9.1	9.1	9.1	9.1		
		S.D.	0.74	0.69	0.82	0.79	0.78	0.79		
		N	8	8	8	8	8	8		
				: 0	ata Unava	ilable				



	INDIVIDUAL BODY WEIGHTS (Kilograms)													
ST	JDY: 1	.93				1-M 0(mg/}	ca)	SI	EX: MA	LE				
ANIMAL #	DAY 97	DAY 104	DAY 111		DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181		
8656	ь	ь	b	b b	Ь	b	b	Ь	Ь	Ь	þ	b		
8687	b	ь	b	b	b	b	b	b	b	ь	ь	b		
8669	b	b	b	b	b	b	b	b	b	b	b	b		
8673	b	b	b	ь	b	b	b	b	b	b	b	b		
8667	11.2	11.4	11.3	11.5	11.3	11.5	11.5	11.2	11.1	11-1	11.1	11.3		
8654	10.3	10.5	10.3	10.0	9.8	10.1	10.2	9.8	10.1	9.7	9.8	10.8		
8680	12.9	13.2	12.7	13.2	13.4	13.4	13.4	13.3	13.2	13.4	13.6	13.9		
8676	14.3	14.6	14.4	15.1	14.9	15.2	15.4	15.3	15.7	16.0	16.0	16.3		
MEAN	12.2	12.4	12.2	12.5	12.4	12.6	12.6	12.4	12.5	12-6	12.6	13.1		
S.D.	1.78	1.83	1.78	2.20	2.25	2.22	2.27	2.41	2.48	2.76	2.75	2.54		
N	4	4	4	4	4	4	4	4	4	4	4	4		
				: Data	Unavaila	ble b	: Schedul	ed Sacrit	ice					



	INDIVIDUAL BODY WEIGHTS (Kilograms)													
ST	UDY: 1	.93				2-M 0.1 (mg	a/ka)	SI	EX: MA	LE				
ANIMAL #	DAY 97	DAY 104	DAY 111		DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181		
8685	Ь	Ь	ь	Ь	ь	Ь	ь	ь	b	b	Ь	b		
8679														
8663	b	ь	ь	ь	Ь	ь	b	b	b	ь	ь	Ь		
8686	b	b	b	b	b	b	b	b	b	b	b	b		
8665	11.4	11.6	11.3	11.8	11.6	11.9	11.9	11.8	11.8	11.7	11.9	12.2		
8666	11.7	12.4	11.7	11.9	11.9	12.0	12.0	11.8	11.8	11.8	11.6	12.0		
8655	11.8	12.0	11.7	12.2	12.0	12.1	12.2	11.9	11.7	12.0	12.2	12.6		
8659	12.3	12.4	12.2	12.3	12.3	12.3	12.2	12.2	11.6	11.9	11.7	11.7		
8677	b	b	b	b	b	b	b	b	b	b	b	b		
MEAN	11.8	12.1	11.7	12.1	12.0	12.1	12.1	11.9	11.7	11.9	11.9	12.1		
S.D.	0.37	0.38	0.37	0.24	0.29	0.17	0.15	0.19	0.10	0.13	0.26	0.38		
N	4	4	4	4	4	4	4	4	4	4	4	4		
				: Data	Unavaila	able I	o: Schedul	ed Sacrif	ice					

				IN	DIVID	UAL BO	DY WE	IGHTS	(Kilogram	ns)				
STU	UDY: 1	.93			COUP:	3-M 0.3 (mg	ı/ka)	SI	EX: MA	LE				
ANIMAL #	DAY 97	DAY 104	DAY 111			DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181		
	40.7	40.0	10.7	10.0	10.0	40.7	40.5	40.7	40 /	40.4	40.5	40.0		
8674	10.7	10.9	10.7	10.8	10.8	10.7	10.5	10.3	10.4	10.4	10.5	10.8		
8653	Ь	Ь	Ь	Ь	Ь	ь	Ь	Ь	b	Ь	Ь	Ь		
8660	Ь	b	b	ь	Ь	Ь	Ь	b	b	b	Ь	b		
8668	ь	b	ь	ь	b	b	b	b	b	b	ь	ь		
8682	8.8	9.1	8.7	8.5	8.9	9.1	9.1	9.0	9.2	9.3	9.3	9.6		
8684	Ь	b	b	b	b	b	Ь	b	b	b	b	b		
8662	10.5	10.7	10.8	10.9	10.8	10.9	11.0	10.8	11.0	11.1	10.7	11.1		
8688	13.4	13.8	13.1	14.2	13.8	14.1	14.1	14.1	13.9	14.4	14.3	14.4		
MEAN	10.9	11.1	10.8	11.1	11.1	11.2	11.2	11.1	11.1	11.3	11.2	11.5		
S.D.	1.90	1.96	1.80	2.35	2.03	2.09	2.11	2.17	2.00	2.20	2.16	2.05		
N	4	4	4	4	4	4	4	4	4	4	4	4		
				: Data	Unavail	able b	: Schedul	ed Sacrif	ice					

	INDIVIDUAL BODY WEIGHTS (Kilograms)													
	INDIVIDUAL BODY WEIGHTS (Kilograms)													
ST	JDY: 1	93			OUP:		r/ka)	SE	X: MA	LE				
ANIMAL #	DAY 97	DAY 104	DAY 111					DAY 146	DAY 153	DAY 160	DAY 167	DAY 181		
0//4	L	L	_			_	_	_			_			
8661	ь	ь	Ь	Ь	р	b	b	b	b	b	Ь	Ь		
8670	Ь	D	D	Ь	Ь	D	Ь	Ь	D	D	Ь	Ь		
8681	Ь	Ь	Ь	Ь	Ь	Ь	b	b	ь	b	Ь	b		
8664	Ь	ь	ь	Ь	ь	Ь	Ь	Ь	Ь	Ь	Ь	ь		
8675	10.1	10.4	10.4	10.4	10.8	11.0	11.2	11.0	11.2	11.3	11.5	11.8		
8683	11.3	11.8	11.5	11.9	11.9	12.2	12.0	11.9	12.0	12.4	12.5	12.4		
8658	10.1	10.1	9.7	9.8	9.7	9.6	9.3	9.0	9.3	9.2	9.3	9.9		
8652	11.8	12.1	11.7	12.4	12.3	12.5	12.3	12.3	12.4	12.6	12.7	13.4		
MEAN	10.8	11.1	10.8	11.1	11.2	11.3	11.2	11.1	11.2	11.4	11.5	11.9		
S.D.	0.86	1.00	0.94	1.23	1.17	1.32	1.35	1.47	1.38	1.56	1.56	1.47		
N	4	4	4	4	4	4	4	4	4	4	4	4		
				: Data	Unavaila	ble b	: Schedul	ed Sacrif	ice					

				IN	DIVID	UAL BO	DY WE	IGHTS	(Kilogram	ns)			
STU	JDY: 1	.93				1-F 0(mg/k	ra)	SI	EX: FE	MALE			
ANIMAL #	DAY 97	DAY 104	DAY 111		DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181	
8721	h	b	b	b	Ь	h	b	b	h	ь	b	Ь	
8712	b	Ь	b	b	Ь	b	b	Ь	b	b	Ь	h	
8710	b	b	b	b	b	Ь	b	Ь	b	b	Ь	b	
8723	b	b	Ь	b	b	Ь	b	b	b	b	b	ь	
8705	8.9	9.1	8.9	9.1	8.8	8.9	9.0	9.0	9.3	9.5	9.8	9.4	
8700	9.4	9.9	9.7	10.0	9.8	10.0	10.1	9.9	10.0	10.2	10.2	10.4	
8699	10.9	10.9	11.0	11.0	11.2	11.5	11.0	10.7	10.8	11.1	11.4	11.0	
8690	11.1	11.3	11.7	11.9	11.9	12.2	12.2	12.2	12.4	12.7	13.0	13.0	
MEAN	10.1	10.3	10.3	1D.5	10.4	10.7	1D.6	1D.5	10.6	10.9	11.1	11.D	
S.D.	1.09	0.99	1.26	1.21	1.39	1.48	1.36	1.36	1.33	1.38	1.44	1.52	
N	4	4	4	4	4	4	4	4	4	4	4	4	
				: Data	Unavaila	ible b	o: Schedul	ed Sacrif	ice				



 				IN	DIVID	UAL BO	DY WE	IGHTS	(Kilogran	ns)			
ST	UDY: 1	.93				2-F 0.1(mg	/ka)	SI	EX: FE	MALE			
 ANIMAL #	DAY 97	DAY 104	DAY 111	DAY 119		DAY 133	DAY 139	DAY 146	DAY- 153	DAY 160	DAY 167	DAY 181	
8717	ь	Ь	ь	b	Ь	b	b	b	b	Ь	b	b	
8703	Ь	Ь	Ь	Ь	Ь	Ь	Ь	Ь	Ь	Ь	b	Ь	
8713	ь	Ь	Ь	Ь	Ь	Ь	Ь	Ь	Ь	Ь	Ь	Ь	
8693	Ь	Ь	Ь	Ь	Ь	Ь	Ь	Ь	Ь	ь	Ь	Ь	
8695	8.9	8.9	8.4	8.8	8.8	9.0	9.1	9.1	9.0	9.3	9.4	9.4	
8709	9.5	9.7	9.7	9.6	9.6	9.9	10.1	9.8	9.8	9.8	9.8	10.1	
8715	10.5	10.7	10.5	10.8	10.8	11.1	10.9	11.0	11.2	11.2	11.2	11.5	
8697	12.4	12.5	12.4	12.5	12.4	12.3	12.6	12.6	12.5	13.0	13.0	12.9	
MEAN	10.3	10.5	10.3	10.4	10.4	10.6	10.7	10.6	10.6	10.8	10.9	11.0	
S.D.	1.53	1.55	1.67	1.61	1.57	1.44	1.48	1.53	1.55	1.66	1.63	1.55	
N	4	4	4	4	4	4	4	4	4	4	4	4	
				: Data	Unavaila	able b	: Schedul	ed Sacrit	ice				



	INDIVIDUAL BODY WEIGHTS (Kilograms) STUDY: 193 GROUP: 3-F SEX: FEMALE													
ST	JDY: 1	.93				3-F 0.3(mg	ı/ka)	SI	EX: FE	MALE				
ANIMAL #	DAY 97	DAY 104	DAY 111			DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181		
,														
8692	Ь	b b	ь	Ь	Ь	ь	b	b	Ь	Ь	Ь	Ь		
8718	ь	b	b	b	b	b	Ь	b	b	b	b	b		
8706	ь	b	ь	ь	Ь	b	b	b	b	Ь	b	b		
8714	b	b	b	b	b	b	b	b	b	b	Ъ	b		
8701	8.8	8.9	8.4	8.9	8.7	8.7	8.3	8.5	8.5	8.6	8.8	9.1		
8702	7.5	7.9	7.6	8.0	7.9	8.1	8.0	7.7	7.7	7.7	8.0	8.2		
8720	10.3	10.5	10.4	10.7	10.5	10.7-	10.5	10.3	10.5	10.5	10.6	10.5		
8704	10.7	10.8	10.7	10.9	10.8	11.2	11.4	11.2	11.1	11.4	11.4	11.7		
MEAN	9.3	9.5	9.3	9.6	9.5	9.7	9.6	9.4	9.5	9.6	9.7	9.9		
S.D.	1.47	1.37	1.51	1.41	1.40	1.51	1.66	1.61	1.61	1.70	1.57	1.54		
N	4	4	4	4	4	4	4	4	4	4	4	4		
				: Data	Unavaila	able h	: Schedul	ed Sacrit	fice					

				IN	DIVID	UAL BO	DY WE	IGHTS	(Kilogram	ns)			
ST	UDY: 1	93			OUP:	4-F 1.0(mg	r/kg)	SI	EX: FE	MALE		,	
ANIMAL #	DAY 97	DAY 104	DAY 111		DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181	
8696	Ь	Ь	Ь	D	Ь	b	b	b	Ь	Ь	b	b	
8719	b	b	b	Ь	b	Ь	b	ь	Ь	b	Ь	Ь	
8711	b	b	b	b	b	b	b	b	b	b	b	b	
8716	Ь	b	ь	b	b	b	b	b	b	b	b	b	
8725	7.9	8.3	8.0	8.0	7.9	8.1	8.0	7.9	8.0	7.9	7.9	8.2	
8707	9.2	9.6	9.5	10.0	9.8	10.1	10.3	9.9	10.1	10.4	10.8	11.0	
8689	9.3	9.7	9.6	9.8	9.7	9.4	9.5	9.6	9.3	9.5	9.6	10.1	
8722	8.7	8.9	8.8	9.2	9.1	9.4	9.5	9.4	9.4	9.7	10.0	10.3	
MEAN	8.8	9.1	9.0	9.3	9.1	9.3	9.3	9.2	9.2	9.4	9.6	9.9	
S.D.	0.64	0.66	0.74	0.90	0.87	0.83	0.96	0.89	0.88	1.06	1.22	1.20	
N	4	4	4	4	4	4	4	4	4	4	4	4	
	•	•	•	: Data	Unavaila	able b	: Schedul	ed Sacrit	ice				

				INDI	VIDUAL	WEIG	HT GA	EN (Kilo	grams) ^a			
STUDY:	193			GROUP DOSE:	: 1-M 0(mg	ı/kg)		SEX:	MALE			
ANIMAL #	DAY 3	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
 										•••••		
8656	-0.2	0.2	0.2	-0.1	-0.3	0.3	-0.1	0.1	0.0	-0.2	0.4	
8687	0.1	0.1	0.7	-0.3	0.1	0.2	-0.2	0.3	-0.2	0.0	0.2	
8669	0.0	0.3	0.0	-0.6	0.7	0.2	-0.1	0.1	0.1	-0.2	0.6	
8673	0.3	0.0	0.4	-0.3	0.1	-0.3	0.1	0.2	-0.4	0.1	0.1	
8667	0.4	0.1	0.0	0.0	0.1	0.1	-0.2	0.0	0.0	0.1	0.0	
8654	-0.2	0.0	0.1	-0.2	0.3	-0.4	-0.1	0.2	-0.1	-0.2	0.1	
8680	0.4	0.1	0.0	0.1	0.2	0.0	-0.1	0.2	-0.1	-0.2	0.5	
8676	0.0	0.0	-0.1	0.0	0.2	0.1	0.0	0.3	-0.3	-0.1	0.3	
MEAN	0.1	0.1	0.2	-0.2	0.2	0.0	-0.1	0.2	-0.1	-0.1	0.3	
S.D.	0.24	0.11	0.27	0.23	0.28	0.25	0.10	0.10	0.17	0.14	0.21	
N	8	8	8	8	8	8	8	8	8	8	8	
					-: Data L	Jnava i lab	le					

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period $^{\rm b}{\rm Baseline}$ is day -5



THIRTEEN WEEK ORAL TOXICITY STUDY OF DR FT

		I	NDIVII	UAL W	EIGHT	GAIN	(Kilograms) ^a	
STUDY: 193		GR DO	OUP: 1 SE: 0	-M (mg/k	g)	SE	X: MAI		
	ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	TOTAL GAIN	
	9454	0.3	-0.2	-0.1	0.1	0.2	-0.1	0.5	
	8656 8687	-0.3	0.1	-0.1 0.0	0.1	-0.3	-0.1 0.0	0.5	
	8669	-0.5	-0.1	0.1	-0.1	0.3	0.1	0.9	
	8673	0.2	0.0	0.1	0.0	0.0	-0.4	0.2	
	8667	0.5	-0.1	0.3	-0.2	0.1	0.0	1.2	
	8654	0.1	-0.1	0.2	-0.3	-0.1	-0.1	-0.8	
	8680	0.0	0.2	0.2	0.3	-0.3	0.1	1.6	
	8676	0.0	0.2	0.2	0.1	-0.1	0.1	0.9	
	MEAN	0.0	0.0	0.1	0.0	0.0	0.0	0.6	
	S.D.	0.32	0.15	0.13	0.19	0.22	0.17	0.72	
	N	8	8	8	8	8	8	8	
			: [ata Unav	ailable				

^aWeight gains compared to the previous period

				RECOV.	EKI PE	RIOD	IN DOC	35				
 				INDI	VIDUAI	WEIG	HT GA	IN (Kilo	grams)			
 STUDY:	193			GROUP DOSE:	: 2-M 0.1	mg/kg)	SEX:	MALE			
ANIMAL #	DAY 3 b	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
 8685	0.1	0.0	0.1	0.1	-0.3	0.2	-0.1	0.1	-0.5	0.1	0.3	
8679	• •	• •			••		• •	••	••		••	
8663	0.2	0.2	0.1	-0.2	0.2	0.1	-0.1	0.0	0.1	-0.1	0.2	
8686	-0.2	-0.3	0.4	-0.3	0.2	-0.2	-0.3	0.6	-0.3	-0.3	-1.1	
8665	0.1	0.0	0.0	-0.1	0.2	0.0	0.0	0.0	0.0	0.1	0.2	
8666	-0.1	0.2	-0.1	0.0	0.1	0.0	-0.1	0.2	-0.4	0.1	0.2	
8655	0.0	-0.1	0.1	0.0	-0.1	0.2	-0.2	0.0	0.2	0.0	0.2	
8659	-0.3	0.2	-0.1	0.1	0.1	0.2	-0.2	-0.2	0.1	-0.2	0.4	
8677	0.2	0.4	-0.1	0.2	0.0	0.0	-0.2	0.3	0.1	-0.2	0.5	
MEAN	0.0	0.1	0.1	0.0	0.1	0.1	-0.2	0.1	-0.1	-0.1	0.1	
S.O.	0.19	0.22	0.17	0.17	0.18	0.14	0.09	0.24	0.27	0.16	0.50	
N	8	8	8	8	8	8	8	8	8	8	8	
					·-: Oata l	Jnavailab	le					

 $^{^{\}rm a}_{\rm b}{\rm Weight}$ gains compared to the previous period $^{\rm b}_{\rm Baseline}$ is day -5



		I	NDIVID	UAL W	EIGHT	GAIN	(Kilograms) ^a	
STUDY: 193			OUP: 2 SE: 0	-M).1(mg	/kg)	SE	X: MAL	E TOTAL	
	ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	GAIN	
	8685 8679 8663 8686 8665 8665 8655 8659 8677	-0.1 0.3 0.2 -0.1 0.1 -0.1 0.3 0.2	-0.3 	0.2 0.1 0.2 0.4 0.7 0.1 0.2	0.0 -0.1 0.2 -0.6 -0.3 -0.2 -0.1	0.1 0.1 0.0 0.6 0.0 0.0 0.1	0.0 -0.1 0.1 0.1 -0.2 -0.3 0.0	0.0 1.1 -0.7 0.7 0.2 0.2 0.2 1.6	
	S.D.	0.18	0.33 8 : [0.20 8 Data Unava	0.24 8 ailable	0.20 8	0.14	0.71 8	

 $^{{}^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period



				INDI	VIDUAI	WEIG	HT GA	E N (Kilo	grams) ^a			
STUDY:	193			GROUP DOSE:	: 3-M 0.3	mg/kg)	SEX:	MALE			
ANIMAL #	DAY 3 b	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
8674 8653	-0.5 0.2	-0.1 -0.3	0.2	0.2	0.1 -0.1	0.2	0.1	0.3	-0.1 -0.3	0.0	0.1	
8660	0.1	0.0	0.1	0.0	0.0	0.0	0.1	-0.1	0.1	0.0	0.0	
8668	0.2	0.1	0.1	0.1	0.1	0.1	-0.2	-0.1	0.0	-0.3	0.1	
8682	-0.4	0.0	0.2	-0.4	-0.4	0.3	-0.3	0.2	-0.6	-0.1	-0.1	
8684	0.3	0.2	0.0	-0.2	0.2	0.1	0.0	-0.1	-0.1	0.1	0.2	
8662	0.2	-0.1	0.4	-0.6	0.0	0.0	-0.1	0.1	-0.4	-0.3	-0.2	
8688	0.2	0.1	0.0	0.1	0.3	0.2	-0.2	0.2	0.0	-0.4	0.4	
MEAN	0.0	0.0	0.1	-0.1	0.0	0.1	-0.1	0.1	-0.2	-0.1	0.0	
S.D.	0.31	0.16	0.13	0.28	0.21	0.13	0.15	0.17	0.24	0.18	0.21	
N	8	8	8	8	8	8	8	8	8	8	8	
					-: Data l	Jnavai lab	le					

 $^{^{\}rm a}\mbox{Weight gains compared to the previous period <math display="inline">^{\rm b}\mbox{Baseline}$ is day -5

			I	NDIVII	UAL W	EIGHT	GAIN	(Kilograms) ^a		
 STUDY:	193		GR DO:	OUP: 3	3-M).3(mg	/kg)	SE	X: MAI			
		ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	TOTAL GAIN	 	
 		8674	0.0	-0.1	0.1	0.0	0.2	-0.4	0.3		
		8653	-0.1	-0.3	-0.4	-0.4	-0.3	-0.4	-2.8		
		8660	0.1	-0.2	0.3	-0.1	0.0	-0.1	0.3		
		8668	-0.1	-0.1	0.2	-0.4	0.0	-1.9	-2.1		
		8682	0.0	0.0	0.1	-0.2	-0.1	0.0	-1.8		
		8684	-0.1	-0.1	0.1 .	0.1	0.1	-0.1	0.7		
		8662	0.3	-0.5	0.2	-0.3	0.1	0.0	-1.2		
		8688	0.3	0.1	0.0	-0.1	0.2	-0.2	1.2		
		MEAN	0.1	-0.2	0.1	-0.2	0.0	-0.4	-0.7		
		S.D.	0.17	0.19	0.21	0.18	0.17	0.64	1.48		
		N	8	8	8	8	8	8	8		
				: [Data Unav	ailable					

aweight gains compared to the previous period



				INDI'	VIDUAI	WEIG	HT GA	[N (Kilo	grams) ^a			
STUDY:				GROUP DOSE:	: 4-M 1.0	mg/kg)	SEX:	MALE			
ANIMAL #	DAY 3 b	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
8661	-0.4	0.3	-0.1	-0.1	0.1	0.0	-0.2	0.0	-0.3	-0.1	0.1	
8670	0.0	-0.1	0.2	-0.4	0.0	0.0	0.0	0.0	-0.2	0.0	0.1	
8681	0.4	0.0	0.2	-0.4	0.2	-0.2	0.0	0.3	-0.3	0.0	0.2	
8664	0.2	0.0	0.1	-0.4	0.0	-0.2	-0.2	-0.2	-0.4	-0.2	0.5	
8675	0.2	-0.1	0.2	-0.2	0.0	0.1	-0.2	0.2	-0.3	0.1	0.3	
8683	0.4	0.1	-0.4	-0.1	-0.1	0.1	0.0	0.0	0.0	0.1	0.5	
8658	-0.2	0.1	-0.1	-0.4	-0.1	0.0	-0.2	0.0	-0.2	-0.1	0.0	
8652	0.0	0.0	-0.2	0.0	-0.1	0.1	-0.3	-0.1	0.1	-0.1	-0.3	
MEAN	0.1	0.0	0.0	-0.3	0.0	0.0	-0.1	0.0	-0.2	0.0	0.2	
S.D.	0.28	0.13	0.22	0.17	0.11	0.12	0.12	0.16	0.17	0.11	0.27	
N	8	8	8	8	8	8	8	8	8	8	8	
					-: Data l	Jnavai Labi	le					

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period $^{\rm b}{\rm Baseline}$ is day -5



		I	NDIVII	DUAL W	EIGHT	GAIN	(Kilograms	s) ^a	
STUDY: 193		GR DO	OUP: 4 SE: 1	1-M L.0(mg	/kg)	SE	X: MA		
	ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	TOTAL GAIN	
	8661	0.4	-0.1	0.0	-0.1	0.0	-0.1	-0.6	
	8670	0.1	0.0	0.0	-0.1	-0.4	0.0	-0.8	
	8681	0.0	0.1	0.3	-0.3	-0.1	0.0	0.4	
	8664	0.0	0.1	-0.1	-0.1	0.1	0.1	-0.7	
	8675 8683	-0.5 -0.1	-0.1 -0.1	0.0	-0.1 0.0	0.1	0.0	-0.3 0.4	
	8658	0.4	0.0	0.1	-0.2	-0.1	0.1	-0.9	
	8652	0.3	-0.1	0.2	-0.1	0.1	-0.1	-0.6	
	MEAN	0.1	0.0	0.1	-0.1	0.0	-0.1	-0.4	
	S.D.	0.30 8	0.09	0.14	0.09	0.19 8	0.16	0.52 8	
				Data Unav		J	J	J	

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period

				INDI'	VIDUAL	WEIG	HT GA	IN (Kilo	grams) ^a			
 STUDY:	193			GROUP DOSE:	: 1-F 0 (mg	r/kg)		SEX:	FEMAL	E		
ANIMAL #	DAY 3 b	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	

8721	0.2	0.0	0.1	0.0	-0.1	0.3	-0.1	-0.2	-0.2	0.1	0.1	
8712	-0.2	0.1	-0.2	0.2	0.3	0.1	-0.4	-0.2	0.1	-0.1	0.4	
8710	0.D	0.3	0.2	0.1	-0.2	0.2	-D.2	0.2	0.0	0.1	0.2	
8723	0.1	-0.1	-0.1	-0.1	0.2	0.2	-0.3	0.0	0.0	0.4	0.0	
8705	0.1	0.2	-0.1	0.1	-0.2	0.3	0.0	-0.1	0.3	0.1	0.2	
87DD	-0.1	0.2	0.0	-0.1	-0.2	0.3	-0.4	0.5	-0.1	-0.1	0.1	
8699	0.1	0.0	0.2	-0.3	0.3	0.2	-0.1	-0.2	0.0	0.0	0.2	
8690	0.6	0.1	0.0	-0.2	-0.1	-0.1	-0.1	0.0	-0.1	0.2	-0.1	
MEAN	0.1	0.1	0.0	D.D	0.D	0.2	-0.2	0.0	0.0	0.1	D.1	
S.D.	0.24	0.13	0.15	0.17	0.23	0.14	0.15	0.24	0.15	0.16	0.15	
N	8	8	8	8	8	8	8	8	8	8	8	
					: Data l	Jnavai lab	le					

 $^{^{\}mbox{\scriptsize d}}\mbox{\scriptsize Weight gains compared to the previous period}$ $^{\mbox{\scriptsize b}}\mbox{\scriptsize Baseline}$ is day -5

DRAFT

		IJ	NDIVII	UAL W	EIGHT	GAIN	(Kilograms	₎ a	
STUDY: 1	93			-F (mg/k	g)	SE	X: FEN		
	ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	TOTAL GAIN	
	8721 8712	0.0	-0.2 -0.3	-0.1 0.3	0.4	0.0	0.1	0.4	
	8710 8723 8705	0.4 -0.4 -0.2	-0.3 0.2 -0.5	0.2 -0.4 0.2	-0.1 0.1 0.0	0.2 0.1 0.1	-0.1 0.5 -0.3	1.2 0.4 0.2	
	8700 8699	-0.2 0.1	-0.1 -0.1	0.1	-0.1 0.2	0.0	-0.2 0.2	-0.4 0.6	
	8690 MEAN	0.4	-0.2	0.2	0.0	0.1	0.0	0.7	
	S.D. N	0.33 8	0.20 8 : I	0.23 8 Data Unava	0.17 8 ailable	0.09	0.25 8	0.46 8	

 $^{^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period

				INDI	VIDUAI	WEIG	HT GA	IN (Kilo	grams) ^a			
STUDY:	-			GROUP DOSE:	: 2-F 0.1	mg/kg)	SEX:	FEMAL	E		
ANIMAL #	DAY 3	DAY 7	0AY 10	OAY 14	0AY 17	0AY 21	0AY 24	0AY 28	OAY 34	OAY 41	DAY 48	
 	- 4											
8717	-0.1	0.1	0.0	0.0	-0.3	0.4	-0.6	-0.3	0.5	0.0	0.8	
8703	0.1	0.0	0.3	-0.2 -0.2	0.0	0.3	-0.6	0.3	-0.4	0.1	0.0	
8713 8693	-0.1 -0.3	-0.1 0.0	0.4	-0.2	0.2	0.0	0.0	0.2	-0.3 -0.3	-0.2 0.2	0.4	
8695	0.0	-0.1	0.2	-0.1	0.3	-0.4	0.3	0.0	0.1	0.1	0.1	
8709	-0.1	-0.1	0.2	-0.4	0.1	0.1	0.1	-0.2	0.0	0.0	0.2	
8715	-0.2	0.2	0.3	0.0	-0.2	0.2	-0.3	0.0	-0.1	0.2	0.5	
8697	0.3	0.3	-0.1	0.0	-0.1	0.3	0.0	0.0	0.0	0.2	0.0	
MEAN	-0.1	0.0	0.2	-0.1	0.0	0.1	-0.2	0.0	-0.1	0.1	0.3	
S.D.	0.19	0.15	0.16	0.14	0.21	0.25	0.33	0.22	0.29	0.14	0.28	
N	8	8	8	8	8	8	8	8	8	8	8	
					: Oata I	Jnava i labi	le					

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period $^{\rm b}{\rm Baseline}$ is day -5

DRAFT

INDIVIDUAL	WEIGHT	GAIN	(Kilograms)
------------	--------	------	-------------

STUDY: 193			OUP: 2 SE: (2-F 0.1(mg	/kg)	SE	X: FEM	MALE	
	ANIMAL #	DAY 54	DAY 62	DAY 69		DAY 83	DAY 90	TOTAL GAIN	
	8717	-0.3	0.3	0.3	0.1	0.0	0.4	1.3	
	8703	0.1	-0.2	-0.1	-0.1	0.1	-0.4	-0.7	
	8713	0.4	0.0	0.2	0.0	-0.4	0.4	0.7	
	8693	0.0	0.3	0.2	-0.4	0.1	0.0	0.6	
	8695	-0.1	-0.1	0.1	0.1	-0.1	0.2	0.6	
	8709	0.3	-0.4	0.0	0.0	0.3	0.1	0.2	
	8715	-0.1	0.0	0.2	-0.3	0.1	0.0	0.5	
	8697	0.2	0.4	-0.1	0.2	0.1	-0.1	1.6	
	MEAN	0.1	0.0	0.1	-0.1	D.D	0.1	0.6	
	S.D.	0.23	0.28	0.15	0.21	0.21	0.27	0.69	
	N	8	8	8	8	8	8	8	
			:	Data Unav	ailable				

 $^{^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period

DRAFT

				INDI	VIDUAI	WEIG	HT GA	IN (Kilo	grams) ⁸			
 STUDY:				GROUP DOSE:	: 3-F 0.3	(mg/kg)	SEX:	FEMAL	Ε		
ANIMAL #	DAY 3 b	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	OAY 41	DAY 48	
8692	-0.1	-0.1	0.0	-0.2	-0.4	0.2	-0.1	0.1	-0.2	0.0	0.1	
8718	-0.1	0.0	0.2	0.1	0.3	0.1	0.0	0.3	-0.5	0.0	0.2	
8706	0.3	0.0	0.0	-0.2	0.0	0.1	0.0	0.2	-0.2	0.0	0.0	
8714	0.1	0.0	0.6	-0.3	0.0	-0.2	-0.5	0.0	0.1	0.0	0.3	
8701	-0.1	0.0	0.2	-0.1	0.0	0.1	-0.3	0.1	-0.1	-0.2	0.3	
8702	-0.2	-0.1	0.0	-0.2	-0.2	0.0	0.0	-0.1	-0.5	0.0	-0.1	
8720	0.0	0.0	-0.2	0.3	-0.1	0.0	0.1	-0.1	0.1	-0.4	0.4	
8704	0.1	-0.3	0.4	-0.2	0.2	-0.4	-0.1	0.3	-0.1	0.0	-0.1	
MEAN	0.0	-0.1	0.2	-0.1	0.0	0.0	-0.1	0.1	-0.2	-0.1	0.1	
S.D.	0.16	0.11	0.26	0.20	0.22	0.19	0.20	0.16	0.23	0.15	0.19	
N	8	8	8	8	8	8	8	8	8	8	8	
					·-: Data I	Jnavai Labi	le					

 $^{^{\}rm a}_{\rm b}{\rm Weight}$ gains compared to the previous period $^{\rm b}_{\rm Baseline}$ is day -5



		I	NDIVII	OUAL W	EIGHT	GAIN	(Kilograms) ^a	
STUDY: 193		GR DO:	OUP: 3	3-F).3(mg	/kg)	SE	X: FEN	MALE	
	ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	TOTAL GAIN	
	8692	0.1	-0.1	0.1	0.2	-0.1	0.1	-0.4	
	8718 8706	0.3	-0.1 -0.4	-0.1 0.2	-0.1 -0.3	-0.3	0.1 -0.1	0.4	
	8714 8701 8702	0.2 0.2 0.2	-0.1 -0.1 -0.2	0.0 0.1 0.1	0.3 -0.1 0.0	0.0 0.1 -0.1	0.2 -0.2 -0.2	1.1 -0.1 -1.6	
	8720 8704	0.0	0.0	0.2	-0.2	-0.1 0.1	0.1	0.1	
	MEAN	0.1	-0.1	0.1	0.0	0.0	0.0	-0.1	
	S.D. N	0.13	0.12	0.15	0.20	0.14	0.16	0.77 8	
			:	Data Unava	allable				

 $^{^{\}rm a}{\rm Weight}$ gains compared to the previous period

						31(10)	III DO	30		10.000.000		
				INDI	VIDUAI	WEIG	HT GA	IN (Kilo	grams) ^a			
 STUDY:	193			GROUP DOSE:	: 4-F 1.0	(mg/kg)	SEX:	FEMAL	E		
ANIMAL #	DAY 3b	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48	
8696	-0.1	-0.1	-0.1	0.0	0.0	0.1	0.0	-0.2	0.0	0.0	0.1	
8719	0.1	0.0	0.1	-0.1	-0.1	0.2	-0.6	0.4	0.0	-0.1	0.0	
8711	-0.3	-0.3	0.2	-0.3	0.9	-1.0	0.0	-0.1	-0.4	0.0	0.2	
8716	-0.1	-0.1	0.1	-0.2	-0.3	0.2	-0.1.	-0.1	-0.2	0.2	0.2	
8725	-0.2	0.0	-0.3	-0.5	-0.1	0.1	0.0	0.1	0.2	0.0	0.0	
8707	0.0	-0.3	0.1	-0.4	0.2	-0.1	0.0	0.1	-0.2	0.0	0.3	
8689	-0.3	-0.1	0.1	-0.1	-0.2	-0.1	0.0	0.0	0.0	0.0	0.0	
8722	-0.5	-0.3	-0.3	-0.1	-0.3	0.1	-0.1	-0.1	0.1	0.1	-0.1	
MEAN	-0.2	-0.2	0.0	-0.2	0.0	-0.1	-0.1	0.0	-0.1	0.0	0.1	
S.D.	0.19	0.13	0.20	0.17	0.39	0.40	0.21	0.19	0.19	0.09	0.14	
N	8	8	8	8	8	8	8	8	8	8	8	
					-: Data i	Jnavai lab	le					

 $^{^{\}mbox{\scriptsize a}}_{\mbox{\scriptsize b}}\mbox{\scriptsize Weight gains compared to the previous period}_{\mbox{\scriptsize b}}\mbox{\scriptsize Baseline is day -5}$

INDIVIDUAL	WEIGHT	GAIN	(Kilograms) ^a	
------------	--------	------	--------------------------	--

STUDY: 193			OUP: 4	-F .0(mg	/kg)	SE	X: FEM		
	ANIMAL #	0AY 54	DAY 62	DAY 69	DAY 76	0AY 83	0AY 90	TOTAL GAIN	*****************
	8696 8719 8711 8716 8725 8707 8689 8722	0.0 0.5 0.3 0.0 0.1 0.0 0.1	0.0 -0.3 -0.2 0.1 0.1 -0.4 -0.1	-0.2 -0.3 0.2 0.2 -0.1 -0.3 0.1	0.3 -0.2 0.2 -0.2 -0.1 0.3 0.2 -0.2	0.0 0.3 0.0 0.1 0.0 0.2 -0.3	-0.1 -0.1 -0.1 0.1 0.0 0.0 -0.1	-0.3 -0.2 -0.7 -0.1 -0.7 -0.5 -0.8 -2.1	
	MEAN S.O. N	0.1 0.18 8	-0.1 0.18 8 : (-0.1 0.21 8 Data Unav	0.0 0.23 8 ailable	0.0 0.20 8	0.0 0.07 8	-0.7 0.63 8	

^aWeight gains compared to the previous period



INDIVIDUAL WEIGHT GAIN (Kilogra	NDIVIDUAL	WEIGHT	GAIN	(Kilograms) a
---------------------------------	-----------	--------	------	---------------

STUDY: 193

GROUP: 1-M DOSE: 0(mg/kg)

SEX: MALE

ANIMAL # DAY 97 DAY 104 DAY 111 DAY 119 DAY 125 DAY 133 DAY 139 DAY 146

8656	b	b	b	b	b	b	b	b
8687	b	b	b	b	b	b	b	b
8669	b	b	b	b	b	b	b	b
8673	b	b	b	b	b	b	b	b
8667	0.0	0.2	-0.1	0.2	-0.2	0.2	0.0	-0.3
8654	0.2	0.2	-0.2	-0.3	-0.2	0.3	0.1	-0.4
8680	-0.3	0.3	-0.5	0.5	0.2	0.0	0.0	-0.1
8676	-0.2	0.3	-0.2	0.7	-0.2	0.3	0.2	-0.1
MEAN	-0.1	0.3	-0.3	0.3	-0.1	0.2	0.1	-0.2
S.D.	0.22	0.06	0.17	0.43	0.20	0.14	0.10	0.15
N	4	4	4	4	4	4	4	4
		: Oat	a Unavail	able	b: Schedu	iled Sacrif	ice	

^aWeight gains compared to the previous period

^CBaseline is day 90

		1000	OVERT	FLICE	OD IIV	DOGD		
		IN	DIVIDU	AL W	EIGHT	GAIN (Ki	lograms) ^a	
STUDY:	193	GRO DOS	UP: 1- E: 0(M mg/k	.g)	SEX:	MALE TOTAL	
	Α	NIMAL # C	AY 153 DA	Y 160	DAY 167	DAY 181	GAIN	
		8656	b	b	ь	b		
		8687	b	Ь	b	b		
		8669	ь ь ь	ь	b	b		
		8673	b	Ь	ь	b		
		8667	-0.1	0.0	0.0	0.2	0.1	
		8654	0.3	-0.4	0.1	1.0	0.7	
		8680	-0.1	0.2	0.2	0.3	0.7	
		8676	0.4	0.3	0.0	0.3	1.8	
		MEAN	0.1	0.0	0.1		0.8	
		S.D.		0.31	0.10	0.37	0.71	
		N	4	4	4	4	4	
		: Data l	Jnavailable	e b	: Schedule	d Sacrifice		

^aWeight gains compared to the previous period

INDIVIDUAL WEIGHT GAIN (Kilograms) a

STUDY: 193

GROUP: 2-M SEX: MDOSE: 0.1(mg/kg)

SEX: MALE

ANIMAL # DAY 97 C DAY 104 DAY 111 DAY 119 DAY 125 DAY 133 DAY 139 DAY 146

8685	Ь	Ь	b	Ь	b	ь	Ь	Ь
8679								
8663	Ь	Ь	Ь	Ь	b	Ь	b	Ь
8686	b	ь	Ь	Ь	Ь	Ь	Ь	Ь
8665	0.0	0.2	-0.3	0.5	-0.2	0.3	0.0	-0.1
8666	-0.1	0.7	-0.7	0.2	0.0	0.1	0.0	-0.2
8655	-0.2	0.2	-0.3	0.5	-0.2	0.1	0.1	-0.3
8659	0.1	0.1	-0.2	0.1	0.0	0.0	-0.1	0.0
8677	ь	b	ь	Ь	b	b	b	Ь
MEAN	-0.1	0.3	-0.4	0.3	-0.1	0.1	0.0	-0.2
S.D.	0.13	0.27	0.22	0.21	0.12	0.13	0.08	0.13
N	4	4	4	4	4	4	4	4
		·: Data	Unavailal	ble	b: Schedul	ed Sacrif	ice	

^aWeight gains compared to the previous period

CBaseline is day 90

THIRTEEN WEEK ORAL TOXICITY STUDY OF RECOVERY PERIOD IN DOGS

 I	NDIVID	UAL W	EIGHT	GAIN (Kil	lograms) ^a	
	OUP: 2 SE: 0		/ka)	SEX:	MALE	
		,5	,		-TOTAL	
ANIMAL #	DAY 153	DAY 160	DAY 167	DAY 181	GAIN	
 	••••••			•••••		
8685	ь	b	b	ь		
8679						
8663	b	b	b	b		
8686	b	b	b	b		
8665	0.0		0.2		0.8	
	0.0			0.4		
8655				0.4		
8659	_			0.0	-0.5	
8677	b	b	b	b		
MEAN	-0.2	0.1	0.0	0.3	0.3	
S.D.	0.28	0.21	0.23	0.19	0.57	
	4		4	4	4	
	Unavailab	le b	: Schedule	d Sacrifice		

 $^{^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period

STUDY: 193

INDIVIDUAL	WEIGHT	GAIN	(Kilograms) a
------------	--------	------	---------------

STUDY: 193

SEX: MALE

GROUP: 3-M DOSE: 0.3(mg/kg)

ANIMAL # DAY 97 DAY 104 DAY 111 DAY 119 DAY 125 DAY 133 DAY 139 DAY 146

8674	0.1	0.2	-0.2	0.1	0.0	-0.1	-0.2	-0.2
8653	b	ь	b	b	b	b	b	b
8660	ь	b	b	b	b	ь	b	b
8668	b	b	b	b	b	b	b	b
8682	-0.2	0.3	-0.4	-0.2	0.4	0.2	0.0	-0.1
8684	Ь	b	b	b	b	b	b	b
8662	0.1	0.2	0.1	0.1	-0.1	0.1	0.1	-0.2
8688	0.0	0.4	-0.7	1.1	-0.4	0.3	0.0	0.0
MEAN	0.0	0.3	-0.3	0.3	0.0	0.1	0.0	-0.1
S.D.	0.14	0.10	0.34	0.57	0.33	0.17	0.13	0.10
N	4	4	4	4	4	4	4	4
		: Data	Unavailal	ble	b: Schedule	ed Sacrif	ice	

^aWeight gains compared to the previous period

^CBaseline is day 90

			100	CO V LIC.	LLLIC	TOD III	DOGD		
-			I	NDIVII	DUAL 1	WEIGHT	GAIN (K	(ilograms) ^a	
	STUDY:	193	GR DO	OUP: 3	3-M 0.3 (m	a/ka)	SEX	: MALE	
						3/ 3/		TOTAL	
			ANIMAL #	DAY 153	DAY 160	DAY 167	DAY 181	GAIN	
-									
			8674	0.1	0.0	0.1	0.3	0.2	
			8653	b	b	Ь	b		
			8660	Ь	b	b	Ь		
			8668	Ь	Ь	Ь	Ь		
			8682	0.2	0.1	0.0	0.3	0.6	
			8684	Ь	b	Ь	b	••	
			8662	0.2	0.1	-0.4	0.4	0.7	
			8688	-0.2	0.5	-0.1	0.1	1.0	٠
			MEAN	0.1	0.2	-0.1	0.3	0.6	
			S.D.	0.19	0.22	0.22	0.13	0.33	
			N	4	4	4	4	4	
			: Data	Unavaila	ble	b: Schedul	ed Sacrific	e	

 $^{^{\}rm a}$ Weight gains compared to the previous period

INDIVIDUAL WEIGHT GAIN (Kilograms) a

STUDY: 193

GROUP: 4-M SEX: MALE DOSE: 1.0 (mg/kg)

ANIMAL # DAY 97 DAY 104 DAY 111 DAY 119 DAY 125 DAY 133 DAY 139 DAY 146

	-							
8661	Ь	b	Ь	b	Ь	ь	ь	ь
8670	b	b	b	b	Ь	b	Ь	b
8681	b	b	b	b	b	b	b	b
8664	b	b	b	b	b	b	b	b
8675	0.1	0.3	0.0	0.0	0.4	0.2	0.2	-0.2
8683	0.0	0.5	-0.3	0.4	0.0	0.3	-0.2	-0.1
8658	-0.5	0.0	-0.4	0.1	-0.1	-0.1	-0.3	-0.3
8652	-0.1	0.3	-0.4	0.7	-0.1	0.2	-0.2	0.0
MEAN	-0.1	0.3	-0.3	0.3	0.1	0.2	-0.1	-0.2
S.D.	0.26	0.21	0.19	0.32	0.24	0.17	0.22	0.13
N	4	4	4	4	4	4	4	4
		: Data	Unavailal	ble	b: Schedule	d Sacrif	ice	

^aWeight gains compared to the previous period

CBaseline is day 90

	IND	CVIDUA	L WE	IGHT G	AIN (Kil	ograms) ^a	
STUDY: 193	GROUE DOSE:	P: 4-M 1.0	(mg/)	kg)		MALE TŌTAL	
AN	IIMAL # DAY	153 DAY	160 DA	Y 167 DA		GAIN	
			L	L	L		
	3661 3670	b	Ь	b b	b b	••	
	1681	b b	ь	b	b	••	
	3664	b	ь	ь	b	••	
			0.1	0.2	0.3	1.8	
8			0.4	0.1	-0.1	1.1	
8	658	0.3 -	0.1	0.1	0.6	-0.7	
8	3652	0.1	0.2	0.1	0.7	1.5	
			0.2	0.1	0.4	0.9	
			.21		0.36	1.12	
	N : Data Una	4 vailable		4 Scheduled	Sacrifice	4	

 $^{^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)

STUDY: 193

GROUP: 1-F DOSE: 0(mg/kg)

SEX: FEMALE

ANIMAL # DAY 97 DAY 104 DAY 111 DAY 119 DAY 125 DAY 133 DAY 139 DAY 146

8721	b	b	b	b	b	b	b	b
8712	b	b	b	b	b	b	b	b
8710	b	b	b	b	Ь	b	ь	b
8723	b	b	b	b	Ь	ь	ь	b
8705	0.1	0.2	-0.2	0.2	-0.3	0.1	0.1	0.0
8700	-0.3	0.5	-0.2	0.3	-0.2	0.2	0.1	-0.2
8699	-0.1	0.0	0.1	0.0	0.2	0.3	-0.5	-0.3
8690	0.1	0.2	0.4	0.2	0.0	0.3	0.0	0.0
MEAN	-0.1	0.2	0.0	0.2	-0.1	0.2	-0.1	-0.1
S.D.	0.19	0.21	0.29	0.13	0.22	0.10	0.29	0.15
N	4	4	4	4	4	4	4	4
		: Data	Unavailal	ole	b: Schedul	led Sacrif	ice	

^aWeight gains compared to the previous period

^CBaseline is day 90

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

STUDY: 193

I	NDIVII	DUAL W	EIGHT	GAIN	(Kilograms) ^a		
 GR DO	OUP: 3	L-F)(ma/k	(a)	SE	X: FEMA	LE	
ANIMAL #				DAY 181	TÕTAL GAIN		
 		• • • • • • • • •					
8721	Ь	Ь	Ь	Ь			
8712	Ь	b	b	ь	• •		
8710	b	b	b	Ь			
8723	Ь	b	b	b	• •		
8705	0.3	0.2	0.3	-0.4	0.6		
8700	0.1	0.2	0.0	0.2	0.7		
8699	0.1	0.3	0.3	-0.4	0.0		
8690	0.2	0.3	0.3	0.0	2.0		
				-0.2			
S.D.	0.10			0.30			
N	4	4	4	4	4		
: Data	Unavaila	ble b	: Schedul	ed Sacrif	ice		

^aWeight gains compared to the previous period

INDI	VIDUAL	WEIGHT	GAIN	(Kilo	grams) ^a
GROUP	: 2-F		SI	EX:	FEMALE

DOSE: 0.1(mg/kg)

ANIMAL # DAY 97 DAY 104 DAY 111 DAY 119 DAY 125 DAY 133 DAY 139 DAY 146

8717	b	b	b	b		b	b	ь	b
8703	b	b	b	b		b	b	b	b
8713	b	b	b	b		b	b	b	b
8693	b	b	Ь	b	_	b	b	b	b
8695	0.0	0.0	-0.5	0.4		0.0	0.2	0.1	0.0
8709	-0.2	0.2	0.0	-0.1		0.0	0.3	0.2	-0.3
8715	-0.3	0.2	-0.2	0.3		0.0	0.3	-0.2	0.1
8697	-0.1	0.1	-0.1	0.1		-0.1	-0.1	0.3	0.0
MEAN	-0.2	0.1	-0.2	0.2		0.0	0.2	0.1	-0.1
S.D.	0.13	0.10	0.22	0.22		0.05	0.19	0.22	0.17
N	4	4	4	4		4	4	4	4
		: Data	Unavailal	ble	b:	Schedule	ed Sacrif	ice	

^aWeight gains compared to the previous period

STUDY: 193

CBaseline is day 90

			•
INDIVIDUAL	WEIGHT	GAIN	(Kilograms)

STUDY:	193	GROUP:	2-F	SEX:	FEMALE
		DOSE:	$\overline{0.1}$ (mg/kg)		rā rai

	2022. 0.1 (3/3/					
ANIMAL	# DAY 153	DAY 160	DAY 167	DAY 181	TOTAL GAIN	
8717	b	b	b	b		
8703	b	b	b	b		
8713	b	b	b	b		
8693	b	b	b	b		
8695	-0.1	0.3	0.1	0.0	0.5	
8709	0.0	0.0	0.0	0.3	0.4	
8715	0.2	0.0	0.0	0.3	0.7	
8697	-0.1	0.5	0.0	-0.1	0.4	
MEAN	0.0	0.2	0.0	0.1	0.5	
S.D.	0.14	0.24	0.05	0.21	0.14	
N	4	4	4	4	4	
: C	ata Unavail	able b	: Schedule	d Sacrifi	ce	

 $^{^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period

	INDIV	IDUAL	WEIGHT	GAIN (Kil	ograms) ^a	
STUDY:	GROUP:				FEMALE	

DOSE: 0.3 (mg/kg)

ANIMAL # DAY 97 DAY 104 DAY 111 DAY 119 DAY 125 DAY 133 DAY 139 DAY 146

8692	Ь	Ь	Ь	Ь	b	Ь	Ь	b
8718	b	Ь	ь	b	Ь	Ь	Ь	b
8706	Ь	b	b	b	Ь	ь	b	b
8714	b	b	b	b	Ь	b	ь	b
8701	-0.1	0.1	-0.5	0.5	-0.2	0.0	-0.4	0.2
8702	-0.1	0.4	-0.3	0.4	-0.1	0.2	-0.1	-0.3
8720	-0.1	0.2	-0.1	0.3	-0.2	0.2	-0.2	-0.2
8704	-0.2	0.1	-0.1	0.2	-0.1	0.4	0.2	-0.2
MEAN	-0.1	0.2	-0.3	0.4	-0.2	0.2	-0.1	-0.1
S.D.	0.05	0.14	0.19	0.13	0.06	0.16	0.25	0.22
N	4	4	4	4	4	4	4	4
		: Data	Unavailal	ble	b: Schedule	ed Sacrif	ice	

^aWeight gains compared to the previous period

^CBaseline is day 90



	I	NDIVII	OUAL W	EIGHT	GAIN (Kilograms)	
STUDY: 193						X: FEMALE	
	ANIMAL #	DAY 153	DAY 160	DAY 167	OAY 181	GAIN	
	8692 8718 8706 8714 8701 8702 8720 8704	b b 0.0 0.0 0.2 -0.1	b b 0.1 0.0 0.0 0.3	b b 0.2 0.3 0.1	b b 0.3 0.2 -0.1	0.2 0.6 0.1 0.8	
	MEAN S.D. N	0.0 0.13 4 Unavaila	0.1 0.14 4	0.2 0.13 4	0.2 0.19 4 ed Sacrifi	0.4 0.33 4	

 $^{^{\}mathrm{a}}\mathrm{Weight}$ gains compared to the previous period

INDIVIDUAL	WRIGHT	CATN	(Viloarams)a
TMDTATDOWD	METGUI	CANTIN	(K1(OGrams)

STUDY: 193

SEX: FEMALE

GROUP: 4-F DOSE: 1.0(mg/kg)

ANIMAL # DAY 97 DAY 104 DAY 111 DAY 119 DAY 125 DAY 133 DAY 139 DAY 146

8696	b	b	Ь	b	b	b	b	b
8719	b	b	b	b	b	b	Ь	b
8711	b	b	ь	b	b	b	ь	b
8716	b	Ь	b	b	b	b	ь	b
8725	0.1	0.4	-0.3	0.0	-0.1	0.2	-0.1	-0.1
8707	0.0	0.4	-0.1	0.5	-0.2	0.3	0.2	-0.4
8689	-0.2	0.4	-0.1	0.2	-0.1	-0.3	0.1	0.1
8722	-0.1	0.2	-0.1	0.4	-0.1	0.3	0.1	-0.1
MEAN	-0.1	0.4	-0.2	0.3	-0.1	0.1	0.1	-0.1
S.D.	0.13	0.10	0.10	0.22	0.05	0.29	0.13	0.21
N	4	4	4	4	4	4	4	4
		Data	Unavaila	hle	h. Schedul	ed Sacrif	ice	

^aWeight gains compared to the previous period

CBaseline is day 90

THIRTEEN WEEK ORAL TOXICITY STUDY OF DRAFT

					2000		
	I	NDIVI	DUAL W	EIGHT	GAIN	(Kilograms) ^a	
STUDY: 193	DC	COUP:	1.0(mg			X: FEMALE	
	ANIMAL #	UAT 105	UAT 100	DAY 167	UAT IOI	GAIN	
	8696	b	ь	b	b	• •	
	8719	ь	Ь	b	Ь		
	8711	b	b	b	Ь	- •	
	8716	ь	ь	b	b		
	8725	0.1	-0.1	0.0	0.3	0.4	
	8707	0.2	0.3	0.4	0.2	1.8	
	8689	-0.3	0.2	0.1	0.5	0.6	
	8722	0.0	0.3	0.3	0.3	1.5	
	MEAN	0.0	0.2	0.2	0.3	1.1	
	S.D.	0.22	0.19	0.18	0.13	0.68	
	N	4	4	4	4	4	

--: Data Unavailable b: Scheduled Sacrifice

^aWeight gains compared to the previous period

DRAFT

APPENDIX E

Individual Food Consumption Data



THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS INDIVIDUAL DAILY FOOD CONSUMPTION (SCOTE)

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)														
 ST	JDY: 1	93		GR	OUP: 1	L-M O(mg/k	.a)	SE	X: MA	LE			•••••	
ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63		
 									~					
8656	242	329	395	326	387	321	380	400	361	400	360	304		
8687	293	400	400	400	400	400	400	326	291	374	400	342		
8669	289	309	372	263	400	229	367	400	200	292	265	233		
8673	229	247	400	400	400	400	400	400	400	400	400	400		
8667	316	355	306	329	391	372	- 400	400	400	400.	400	400		
8654	400	400	400	400	400	400	400	400	400	400	400	400		
8680	366	400	400	400	400	400	400	400	400	400	341	400		
8676	361	355	400	400	400	400	400	400	366	349	344	400		
MEAN	312	349	384	365	397	365	393	391	352	377	364	360		
S.D.	60.7	53.8	33.0	52.6	5.2	61.7	12.7	26.2	72.0	39.0	47.7	62.8		
N	8	8	8	8	8	8	8	8	8	8	8	8		
					:	Data Unav	ailable							



	INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)														
1	ST	JDY: 1	93			OUP: SE:	1-M 0(mg/}	(a)	SI	EX: MA	LE				
	ANIMAL #	OAY 70	0AY 77	OAY 84	0AY 91	DAY 98	OAY 105	DAY 112	OAY 119	0AY 126	OAY 133	DAY 140	0AY 147		
		400	400	400	400										
	8656	400	400	400	400	ь	Ь	b	Ь	Ь	Ь	b	Ь		
	8687	232	391	400	400	b	ь	b	b	Ь	b	b	b		
	8669	400	391	371	239	Ь	b	b	Ь	Ь	Ь	Ь	Ь		
	8673	400	400	400	400	b	b	ь	ь	b	b	b	ь		
	8667	400	382	400	400	400	400	400	400	400	400	400	400		
	8654	400	400	400	400	400	400	400	400	400	400	400	400		
	8680	400	74	400	400	352	217	400	400	400	400	400	400		
	8676	400	400	400	400	400	400	400	400	400	400	400	400		
	MEAN	379	355	396	380	388	354	400	400	400	400	400	400		
	S.D.	59.4	113.6	10.3	56.9	24.0	91.5	0.0	0.0	0.0	0.0	0.0	0.0		
1	N	8	8	8	8	4	4	4	4	4	4	4	4		
					: Oata	Unavaila	ible b	o: Schedu	led Sacrif	ice					

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)														
STUDY: 193	ANTMAL #	GROUP DOSE:	0 (m	g/kg) DAY 168	DAY 470		MALE -							
	ANIMAL #	DAT 134	DAT TOT	DA1 100	DAT 175	UAT 102								
	8656	b	b	b	ь	b								
	8687	b	b	ь	b	ь								
	8669	b	b	Ь	b	ь								
	8673	ь	b	b	b	ь								
	8667	400	400	400	400	400								
	8654	400	400	400	400	400								
	8680	400	400	400	400	331								
	8676	400	400	400	400	285								
	MEAN	400	400	400	400	354								
	S.D.	0.0	0.0	0.0	0.0	56.3								
	N	4	4	4	4	4								
	:	Data Unav	ailable	b: Sch	eduled Sa	acrifice								

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)														
ST	JDY: 1	93		GR DO	OUP: 2 SE: (2-M 0.1(mg	/kg)	SE	X: MA	LE				
ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63		
8685	400	400	340	360	400	385	400	400	400	400	400	381		
8679														
8663	222	357	400	400	400	400	400	400	400	400	400	400		
8686	293	238	400	400	400	400	400	400	400	400	400	400		
8665	315	321	310	386	398	331	400	400	400	400	291	400		
8666	400	258	371	347	400	400	400	400	400	400	310	400		
8655	270	264	218	248	400	256	400	361	400	244	290	400		
8659	233	289	336	338	400	400	400	400	400	400	400	345		
8677	210	210	400	369	400	324	400	400	400	268	400	400		
MEAN	293	292	347	356	400	362	400	395	400	364	361	391		
S.D.	75.1	63.6	62.3	49.3	0.7	53.4	0.0	13.8	0.0	67.0	53.6	19.6		
N	8	8	8	8	8	8	8	8	8	8	8	8		
					:	Data Unav	ailable							

DRAFT

				I	NDIVI	DUAL I	AILY	FOOD	CONSUN	MPTION	(Grams)			
1	ST	UDY: 1	93		GR DO	OUP: 2 SE: 0	-M).1(mc	g/kg)	SI	EX: MA	LE			• • • • • • • •
	ANIMAL #	0AY 70	0AY 77	0AY 84	DAY 91	DAY 98	OAY 105	0AY 112	OAY 119	0AY 126	0AY 133	OAY 140	DAY 147	
	8685	400	400	400	400	Ь	Ь	Ь	b	Ь	Ь	Ь	Ь	
	8679					• •	• •							
	8663	259	400	400	400	Ь	ь	Ь	Ь	Ь	b	Ь	Ь	
	8686	400	400	400	400	Ь	b	Ь	b	Ь	Ь	b	b	
	8665	400	400	400	400	400	400	400	400	400	400	400	400	
	8666	400	400	400	400	400	400	400	400	400	400	400	400	
	8655	400	400	325	400	400	400	400	400	400	400	400	400	
	8659	400	400	400	400	321	400	400	400	400	400	400	400	
	8677	400	400	400	400	b	Ь	Ь	Ь	Ь	Ь	b	Ь	
	MEAN	382	400	391	400	380	400	400	400	400	400	400	400	
,	S.D.	49.9	0.0	26.5	0.0	39.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
	N	8	8	8	8	4	4	4	4	4	4	4	4	
					: Data	Unavailab	ole b	: Schedu	led Sacrif	ice				



	IND	IVIDUA	L DAI	LY FOO	D CON	SUMPT:	ION (Grams)	
STUDY: 193	ANIMAL #	GROUP DOSE: DAY 154	0.1	(mg/kg DAY 168) DAY 175		MALE -	
	8685 8679 8663 8686 8665 8666 8655 8659 8677	b b 400 400 400 400 400	b b 361 400 400 400 b	b b 400 400 400 400 400	b b 400 400 400 400 400	6 6 400 400 400 400 400		
	S.D. N	0.0 4 Data Unav	19.5 4 ailable	0.0 4 b: Sche	0.0 4 eduled Sa	0.0 4 crifice		

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)														
 ST	UDY: 1	93				3-M 0.3(mg	/ka)	SE	X: MA	LE				
ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63		
8674	114	360	240	328	400	400	400	400	400	364	400	400		
8653	295	390	263	227	360	305	400	400	400	400	400	356		
8660	400	360	320	269	400	162	252	394	400	358	316	400		
8668	234	319	400	400	400	382	400	400	400	400	400	400		
8682	326	225	400	400	400	400	400	400	400	400	400	400		
8684	233	352	309	247	400	373	400	400	218	299	400	400		
8662	382	375	400	400	400	400	400	400	400	400	400	400		
8688	372	400	286	210	288	390	369	400	400	330	372	139		
MEAN	295	348	327	310	381	352	378	399	377	369	386	362		
S.D.	97.0	55.4	65.1	82.1	40.1	82.8	51.9	2.1	64.3	38.6	29.9	91.4		
N	8	8	8	8	8	8	8	8	8	8	8	8		
					:	Data Unav	ailable							

	INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)														
-	ST	UDY: 1	93		GRO	OUP: 3	3 - M	r/ka)	SE	X: MA	LE				
	ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147		
	8674	400	400	400	400	400	400	400	400	400	400	400	400		
	8653	400	400	400	400	b	b	ь	b	ь	ь	b	Ь		
	8660	371	349	400	400	Ъ	b	b	b	b	b	b	b		
	8668	400	400	400	400	ь	b	b	b	b	b	b	b		
	8682	400	400	400	400	400	400	400	400	400	400	400	400		
	8684	400	400	400	400	b	ь	· b	ь	. b	b	b	b		
	8662	400	400	400	400	400	400	400	400	400	400	400	400		
	8688	237	322	400	400	400	400	400	400	400	400	342	400		
	MEAN	376	384	400	400	400	400	400	400	400	400	386	400		
	S.D.	57.1	30.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.0	0.0		
	N	8	8	8	8	4	4	4	4	4	4	4	4		
					: Data	Unavailal	ble t	: Schedul	led Sacrif	ice					

DRAFT

The state of the s							
	IND	IVIDUA	L DAI	LY FOO	D CON	SUMPT	ION (Grams)
STUDY: 193		GROUP DOSE:	: 3-M 0.3	(mg/kg)	SEX:	MALE
	ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182	
	0/7/	/00	400	100	400	400	
	8674	400	400	400	400	400	
	8653	ь	Ь	ь	Ь	ь	
	8660	b	ь	b	b	ь	
	8668	b	ь	ь	b	ь	
	8682	400	400	400	400	400	
	8684	b	ь	Ь	Ь	b	
	8662	400	400	400	400	400	
	8688	400	400	358	213	242	
	MEAN	400	400	390	353	361	
	S.D.	0.0	0.0	21.0	93.5	79.0	
	N	4	4	4	4	4	
			* * * * *				

b: Scheduled Sacrifice

--: Data Unavailable



INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)														
 ST	UDY: 1	93		GR DO	OUP: 4	4-M 1.0(mg	(ka)	SE	X: MA	LE				
ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63		
8661	379	343	400	399	398	388	400	400	400	400	400	400		
8670	130	296	247	130	400	222	400	400	400	400	400	400		
8681	316	190	216	239	387	391	400	400	400	400	400	400		
8664	351	390	376	256	75	35	42	321	307	383	400	394		
8675	213	370	325	336	368	296	400	277	400	400	400	400		
8683	297	400	400	252	362	212	400	400	400	201	389	284		
8658	400	400	400	307	374	327	400	400	400	400	400	400		
8652	288	400	214	191	385	247	349	303	400	400	378	400		
MEAN	297	349	322	264	344	265	349	363	388	373	396	385		
S.D.	89.2	73.7	84.3	84.0	109.4	115.7	125.3	52.9	32.9	69.8	8.2	40.8		
N	8	8	8	8	8	8	8	8	8	8	8	8		
					:	Data Unav	ailable							

THIRTEEN WEEK ORAL TOXICITY STUDY OF RECOVERY PERIOD IN DOGS

]	INDIVI	DUAL 1	DAILY	FOOD	CONSUM	IPTION	(Grams)			
	STU	JDY: 1	93		GR DO	OUP:	1-M 1.0(mg	/kg)	SE	X: MA	LE			
	ANIMAL #	DAY 70	DAY 77	OAY 84	DAY 91	DAY 98	0AY 105	0AY 112	0AY 119	0AY 126	0AY 133	DAY 140	DAY 147	
	200													
	8661	400	400	400	400	ь	b	Ь	Ь	Ь	ь	Ь	Ь	
_	8670	400	326	400	400	b	b	b	Ь	b	b	b	b	
	8681	400	400	400	400	b	b	b	b	b	b	b	b	
	8664	400	400	400	400	b	b	b	b	b	b	b	b	
	8675	207	400	400	400	400	400	400	400	400	400	400	400	
	8683	400	400	400	400	400	400	400	400	400	400	400	400	
	8658	400	400	400	400	400	400	400	400	400	400	400	400	
	8652	400	400	400	400	400	400	400	400	400	400	400	400	
	MEAN	376	391	400	400	400	400	400	400	400	400	400	400	
	S.D.	68.2	26.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
	N	8	8	8	8	4	4	4	4	4	4	4	4	
					: Data	Unavaila	ble b	: Schedu	led Sacrif	ice				

DRAFT

	IND	IVIDUA	L DAI	LY FOO	D CON	SUMPT:	ION (Grams)	
STUDY: 193		GROUP DOSE:	: 4-M 1.0	(mg/kg	·)	SEX:	MALE	-
	ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182		_
	8661	b	b	b	b	Ь		
	8670	b	b	Ь	b	ь		
	8681	b	b	b	b	b		
	8664	b	b	b	b	b		
	8675	400	400	400	400	400		
	8683	400	400	400	194	400		
	8658	400	400	400	400	400		
	8652	400	400	400	400	400		
	0072	400	400	400	400	400		
	MEAN	400	400	400	349	400		
	S.D.	0.0	0.0	0.0	103.0	0.0		
	N	4	4	4	4	4		
	**	Data Unav	ailable		eduled Sa	crifice		



			1	NDIVI	DUAL 1	DAILY	FOOD	CONSUM	IPTION	(Grams)			
ST	'UDY: 1	93		GR DO	OUP:	1-F 0(mg/k	(a)	SE	X: FE	MALE			
ANIMAL #	B- YAD	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63	
8721 8712	301 264	376 265	400 236	333 194	389 374	267 336	371 333	400 400	400 400	400 400	400 400	400 400	
8710	394	380	400	400	400	400	383	400	400	400	393	305	
8723	229	253	205	88	289	380	321	237	44	45	157	243	
8705	280	254	236	304	253	212	215	302	238	269	121	150	
8700	300	296	276	271	349	342	400	318	250	290	381	382	
8699	339	259	348	294	350	302	208	309	298	312	400	400	
8690	229	400	40D	375	399	400	400	276	373	400	400	40D	
MEAN	292	310	313	282	350	330	329	330	300	315	332	335	
S.D.	55.6	63.9	83.5	1DD.9	53.6	66.7	77.9	62.8	123.8	122.2	119.4	94.6	
N	8	. 8	8	8	8	8	8	8	8	8	8	8	
					:	Data Unav	ailable						

				I	INDIVI	DUAL :	DAILY	FOOD	CONSU	MOITAN	(Grams)			
	ST	UDY: 1	93		GR		1-F 0(mg/}	ca)	SI	EX: FE	MALE			
	ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91				DAY 119	DAY 126	DAY 133	DAY 140	DAY 147	
	8721	400	400	400	400	Ь	Ь	Ь	Ь	Ь	Ь	Ь	Ь	
_	8712	361	400	400	343	Ь	Ь	b	b	b	b	b	b	
	8710	400	400	400	400	b	b	b	b	b	b	b	b	
	8723	103	301	317	367	b	b	b	b	b	b	b	b	
	8705	160	277	280	335	213	285	56	375	338	279	306	400	
	8700	400	183	400	400	400	400	400	400	400	335	240	400	
	8699	400	400	400	400	226	294	360	257	310	400	222	400	
	8690	400	400	400	400	400	400	400	400	400	400	310	400	
	MEAN	328	345	375	381	310	345	304	358	362	354	270	400	
	S.D.	123.0	82.7	48.0	28.2	104.3	63.9	166.4	68.4	45.3	58.4	45.1	0.0	
	N	8	8	8	8	4	4	4	4	4	4	4	4	
					: Data	Unavaila	able b	o: Schedu	led Sacrif	ice				

	IND	CVIDUA	L DAI	LY FOO	D CON	SUMPT:	ION (Grams)
STUDY: 193		GROUP DOSE:	: 1-F 0 (m	g/kg)		SEX:	FEMALE
	ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182	
	0774	_	_				
	8721	b	Ь	b	Ь	ь	
	8712	b	Ь	b	Ь	b	
	8710	b	b	b	b	b	
	8723	b	Ь	b	b	b	
	8705	400	400	274	193	127	
	87D0	327	337	400	400	400	
	8699	190	269	146	262	256	
	8690	400	400	400	204	266	
	MEAN	329	352	305	265	262	
	S.D.	99.0	62.5	121.5	95.1	111.5	
	N	4	4	4	4	4	
	•••	Data Unav	ailable	b: Sch	eduled Sa	crifice	

			I	NDIVI	DUAL I	DAILY	FOOD	CONSUM	PTION	(Grams)			
ST	JDY: 1	93		GR	OUP: 2	2-F 0.1(mg	r/ka)	SE	X: FE	MALE			
ANIMAL #	DAY -8	DAY -4	DAY 7		DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63	
8717	329	338	386	400	400	400	400	400	368	324	342	371	
8703	303	297	333	272	318	256	227	348	400	400	276	400	
8713	400	400	400	400	400	400	400	400	400	400	400	400	
8693	194	250	214	341	317	190	392	400	190	238	314	236	
8695	142	102	234	247	223	298	238	269	151	239	246	153	
8709	271	278	275	211	400	400	400	400	400	400	400	400	
8715	353	400	240	348	400	278	307	400	166	191	400	261	
8697	199	387	362	259	301	268	293	283	400	305	364	308	
MEAN	274	307	306	310	345	311	332	363	309	312	343	316	
S.D.	89.0	100.6	73.7	72.1	65.9	79.8	75.1	56.4	117.2	83.6	59.7	92.8	
N	8	8	8	8	8	8	8	8	8	8	8	8	
					:	Data Unav	ailable						

				I	NDIVI	DUAL :	DAILY	FOOD	CONSUM	1PTION	(Grams)			
	ST	JDY: 1	93		GR	OUP:	2-F 0.1(mg	r/ka)	SI	EX: FE	MALE			
	ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147	
	0747	400	400	/00	400									
	8717 8703	400 335	400 344	400 363	400 400	b	b	b	b b	b	b	b	b	
	8713 8693	400 219	400 400	400 400	400 305	b	b b	b	b	b	b	b b	b	
	8695 8709	186 249	240 400	400 400	263 378	192 400	139 400	225 400	183 400	270 400	260 400	188 400	235 400	
	8715	231	400	316	349	260	331	400	400	346	400	400	400	
	8697	377	400	400	188	287	400	312	253	259	224	327	400	
	MEAN S.D.	300 87.9	373 57.2	385 30.7	335 77.8	285 86.6	318 123.4	334 83.8	309 108.9	319 66.6	321 92.4	329 99.9	359 82.5	
	N	8	8	8	8 : Data	4 Unavaila	4	4	4 led Sacrif	4	4	4	4	
-														

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 2-F DOSE: 0.1(mg/kg) ANIMAL # DAY 154 DAY 161 DAY 168 DAY 175 DAY 182 8717 BY DAY 154 DAY 161 DAY 168 DAY 175 DAY 182 8713 BY DAY 175 DAY 182 8713 BY DAY 175 DAY 182	
8703 b b b b b 8713 b b b b b 8693 b b b b b 8695 339 225 192 145 209	
8715	

				I	NDIVI	DUAL 1	DAILY	FOOD	CONSUM	PTION	(Grams)			
	ST	UDY: 1	93				3-F 0.3(mg	r/kg)	SE	X: FE	MALE			
	ANIMAL #	8- YAO	DAY -4	DAY 7	DAY 14	DAY 21	0AY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63	
	8692 8718	209 330	280 400	152 295	286 400	262 400	234 400	306 229	381 400	196 207	170 252	247 299	300 206	
	8706 8714	292 400	255 400	392 400	361 400	400 400	379 400	400	387 400	400 400	400 400	333 400	328 400	
	8701	328	289	180	166 398	310 400	140	212	304	205	278 400	400 400	400 400	
	8702 8720	290 260	299 400	321 209	246	187	400 200	400 199	400 315	400 311	355	296	294	
	8704	361	312	249	400	400	400	400	400	400	400	400	400	
_	MEAN S.D.	309 59.6	329 60.7	275 93.4	332 89.6	345 83.0	319 109.1	318 92.9	373 40.2	315 97.7	332 88.3	347 61.3	341 71.9	
	N	8	8	8	8	8	8	8	8	8	8	8	8	
						:	Oata Unav	allable						

]	NDIVI	DUAL	DAILY	FOOD	CONSU	IPTION	(Grams)			
U	ST	JDY: 1	93		GR DO	OUP: SE:	3-F 0.3(mo	r/ka)	SE	EX: FE	MALE			
	ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	g/kg) DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147	
	8692	224	195	358	270	ь	ь	ь	ь	b	Ь	Ь	Ь	
_	8718	329	400	377	276	ь	b	b	ь	b	Ь	Ь	b	
	8706	350	400	394	323	b	b	b	b	b	b	b	b	
	8714	400	400	400	400	b	b	b	b	b	b	b	b	•
	8701	302	400	305	169	252	144	243	246	382	400	400	400	
	8702	400	400	400	400	400	400	400	400	400	400	400	400	
	8720	400	392	400	400	400	400	400	400	400	400	400	400	
	8704	400	400	400	400	400	400	400	400	400	400	400	400	
	MEAN	351	373	379	330	363	336	361	362	396	400	400	400	
_	S.D.	63.9	72.1	33.6	86.3	74.0	128.0	78.5	77.0	9.0	0.0	0.0	0.0	
	N	8	8	8	8	4	4	4	4	4	4	4	4	
					: Data	Unavaila	able I	o: Schedu	led Sacrif	ice				



				IND	IVIDUA	L DAI	LY FOO	D CON	SUMPT:	ION (Grams)	
ST	UDY:	193	A	NIMAL #	GROUP DOSE: DAY 154	0.3	(mg/kg DAY 168) DAY 175		FEMALE -	
	5			8692 8718 8706 8714 8701 8702 8720 8720 8704 MEAN S.D.	b b 400 400 400 400 400 0.0	b b b 400 400 400 400 0.0	b b b 400 400 400 400 0.0	b b b 313 400 400 400 43.5	b b b 400 400 400 400 0.0 4		
				:	Data Unav	alcapte	D: Scn	eduled Sa	critice		

DRAFT

			I	NDIVI	DUAL 1	DAILY	FOOD	CONSUM	PTION	(Grams)			
STU	JDY: 1	93		GR DO	OUP:	4-F 1.0(mg	r/ka)	SE	X: FE	MALE			
ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63	
8696 8719 8711 8716 8725 8707 8689 8722	159 400 248 362 192 226 340 233	217 391 298 307 350 233 221 127	184 400 155 190 166 112 274 84	127 395 231 244 53 126 337	333 400 400 238 261 172 273 214	137 400 395 339 283 225 314	188 400 400 239 257 - 314 400 367	373 400 400 325 353 300 400 260	206 400 400 171 368 172 400 301	229 400 400 334 285 291 400 200	275 381 389 324 307 232 347 321	152 389 400 283 357 131 400 226	
MEAN S.D. N	270 86.6 8	268 84.7 8	196 100.0 8	205 118.0 8	286 84.1 8	272 115.7 8 Data Unav	321 84.0 8	351 52.4 8	302 104.5 8	317 79.4 8	322 52.3 8	292 111.4 8	

	000	B	T
1	uu		_

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)														
	STUDY: 193				GR	OUP: 4	-F	r/kg)	SEX: FEMALE					********
	ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147	
							,							
	8696	400	351	217	400	b	b	b b	b b	b b	Ь	Ь	b	
	8719	400	400	334	335	ь					Ь	Ь	b	
	8711	400	400	400	400	b	Ь	Ь	Ь	Ь	Ь	Ь	b	
	8716	400	380	400	400	ь	b	Ь	b	ь	ь	Ь	b	
	8725	190	400	400	400	258	400	400	400	400	400	400	400	
	8707	235	317	400	334	378	400	400	400	400	400	400	400	
	8689	400	400	400	333	400	400	400	400	400	400	400	400	
	8722	277	310	393	396	400	400	400	400	400	400	400	400	
	MEAN	338	370	368	375	359	400	400	400	400	400	400	400	
	S.D.	89.0	38.7	65.1	33.8	68.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
	N	8	8	8	8	4	4	4	4	4	4	4	4	
					: Data	Unavaila	ble b	: Schedul	ed Sacrif	ice				

	IND:	IVIDUA	L DAI	LY FOO	D CON	SUMPT:	ION (Grams)
STUDY: 193		GROUP DOSE:	1.0	(mg/kg)		FEMALE
	ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182	
	8696	Ь	Ь	b	Ь	Ь	
	8719	b	b	b	b	Ь	
	8711	Ь	b	Ь	b	b	
	8716	b	b	b	b	b	
	8725	400	400	400	400	400	
	8707	400	400	225	331	293	
	8689	400	400	400	400	400	
	8722	400	400	400	400	343	
	MEAN	400	400	356	383	359	
	S.D.	0.0	0.0	87.5	34.5	51.6	
	N	4	4	4	4	4	
	**	Data Unava	ailable	•	eduled Sa	crifice	
	7						

DRAFT

APPENDIX F

Individual Clinical Chemistry Data

Clinical Chemistry Test Directory

10	ABBR.	DESCRIPTION			NUFP	LIMIT	IIPPED	LIMIT
	UNITS	PRECISION	CALCULATED	OPERAND A OPERAND B		FEMALE	MALE	FEMALE
	ALT	Alanine Aminoti						
	IU/L	Integer	NO		20	20	50	50
2.	AST	Aspartate Amino	otransferase					
	IU/L	Integer	NO		20	20	50	50
3.		Total Protein						
	g/dL	0.0	NO		5.5	5.5	7.5	7.5
4.	ALB	Albumin						
	g/dL	0.0	NO		2.7	2.7	4.0	4.0
	TBILI	Total Bilirubir						
	mg/dL	0.00	NO		0.00	0.00	0.50	0.50
	ALKP	Alkaline Phosph				2220		
	IU/L	Integer	NO		50	50	200	150
	GGT	Gamma Glutamyl			100	4		
	IU/L	Integer	NO		0	0	10	10
	CHOL	Cholesterol						
	mg/dL	Integer	NO		150	150	250	250
	TRIG	Triglycerides					***	700
	mg/dL	Integer	NO		20	20	70	70
	LDH	Lactate Dehydro			25	-	450	450
	IU/L	Integer	NO		25	25	150	150
11.		Creatine Kinase			400	100	/00	400
	IU/L	Integer	NO		100	100	400	400
	BUN	Blood Urea Niti	rogen NO		8.0	8.0	20.0	20.0
	mg/dL	0.0	NC		6.0	0.0	20.0	20.0
	CREAT	Creatinine	NO		0.50	0.50	1.00	1.00
	mg/dL	0.00	NO		0.50	0.50	1.00	1.00
14.		Sodium	NO		140	140	150	150
	mEq/L	Integer	NO		140	140	130	130
15.		Potassium	NO		4 00	4 00	5 25	E 26
	mEq/L	0.00	NO		4.00	4.00	5.25	5.25

(REPORT CONTINUED)

Clinical Chemistry Test Directory

STU	STUDY: UIC-18A											
NO.	ABBR. UNITS	DESCRIPTION PRECISION	CALCULATED	OPERAND A	OPERAND B	LOWER L MALE	IMIT FEMALE	UPPER L MALE	IMIT FEMALE			
16.	CL mEq/L	Chloride Integer	NO			110	110	130	130			
17.	CA mg/dL	Calcium 0.0	NO			9.0	9.0	12.0	12.0			
18.	IP mg/dL	Inorganic Phospi 0.0	horus NO			4.0	4.0	8.0	8.0			
19.	GLU mg/dL	Glucose Integer	NO			90	90	140	140			
20.	HAPT mg/dL	Haptoglobin 0.0	NO			0.0	0.0	200.0	200.0			
21.	GLOB g/dL	Globulin 0.0	Operand A - Operand B	TP	ALB	2.7	2.7	4.0	4.0			
22.	A/G	A/G Ratio 0.00	Operand A / Operand B	ALB	GLOB	0.70	0.70	1.50	1.50			

(END OF REPORT)

UIC/TRL - CLINICAL CHEMISTRY



HISTORICAL DATABASE REPORT

		ALB	ALKP	ALT	AST	BUN	CA	CHOL	СК
DOG BEAGLE	Male								
CONTROL DATA	MEAN	3.2	118	35	35	13.2	10.4	180	82
	SD	0.17	44.1	9.6	6.7	2.71	0.37	28.8	121.0
	N	136	136	136	136	136	136	136	216
DOG BEAGLE	Female								
CONTROL DATA	MEAN	3.3	104	31	36	13.7	10.5	183	66
	SD	0.17	27.8	7.5	9.1	3.21	0.44	36.3	101.6
	N	136	136	136	136	136	136	136	216
DOG BEAGLE	Both								
CONTROL DATA	MEAN	3.2	111	33	35	13.4	10.5	182	74
	SD	0.17	37.5	8.9	8.0	2.97	0.41	32.7	111.9
	N	272	272	272	272	272	272	272	432

CONTROL DATA-189-336 days

LABCAT CC4.32

DRAFT

UIC/TRL - CLINICAL CHEMISTRY

HISTORICAL DATABASE REPORT

		CL	CREAT	GGT	GLU	HAPT	IP	Κ	LDH
DOG BEAGLE	Male								
CONTROL DATA		114	0.74	4	109	58.6	9	4.49	45
	SD	4.5	0.075	1.5	9.1	31.42	10.2	0.263	18.6
	N	136	112	78	136	68	152	136	80
DOG BEAGLE	Female								
CONTROL DATA	MEAN	114	0.73	4	106	49.7	9	4.44	50
	SD	4.6	0.083	1.5	9.0	31.77	10.5	0.261	20.9
	N	136	112	79	136	46	152	136	80
DOG BEAGLE	Both								
CONTROL DATA	MEAN	114	0.73	4	107	55.0	9	4.46	47
	SD	4.6	0.079	1.5	9.1	31.73	10.4	0.263	19.8
	N	272	224	157	272	114	304	272	160

CONTROL DATA-189-336 days

LABCAT CC4.32

UIC/TRL - CLINICAL CHEMISTRY



HISTORICAL DATABASE REPORT

		NA	TBILI	TP	TRIG	
DOG BEAGLE	Male					
CONTROL DATA	MEAN	145	0.14	10	38	
	SD	1.6	0.027	10.1 -	10.0	
	N	136	136	152	112	
DOG BEAGLE	Female					
CONTROL DATA	MEAN	146	0.15	10	39	
	SD	1.5	0.036	10.3	9.8	
	N	136	136	152	112	
DOG BEAGLE	Both					
CONTROL DATA	MEAN	146	0.15	10	39	
	SD	1.6	0.033	10.2	9.9	
	N	272	272	304	224	

CONTROL DATA-189-336 days

LABCAT CC4.32



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alanine Aminotransferase

STUDY ID: UIC-18A

STUDY NO: 193 UNITS: IU/L ABBR: ALT

Animal ID Week -3 Week -1 Week 4 Week 8 Week 13 Week 18 Week 26 GROUP: 1-M:0 mg base/kg/day 33 27 33 38 58 28 35 40 29 21 34 35 39 24 30 30 43 27 41 52 41 27 39 43 32 23 27 26 63 23 26 31 43 37 45 47 44 34 -------43 48
 42
 25
 33
 37
 39
 39

 12.3
 2.6
 5.3
 8.3
 7.5
 9.4

 8
 8
 8
 8
 8
 4
 MEAN 6.4 SD N GROUP: 2-M:0.1 mg base/kg/day 36 41 34 37 37 8.5 7.9 7.9 4.9 MEAN 3.9 11.3 SD 8.4

(--) - Data Unavailable

N



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alanine Aminotransferase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: ALT

UNITS: IU/L

A-i1 10	Week -3	Usek -1	Uppk /	Uppk R	Uppk 13	Uppl 18	Uppk 26	
	week -2		WCCK 4	week o	week 13	week 10		
GROUP: 3-	M:0.3 mg base/	'kg/day						
8674	87	49	52	56	55	73	72	
8653	51	35	30	3 5	45			
8660	25	25	19	27	27			
8668	32	23	24	28	25			
8682	34	23	30	30	24	16	29	
8684	38	29	45	40	45			
8662	42	26	31	30	32	26	42	
8688	34	24	24	31	31	39	35	
MEAN	43	29	32	35	36	39	45	
SD	19.4	8.9	11.2	9.6	11.4	24.9	19.1	
N	8	8	8	8	8	4	4	
GROUP: 4-	M:1.0 mg base/	'ka/dav	•••••••					
8661	36	30	35	34	37			
8670	33	30	27	32	32	• •		
8681	34	23	25	34	34			
8664	25	16	28	25	33			
8675	29	20	24	37	28	33	32	
8683	46	32	24	35	29	37	47	
8658	40	37	33	36	44	40	47	
8652	36	28	28	40	33	30	33	
MEAN	35	27	28	34	34	35	40	
SD	6.4	6.9	4.1	4.4	5.0	4.4	8.4	
N	8	8	8	. 8	8	4	4	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Aspartate Aminotransferase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193

ABBR: AST

UNITS: IU/L

Animal I	D Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	-M:0 mg base/kg				• • • • • • • • • • • • • • • • • • • •			
8656	26	24	32	34	34			
8687	34	31	33	27	35			
8669	31	32	66	30	40			
8673	35	30	30	33	27			
8667	33	26	37	38	33	32	31	
8654	33	35	34	26	30	32	45	
8680	37	38	30	30	29	41	44	
8676	35	44	33	46	36	30	38	
MEAN	33	33	37	33	33	34	40	
SD	3.3	6.5	12.0	6.5	4.2	4.9	6.5	
N	8	8	8	8	8	4	4	
	!-M:0.1 mg base/		-7		-			
8685	26	29	27	29	29		• •	
8663	32	25	34	32	34			
8686	39	79	39	42	36			
8665	35	37	39	40	42	43	55	
8666	32	32	51	50	32	34	45	
8655	29	30	40	40	37	46	32	
8659	25	23	24	35	44	25	36	
8677	37	52	41	22	40	••	••	
MEAN	32	38	37	36	37	37	42	
SD	5.0	18.7	8.5	8.7	5.1	9.5	10.2	
N	8	8	8	. 8	8	4	4	

^{(--) -} Data Unavailable



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Aspartate Aminotransferase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193

ABBR: AST

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
				• • • • • • • • • • • • • • • • • • • •				
	1:0.3 mg base/		7.			7.4		
8674	35	34	34	47	52	31	41	
8653	33	27	33	30	52		••	
8660	~ >	30	34	29	40		• •	
8668	30	23	36	28	32			
8682	30	33	34	47	28	27	28	
8684	34	31	48	45	41			
8662	41	32	47	53	47	31	51	
8688	38	37	38	52	38	44	48	
MEAN	33	31	38	41	41	33	42	
SD	5.0	4.3	6.1	10.6	8.8	7.4	10.2	
N	8	8	8	8	8	4	4	
GROUP: 4-N	1:1.0 mg base/	kg/day						
8661	37	42	58	46	50			
8670	29	38	34	46	32			
8681	45	40	50	75	58			
8664	25	26	50	54	40			
8675	37	29	48	61	44	41	37	
8683	31	35	36	43	43	44	47	
8658	37	41	60	39	39	29	41	
8652	34	30	41	51	37	29	30	
MEAN	34	35	47	52	43	36	39	
SD	6.1	6.1	9.5	11.6	8.1	7.9	7.1	
N	8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Protein

.....

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: TP

UNITS: g/dL

, , , , , , , , , , , , , , , , , , ,								. 3,
	Week -3				Week 13			
	M:0 mg base/kg							
8656	6.6	5.6	6.2	6.4	5.9			
8687	6.6	5.8	6.1	5.8	5.3			
8669	6.1		6.0	6.3	6.1	* *		
8673	6.6	5.7	5.8	6.3	6.4			
8667	6.1	5.4	5.5	6.1	6.2	6.3	6.5	
8654	6.0	5.5	5.3	6.0	6.1	6.0	6.4	
8680	6.5	6.3	5.9	6.9	6.4	6.6	6.7	
8676	6.4	5.8	6.0	6.0	5.7	6.3	6.7	
MEAN	6.4	5.7	5.9	6.2	6.0	6.3	6.6	
SO		0.28			0.37			
N	8	8	8	8	8	4	4	
GROUP: 2-	M:0.1 mg base/	kg/day						
8685	6.6	5.7	6.4	5.9	5.9	• •	• •	
8663	6.1	5.7	5.7	6.3	5.7		••	
8686	6.3	5.6	4.9	5.7	5.7		• •	
8665	6.2	5.5	6.0	5.8	6.1	6.2	6.1	
8666	6.0	5.9	5.9	5.9	5.7	6.4	6.4	
8655	6.0	5.8	6.2	6.1	6.4	5.6	6.6	
8659	6.4	5.4	6.4	6.0	6.4	6.4	6.3	
8677	6.6	6.3	6.2	6.5	6.5			
MEAN	6.3							
SD	0.24							
M	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Protein

STUDY ID: UIC-18A - SEX: MALE

STUDY ID: UIC-18A STUDY NO: 193

ABBR: TP UNITS: g/dL

DDK: II								9,
		Week -1			Week 13			
	:0.3 mg base/			•				
8674	5.9	5.3	5.1	6.0	5.6	5.5	6.3	
8653	6.2	5.7	5.7	6.2	6.1	••		
8660	6.1	5.4	5.9	6.5	5.6			
8668	6.5	5.3	5.7	6.2	6.2			
8682	6.3	5.7	5.8	5.8	5.8	6.2	6.3	
8684	6.2	5.5	6.1	6.3	6.5			
8662	6.6	5.9	6.0	6.1	6.3	6.2	6.7	
8688	5.8	5.8	6.5	6.3	6.2	6.8	6.7	
MEAN	6.2	5.6	5.9	6.2	6.0	6.2	6.5	
SD	0.27	0.23	0.40	0.21	0.33	0.53	0.23	
N	8	8	8	8	8	4	4	
GROUP: 4-M:	:1.0 mg base/							
8661	6.4	5.6	5.8	5.8				
8670	6.3	5.7	6.2	6.4	6.1	••	• •	
8681	6.1	5.6	5.6	6.7	6.2			
8664	5.9	5.3	4.9	5.6	6.1	••	• •	
8675	6.8	5.8	6.2	6.3	6.3	6.5	6.2	
8683	6.2	5.7	5.5	6.4	6.0	6.6	6.9	
8658	6.4	6.0	5.7	6.4	6.3	6.4	6.7	
8652	6.6	6.0	6.1	6.5	6.9	6.4	6.8	
MEAN	6.3	5.7	5.8	6.3	6.2	6.5	6.7	
SD	0.28	0.23	0.44	0.37	0.29	0.10	0.31	
N	8	8	8	8	8	4	4	

THIRTEEN WEEK ORAL TOXICITY STUDY OF ST

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Albumin

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: ALB

UNITS: g/dL

	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	M:0 mg base/kg		• • • • • • • • • • • • • • • • • • • •	*****************			• • • • • • • • • • • • • •	
8656			3.3	3.2	3.0		• •	
8687	3.3	3.3	3.4	3.3	3.0			
8669	2.8	2.9	3.0	3.1	3.1			
8673			3.2	3.3	3.4			
8667	3.2	3.2	3.2	3.3	3.2	3.1	3.6	
8654	3.1	3.0	3.1	3.2	3.1	3.2	3.5	
8680	3.2	3.3	3.2	3.4	3.3	3.3	3.8	
8676	3.3	3.1	3.1	3.2	3.1	3.4	3.6	
MEAN	3.2	3.1	3.2	3.3	3.2	3.3	3.6	
SD				0.09				
N	8	8	8	8	8	4	4	
GROUP: 2-	M:0.1 mg base/	kg/day	• • • • • • • • • • • • • • • • • • • •				• • • • • • • • • • • • • • •	
8685	_	-	3.4	3.1	3.1			
8663	3.0	3.2	2.9	3.3	3.1	• •		
8686	3.2	3.0	2.8	3.0	3.1			
8665	3.1	3.1	3.1	3.0	3.0	3.0	3.2	
8666	3.0	3.2	3.2	3.1	3.0	3.4	3.6	
8655	3.1	3.2	3.3	3.3	3.4	3.2	3.7	
8659	3.2	3.0	3.4	3.3	3.4	3.1	3.6	
8677	3.5	3.6	3.4	3.4	3.5	••	• •	
MEAN	3.2	3.2	3.2	3.2	3.2	3.2	3.5	
SD	0.17	0.19	0.24	0.16		0.17	0.22	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Albumin

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193

ABBR: ALB

UNITS: g/dL

DOK. ALD									. 3/ 42
		Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
		0.3 mg base/							
8674		3.1		2.8	3.1	2.9	2.7	3.2	
8653		2.9	3.0	3.1	3.1	2.8			
8660		2.9	2.8	2.9	3.2	2.9			
8668		3.2	3.1	2.8	3.0	3.2			
8682		3.1	3.2	3.0	2.9	2.9	2.9	3.1	
8684		3.3	3.1	3.2	3.2	3.4			
8662		3.3	3.1	3.2	3.1	3.0	3.0	3.6	
8688		3.3	3.3	3.3	3.3	3.2	3.3	3.7	
MEAN		3.1	3.1	3.0	3.1	3.0	3.0	3.4	
SD		0.17	0.15	0.19	0.12	0.21	0.25	0.29	
N		8	8	8	8	8	4	4	
				•••••				• • • • • • • • • • • • • • • • • • • •	
	: 4-M:	1.0 mg base/	_						
8661		3.1	3.1	2.9	3.0				
8670		2.9		2.9	3.2	3.1	• •		
8681		3.2	3.1	2.8	3.2	3.1			
8664		3.0	3.0	2.4	3.0	3.1	• •		
8675		3.3	3.2	2.8	3.2	3.1	2.9	3.3	
8683		3.3	3.3	2.7	3.3	3.2	. 3.3	3.9	
8658		3.1	3.3	2.9	3.0	2.8	3.1	3.5	
8652		3.4	3.3	3.0	3.2	3.5	3.0	3.6	
MEAN		3.2	3.2	2.8	3.1	3.1	3.1	3.6	
SD		0.17	0.12	0.19	0.12	0.20	0.17	0.25	
-									



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Globulin

•••••

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: GLOB

UNITS: g/dL

	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	M:0 mg base/kg			• • • • • • • • • • • • • • • • • • • •				
8656	3.5		2.9	3.2	2.9		* •	
	3.3		2.7	2.5			* =	
8669			3.0	3.2	3.0	••		
8673		-	2.6	3.0	3.0			
8667	2.9	2.2	2.3	2.8	3.0	3.2	2.9	
8654	2.9		2.2	2.8	3.0	2.8	2.9	
8680	3.3	3.0	2.7	3.5	3.1	3.3	2.9	
8676	3.1	2.7	2.9	2.8	2.6	2.9	3.1	
MEAN	3.2	2.6	2 7	3.0	2 0	3.1	3.0	
SD		0.23					0.10	
N	8	8	8	8	8	4	4	
CPOLID: 2-	M:0.1 mg base	/ka/dav	•	• • • • • • • • • • • •				
8685		2.4	3.0	2.8	2.8			
8663		2.5	2.8	3.0			* *	
8686				2.7			••	
8665	3.1	2.4	2.9	2.8	3.1		2.9	
8666			2.7			3.0		
8655			2.9	2.8				
8659	3.2	2.4	3.0	2.7	3.0			
8677	3.1	2.7	2.8	3.1				
		2.5	2.0		2.0	7.0	2.0	
	3.1						2.8 0.10	
SD					0.20 8	0.40		
N	8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Globulin

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: GLOB

UNITS: g/dL

Animal ID	Week -3							
	M:0.3 mg base/		••••••					
8674		2.3	2.3	2.9	2.7	2.8	3.1	
8653		2.7	2.6	3.1	3.3			
8660	3.2	2.6	3.0	3.3	2.7			
8668	3.3	2.2	2.9	3.2	3.0			
8682			2.8	2.9	2.9	3.3	3.2	
8684	2.9	2.4	2.9	3.1	3.1			
8662	3.3	2.8	2.8	3.0	3.3	3.2	3.1	
8688	2.5	2.5	3.2	3.0	3.0	3.5	3.0	
MEAN	3.1	2.5	2.8	3.1	3.0	3.2	3.1	
SD	0.30	0.20		0.14	0.23	0.29	0.08	
N	8	8 .	8	8	8	4	4	
			• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •				
	M:1.0 mg base/	2.5	2.0	2 0	7.0			
			3.3	2.8 3.2	3.0			
8670 8681		2.6						
	-		2.8		3.0			
8664 8675	3.5	2.6	3.4	2.6 3.1	3.2	3.6		
8683			2.8	3.1				
8658	3.3	2.7	2.8	3.4				
8652	3.2	2.7	3.1				3.2	
0032	3.2	2.1	3.1	3.3	3.4	3.4	٥.٤	
MEAN	3.2	2.5	3.0	3.1	3.1	3.4	3.1	
00	0.24	0.14	0.30	0.30	0.23	0.14	0.15	
SD	0.24	0.17	0100					



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: A/G Ratio

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: A/G

UNITS: -

noo	N. A/U							·	
					Week 8	Week 13	Week 18	Week 26	
		:0 mg base/kg	g/day			• • • • • • • • • • • • •			
	8656	0.89	1.24	1.14	1.00	1.03	••		
	8687	1.00	1.32	1.26	1.32	1.30			
	8669	0.85	1.12	1.00	0.97	1.03			
	8673	1.06	1.19	1.23	1.10	1.13		• •	
	8667	1.10	1.45	1.39	1.18	1.07	0.97	1.24	
	8654	1.07	1.20	1.41	1.14	1.03	1.14	1.21	
	8680	0.97	1.10	1.19	0.97	1.06	1.00	1.31	
	8676	1.06	1.15	1.07	1.14	1.19	1.17	1.16	
	MEAN	1.00	1.22	1.21	1.10	1.11	1.07	1.23	
	SD	0.091	0.116	0.144	0.121	0.097	0.100	0.063	
	N	8	8	8	8	8	4	4	
	GROUP: 2-M	:0.1 mg base/	/kg/day		************				
	8685	1.00	1.38	1.13	1.11	1.11			
	8663	0.97	1.28	1.04	1.10	1.19		• •	
	8686	1.03	1.15	1.33	1.11	1.19			
	8665	1.00	1.29	1.07	1.07	0.97	0.94	1.10	
	8666	1.00	1.19	1.19	1.11	1.11	1.13	1.29	
	8655	1.07	1.23	1.14	1.18	1.13	1.33	1.28	
	8659	1.00	1.25	1.13	1.22	1.13	0.94	1.33	
	8677	1.13	1.33	1.21	1.10	1.17			
	MEAN		1.26		1.13				
	SD	0.052	0.074	0.090				0.102	
	N	8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: A/G Ratio

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: A/G

UNITS: -

An	mal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GRO	UP: 3-	M:0.3 mg base/	kg/day			• • • • • • • • • • • • • • • • • • • •	******	• • • • • • • • • • • • • • • • • • • •	
867			1.30	1.22	1.07	1.07	0.96	1.03	
865	3	0.88	1.11	1.19	1.00	0.85		- •	
866	0	0.91	1.08	0.97	0.97	1.07			
866	8	0.97	1.41	0.97	0.94	1.07			
868	2	0.97	1.28	1.07	1.00	1.00	0.88	0.97	
868	4	1.14	1.29	1.10	1.03	1.10			
866	2	1.00	1.11	1.14	1.03	0.91	0.94	1.16	
868	8	1.32	1.32	1.03	1.10	1.07	0.94	1.23	
ME/	N	1.04	1.24	1.09	1.02	1.02	0.93	1.10	
	D	0.145	0.121	0.094	0.052	0.091	0.035	0.119	
	N	8	8	8	8	8	4	4	
	11P · 4-	M:1.0 mg base/	ka/dav		•••••	• • • • • • • • • • • • • • • • • • • •			
866		0.94		1.00	1.07	1.00			
867		0.85	1.19	0.88	1.00	1.03			
868	_	1.10	1.24	1.00	0.91	1.00			
866		1.03	1.30	0.96	1.15	1.03			
867		0.94	1.23	0.82	1.03	0.97	0.81	1.14	
868			1.38	0.96	1.06	1.14	1.00	1.30	
865		0.94	1.22	1.04	0.88	0.80	0.94	1.09	
865		1.06	1.22	0.97	0.97	1.03	0.88	1.13	
ME	.N	1.00	1.25	0.95	1.01	1.00	0.91	1.17	
	D	0.098	0.060	0.071	0.088	0.095	0.081	0.093	
	N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Bilirubin

STUDY ID: UIC-18A

_

FX - MALE

STUDY NO: 193 ABBR: TBILI

UNITS: mg/dL

 Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 GROUP: 1-M	:0 mg base/kg	/day						
8656	0.18	0.14	0.17	0.17	0.12			
8687	0.19	0.11	0.14	0.13	0.14			
8669	0.15	0.12	0.13	0.13	0.17			
8673	0.20	0.11	0.13	0.14	0.17			
8667	0.16	0.12	0.15	0.15	0.17	0.15	0.17	
8654	0.15	0.14	0.18	0.14	0.14	0.15	0.15	,
8680	0.17	0.17	0.13	0.12	0.16	0.17	0.22	
8676	0.20	0.14	0.12	0.15	0.12	0.16	0.17	
MEAN	0.18	0.13	0.14	0.14	0.15	0.16	0.18	
SD	0.021	0.020	0.021	0.016	0.022	0.010	0.030	
N ,	8	8	8	8	8	4	4	
 GROUP: 2-M	:0.1 mg base/	'kg/day						
8685	0.19	0.12	0.17	0.15	0.14			
8663	0.15	0.11	0.12	0.14	0.16			
8686	0.20	0.14	0.16	0.15	0.16			
8665	0.15	0.15	0.19	0.20	0.15	0.20	0.20	
8666	0.17	0.13	0.16	0.20	0.16	0.18	0.19	
8655	0.13	0.11	0.20	0.18	0.14	0.16	0.18	
8659	0.16	0.11	0.16	0.12	0.11	0.16	0.18	
8677	0.20	0.12	0.14	0.15	0.12	••		
MEAN	0.17	0.12	0.16	0.16	0.14	0.18	0.19	
SD	0.026	0.0.0	0.025	0.029	0.019	0.019	0.010	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Bilirubin

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: TBILI

UNITS: mg/dL

ok. IDILI								
	Week -3					Week 18	Week 26	
	M:0.3 mg base/							
8674	0.19	0.14	0.21	0.20	0.16	0.17	0.18	
8653	0.18	0.12	0.24	0.14	0.24		• •	
8660	0.13	0.10	0.13	0.11	0.10			
8668	0.20	0.14	0.23	0.17	0.17			
8682	0.25	0.20	0.18	0.23	0.16	0.17	0.18	
8684	0.22	0.13	0.27	0.20	0.20			
8662	0.16	0.13	0.21	0.22	0.15	0.13	0.22	
8688	0.18	0.13	0.23	0.23	0.18	0.21	0.30	
MEAN	0.19	0.14	0.21	0.19	0.17	0.17	0.22	
SD					0.040			
N	8	8	8	8	8	4	4	
GROUP: 4-	M:1.0 mg base/	'kg/day			• • • • • • • • • • • • • • • • • • • •			
8661	0.18	0.14	0.28	0.18	0.19	• •	- +	
8670	0.17	0.15	0.18	0.17	0.16	• •	• •	
8681	0.20	0.12	0.18	0.18	0.16		• •	
8664	0.14	0.10	0.19	0.10	0.12	• •	• •	
8675	0.20	0.12	0.20	0.15	0.14	0.11	0.13	
8683	0.17	0.13	0.18	0.13	0.15	0.15	0.15	
8658	0.17	0.13	0.23	0.15	0.12	0.23	0.18	
8652	0.15	0.12	0.16	0.14	0.16	0.13	0.14	
MEAN	0.17	0.13	0.20	0.15	0.15			
SO	0.021	0.015	0.038	0.027	0.023	0.053	0.022	
M	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alkaline Phosphatase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: ALKP

UNITS: IU/L

DR. ALKF								
	Week -3			Week 8	Week 13	Week 18	Week 26	
	4:0 mg base/kg							
8656	136	117	131	119	100	••		
8687	79	68	78	70	52			
8669	163	144	160	130	104			
8673	178	146	136	130	110			
8667	132	124	136	134	110	103	90	
8654	167	147	146	153	126	94	109	
8680	103	94	82	88	62	70	57	
8676	145	122	115	85	75	75	71	
MEAN	138	120	123	114	92	86	82	
SD	33.5	27.7	29.4	29.1	26.2	15.6	22.6	
N	8	8	8	8	8	4	4	
GROUP: 2-1	4:0.1 mg base/	kg/day					• • • • • • • • • • • • • • • • • • • •	
8685	117	103	89	76	76	• •		
8663	111	105	108	93	71		• •	
8686	160	139	106	124	108			
8665	105	100	104	84	74	74	68	
8666	280	233	207	169	133	121	114	
8655	105	95	97	92	72	64	82	
8659	118	83	84	67	57	47	42	
8677	145	149	113	95	80			
MEAN	143	126	114	100	84	77	77	
SD	58.9	48.7	39.0	32.5	24.5	31.7	30.0	
N	8	8	8	8	8	4	4	*



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alkaline Phosphatase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: ALKP

UNITS: IU/L

Animal 1	D Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 3	-M:0.3 mg base	/kg/dav	• • • • • • • • • • • • • • • • • • • •					
8674	136	116	98	130	74	77	101	
8653	69	67	62	72	64			
8660	90	77	67	70	53			
8668	95	88	89	84	80		- •	
8682	97	91	90	113	113	128	111	
8684	152	138	120	92	92			
8662	108	89	90	98	77	62	86	
8688	117	100	103	87	72	67	56	
MEAN	108	96	90	93	78	84	89	
SD	26.6	22.4	18.7	20.3	18.1	30.3	24.0	
N	8	8	8	8	8	4	4	
GROUP · 4	-M:1.0 mg base	/kg/dav	•••••				•••••	
8661	186	174	132	137	104			
8670	142	106	125	127	94			
8681	91	85	95	86	60			
8664	86	81	72	68	61			
8675	73	61	75	65	63	58	51	
8683	154	131	85	88	74	74	78	
8658	173	155	95	123	143	119	161	
8652	105	90	102	89	92	87	116	
MEAN	126	110	98	98	86	85	102	
SD	43.0	39.4	21.7	27.5	28.4	25.9	47.8	
N	8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: GGT

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 1-M	:0 mg base/kg	/day						
8656	6	5	5	7	6			
8687	2	4	3	4	5			
8669	4	3	2	4	6			
8673	2	4	3	4	7			
8667	2	0	2	5	7	5	7	
8654	4	1	0	4	6	6	4	
8680	1	4	4	6	7	5	4	
8676	4	2	5	3	6	6	7	
MEAN	3	3	3	5	6	6	6	
SD	1.6	1.7	1.7	1.3	0.7	0.6	1.7	
N	8	8	8	8	8	4	4	
							• • • • • • • • • • • • • • • • • • • •	
	:0.1 mg base/	kg/day	_		_			
8685	3	4	5	4	7	• •		
8663	1	3	3	5	6		• •	
8686	4	0	4	5	7			
8665	5	4	4	4	6	6	4	
8666	4	3	3	3	7	7	4	
8655	4	3	2	3	5	5	6	
8659	0	5	2	4	6	5	6	
8677	3	4	4	5	6	••	••	
MEAN	3	3	3	4	6	6	5	
SD	1.7	1.5	1.1	0.8	0.7	1.0	1.2	
N	8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: GGT

UNITS: IU/L

Anin	nal I	D Uaak	-3	Week -1	Week A	Week 8	Week 13	Week 18	Week 26	
ALLIN							week 15	week 10	WCCK 20	
GROU	JP: 3	-M:0.3 mg	base/	kg/day						
8674		_	3	4	7	5	6	5	5	
8653	3		1	3	4	2	6		••	
8660)		5	2	4	4	6			
8668	3		2	4	2	6	5	••		
8682	2		1	1	2	3	8	6	8	
8684			3	0	5	4	6			
8662	2		5	4	3	3	7	6	6	
8688	3		6	4	4	4	6	6	5	
MEAN	1		3	3	4	4	6	6	6	
SE)	1	.9	1.6	1.6	1.2	0.9	0.5	1.4	
N	1		8	8	8	8	8	4	4	
GROU	JP: 4	-M:1.0 mg	base/	kg/day						
8661			6	5	4	4	7			
8670			4	4	5	5	5			
8681			4	1	5	4	6			
8664			0	2	1	2	9	• •		
8675			1	11	4	4	6	5	0	
8683			3	4	5	5	8	6	6	
8658			3	4	2	3	5	6	5	
8652			3	3	2	0	6	4	6	
MEAN			3	4	4	3	7	5	4	
32)	1	.9	3.0	1.6	1.7	1.4	1.0	2.9	
N	1		8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Cholesterol

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: CHOL

UNITS: mg/dL

Animal I	D Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP 1	-M:0 mg base/kg							
8656	222	155	202	174	163			
8687	211	173	181	162	114		••	
8669	209	185	191	185	155	• •		
8673	217	156	146	162	153			
8667	177	127	144	159	145	151	144	
8654	237	144	156	174	176	175	153	
8680	219	184	176	215	170	190	175	
8676	227	157	157	159	154	175	174	
MEAN	215	160	169	174	154	173	162	
SD	17.7	19.9	21.5	19.0	18.9	16.1	15.5	
N	8	8	8	8	8	4	4	
GROUP: 2	-M:0.1 mg base,	/kg/day						
8685	204	136	169	147	134	••		
8663	162	151	187	175	156	••	**	
8686	235	177	129	207	180		• •	
8665	223	174	186	145	173	174	155	
8666	158	131	129	121	113	141	125	
8655	142	118	124	108	109	112	130	
8659	208	164	194	164	162	170	152	
8677	. 215	148	144	147	145			
MEAN	193	150	158	152	147	149	141	
SD	34.4	21.0	29.5	30.9	26.3	28.9	15.2	
N	8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Cholesterol

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: CHOL

UNITS: mg/dL

) Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
CDOUD. 7	-M:0.3 mg base/	'ka/day					
8674	194	128	132	158	117	134	138
	181	162	173	187	174	134	136
8653	237	183	211	224	168		
8660		160	151				••
8668	223			184	160		
8682	177	144	182	195	174	166	165
8684	181	126	137	130	144		
8662	209	157	169	169	160	150	146
8688	179	147	168	144	139	172	147
MEAN	198	151	165	174	155	156	149
SD	22.9	18.8	25.5	30.1	19.9	17.1	11.4
N	8	8	8	8	8	4	4
GROUP: 4	-M:1.0 mg base/	kg/day					
8661	214	178	176	186	165		
0/70	215	181	007				
8670		101	223	204	155	• •	
8670 8681	202	162	169	204 165	155 167	••	
8681 8664	202 157	162	169	165	167		••
8681 8664 8675	202 157 256	162 134 164	169 135 188	165 155 165	167 159	189	
8681 8664 8675 8683	202 157 256 176	162 134 164 132	169 135 188 129	165 155 165 127	167 159 185 118	189 126	150 130
8681 8664 8675	202 157 256	162 134 164	169 135 188	165 155 165	167 159 185	189	 150
8681 8664 8675 8683 8658 8652	202 157 256 176 230 227	162 134 164 132 210 175	169 135 188 129 185 178	165 155 165 127 211 152	167 159 185 118 230 175	189 126 282 182	150 130 253 175
8681 8664 8675 8683 8658	202 157 256 176 230	162 134 164 132 210	169 135 188 129 185	165 155 165 127 211	167 159 185 118 230	189 126 282	150 130 253



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Triglycerides

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: TRIG

UNITS: mg/dL

A. IKIU							01111	o. mg/ ac
	Week -3		Week 4	Week 8	Week 13	Week 18	Week 26	
	:0 mg base/kg							
8656	53	38	35	43	34			
8687	49	36	34	30	36		***	
8669	40	39	40	46	38		• •	
8673	47	40	31	40	29			
8667	33	39	24	35	40	32	37	
8654	36	48	31	45	43	27	33	
8680	45	66	24	35	33	37	31	
8676	39	47	46	29	39	31	35	
MEAN	43	44	33	38	37	32	34	
SD	6.9	9.8	7.5	6.6	4.4	4.1	2.6	
N	8	8	8	8	8	4	4	
GROUP: 2-M	:0.1 mg base/	'kg/day		+				
8685	36	33	48	35	44	• •		
8663	35	31	27	26	33			
8686	37	37	36	23	42			
8665	35	47	40	40	32	25	25	
8666	29	35	32	31	27	35	26	
8655	30	42	29	31	29	24	40	
8659	50	43	36	38	30	27	24	
8677	38	38	43	39	32			
MEAN	36	38	36	33	34	28	29	
SD	6.4	5.4	7.1	6.2	6.1	5.0	7.5	
N	8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Triglycerides

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193

Animal II	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3	M:0.3 mg base/	kg/day					
8674	50	40	28	36	26	26	37
8653	43	44	34	21	45		• •
8660	40	34	42	49	42		
8668	40	31	38	38	39		
8682	38	55	54	36	25	38	32
8684	25	26	25	21	34		
8662	40	39	33	51	30	29	38
8688	34	40	39	52	47	64	43
MEAN	39	39	37	38	36	39	38
SD	7.2	8.8	9.0	12.4	8.5	17.3	4.5
N	8	8	8	8	8	4	4
00010. /		les (day)					•••••
8661	M:1.0 mg base/ 45	38	35	41	42		
8670	38	46	45	67	38	••	••
8681	40	38	39	61	44		
8664	49	43	48	52	84		
8675	32	36	39	38	46	37	25
8683	33	41	35	37	35	30	33
	39	29	47	43	45	38	29
8658	39	30	37	60	53	37	32
8652	34	30	31	60	23	31	32
MEAN	39	38	41	50	48	36	30
SD	5.6	5.9	5.3	11.7	15.4	3.7	3.6
N	8	8	8	. 8	8	4	4



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: LDH

UNITS: IU/L

N. LUII							0.11.10	
	Week -3		Week 4	Week 8	Week 13	Week 18	Week 26	
	M:0 mg base/kg							
8656	24	23	37	31	40			
8687	60	41	36	24	26			
8669	33	38	81	33	44	• •		
8673	33	32	53	35	33			
8667	24	50	54	59	74	48	59	
8654	29	54	43	47	39	42	46	
8680	56	69	32	40	28	55	60	
8676	28	46	36	41	29	66	34	
MEAN	36	44	47	39	39	53	50	
SD	14.1	14.1	16.1	10.8	15.5	10.3	12.3	
N	8	8 -	8	8	8	4	4	
GROUP: 2-	M:0.1 mg base/	'kg/day						
8685	62	38	33	20	27	• •		
8663	35	27	27	20	34	••	••	
8686	35	75	51	41	32			
8665	20	31	25	35	37	38	40	
8666	23	32	43	51	27	38	76	
8655	29	43	43	67	23	59	54	
8659	37	21	34	26	81	46	34	
8677	39	85	36	28	28		••	
MEAN	35	44	37	36	36	45	51	
SD	12.8	23.3	8.8	16.4	18.7	9.9	18.7	
N	8	8	8	. 8	8	4	4	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: LDH

UNITS: IU/L

DDK. LUII								, .
Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 3-	M:0.3 mg base/	kg/day			•			
8674	41	42	20	57	27	49	38	
8653	38	43	38	22	44			
8660	26	29	53	25	20			
8668	30	30	49	39	23			
8682	47	37	23	43	36	41	46	
8684	59	57	54	47	45	• •		
8662	39	34	58	62	40	59	59	
8688	37	39	42	44	· 18	39	85	
MEAN	40	39	42	42	32	47	57	
SD	10.1	8.9	14.3	13.9	10.9	9.1	20.6	
N	8	8	8	8	8	4	4	
GROUP: 4-	M:1.0 mg base/	kg/day		• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •		• • • • • • • • • • • • • • • • • • • •	
8661	36	39	62	44	31			
8670	27	35	27	52	46		••	
8681	35	62	85	65	38		* -	
8664	68	24	85	67	54		• •	
8675	35	27	80	54	21	40	80	
8683	37	51	70	52	55	55	62	
8658	52	72	109	55	43	48	41	
8652	20	42	47	141	52	42	39	
MEAN	39	44	71	66	43	46	56	
SD	14.9	16.7	25.4	31.1	12.0	6.8	19.4	
N	8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatine Kinase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193

ABBR: CK

UNITS: IU/L

199

94.6

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-	M:0 mg base/kg	/day					
8656	216	140	170	236	160		
8687	347	229	130	118	91		
8669	235	206	935	232	222		
8673	227	230	195	146	157		
8667	147	156	259	249	178	109	106
8654	271	434	170	334	193	158	157
8680	211	202	174	223	97	155	155
8676	142	263	118	150	140	159	178
MEAN	225	233	269	211	155	145	149
SD	65.8	90.7	272.5	70.1	45.0	24.2	30.5
N	8	8	8	8	8	4	4
GROUP: 2-	M:0.1 mg base/	kg/day					• • • • • • • • • • • • • • • • • • • •
8685	148	137	104	78	97		• •
8663	185	168	145	119	235	••	
8686	275	912	285	259	134		• •
8665	217	268	170	211	210	149	340
8666	140	176	176	165	106	95	152
8655	177	191	251	235	178	157	165
8659	183	124	93	179	1069	100	139
8677	268	422	203	203	223		

 300
 178
 181
 282
 125

 265.3
 66.8
 59.9
 322.5
 32.3

 8
 8
 8
 8
 4

(--) - Data Unavailable

MEAN

SD

199 50.5

8



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatine Kinase

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: CK

121.4

40.0 8

88.1

Animal ID Week -3 Week -1 Week 4 Week 8 Week 13 Week 18 Week 26 GROUP: 3-M:0.3 mg base/kg/day 8674 154 153 142 --- -----105 239 213 135 --162 190 194 144 94 71.0 MEAN 87.1 54.0 52.4 35.4 21.6 35.6 SD ______ GROUP: 4-M:1.0 mg base/kg/day --326 182 154 278 308 316 --. . ---135 245 146 126 599 141

74.2

154.0

105.3

73.2

(--) - Data Unavailable

MEAN

SD

N

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS RECOVERY PERIOD IN DOGS



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A

STUDY NO: 193 ABBR: BUN

	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18		
	M:0 mg base/kg							
8656	9.8	8.9	12.3	11.4	14.2			
8687	10.1	9.8	14.5	15.4	14.1			
8669	12.3	12.8	10.9	13.5	12.3			
8673	10.0	14.4	14.2	14.9	15.6			
8667	10.2	11.4	12.1	12.6	13.0	19.0	13.5	
8654	17.0	17.0	18.0	18.9	18.2	18.3	16.5	
8680	7.3	12.4	11.8	11.6	12.3	13.1	12.1	
8676	10.0	11.8	11.9	9.6	12.8	13.7	13.0	
MEAN	10.8	12.3	13.2	13.5	14.1	16.0	13.8	
SD	2.83	2.55	2.29	2.90	2.02	3.05	1.91	
N	8	8	8	8	8	4	4	
cooun. 2-	M:0.1 mg base/	······································			• • • • • • • • • • • • • • • • • • • •	••••••		
8685		6.9	11 8	0.7	12.2			
		11.8	13.7	15.7				
8663 8686	11.3	16.4	13.2	12.7	16.9			
8665	12.9	12.7	15.3	17.7	19.0	17.1		
8666	10.4	9.4	14.8	13.0	21.1	17.5	14.2	
8655		9.3	10.3	9.4	11.9		16.6	
					18.5	15.9	12.9	
8659	13.5	12.0 13.3	12.9	13.0	18.2	13.9	12.9	
8677	13.6	13.3	12.2	15.1	18.2	• •		
MEAN	11.7	11.5	13.0	13.3	17.2	16.0		
SD	1.55	2.91	1.62	2.86	3.39	1.75	2.57	
N	8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A

SEY. MALE

STUDY NO: 193 ABBR: BUN

UNITS: mg/dL

70	BK. BON							0111101	mg/ ac
			Week -1						
		0.3 mg base/							
	8674	12.0	7.5	10.8	8.4	12.7	14.1	12.2	
	8653	9.6	11.0	15.1	18.1	18.0			
	8660	13.6	13.4	14.7	18.5	18.6			
	8668	9.4	8.1	12.2	12.6	15.0			
	8682	16.7	19.7	20.9	18.3	17.3	16.9	16.8	
	8684	13.6	14.7	12.6	14.9	16.5			
	8662	13.9	12.3	15.4	19.0	17.8	16.9	13.5	
	8688	10.8	9.3	12.0	13.5	11.7	13.4	13.0	
	MEAN	12.5	12.0	14.2	15.4	16.0	15.3	13.9	
	SD		4.01			2.57			
	N	8	8	8	8	8	4	4	
	GROUP: 4-M	:1.0 mg base/	'kg/day						
	8661	13.6	14.1	17.5	17.8	19.9			
	8670	11.5	11.0	11.3	13.8	15.7			
	8681	8.9	13.4	12.8	16.3	14.8			
	8664	9.3	10.3	9.4	14.2	18.5			
	8675	15.6	11.3	13.0	14.3	18.3	14.4	12.6	
	8683	13.5	13.0	11.9	13.3	13.7	16.0	15.0	
	8658	10.8	12.6	16.4	14.5	12.8	19.7	16.1	
	8652	10.6	11.6	15.5	15.5	17.0	19.9	15.5	
	MEAN	11.7	12.2	13.5	15.0	16.3	17.5	14.8	
	SD	2.32	1.31	2.76	1.49	2.50	2.74	1.53	
	N	8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatinine

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: CREAT

UNITS: mg/dL

	RI CREAT							0,110	ing/ut
••••	Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	GROUP: 1-N	1:0 mg base/kg	/day						
	8656	0.71	0.72	0.73	0.72	0.73		• •	
	8687	0.79	0.71	0.86	0.84	0.86		• •	
	8669	0.77	0.76	0.79	0.86	0.81			
	8673	0.84	0.73	0.73	0.81	0.82			
	8667	0.70	0.72	0.78	0.78	0.78	0.88	0.86	
	8654	0.84	0.76	0.73	0.79	0.74	0.81	0.83	
	8680	0.66	0.72	0.69	0.70	0.80	0.79	0.76	
	8676	0.73	0.67	0.72	0.76	0.77	0.87	0.94	
	MEAN	0.76	0.72	0.75	0.78	0.79	0.84	0.85	
	SD	0.066	0.029	0.054	0.055	0.043	0.044	0.075	
	N	8	8	8	8	8	4	4	
				•••••					
		1:0.1 mg base/							
	8685	0.54	0.57	0.68	0.69	0.70	* *		
	8663	0.74	0.74	0.73	0.88	0.85	• •		
	8686	0.79	0.86	0.76	0.80	0.79		• •	
	8665	0.69	0.73	0.75	0.80	0.80	0.83	0.85	
	8666	0.81	0.78	0.88	0.88	0.90	0.93	0.87	
	8655	0.66	0.65	0.65	0.69	0.70	0.71	0.68	
	8659	0.67	0.66	0.69	0.74	0.80	0.84	0.84	
	8677	0.70	0.77	0.78	0.76	0.82			
	MEAN	0.70	0.72	0.74	0.78	0.80	0.83	0.81	
	SD	0.085	0.090	0.072	0.075	0.068	0.090	0.088	
	N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatinine

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: CREAT

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 3-N	1:0.3 mg base/	kg/day						
8674	0.80	0.72	0.68	0.73	0.77	0.74	0.84	
8653	0.78	0.82	0.76	0.70	0.73			
8660	0.78	0.76	0.83	0.80	0.84			
8668	0.69	0.65	0.67	0.68	0.69			
8682	0.84	0.77	0.68	0.71	0.64	0.68	0.72	
8684	0.77	0.71	0.77	0.78	0.86			
8662	0.73	0.63	0.82	0.79	0.72	0.70	0.70	
8688	0.76	0.73	0.84	0.84	0.91	0.93	0.97	
MEAN	0.77	0.72	0.76	0.75	0.77	0.76	0.81	
SD	0.045	0.062	0.072	0.057	0.093	0.114	0.125	
N	8	8	8	8	8	4	4	
	1:1.0 mg base/							
8661	0.79	0.75						
8670		0.74	0.72	0.81				
8681	0.70	0.68	0.76	0.93				
8664	0.55	0.63	0.62	. 0.69	0.71			
8675	0.84	0.71	0.70	0.78	0.75	0.78	0.66	
8683	0.77	0.71	0.75	0.86	0.81	0.94	0.98	
8658	0.75	0.71	0.74	0.81	0.76	0.77	0.77	
8652	0.65	0.67	0.80	0.67	0.84	0.90	0.79	
MEAN	0.72	0.70	0.74	0.80	0.79			
\$0	0.090	0.039	0.060	0.085	0.067	0.085	0.133	
N	8	8	8	. 8	8	4	4	

^{(--) -} Oata Unavailable



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sodium

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: NA

UNITS: mEq/L

 								1.
 Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	:0 mg base/kg							
8656	149	148	146	147	149			
8687	145	144	147	145	146		- •	
8669	147	146	145	147	145			
8673	146	146	146	145	147			
8667	145	144	146	145	147	148	145	
8654	147	143	148	145	147	147	148	
8680	148	145	146	146	148	146	148	
8676	147	143	145	145	147	146	149	
	,							
MEAN	147	145	146	146	147	147	148	
SD	1.4	1.7	1.0	0.9	1.2	1.0	1.7	
N	8	8	8	8	8	4	4	
GROUP: 2-M	:0.1 mg base/	kg/day						
8685	146	145	146	143	146			
8663	147	147	144	147	148		• •	
8686	146	146	144	145	144			
8665	145	144	142	142	145	146	145	
8666	146	144	142	145	147	149	147	
8655	146	145	144	142	146	144	146	
8659	147	145	146	146	147	147	148	
8677	145	148	145	145	147			
MEAN	146	146	144	144	146	147	147	
SD	8.0	1.4	1.6	1.8	1.3	2.1	1.3	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sodium

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193

ABBR: NA

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 3-M	:0.3 mg base/	kg/day		**************				
8674	145	144	144	144	145	142	147	
8653	144	145	145	147	142			
8660	146	144	145	146	146			
8668	147	147	148	146	148		**	
8682	148	147	145	147	148	148	149	
8684	148	146	147	147	147	••		
8662	149	146	145	149	146	149	144	
8688	147	147	146	146	149	150	148	
MEAN	147	146	146	147	146	147	147	
SD	1.7	1.3	1.3	1.4	2.2	3.6	2.2	
N	8	8	8	8	8	4	4	
			•••••	•••••				
	1:1.0 mg base/		4/7		***			
8661	147	148	143	146	146			
8670	144	147	147	145	148		~ •	
8681	146	145	143	148	147			
8664	143	143	143	143	141			
8675	148	147	146	147	147	147	147	
8683	146	145	147	146	148	147	148	
8658	148	146	147	144	144	150	150	
8652	148	146	147	148	148	147	147	
MEAN	146	146	145	146	146	148	148	
SD	1.9	1.6	2.0	1.8	2.5	1.5	1.4	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Potassium

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193

UNITS: mEa/L

ABE	BR: K							UNITS	mEq/L
	Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	GROUP: 1-M	:0 mg base/kg	/day					• • • • • • • • • • • • • • • • • • • •	
	8656	4.35	4.08	3.87	4.02	4.36	**		
	8687	4.39	4.44	4.43	4.23	4.29			
	8669	4.59	4.59	4.74	4.91	4.52			
	8673	4.81	4.37	4.44	4.49	4.29			
	8667	4.59	4.83	4.74	4.53	4.51	4.64	4.30	
	8654	4.72	4.36	4.52	4.79	4.52	4.64	4.50	
	8680	4.39	4.55	4.44	4.45	4.52	4.49	4.50	
	8676	4.56	4.74	4.35	4.52	4.50	4.44	4.30	
	MEAN	4.55	4.50	4.44	4.49	4.44	4.55	4.40	
	SD	0.165	0.237	0.272	0.283	0.106	0.103	0.115	
	N	8	8	8	8	8	4	4	
	GROUP: 2-M	:0.1 mg base/	'kg/day						
	8685	4.37		4.40	4.43	4.26			
	8663	4.69	4.36	3.97	4.50	4.31			
	8686	3.98	4.48	4.23	4.37	4.48			
	8665	4.42	3.97	4.38	4.54	4.62	4.16	4.13	
	8666	4.37	4.47	4.26	4.58	4.29	4.86	4.34	
	8655	4.68	4.18	4.11	4.34	4.44	4.11	4.40	
	8659	4.71	4.84	4.37	4.25	4.65	4.30	4.47	
•	8677	4.74	5.46	4.48	4.41	4.35			
	MEAN	4.50	4.54	4.28	4.43	4.43	4.36	4.34	
	SD	0.262	0.452	0.169	0.110	0.149	0.345	0.147	
	N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Potassium

STUDY ID: UIC-18A

UNITS: mEq/L

STUDY	Y NO:	19
ABBR:	. K	

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M	:0.3 mg base/	'kg/day	• • • • • • • • • • • • • • • • • • • •				
8674		4.12	3.88	4,17	3.85	4.42	4.07
8653		4.24	4.09	4.35	4.58		
8660	4.76	4.55	4.33	4.73	4.17		
8668	4.42	4.25	4.18	4.30	4.21		
8682	4.25	4.50	4.28	4.12	4.20	4.69	4.32
8684	4.D4	4.62	4.16	4.33	4.52	••	
8662	4.83	4.74	4.11	4.24	4.11	4.66	4.18
8688	4.36	4.09	4.36	4.59	4.45	4.59	4.32
MEAN	4.45	4.39	4.17	4.35	4.26	4.59	4.22
SD	0.262	0.244	0.155	0.208	0.242	0.121	0.121
N	8	8	8	8	8	4	4
coole, / N		· · · · · · · · · · · · · · · · · · ·		••••••			
8661	:1.0 mg base/		4.14	/ 20	4.38		
		4.13	4.30	4.52	4.31	••	
8670		4.72	4.28	4.66	4.23		
8681 8664	4.49 4.57	4.39	4.41	4.41	4.55	••	
		4.46	4.36	4.56	4.38	4.83	4.49
8675					4.65	5.19	
8683	4.34	4.54	4.33	4.51			
8658		4.28	4.42	4.59	4.35	4.36	4.16
8652	4.42	4.52	4.37	4.36	4.80	4.59	4.36
MEAN		4.42			4.46		
SD	0.208	0.182	0.090	0.147	0.193	0.355	0.186



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Chloride

STUDY ID: UIC-18A

STUDY NO: 193

Animal II	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1	M:0 mg base/kg	/day					
8656	113	112	110	113	111		
8687	116	107	107	110	109		- •
8669	114	109	109	112	112	• •	
8673	114	109	115	112	115		
8667	113	111	112	109	115	113	113
8654	114	109	114	113	113	115	117
8680	113	107	113	111	113	113	113
8676	112	106	114	111	114	111	113
MEAN	114	109	112	111	113	113	114
SD	1.2	2.1	2.8	1.4	2.1	1.6	2.0
N	8	8	8	8	8	4	4
CDOUD. 3.	 -M:0.1 mg base/		**********		• • • • • • • • • • • • • • • • • • • •		
8685	117	109	113	112	114		••
8663	114	107	109	110	112		
8686	115	112	110	110	112		
8665	113	110	108	111	111	115	115
8666	112	109	114	111	115	113	118
8655	114	110	112	108	113	114	115
8659	115	110	108	110	111	113	114
	113	104	110	107	114	113	114
8677	113	104	110	107	114		
MEAN	114	109	111	110	113	114	116
SD	1.6	2.4	2.3	1.6	1.5	1.0	1.7
N	8	8	8	8	8	4	4



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Chloride

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193

UNITS: mEq/L

	Week -3				Week 13		
	M:0.3 mg base/						
8674	117	108	108	113	111	113	115
8653	111	107	111	113	113		
8660	111	107	109	111	113		
8668	113	107	115	114	115		
8682	117	113	114	114	118	116	116
8684	119	110	110	113	115		
8662	111	109	112	112	115	112	116
8688	113	110	109	109	111	115	118
MEAN	114	109	111	112	114	114	116
SD	3.2	2.1	2.5	1.7	2.4	1.8	1.3
N	8	8	8	8	8	4	4
GROUP: 4-	M:1.0 mg base/	'kg/day					
8661	112	108	113	113	113		
8670	112	111	111	110	116		
8681	111	107	112	112	115		
8664	113	106	118	112	112		
8675	115	107	110	112	114	114	117
8683	114	104	111	110	112	115	114
8658	109	104	112	109	112	116	121
8652	111	104	111	111	111	113	111
MEAN	112	106	112	111	113	115	116
SD	1.9	2.4	2.5	1.4	1.7	1.3	4.3
N	8	8	8	. 8	8	4	4



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Calcium

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: CA

UNITS: mg/dL

Animal I	D Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 1	-M:0 mg base/kg	g/day						
8656	10.2	10.2	9.8	9.9	10.5			
8687	10.6	10.4	10.3	10.0	10.5			
8669	9.9	10.3	9.9	10.2	10.1		* *	
8673	10.4	10.0	9.8	9.9	10.4			
8667	9.8	9.8	10.3	10.1	10.5	10.5	9.7	
8654	10.2	9.9	10.0	9.7	10.1	10.5	9.7	
8680	10.4	10.2	10.2	10.3	10.7	10.8	10.0	
8676	10.8	10.4	10.3	10.4	10.7	10.9	10.2	
MEAN	10.3	10.2	10.1	10.1	10.4	10.7	9.9	
SD	0.34	0.23	0.23	0.23	0.23	0.21	0.24	
N	8	8	8	8	8	4	4	
GROUP: 2	-M:0.1 mg base/	/kg/day						
8685	10.4	10.1	10.1	9.4	10.3			
8663	9.9	10.5	9.9	10.1	10.3			
8686	10.5	10.4	9.8	10.0	10.0			
8665	10.4	10.3	9.9	9.6	10.4	10.3	9.7	
8666	10.1	10.2	10.0	9.8	10.3	10.7	10.0	
8655	10.3	10.4	10.2	9.5	10.6	10.0	9.7	
8659	10.1	10.3	10.2	10.0	10.9	10.4	9.5	
8677	10.7	11.0	10.4	10.3	10.6	••	••	
MEAN	10.3	10.4	10.1	9.8	10.4	10.4	9.7	
SD	0.26	0.27	0.20	0.32	0.27	0.29	0.21	
N	8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Calcium

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: CA

UNITS: mg/dL

DR: CA							ONITS.	ilig/ GE
	Week -3						Week 26	
	M:0.3 mg base,							
8674	10.4	9.9	9.8	9.9	10.1	9.6	9.6	
8653	9.9	10.2	10.0	9.9	9.4			
8660	9.9	10.2	10.0	10.1	10.4	• •		
8668	10.3	10.1	9.9	10.2	10.4	• •		
8682	10.3	10.2	9.9	9.8	9.8	10.2	9.2	
8684	10.3	10.7	10.5	10.2	10.6			
8662	10.2	9.9	9.8	9.1	9.8	10.2	8.9	
8688	10.9	10.4	10.6	10.1	10.4	11.3	10.1	
MEAN	10.3	10.2	10.1	9.9	10.1	10.3	9.5	
SD	0.32	0.26	0.31	0.36	0.41	0.71	0.52	
N	8	8	8	8	8	4	4	
GROUP: 4-	M:1.0 mg base	/kg/day						
8661	-	- '	9.7	9.7	10.2			
8670	10.0	10.2	10.0	10.1	10.6			
8681	10.4	10.4	9.9	10.3	10.5			
8664	10.2	10.4	9.9	10.3	10.4			
8675	10.6	10.2	10.1	10.0	10.3	10.8	10.0	
8683	10.4	10.4	9.9	10.2	10.4	10.8	10.1	
8658	10.0	10.0	9.9	9.9	10.0	9.9	9.4	
8652	10.5	10.5	10.4	10.1	10.9	10.6	10.1	
MEAN	10.3	10.3		10.1	10.4		9.9	
SD	0.22	0.16	0.21	0.21	0.27	0.43	0.34	
N	8	8	8	. 8	8	4	4	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Inorganic Phosphorus

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193

ABBR: IP

UNITS: mg/dL

	Week -3							
	1:0 mg base/kg		***********				•••••	
8656	5.4	5.5	6.0	5.6	5.8			
8687	5.5	6.0	5.5	5.2	5.1		• •	
8669	5.8	7.1	6.9	6.8	5.1			
8673	6.0	5.9	5.8	5.6	6.1		••	
8667	6.3	5.8	6.2	6.4	4.2	5.1	3.9	
8654	5.2	5.9	5.6	6.0	6.1	5.0	4.4	
8680	5.4	5.6	6.1	5.9	4.9	5.2	3.6	
8676	6.0	5.7	5.5	5.1	5.2	4.3	4.4	
MEAN	5.7	5.9	6.0	5.8	5.3	4.9	4.1	
SD	0.38	0.50	0.47	0.58	0.65	0.41	0.39	
N	8	8	8	8	8	4	4	
GROUP: 2-N	1:0.1 mg base/							
8685	5.7	5.8	6.8	5.1	5.0	+ -		
8663	5.2	6.5	5.8	5.9	4.5			
8686	5.7	6.9	5.7	5.6	4.7	••		
8665	5.6	4.6	5.9	4.3	4.8	4.3	3.9	
8666	5.3	5.8	5.6	4.5	5.4	5.4	3.9	
8655	5.8	6.4	5.1	4.8	5.9	4.7	4.6	
8659	5.8	6.1	5.3	5.4	6.0	5.1	4.2	
8677	6.1	6.7	7.2	6.5	5.3	••	••	
MEAN	5.7	6.1	5.9			4.9		
SD	0.29	0.73	0.72	0.74			0.33	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Inorganic Phosphorus

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193

ABBR: IP								UNITS:	mg/d
			Week -1				Week 18	Week 26	
		:0.3 mg base/				•			
8674			5.0	5.1	4.5	4.7	4.5	3.9	
8653		4.9	5.6	5.1	4.9	3.3			
8660		5.6	5.9	5.6	5.8	4.8			
8668		4.9	5.5	4.9	5.5	5.3			
8682		5.1	5.5	6.0	5.4	4.6	4.4	4.7	
8684		5.0	6.1	5.4	5.2	5.0			
8662		5.3	5.5	4.7	4.1	3.8	4.7	2.7	
8688		6.0	5-8	5.7	5.3	5.3	5.5	2.8	
MEAN		5.3	5.6	5.3	5.1	4.6	4.8	3.5	
SD			0.33						
N		8	8	8	8	8	4	4	
GROUP	: 4-M	:1.0 mg base/	kg/day	• • • • • • • • • • • • • • • • • • • •					
8661			5.8	5.4	5.3	5.2			
8670			6.0	5.7	5.9	5.7			
8681			6.0	5.4	4.9				
8664			_	5.4	5.5	5.2			
8675		5.8	5.9	5.4	5.9	5.9	5.9	4.0	
8683			5.5	5.7	6.2	6.0	5.2	3.9	
8658				4.4		5.2	4.1	4.2	
8652		6.0	6.0	5.5	3.8	5.7		4.0	
MEAN			5.8					4.0	
SD		0.52	0.24	0.41	0.76	0.36		0.13	
N		8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Glucose

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: GLU

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
CDOUR 1	M:0 mg base/kg	· /day						
8656	99	104	104	94	101			
8687	101	115	113	98	85			
8669	107	115	107	109	120	• •		
8673	121	109	107	106	113			
8667	107	99	93	97	105	101	98	
	96	95	94	98	92	101	90	
8654								
8680	107	121	104	107	117	119	106	
8676	121	108	116	107	114	109	108	
MEAN	107	108	105	102	106	108	101	
SD	9.3	8.7	8.1	5.8	12.5	8.5	8.2	
N	8	8	8	8	8	4	4	
	M:0.1 mg base/		444	***	400			
8685	113	122	116	119	129		**	
8663	98	115	121	109	116	••		
8686	122	116	105	101	117	••	• •	
8665	96	104	106	107	102	106	101	
8666	112	111	106	102	110	112	99	
8655	97	115	113	106	113	106	99	
8659	100	108	107	102	110	102	98	
8677	115	124	112	99	120			
MEAN	107	114	111	106	115	107	99	
SD	10.0	6.7	5.8	6.4	8.0	4.1	1.3	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Glucose

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: GLU

UNITS: mg/dL

 Animal	10	Week -3	Week -1	Week 4			Week 18	Week 26	
 GROUP:	3-M:	0.3 mg base/	kg/day		***********		• • • • • • • • • • • • • • • • • • • •		
8674		117	111	106	113	122	112	113	
8653		95	106	96	104	104			
8660		98	96	101	95	101		**	
8668		107	103	104	103	108			
8682		117	118	115	99	110	109	129	
8684		106	106	110	102	107			
8662		106	107	107	107	118	100	105	
8688		92	111	112	92	103	108	98	
MEAN		105	107	106	102	109	107	111	
SO		9.3	6.5	6.1	6.6	7.4	5.1	13.3	
N		8	8	8	8	8	4	4	
 GROUP:	4-M:	1.0 mg base/	ka/dav						
8661		114	111	124	110	113			
8670		104	104	104	108	98		• •	
8681		99	94	95	106	105			
8664		91	97	90	97	103			
8675		100	93	101	86	96	100	89	
8683		109	114	109	114	112	135	109	
8658		108	106	100	99	100	101	109	
8652		104	99	110	86	96	109	102	
MEAN		104	102	104	101	103	111	102	
SD		7.1	7.8	10.4	10.6	6.7	16.3	9.4	
N		8	8	8	. 8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Haptoglobin

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: HAPT

UNITS: mg/dL

	Week -3						Week 26	
	M:0 mg base/kg							
8656	55.1	50.7	41.1	25.1	18.2			
8687	16.7	47.1	17.3	B	B			
8669	92.3	70.8	70.1	B	B			
8673	49.7	88.6	87.2	78.8	72.6			
8667	19.7	71.3	18.2	17.3	B	103.8	B	
8654	B	B	B	B	B	B	23.0	
8680	44.9	108.1	50.3	100.2	34.4	76.1	48.7	
8676	76.9	129.3	140.0	107.5	106.5	130.9	126.0	
MEAN	50.8	80.8	60.6	65.8	57.9	103.6	65.9	
SD	27.65	29.97	43.32	42.13	39.61	27.40	53.61	
N	7	7		5			3	
GROUP 2	M:0.1 mg base/	kg/dav						
8685		35.2	114.5	58.6	41.6			
8663		67.8		37.8				
8686		B	34.2	B	22.4			
8665	22.1	34.5		B		23.0	B	
8666	19.4	71.2	22.8	20.0	24.2	B	B	
8655			51.3	B		42.1	61.2	
8659				91.2				
8677	135.9	110.0	141.2		112.5			
MEAN	42.0	69.7	66.1	66.1	50.1	55.5	68.7	
SD	39.18	32.24	50.55		32.43	40.83	10.61	
N	8	7	8	5	7	3	2	

(--) - Data Unavailable

B - Below Linearity



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Haptoglobin

STUDY ID: UIC-18A

SEX: MALE

STUDY NO: 193 ABBR: HAPT

UNITS: mg/dL

Animal II	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
CROUD. 7	-M:0.3 mg base/	ka/day	••••••				
8674		84.5	131 0	154 8	65.0	72.5	57.9
8653		B					
8660	_	82.8		_	82.5		
8668		46.7	119.6		67.4		
8682		B	29.8	36.3	32.7	99.9	49.6
8684		94.2		49.8	B		
	55.4				_	29.9	B
8688		114.4					
5000	0,,,			3313		,	
MEAN	44.1	86.1	83.1	78.5	64.6	73.6	41.5
SD		22.34					
N	7		8	7	5	4	3
GROUP: 4	-M:1.0 mg base/						
8661	18.6				69.9		
8670	·	76.9					
8681	20.8	B	189.1		23.0		
8664	25.6	37.4			40.4		
8675	19.8	89.1		62.3			6.5
8683	39.2	81.7	279.5	134.4			112.4
8658	50.2	76.4		37.2		B	B
8652	105.4	108.9	237.7	17.1	92.7	105.4	115.0
MEAN	40.2	70.1	183.6	60.1	68.8	97.8	87.2
SD	28.85	30.68	71.58	38.91	31.06	8.64	45.86
N	8	7	8	8	8	3	3

(--) - Data Unavailable B - Below Linearity

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alanine Aminotransferase

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: ALT

UNITS: IU/L

Ac	BK: ALI							ONIIS	: 10/L
	Animal ID	Week -3		Week 4	Week 8	Week 13	Week 18	Week 26	
		:0 mg base/kg							
	8721	32	33	46	49	54	• •		
	8712	41	26	25	34	36			
	8710	30	27	32	38	37			
	8723	29	33	20	29	16			
	8705	32	24	25	18	23	33	23	
	8700	35	33	38	36	47	36	35	
	8699	36	26	34	33	27	27	37	
	8690	27	26	33	28	37	36	27	
	MEAN	33	29	32	33	35	33	31	
	SD	4.5	3.8	8.3	8.9	12.4	4.2	6.6	
	N	8	8	8	8	8	4	4	
	GROUP: 2-F	:0.1 mg base/	kg/day		**				
	8717	41	28	26	28	26	• •		
	8703	37	34	34	36	34			
	8713	30	26	32	30	28			
	8693	33	31	33	35	39			
	8695	34	29	25	34	32	21	28	
	8709	26	30	29	31	28	20	33	
	8715	31	31	33	38	37	33	27	
	8697	25	23	34	26	27	34	33	
	MEAN	32	29	31	32	31	27	30	
	SD	5.4	3.4	3.6	4.2	4.9	7.5	3.2	
	N	8	8	8	8	8	4	4	

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alanine Aminotransferase

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: ALT

UNITS: IU/L

ARRK: WI							ON112	: 10/L
Animal II	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 3-	F:0.3 mg base	/kg/day						,
8692	22	21	19	17	24			
8718	18	18	20	24	28			
8706	24	17	21	27	28		• •	
8714	25	27	17	28	24			
8701	34	26	27	32	32	25	34	
8702	24	32	44	38	29	23	29	
8720	26	25	31	32	30	23	32	
8704	36	23	26	32	33	29	43	
MEAN	26	24	26	29	29	25	35	
SD	6.0	5.0	8.8	6.3	3.3	2.8	6.0	
N	8	8	8	8	8	4	4	
GROUP: 4-	F:1.0 mg base/	 /kg/day						
8696	25	22	35	26	31			
8719	27	27	22	23	20			
8711	29	29	29	31	31			
8716	27	24	29	33	42	• •		
8725	42	30	25	27	28	37	28	
8707	30	25	27	24	30	27	24	
8689	34	28	26	27	38	23	34	
8722	25	23	19	23	30	25	23	
MEAN	30	26	27	27	31	28	27	
SD	5.7	2.9	4.8	3.7	6.6	6.2	5.0	
N	8	8	8 .	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Aspartate Aminotransferase

STUDY ID: UIC-18A

STUDY NO: 193

ABBR: AST

SEX: FEMALE

UNITS: IU/L

 				•••••				
Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 GROUP: 1-F	:0 mg base/kg	/day						
8721	36	32	48	46	49			
8712	52	27	41	45	47			
8710	38	33	48	72	42			
8723	31	33	27	27	23	**		
8705	40	34	34	31	38	53	41	
8700	31	35	28	36	52	32	45	
8699	31	44	42	27	36	25	38	
8690	32	26	41	28	32	32	29	
MEAN	36	. 33	39	39	40	36	38	
SD	7.2	5.5	8.2	15.4	9.6	12.1	6.8	
N	8	8	8	8	8	4	4	
GROUP: 2-F:	:0.1 mg base/	kg/day						
8717	37	30	25	38	46			
8703	27	36	29	31	35			
8713	46	44	44	42	42		• •	
8693	34	28	28	30	36	• •		
8695	26	27	39	34	44	19	34	
8709	24	34	32	32	43	24	34	
8715	21	22	31	37	38	29	36	
8697	24	22	26	20	34	25	26	
MEAN	30	30	32	33	40	24	33	
SD	8.4	7.4	6.6	6.6	4.6	4.1	4.4	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Aspartate Aminotransferase

-

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: AST

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	F:0.3 mg base/							
8692	24	29	31	26	30			
8718	23	30	36	- 26	34			
8706	25	21	27	30	31			
8714	51	41	40	49	45			
8701	29	31	41	36	38	49	47	
8702	30	40	6D	55	51	43	55	
8720	21	26	37	31	37	36	35	
8704	30	34	41	44	44	34	55	
0104	30							
MEAN	29	32	39	37	39	41	48	
SD	9.5	6.7	9.8	11.0	7.4	6.9	9.5	
N	8	8	8	8	8	4	4	
	F:1.0 mg base							
8696	23	28	43	42	43			
8719	42	33	49	52	61	••		
8711	37	35	58	43	47			
8716	24	34	40	41	60			
8725	37	26	36	39	50	23	26	
8707	27	21	40	40	55	32	41	
8689	29	34	59	45	52	30	39	
8722	18	30	39	35	55	27	34	
MEAN	30	30	46	42	53	28	35	
SD	8.3	4.9	8.9	5.0	6.2	3.9	6.7	
N	8	8	8 .	8	8	4	4	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Protein

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: TP

UNITS: g/dL

	Week -3							
	:0 mg base/kg							
8721	6.0	6.2	6.1	6.2	6.2			
8712	6.6	5.8	5.5	6.0	6.0			
8710	6.4	6.0	5.6	6.2	6.5			
8723	5.8	5.3	6.0	5.7	6.0			
8705	6.5	6.0	6.3	6.1	6.7	6.3	6.9	
8700	5.4	5.3	5.9	5.4	5.7	6.0	6.1	
8699	5.5	5.3	6.3	5.7	6.1	6.0	6.5	
8690	6.0	5.6	6.4	6.1	6.2	6.5	6.9	
MEAN	6.0	5.7	6.0	5.9	6.2	6.2	6.6	
SD	0.45	0.36	0.33	0.29	0.31	0.24	0.38	
N	8	8	8	8	8	4	4	
GROUP: 2-F	:0.1 mg base/	kg/day	•••••		••••••		• • • • • • • • • • • • • • • • • • • •	• • • • •
8717		5.4	5.1	5.7	6.0			
8703	6.1	6.2	6.1	5.8	6.1			
8713	5.9	5.5	6.0	5.4	6.2	• •		
8693	6.6	5.9	6.4	5.6	6.4	• •		
8695	6.1	5.7	5.8	6.4	6.4	6.4	6.6	
8709	7.0	6.1	5.9	5.9	6.4	6.3	6.1	
8715	6.4	5.4	5.5	6.2	6.3	6.4	6.4	
8697	6.2	5.8	6.5	6.6	6.9	6.6	7.1	
MEAN	6.3	5.8	5.9	6.0	6.3	6.4	6.6	
SD	0.35	0.31	0.46	0.41	0.27	0.13	0.42	
N	8	8	8	8	8	4	4	

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Protein

STUDY ID: UIC-18A

_

SEX: FEMALE

STUDY NO: 193

UNITS: q/dL

ABBR: TP							UNITS	: g/dL
Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
					• • • • • • • • • • • • • • • • • • • •			
	:0.3 mg base/							
8692		5.4	5.9	5.7	5.9			
8718	6.3	5.6	5.8	5.7	6.2			
8706	6.2		6.2	6.2	6.3			
8714	6.2	5.6	5.2	5.9	6.8			
8701	6.0	6.0	5.9	5.9	6.4	6.2	6.7	
8702	5.8	6.0	6.1	5.9	5.9	6.1	6.8	
8720	6.4	5.6	6.4	6.5	6.3	6.2	6.1	
8704	5.7	5.5	5.4	5.3	6.2	6.1	6.3	
MEAN	6.1	5.7	5.9	5.9	6.3	6.2	6.5	
SD	0.28	0.23	0.40	0.36	0.29	0.06	0.33	
N	8	8	8	8	8	4	4	
coolo. / .r	:1.0 mg base/	lka (dov				•••••	• • • • • • • • • • • • • • • • • • • •	
8696		6.1	5.5	E 7	6.2			
							• •	
				5.9				
8711	6.7	5.6	5.6	5.7			**	
8716		6.7						
8725		6.5	6.0	6.0	_	_		
8707	6.2	5.9	5.3	5.6				
8689		-	5.8	6.5				
8722	5.9	5.4	5.5	5.5	6.2	5.8	6.6	
		5.9			6.3			
\$D		0.50	0.25					
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Albumin

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: ALB

UNITS: g/dL

	Week -3						Week 26	
	F:0 mg base/kg							
8721	3.2	3.3	3.5	3.5	3.1			
8712	3.5	3.1	3.1	3.1	3.1			
8710	3.2	3.3	3.1	3.4	3.3			
8723	3.2	3.1	3.3	3.1	3.0			
8705	3.1	3.1	3.4	3.1	3.1	3.3	3.5	
8700	2.9	3.0	3.2	3.1	3.2	3.3	3.4	
8699	2.9	3.1	3.3	3.2	3.2	2.9	3.5	
8690	3.2	3.2	3.4	3.3	3.4	3.1	3.5	
MEAN	3.2	3.2	3.3	3.2	3.2	3.2	3.5	
SD	0.19	0.11	0.15	0.16	0.13	0.19	0.05	
N	8	8	8	8	8	4	4	
						•••••		
	F:0.1 mg base/	-						
8717	3.3	3.1	2.9	3.2	3.1			
8703		3.3	3.4	3.1	3.3	• •		
8713	3.1	2.7	3.3	2.9	3.2	• •		
8693	3.4	3.4	3.2	3.2	3.3			
8695	3.3	3.4	3.4	3.6	3.4	3.2	3.5	
8709	3.5	3.3	3.3	3.2	3.2	3.2	3.3	
8715	3.4	3.0	3.1	3.2	3.2	3.4	3.2	
8697	3.1	3.2	3.5	3.6	3.6	3.3	3.4	
MEAN	3.3	3.2	3.3	3.3	3.3	3.3	3.4	
SD	0.14	0.24	0.19	0.24	0.16	0.10	0.13	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Albumin

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: ALB

UNITS: g/dL

ADDI	C. ALD							01113	. g/uL
	Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
		0.3 mg base/							
	8692	3.1	2.7	3.1	3.0	2.8			
	8718	3.2	2.7	3.1	3.1	3.1		••	
	8706	3.1	3.2	3.2	3.2	3.1			
	8714	2.9	3.0	2.9	3.3	3.3			
	8701	3.5	3.2	3.3	3.3	3.3	3.2	3.5	
	8702	3.2	3.0	3.2	3.2	3.0	3.0	3.4	
	8720	3.4	3.0	3.4	3.5	3.1	3.3	3.6	
	8704	3.0	3.0	3.1	3.1	3.1	2.9	3.5	
	MEAN	3.2	3.0	3.2	3.2	3.1	3.1	3.5	7
	SD	0.20	0.19	0.15	0.16	0.16	0.18	0.08	
	N	8	8	8	8	8	4	4	
	GROUP: 4-F:	1.0 mg base/	kg/day		••••••				
	8696	3.2	3.2	3.1	3.1	3.1			
	8719	3.1	3.0	2.8	3.0	3.1		• •	
	8711	3.5	3.2	3.0	3.0	3.3	••		
	8716	3.4	3.5	3.0	3.1	3.1			
	8725	3.7	3.4	2.9	3.2	3.3	3.0	3.4	
	8707	3.2	3.2	2.8	3.1	3.2	3.3	3.5	
	8689	3.2	3.0	3.0	3.3	3.1	3.0	3.4	
	8722	3.2	3.1	2.6	3.0	3.3	3.1	3.4	
	MEAN	3.3	3.2	2.9	3.1	3.2	3.1	3.4	
	SD	0.20	0.18	0.16	0.11	0.10	0.14	0.05	
	N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Globulin

STUDY ID: UIC-18A

STUDY NO: 193

UNITS: g/dL

ABBR: GLOB

			11aab - 1	Unak /	Linet 0	Haab 17	11-ab 10	Hank 24	
				Week 4				week 20	
		0 mg base/kg							
8721			2.9	2.6	2.7	3.1	- •		
8712				2.4	2.9	2.9			
8710		3.2		2.5	2.8	3.2			
8723		2.6	2.2	2.7	2.6	3.0			
8705		3.4	2.9	2.9	3.0	3.6	3.0	3.4	
8700		2.5	2.3	2.7	2.3	2.5	2.7	2.7	
8699		2.6	2.2	3.0	2.5	2.9	3.1	3.0	
8690		2.8	2.4	3.0	2.8	2.8	3.4	3.4	
MEAN		2.9	2.5	2.7	2.7	3.0	3.1	3.1	
SD		0.32	0.30	0.23	0.23	0.32	0.29	0.34	
N		8	8	8	8	8	4	4	
GPOLIP •	2-F·I	0.1 mg base/	kg/day						
				2.2	2.5	2.9			
8703			2.9	2.7	2.7				
8713		2.8		2.7					
8693			2.5	3.2	2.4	3.1			
8695			2.3	2.4	2.8			3.1	
8709				2.6					
8715		3.0	2.4	2.4					
8697		3.1		3.0	3.0	3.3			
MEAN				2.7					
SD		0.26	0.24	0.33	0.23	0.16	0.13	0.37	
N		8	8	8	8	8	4	4	

^{(--) -} Data Unavailable

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Globulin

SEX: FEMALE

STUDY ID: UIC-18A

STUDY NO: 193 ABBR: GLOB

UNITS: g/dL

Animal ID	Week -3	Week -1			Week 13			
 GROUP: 3-F:	0.3 mg base/		***************************************					
8692	_	2.7	2.8	2.7	3.1		"	
8718	3.1	2.9	2.7	2.6	3.1			
8706	3.1	2.7	3.0	3.0	3.2			
8714	3.3	2.6	2.3	2.6	3.5			
8701	2.5	2.8	2.6	2.6	3.1	3.0	3.2	
8702	2.6	3.0	2.9	2.7	2.9	3.1	3.4	
8720	3.0	2.6	3.0	3.0	3.2	2.9	2.5	
8704	2.7	2.5	2.3	2.2	3.1	3.2	2.8	
MEAN	3.0	2.7	2.7	2.7	3.2	3.1	3.0	
SD		0.17					0.40	
N	8	8	8	8	8	4	4	
 			• • • • • • • • • • • • • • • • • • • •					
	:1.0 mg base/			100				
8696		2.9	2.4	2.2	3.1			
8719		2.3	2.9	2.9	3.1	• •		
8711			2.6	2.7	3.0		* *	
8716	3.1	3.2	3.0	2.9	3.6			
8725	3.0	3.1	3.1	2.8	2.9	3.3	2.8	
8707	3.0	2.7	2.5	2.5	2.9	3.0	3.0	
8689	3.4	3.0	2.8	3.2	3.6	3.6	3.1	
8722	2.7	2.3	2.9	2.5	2.9	2.7	3.2	
MEAN	3.0	2.7	2.8	2.7	3.1	3.2	3.0	
SD	0.28	0.37	0.25	0.31	0.30	0.39	0.17	
N	8	8	8	8	8	4	4	

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK

RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: A/G Ratio

STUDY ID: UIC-18A SEX: FEMALE

STUDY NO: 193

ABBR: A/G UNITS: -

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 1-	F:0 mg base/kg	/day						
8721	1.14	1.14	1.35	1.30	1.00			
8712	1.13	1.15	1.29	1.07	1.07			
8710	1.00	1.22	1.24	1.21	1.03			
8723	1.23	1.41	1.22	1.19	1.00			
8705	0.91	1.07	1.17	1.03	0.86	1.10	1.03	
8700	1.16	1.30	1.19	1.35	1.28	1.22	1.26	
8699	1.12	1.41	1.10	1.28	1.10	0.94	1.17	
8690	1.14	1.33	1.13	1.18	1.21	0.91	1.03	
MEAN	1.10	1.25	1.21	1.20	1.07	1.04	1.12	
SD	0.101	0.128	0.082	0.110	0.131	0.145	0.113	
N	8	8	8	8	8	4	4	
	F:0.1 mg base/							
8717		1.35	1.32					
8703		1.14	1.26	1.15	1.18	• •		
8713	1.11	0.96	1.22	1.16	1.07	• •		
8693	1.06	1.36	1.00	1.33	1.06			
8695	1.18	1.48	1.42	1.29	1.13	1.00	1.13	
8709	1.00	1.18	1.27	1.19	1.00	1.03	1.18	
8715	1.13	1.25	1.29	1.07	1.03	1.13	1.00	
8697	1.00	1.23	1.17	1.20	1.09	1.00	0.92	
MEAN	1.11	1.24	1.24	1.21	1.08	1.04	1.06	
SD	0.077	0.159	0.123	0.086	0.056	0.062	0.119	
N	8	8	8	8	8	4	4	

^{(--) -} Data Unavailable



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: A/G Ratio

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: A/G

UNITS: -

	Week -3			Week 8	Week 13	Week 18	Week 26	
	F:0.3 mg base/							
8692	0.91	1.00	1.11	1.11	0.90			
8718	1.03	0.93	1.15	1.19	1.00		y	
8706	1.00	1.19	1.07	1.07	0.97	••		
8714	0.88	1.15	1.26	1.27	0.94			
8701	1.40	1.14	1.27	1.27	1.06	1.07	1.09	
8702	1.23	1.00	1.10	1.19	1.03	0.97	1.00	
8720	1.13	1.15	1.13	1.17	0.97	1.14	1.44	
8704	1.11	1.20	1.35	1.41	1.00	0.91	1.25	
MEAN	1.09	1.10	1.18	1.21	0.98	1.02	1.20	
SD	0.171	0.102	0.100	0.106	0.050	0.102	0.193	
N	8	8	8	8	8	4	4	
CPOLID. A.	F:1.0 mg base/	'ka/day						
8696		1.10	1.29	1.41	1.00			
8719	1.15	1.30	0.97	1.03	1.00		• •	
8711	1.09	1.33	1.15	1.11	1.10			
8716	1.10	1.09	1.00	1.07	0.86			
8725	1.23	1.10	0.94	1.14	1.14	0.91	1.21	
8707	1.07	1.19	1.12	1.24	1.10	1.10	1.17	
8689	0.94	1.00	1.07	1.03	0.86	0.83	1.10	
8722	1.19	1.35	0.90	1.20	1.14	1.15	1.06	
MEAN	1.13	1.18	1.06	1.15	1.03	1.00	1.14	
SD	0.097	0.130	0.129	0.128	0.116	0.152	0.068	
N	8	8	8 .	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Bilirubin

STUDY ID: UIC-18A - SEX: FEMALE

STUDY NO: 193

ABBR: TBILI UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-	F:0 mg base/kg	/day					**********
8721	0.14	0.14	0.19	0.18	0.18		
8712	0.24	0.17	0.24	0.26	0.18		
8710	0.16	0.13	0.19	0.30	0.16		
8723	0.19	0.14	0.19	0.21	0.17	**	
8705	0.13	0.15	0.18	0.13	0.17	0.15	0.21
8700	0.11	0.13	0.16	0.17	0.17	0.17	0.18
8699	0.16	0.17	0.19	0.19	0.18	0.16	0.27
8690	0.14	0.14	0.17	0.13	0.20	0.12	0.19
MEAN	0.16	0.15	0.19	0.20	0.18	0.15	0.21
SD	0.041	0.016	0.024	0.060	0.012	0.022	0.040
N	8	8	8	8	8	4	4
CDOUD. 3.	F:0.1 mg base/	'ka/day					
8717	0.16	0.13	0.16	0.10	0.16		••
8703	0.16		0.19				
8713	0.14		0.21	0.15	0.19		••
8693	0.14	0.15	0.17	0.19	0.16		
8695	0.14	0.13	0.17	0.22	0.18	0.16	0.19
8709	0.17	0.14	0.18	0.20			
8715	0.17	0.17	0.24	0.23	0.15		
8697	0.19	0.17	0.14	0.18	0.17	0.22	0.22
0097	0.13	0.17	0.14	0.10	0.17	0.22	0.22
MEAN	0.16	0.15	0.18	0.20	0.17	0.18	0.22
SD	0.024	0.016	0.031	0.029	0.015	0.039	0.025
N	8	8	8	8	8	4	4

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Total Bilirubin

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: TBILI

UNITS: mg/dL

	Week -3		Week 4	Week 8	Week 13	Week 18	Week 26	
	F:0.3 mg base,							
8692	0.11	0.14	0.16	0.15	0.12			
8718	0.14	0.14	0.18	0.14	0.15			
8706	0.10	0.12	0.14	0.13	0.12			
8714	0.18	0.14	0.27	0.16	0.13			
8701	0.11	0.11	0.21	0.18	0.18	0.18	0.20	
8702	0.17	0.16	0.21	0.27	0.25	0.19	0.24	
8720	0.15	0.12	0.20	0.14	0.14	0.10	0.10	
8704	0.15	0.13	0.26	0.16	0.17	0.11	0.16	
MEAN	0.14	0.13	. 0.20	0 17	0.16	0.15	0.18	
SD	0.029			0.045				
N	8	8	8	8	8	4	4	
00010- /	r.1 0 boo							
	F:1.0 mg base,	-	0.71	0.20	0.18		••	
8696	0.13	0.18	0.31					
8719	0.14	0.13	0.22	0.13	0.12			
8711	0.17	0.18	0.32	0.18	0.19	••	• •	
8716	0.14	0.12	0.14	0.10	0.12			
8725	0.18	0.15	0.18	0.15	0.21	0.13	0.14	
8707	0.15	0.11	0.18	0.18	0.17	0.16	0.17	
8689	0.14	0.16	0.24	0.20	0.19	0.12	0.16	
8722	0.14	0.13	0.18	0.13	0.19	0.11	0.21	
MEAN	0.15	0.15	0.22	0.16	0.17	0.13	0.17	
SD	0.017	0.027	0.065	0.037	0.034	0.022	0.029	
N	8	8	8 .	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alkaline Phosphatase

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: ALKP

UNITS: IU/L

Week 4	Week 8	Week 13	Week 18	Week 26	
143	134	142			
86	74	71			
105	104	96			
102	75	66			
84	129	106	87	78	
104	86	89	95	79	
129	107	85	73	69	
108	113	89	75	81	
108	103	93	83	77	
19.9	22.9	23.6	10.4	5.3	
8	8	8	4	4 .	
102	95	105	• •		
			• •		
			71	73	
65	57	45	39	47	
86	77	72	77	77	
17.0	15.2	21.6	32.9	23.3	
8	8	8	4	4	
	143 86 105 102 84 104 129 108 108 19.9 8 102 66 81 87 104 76 108 65	143 134 86 74 105 104 102 75 84 129 104 86 129 107 108 113 108 103 19.9 22.9 8 8 8 102 95 66 58 81 77 87 68 104 90 76 79 108 94 65 57	143 134 142 86 74 71 105 104 96 102 75 66 84 129 106 104 86 89 129 107 85 108 113 89 108 103 93 19.9 22.9 23.6 8 8 8 8 102 95 105 66 58 50 81 77 61 87 68 58 104 90 89 76 79 86 108 94 85 65 57 45	143 134 142 86 74 71 105 104 96 102 75 66 84 129 106 87 104 86 89 95 129 107 85 73 108 113 89 75 108 103 93 83 19.9 22.9 23.6 10.4 8 8 8 4 102 95 105 66 58 50 81 77 61 87 68 58 104 90 89 71 76 79 86 119 108 94 85 80 65 57 45 39 86 77 72 77 17.0 15.2 21.6 32.9	143

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Alkaline Phosphatase

STUDY ID: UIC-18A

STUDY NO: 193

ABBR: ALKP

SEX: FEMALE

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 3-	F:0.3 mg base/	'kg/day						
8692	69	55	62	52	62			
8718	114	102	86	77	61		• •	
8706	105	88	76	88	78			
8714	91	88	82	78	74			
8701	96	86	85	74	71	63	92	
8702	96	97	104	105	86	91	128	
8720	239	192	156	123	105	141	92	
8704	125	102	95	89	75	84	85	
MEAN	117	101	93	86	77	95	99	
SD	52.0	39.6	28.2	21.3	14.1	33.0	19.4	
N	8	8	8	8	8	4	4	
- A - 911093	F:1.0 mg base/	ka/day		• • • • • • • • • • • • • • • • • • • •				
8696	83	71	54	61	52			
8719	134	112	89	77	70			
8711	93	88	83	73	72	••		
8716	83	89	108	81	90			
8725	74	63	68	65	61	82	129	
8707	96	70	77	74	68	58	61	
8689	77	73	127	90	79	142	143	
8722	104	109	111	95	98	88	121	
MEAN	93	84	90	77	74	93	114	
SD	19.4	18.4	24.3	11.6	15.0	35.5	36.2	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A

STUDY NO: 193

UNITS: IU/L

ABBR	: GGT			*				UNITS	S: IU/L
	Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	GROUP: 1-F:	0 mg base/kg	/day						
	8721	4	3	2	3	5			
	8712	0	3	5	4	6			
	8710	4	3	4	6	6			
	8723	2	2	1	2	5			
	8705	2	4	6	4	10	1	7	
	8700	1	2	3	2	4	5	2	
	8699	2	3	2	5	6	5	12	
	8690	3	5	4	4	6	0	3	
	MEAN	2	- 3	3	4	6	3	6	
	SD	1.4	1.0	1.7	1.4	1.8	2.6	4.5	
	N	8	8	8	8	8	4	4	
	GROUP: 2-F:	:0.1 mg base/	kg/day						
	8717	0	2	4	3	6			
	8703	4	3	5	5	6			
	8713	1	3	5	6	8			
	8693	3	1	3	3	6			
	8695	1	3	3	4	6	5	5	
	8709	3	4	5	1	9	6	6	
	8715	3	3	5	4	5	5	6	
	8697	2	4	4	4	6	3	6	
	MEAN	2	3	4	4	7	5	6	
	SD	1.4	1.0	0.9	1.5	1.3	1.3	0.5	
	N	8	8	8	8	8	4	. 4	

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK

RECOVERY PERIOD IN DOGS



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A

STUDY NO: 193 ARRR - GGT

ABBR: GGT								UNI	TS: IU/L
Anima	l ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP	: 3-F:	0.3 mg bas	se/kg/day			***********		• • • • • • • • • • • • • • • • • • • •	
8692		3	1	3	5	7			
8718		3	2	2	. 5	6	••		
8706		5	4	4	4	7			
8714		5	3	5	6	7			
8701		3	4	4	5	8	5	2	
8702		1	4	6	4	9	7	11	
8720		4	3	4	3	7	6	8	
8704		2	1	3	3	6	6	4	
MEAN		3	3	4	4	7	6	6	
SD		1.4	1.3	1.2	1.1	1.0	0.8	4.0	
N		8	8	8	8	8	4	4	
CP(I)	• /-E	1.0 mg bas	e /ka/dav			• • • • • • • • • • • • •		• • • • • • • • • • • • •	
8696		2	2	4	4	6		1.2	
8719		4	3	3	5	6	••		
8711		4	4	4	3	8			
8716		1	5	3	4	6			
8725		3	2	5	5	6	2	6	
8707		3	4	4	4	6	4	7	
8689		5	4	0	4	7	6	5	
8722		0	1	3	6	10	5	5	
MEAN		3	3	3	4	7	4	6	
SD		1.7	1.4	1.5	0.9	1.5	1.7	1.0	
N		8	8	8	8	8	4	4	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Cholesterol

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193

IIMITE, martali

ABBR: CI	HOL								UNITS	: mg/dL
A	nimal I	D Wee	k -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
		-F:0 mg								
	721		232	229	239	226	235			
	712		191	168	153	157	149			
8	710		216	185	147	185	191			
8	723		168	142	164	140	236			
8	705	1	199	186	206	166	162	161	182	
8	700		154	135	167	141	143	155	134	
8	699		181	145	180	155	196	243	145	
8	690		199	153	227	199	200	192	308	
М	EAN		193	168	185	171	189	188	192	
	SD	2	5.1	31.3	34.6	30.1	35.7	40.2	79.9	
	N		8	8	8	8	8	4	4	
	noun. 2	-F:0.1 mg		/ka/day	• • • • • • • • • • • • • • • • • • • •		• • • • • • • • • • • • • • • • • • • •	••••••		•••••
	717		220	184	193	157	180	••		
	703		155	152	167	141	169	••		
	713		191	150	168	144	168			
			235	181	190	165	196			
	693									
	695		182	156	159	169	181	264	203	
	709		230	175	168	157	192	205	168	
	715		197	146	140	176	179	185	167	
8	697		802	164	199	224	211	232	196	
м	EAN		202	164	173	167	185	222	184	
	SD	2	5.7	14.8	19.8	26.0	14.5	34.3	18.7	
	N		8	8	8	8	8	4	4	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Cholesterol

STUDY ID: UIC-18A

STUDY NO: 193

SEX: FEMALE

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F	:0.3 mg base/	kg/day					
8692	178	138	174	173	212	• •	• •
8718	244	190	208	206	184	• •	• •
8706	216	202	228	215	174		
8714	169	137	120	150	182		
8701	165	166	156	149	205	146	137
8702	217	181	190	183	170	221	180
8720	217	166	189	189	179	227	129
8704	179	153	150	131	159	183	116
MEAN	198	167	177	175	183	194	141
SD	28.9	23.6	34.4	29.4	17.6	37.6	27.7
N	8	8	8	8	8	4	4
GROUP: 4-F	:1.0 mg base/	kg/dav	••••••				
8696	141	133	127	123	141		
8719	177	149	191	154	196		• •
8711	191	140	149	121	150		
8716	175	158	143	128	138	• •	• •
8725	194	180	165	162	174	181	209
8707	202	165	142	163	145	153	172
8689	227	190	208	257	291	225	184
8722	179	159	169	157	183	181	286
MEAN	186	159	162	158	177	185	213
SD	24.8	19.2	27.2	43.7	50.7	29.8	51.2
N	8	8	8	8	8	4	4

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Triglycerides

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: TRIG

UNITS: mg/dL

AB	BK: IKIG							Oulla:	ilig/aL
	Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	GROUP: 1-F	:0 mg base/kg	g/day						
	8721	37	35	37	44	43			
	8712	47	54	56	55	49			
	8710	44	37	45	55	46			
	8723	42	26	31	36	35	••		
	8705	49	56	40	47	55	41	34	
	8700	36	29	52	28	36	30	28	
	8699	50	46	44	41	46	31	41	
	8690	35	38	55	37	38	58	34	
	MEAN	43	40	45	43	44	40	34	
	SD	6.0	11.0	8.9	9.4	6.9	13.0	5.3	
	N	8	8	8	8	8	4	4	
••••	GROUP: 2-F	:0.1 mg base/	'kg/day		••••••				•••••
	8717	28	27	25	25	28			
	8703	31	45	52	22	32			
	8713	33	27	37	23	42			
	8693	57	36	47	33	44	••		
	8695	34	30	35	46	42	51	33	
	8709	54	64	47	39	53	45	37	
	8715	35	31	32	30	29	29	28	
	8697	38	33	47	46	39	25	23	
	MEAN	39	37	40	33	39	38	30	
	SD	10.8	12.5	9.4	9.8	8.5	12.5	6.1	
	N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Triglycerides

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: TRIG

UNITS: mg/dL

ARRK: IKIG							ON 1 (3;	
Animal 1	D Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 3	S-F:0.3 mg base	/kg/day						
8692	39	28	52	40	36			
8718	37	39	41	32	34			
8706	55	37	51	53	47			
8714	42	30	32	30	53	••		
8701	29	37	38	40	55	51	27	
8702	40	36	29	41	48	31	36	
8720	34	23	38	44	51	57	15	
8704	33	43	42	46	33	49	26	
MEAN	39	34	40	41	45	47	26	
SD	7.8	6.6	8.1	7.4	8.9	11.2	8.6	
N	8	8	8	8	8	4	4	
GROUP: 4	-F:1.0 mg base	/kg/day						
8696	37	46	46	49	50	**		
8719	32	28	49	31	38			
8711	42	35	74	53	57			
8716	40	29	42	41	46	• •		
8725	48	46	50	48	69	40	21	
8707	40	35	59	52	49	32	30	
8689	44	47	77	83	70	52 .	43	
8722	41	46	58	36	52	23	52	
MEAN	41	39	57	49	54	37	37	
SD	4.7	8.1	12.8	15.8	11.1	12.3	13.7	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193

DITTO

ABBR	: LDH							UNITS	: IU/L
	Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	GROUP: 1-F:	0 mg base/kg	/day						
	8721	43	67	112	39	59	• •		
	8712	41	29	53	57	44			
	8710	46	50	61	119	21			
	8723	38	47	64	80	19			
	8705	74	38	35	30	48	60	31	
	8700	66	57	56	52	82	57	59	
	8699	46	30	142	26	37	32	40	
	8690	31	55	54	23	34	57	28	
	MEAN	48	47	72	53	43	52	40	
	SD	14.5	13.4	35.8	32.6	20.6	13.1	14.0	
	N	8	8	8	8	8	4	4	
	GROUP: 2-F:	0.1 mg base/	kg/day		••••••			• • • • • • • • • • • • • • • • • • • •	
	8717	54	39	39	65	25			
	8703	43	64	32	37	37	• •		
	8713	47	29	54	46	47		• •	
	8693	42	28	42	29	29			
	8695	27	31	39	25	47	49	39	
	8709	67	49	37	43	110	25	30	

40 33 40 52 45 30

30

41

13.4

8

21

45

28.1

8

106

53

37.1

4

41

47

20.7

4

29

39

7.4

8 .

(--) - Data Unavailable

8715

51

46

11.7

8

32

38

12.5

8

8697

SD

N



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: LDH

UNITS: IU/L

		Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	:0.3 mg base/			• • • • • • • • • • • • • • • • • • • •				
8692	77	119	81	38	75			
8718	29	50	47	21	32			
8706	34	20	21	32	37			
8714	41	29	45	46	38			
8701	37	29	58	38	51	50	54	
8702	106	52	57	51	36	102	32	
8720	32	50	33	28	26	27	31	
8704	24	41	33	40	21	24	50	
MEAN	48	49	47	37	40	51	42	
SD	28.7	30.7	18.7	9.6	16.9	36.1	12.0	
N	8	8	8	8	8	4	4	
 CPOLID - A-F	:1.0 mg base/	ko/dav						
8696	52	173	127	60	57			
8719	36	59	58	35	57			
8711	19	27	91	36	35			
8716	48	45	156	39	56			
8725	43	70	125	90	139	121	46	
8707	33	35	65	40	84	40	38	
8689	78	64	221	48	62	98	59	
8722	39	37	184	55	86	42	60	
MEAN	44	64	128	50	72	75	51	
SD	17.2	46.7	57.1	18.4	31.6	40.7	10.6	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatine Kinase

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: CK

UNITS: IU/L

ADDR. CK							01110	. 10/2
	ID Week -3			Week 8	Week 13	Week 18	Week 26	
	1-F:0 mg base/kg							
8721	178	152	240	-155	188			
8712	805	155	213	174	213			
8710	167	125	133	288	82		• •	
8723	153	111	165	136	102			
8705	151	130	165	90	83	210	163	
8700	263	224	129	133	495	130	213	
8699	186	156	172	81	75	60	195	
8690	217	172	244	117	223	135	183	
MEAN	265	153	183	147	183	134	189	
SD	221.3	34.8	44.8	64.9	140.6	61.3	21.0	
N	8	8	8	8	8	4	4	
GROUP:	2-F:0.1 mg base/	 /kg/day						• • • • • •
8717	163	112	109	299	128			
8703	167	181	126	115	255			
8713	580	233	277	178	452			
8693	307	167	228	106	82	• •		
8695	137	128	145	264	173	104	171	
8709	174	235	126	132	591	136	242	
8715	122	125	90	109	133	75	149	
8697	188	126	103	101	71	162	93	
MEAN	230	163	151	163	236	119	164	
SD	152.2	49.4	66.4	77.6	189.1	37.9	61.6	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatine Kinase

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: CK

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 3-	F:0.3 mg base/	kg/day					• • • • • • • • • • • • • • • • • • • •	
8692	320	360	127	178	120			
8718	121	183	127	86	86			
8706	180	99	75	132	130	••		
8714	225	167	121	210	113			
8701	155	132	157	162	120	208	205	
8702	168	171	291	171	159	203	184	
8720	129	116	91	102	76	101	100	
8704	151	194	176	128	124	81	346	
MEAN	181	178	146	146	116	148	209	
SD	64.7	80.9	67.0	41.5	25.8	66.6	102.1	
N	8	8	8	8	8	4	4	
CPOLID · A	F:1.0 mg base/	ka/day					• • • • • • • • • • • • • • • • • • • •	• • • • • •
8696	128	285	365	136	97			
8719	241	166	100	129	160			
8711	148	170	409	171	114			
8716	133	162	142	104	116	••	• •	
8725	174	131	142	184	273	252	131	
8707	178	125	91	153	181	129	272	
8689	179	209	236	127	128	138	271	
8722	188	155	190	118	267	157	126	
MEAN	171	175	209	140	167	169	200	
SD	36.1	51.2	119.6	27.1	69.0	56.6	82.6	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: BUN

UNITS: mg/dL

ADDR. DUN							014110.	mg/ GL
	Week -3			Week 8	Week 13	Week 18	Week 26	
GROUP: 1-	F:0 mg base/kg							
8721	11.7	12.3	15.0	14.9	18.3			
8712	14.0	7.3	17.0	15.3	14.2	••		
8710	15.6	16.1	16.4	17.9	20.4		• •	
8723	13.3	7.8	10.7	14.9	18.0			
8705	10.5	9.7	15.0	15.5	16.6	13.9	16.8	
8700	11.9	11.0	10.5	11.4	14.1	10.6	12.8	
8699	16.4	18.4	23.5	23.3	25.9	20.8	22.8	
8690	10.1	10.2	15.4	13.9	19.0	15.3	15.2	
MEAN	12.9	11.6	15.4	15.9	18.3	15.2	16.9	
SD	2.30	3.89		3.50		4.25	4.26	
N	8	8	8	8	8	4	4	
GROUP: 2-	F:0.1 mg base/	/kg/day	• • • • • • • • • • • • • • • • • • • •				• • • • • • • • • • • • • • • • • • • •	
8717	_	8.8	12.5	12.6	13.6			
8703	12.5	12.0	11.8	13.1	13.5	• •		
8713	13.2	13.7	16.2	17.1	21.9			
8693	10.6	9.9	11.5	11.3	13.7			
8695		18.3	16.7	17.4	15.7	18.8	18.5	
8709	15.8	15.9	17.4	16.4	21.2	19.5	19.0	
8715	13.2	9.9	15.4	14.8	17.2	15.5	13.4	
8697	10.1	7.8	15.9	9.7	12.5	9.0	12.1	
MEAN	13.2	12.0	14.7	14.1	16.2	15.7	15.8	
SD	2.33	3.67	2.36	2.83	3.64	4.80	3.51	
N	8	8	8 -	8	8	4	4	

4. N. Arrelline Units

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193

UNITS: mg/dL

ABBR: BUN				22000000000000			UNITS:	mg/dL
Animal	ID Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP :	3-F:0.3 mg base/	/kg/dav			• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	
8692		9.2	11.1	18.6	19.3			
8718	12.4	11.1	13.8	14.9	10.9			
8706	9.8	11.0	13.8	13.9	13.6			
8714	12.5	14.2	18.4	16.6	27.9			
8701	8.9	7.5	10.9	11.2	17.1	10.0	11.1	
8702	11.3	12.3	13.0	19.7	22.5	14.8	14.5	
8720	9.6	9.3	9.3	9.3	14.6	11.9	11.3	
8704	10.5	11.3	14.1	14.6	14.3	13.6	12.9	
MEAN	10.7	10.7	13.1	14.9	17.5	12.6	12.5	
SD	1.30	2.07	2.76	3.50	5.53	2.09	1.59	
N	8	8	8	8	8	4	4	
			• • • • • • • • • • • • • • • • • • • •					
GROUP: 4	4-F:1.0 mg base/	kg/day						
8696	6.9	6.0	10.5	10.0	11.5			
8719	12.2	14.1	16.9	17.0	17.3			
8711	13.2	9.8	17.2	17.6	19.8	• •		
8716	16.4	15.1	12.4	15.8	18.2			
8725	13.7	10.6	12.0	14.4	14.7	14.8	12.6	
8707	13.7	16.0	13.9	16.7	16.8	14.0	23.7	
8689	13.3	11.4	16.3	18.1	18.1	15.7	16.3	
8722	10.0	9.5	9.5	12.6	16.2	11.3	17.2	
MEAN	12.4	11.6	13.6	15.3	16.6	14.0	17.5	
SD	2.85	3.34	2.97	2.79	2.55	1.90	4.62	
N	8	8	8	8	8	4	4	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatinine

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: CREAT

UNITS: mg/dL

DDK. OKENI								
Animal I	D Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 1	-F:0 mg base/kg	/day						
8721	0.79	0.78	0.90	0.89	0.91		• •	
8712	0.78	0.77	0.83	0.74	0.89			
8710	0.81	0.81	0.82	0.87	0.86			
8723	0.77	0.73	0.83	0.75	0.79			
8705	0.76	0.82	0.85	0.82	0.83	0.85	0.85	
8700	0.64	0.69	0.66	0.63	0.73	0.71	0.73	
8699	0.83	0.84	0.79	0.81	0.83	0.80	0.94	
8690	0.75	0.77	0.76	0.71	0.79	0.80	0.80	
MEAN	0.77	0.78	0.81	0.78	0.83	0.79	0.83	
SD	0.057	0.049	0.072	0.087	0.059	0.058	0.088	
N	8	8	8	8	8	4	4	
GROUP: 2	-F:0.1 mg base/	/kg/day						
8717	0.77	0.66	0.66	0.68	0.77			
8703	0.72	0.77	0.86	0.80	0.90		• •	
8713	0.92	0.91	0.97	0.89	0.93			
8693	0.72	0.71	0.78	0.77	0.82			
8695	0.88	0.93	0.84	0.95	0.92	0.79	0.87	
8709	0.90	0.89	0.69	0.74	0.80	0.74	0.93	
8715	0.84	0.75	0.80	0.80	0.89	0.86	0.82	
8697	0.82	0.77	0.82	0.76	0.89	0.84	0.86	
MEAN	0.82		0.80	0.80	0.87	0.81	0.87	
SD	0.078	0.099	0.098	0.085	0.060	0.054	0.045	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Creatinine

STUDY ID: UIC-18A

STUDY NO: 193

UNITS: mg/dL

ABBR: CREAT

Animal II	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
COOLID. 7.	F:0.3 mg base/	'ka/dav						
8692	0.67	0.70	0.73	0.73	0.71			
8718	0.68	0.68	0.70	0.68	0.75			
8706	0.66	0.70	0.73	0.76	0.80			
8714	0.89	0.85	0.98	0.88	0.98			
8701	0.59	0.59	0.67	0.64	0.69	0.64	0.62	
8702	0.64	0.72	0.69	0.66	0.66	0.60	0.68	
8720	0.63	0.63	0.72	0.64	0.71	0.65	0.73	
8704	0.70	0.70	0.69	0.65	0.71	0.64	0.88	
8704	0.70	0.70	0.07	0.05	0.11	0.04	0.00	
MEAN	0.68	0.70	0.74	0.71	0.75	0.63	0.73	
SD	0.090	0.076	0.100	0.083	0.101	0.022	0.111	
N	8	8	8	8	8	4	4	
GROUP: 4	F:1.0 mg base/	kg/day						
8696	0.57	0.60	0.66	0.57	0.80			
8719	0.77	0.73	0.75	0.79	0.96			
8711	0.96	0.83	0.89	0.85	0.94		••	
8716	0.80	0.75	0.77	0.83	1.01			
8725	0.69	0.69	0.71	0.76	0.87	0.60	0.66	
8707	0.75	0.75	0.79	0.73	0.90	0.82	0.73	
8689	0.72	0.78	0.71	0.75	0.83	0.64	0.66	
8722	0.79	0.81	0.77	0.75	0.86	0.68	0.78	
MEAN	0.76	0.74	0.76	0.75	0.90	0.69	0.71	
SD	0.110	0.073	0.069	0.085	0.070	0.096	0.059	
N	8	8	8	8	8	4	4	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sodium

STUDY ID: UIC-18A SEX: FEMAL

STUDY NO: 193

ABBR: NA UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
	:0 mg base/kg							
8721	146	146	147	146	148	• •		
8712	146	146	147	146	148			
8710	145	143	143	146	147			
8723	147	145	146	145	146			
8705	147	147	144	143	146	145	145	
8700	147	149	145	145	148	145	145	
8699	147	149	146	145	146	145	145	
8690	145	147	146	146	149	145	145	
MEAN	146	147	146	145	147	145	145	
SD	0.9	2.0	1.4	1.0	1.2	0.0	0.0	
N	8	8	8	8	8	4	4	
 					• • • • • • • • • • • • • • • • • • • •			
GROUP: 2-F	:0.1 mg base/	kg/day						
8717	147	147	145	145	146			
8703	147	149	146	145	148	• •	* *	
8713	144	146	143	144	146			
8693	146	149	146	146	146			
8695	148	149	146	147	149	146	146	
8709	148	149	144	145	147	144	143	
8715	147	146	146	145	147	147	144	
8697	147	148	148	146	148	146	147	
MEAN	147	148	146	145	147	146	145	
SO	1.3	1.4	1.5	0.9	1.1	1.3	1.8	
N	8	8	8	8	8	4	4	

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Sodium

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: NA

UNITS: mEq/L

Animal ID		Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 3-	F:0.3 mg base/	'kg/day			• • • • • • • • • • • • • • • • • • • •			
8692	146	147	145	- 145	145	••		
8718	147	147	145	146	145	• •		
8706	146	147	145	144	147	• •		
8714	146	147	143	145	151		• •	
8701	148	146	146	146	146	148	146	
8702	145	148	145	145	146	144	146	
8720	145	147	146	145	149	145	145	
8704	147	146	146	146	145	145	144	
MEAN	146	147	145	145	147	146	145	
SD	1.0	0.6	1.0	0.7	2.2	1.7	1.0	
N	8	8	8	8	8	4	4	
GROUP: 4-	F:1.0 mg base/	kg/day	• • • • • • • • • • • • • • • • • • • •				•••••	
8696	145	145	144	143	145			
8719	146	148	148	145	148			
8711	147	148	147	144	146	• •		
8716	146	147	146	146	148			
8725	147	145	146	145	147	145	145	
8707	147	149	146	142	148	145	144	
8689	144	145	146	147	148	147	145	
8722	147	147	146	144	146	143	142	
MEAN	146	147	146	145	147	145	144	
SD	1.1	1.6	1.1	1.6	1.2	1.6	1.4	
N	8	8	8	8	8	4	4	

^{(--) -} Data Unavailable



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Potassium

STUDY NO: 193

STUDY ID: UIC-18A

ARRR - K

INITE. -C- O

ABBR: K							UNITS:	mEq/L
Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 1-	F:0 mg base/kg	/dav					• • • • • • • • • • • • • • • • • • • •	
8721	4.21	4.55	4.58	4.56	4.76			
8712	4.07	4.13	4.55	4.54	4.50			
8710	4.52	4.50	4.84	4.65	4.41			
8723	4.52	4.29	4.75	4.32	4.76			
8705	4.34	4.70	4.80	4.49	4.62	4.42	4.22	
8700	4.33	4.13	4.70	4.47	4.31	4.45	4.31	
8699	4.26	3.97	4.03	3.95	4.18	4.42	4.06	
8690	4.64	4.49	4.58	4.36	4.48	4.72	4.53	
MEAN	4.36	4.35	4.60	4.42	4.50	4.50	4.28	
SD	0.188	0.253	0.256	0.217	0.206	0.146	0.196	
N	8	8	8	8	8	4	4	
	r 0 4 b						• • • • • • • • • • • • • • • • • • • •	
	F:0.1 mg base/		1 41	/ FF	/ 57			
8717	4.56				4.53		• •	
8703			4.72		4.47			
8713	4.36	4.44	4.67	4.44	4.62			
8693	4.74	4.26	4.47	4.39	4.57			
8695		4.37	4.29	4.34	4.06			
8709	4.54	4.26	4.53	4.31				
8715	4.67	4.19	4.46	4.20	4.44	4.20	4.52	
8697	4.73	4.32	4.70	4.62	4.67	4.70	4.37	
MEAN	4.55	4.24	4.56	4.39	4.52	4.50	4.43	
SD	0.163	0.145	0.149	0.147	0.217	0.242	0.111	
N	8	8	8 .	8	8	4	4	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Potassium

STUDY ID: UIC-18A

SEX - FEMALE

STUDY NO: 193

DUTTO: -F-4

ABBR: K																UN	ITS: mEq/L
Ar	nimal	ID	Week	-3	Wee	k -1	We	ek 4	Week 8	3	Week '	13	Week	18	Wee	k 26	
									 		• • • • • • • • • • • • • • • • • • • •						
GR	OUP:	3-F:0	.3 mg	base,	/kg/day	,											
86	92		5.	04	4	.47	4	. 67	4.49		4.36	5	-	-			
87	18		4.	61	4	.70	4	.39	4.46		4.12	2	-	-			
87	06		4.	19	3	.96	4	.47	4.05		4.22	2	-	•			
87	14		4.	60	4	.50	4	.43	4.44		4.56	5	-	-			
87	01		4.	30	4	.37	4	.47	4.23		4.64	*	4.5	2	3	.87	
87	'02		3.	86	4	.34	4	.34	4.16		4.11	1	4.6	8	4	.06	
87	20		4.	32	3	.95	4	.22	4.15		3.92	2	4.1	6	4	.33	
87	04		4.	45	4	.28	4	.20	4.51		4.05	5	4.3	1	4	.16	
ME	AN		4.	42	4	.32	4	.40	4.31		4.25	5	4.4	2	4	.11	
	SD		0.3	47	0.	259	0.	151	0.183		0.253	3	0.22	9	0.	192	
	N			8		8		8	8		8	3		4		4	
GR	OUP:	4-F:1	.0 ma	base	/kg/day	,	• • • • • • •		 								
	96		4.			.98	4	.42	4.08		4.46	5		-		• •	
	19		4.			.52		. 23	4.16		4.58		-	-			
	11		4.			.26		.41	4.26		4.49						
	16		4.			.81		.40	4.41		4.54		-	-			
	25		4.			.41		.84	4.38		4.63		4.5	3	3	.65	
	07		4.			.28		.62	4.24		3.97		4.2	_		. 15	
	89		4.			.42		.57	4.29		4.42		4.4			.13	
	22		4.			.43		.56	4.41		4.55		4.2			.35	
ME	AN		4.	37	4	.39	4	.51	4.28		4.46	5	4.3	7	4	.07	
	SD		0.1	73	0.	237	0.	183	0.120		0.207	7	0.16	3	0.	297	
	N			8		8		8	8		8	3		4		4	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Chloride

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: CL

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
GROUP: 1-	F:0 mg base/kg	/dav	• • • • • • • • • • • • • • • • • • • •					
8721	110	109	108	109	113			
8712	113	107	114	111	113			
8710	113	109	109	111	111		• •	
8723	115	107	110	114	113			
8705	109	107	108	112	112	108	111	
8700	112	109	106	108	114	110	113	
8699	112	111	110	111	117	109	118	
8690	112	107	108	108	112	107	115	
MEAN	112	108	109	111	113	109	114	
SD	1.9	1.5	2.4	2.1	1.8	1.3	3.0	
N	8	8	8	8	8	4	4	
					• • • • • • • • • • • • • • • • • • • •			
	F:0.1 mg base/							
8717	112	110	110	108	115	••		
8703	107	109	108	109	111			
8713	110	105	105	110	114			
8693	107	107	105	108	111		• •	
8695	105	110	107	112	115	109	113	
8709	113	111	110	107	115	110	114	
8715	110	110	109	111	111	112	111	
8697	107	107	108	106	113	110	114	
MEAN	109	109	108	109	113	110	113	
SD	2.8	2.1	2.0	2.0	1.9	1.3	1.4	
N	8	8	8 -	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Chloride

STUDY ID: UIC-18A SEX: FEMALE

STUDY NO: 193

ABBR: CL UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F	:0.3 mg base/	kg/day					
8692	104	108	107	111	114		
8718	110	108	105	110	112		
8706	110	106	104	107	112		
8714	113	110	111	110	114		
8701	109	107	114	112	113	113	115
8702	105	107	108	111	115	113	115
8720	105	106	106	110	111	109	113
8704	108	110	114	115	117	111	113
MEAN	108	108	109	111	114	112	114
SD	3.1	1.6	3.9	2.3	1.9	1.9	1.2
N	8	8	8	8	8	4	4
							•••••
8696	:1.0 mg base/ 104	106	108	110	115		
8719	109	108	108				
8711	115	111	112	106 109	113 118		
8716	111	107	111	112	112		
8725	111	107	107				
		109	115	110	114	110	113
8707	110			107	114	111	116
8689	109	108	110	109	115	110	114
8722	115	108	110	108	113	109	113
MEAN	111	108	110	109	114	110	114
SD	3.5	1.6	2.6	1.9	1.8	0.8	1.4
N N	8	8	8 .	8	8	4	4



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Calcium

STUDY ID: UIC-18A

STUDY NO: 193

SEX: FEMALE

UNITS: mg/dL

	7		Itaala /	the also	111- 47	11l- 40	Usala 24	
Animal ID	Week -3	Week -1				Week 18	week 26	
GROUP: 1-F	:0 mg base/kg	/day						
8721	11.7	10.5	10.3	9.9	10.7	••		
8712	11.4	9.7	10.1	9.8	11.0			
8710	11.9	10.6	10.4	10.2	10.8	••		
8723	11.2	10.2	10.4	10.3	10.4			
8705	10.9	10.3	10.7	10.1	10.8	10.3	10.3	
8700	10.3	9.9	10.2	9.6	10.0	9.7	10.1	
8699	10.5	10.4	10.5	10.1	10.8	9.6	9.9	
8690	11.5	10.4	10.5	10.1	10.5	10.1	10.0	
MEAN	11.2	10.3	10.4	10.0	10.6	9.9	10.1	
SD	0.57	0.31	0.19	0.23	0.32	0.33	0.17	
N	8	8	8	8	8	4	4	
	:0.1 mg base/		0.5	0.5	40 5			
8717	11.1	9.9	9.5	9.5	10.5		••	
8703	10.6	10.2	10.5	9.9	10.7			
8713	10.8	10.5	10.3	10.0	11.1			
8693	10.8	10.5	10.3	10.1	10.9			
8695	10.6	10.6	10.4	10.1	10.8	9.7	10.0	
8709	11.0	10.2	10.2	10.0	10.4	9.9	9.7	
8715	11.1	10.3	10.1	10.0	11.0	10.0	9.8	
8697	10.7	10.2	10.3	10.3	11.1	10.0	10.3	
MEAN	10.8	10.3	10.2	10.0	10.8	9.9	10.0	
SD	0.21	0.23	0.31	0.23	0.26	0.14	0.26	
N	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Calcium

STUDY ID: UIC-18A

.....

OCK. TEMALE

STUDY NO: 193 ABBR: CA

UNITS: mg/dL

ABBR	: CA							UNITS:	mg/dL
	Animal ID		Week -1					Week 26	
	GROUP: 3-F:	0.3 mg base/							
	8692	10.7	10.0	9.8	9.7	10.3			
	8718	11.2	10.1	10.4	9.8	10.7			
	8706	10.8	10.7	10.4	10.1	10.7			
	8714	10.5	10.6	10.1	10.5	11.4			
	8701	10.8	10.2	10.1	9.7	10.6	9.3	9.9	
	8702	10.5	10.4	10.0	9.1	10.5	9.0	9.5	
	8720	11.0	9.9	10.3	9.9	10.7	9.6	9.8	
	8704	10.7	9.9	9.8	9.4	10.4	9.4	9.8	
	MEAN	10.8	10.2	10.1	9.8	10.7	9.3	9.8	
	SD	0.24	0.31	0.24	0.42	0.33	0.25	0.17	
	N N	8	8	8	8	8	4	4	
						• • • • • • • • • • • • • • • • • • • •			
	GROUP: 4-F:	1.0 mg base/	-						
	8696	10.4	10.2	9.9	9.6	10.9		••	
	8719	11.3	10.3	9.9	10.0	10.6			
	8711	11.8	10.1	9.6	9.4	10.4	• •		
	8716	11.8	11.0	10.0	10.1	10.8		• •	
	8725	11.6	10.2	9.7	10.0	10.5	9.6	9.7	
	8707	10.7	10.5	10.0	9.5	10.6	9.6	10.0	
	8689	10.5	10.1	9.6	10.0	10.5	9.6	9.9	
	8722	11.2	9.7	9.8	9.7	10.7	9.3	10.0	
	MEAN	11.2	10.3	9.8	9.8	10.6	9.5	9.9	
	SD	0.57	0.37	0.16	0.27	0.17	0.15	0.14	
	N	8	8	8	8	8	4	4	

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Inorganic Phosphorus

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: IP

UNITS: mg/dL

DDA. IF				4000000000000			0111101	mg/ GL
	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18		
	F:0 mg base/kg						• • • • • • • • • • • • • • • • • • • •	
8721	6.2	5.4	4.5	4.5	5.0			
8712	7.1	5.4	6.1	5.9	6.5			
8710	6.2	6.4	5.7	5.6	6.3			
8723	6.3	5.1	5.1	3.7	5.8			
8705	4.7	5.1	6.5	5.5	5.5	3.6	4.4	
8700	5.8	4.7	5.5	4.3	4.3	3.6	3.7	
8699	4.2	5.1	4.5	4.7	6.0	4.8	3.7	
8690	7.1	5.3	6.9	5.6	6.5	4.8	4.7	
MEAN	6.0	5.3	5.6	5.0	5.7	4.2	4.1	
SD	1.04	0.49	0.88	0.78	0.78	0.69	0.51	
N	8	8	8	8	8	4	4	
GROUP: 2-	F:0.1 mg base/	/kg/day		••••••			•••••	
8717	6.6	4.5	4.9	4.2	6.5			
8703	5.4	4.0	5.8	4.4	4.9			
8713	6.8	5.3	5.5	5.2	5.4			
8693	5.4	4.8	5.8	4.9	5.7			
8695	5.1	5.6	5.7	4.6	5.1	4.4	4.1	
8709	5.9	4.1	5.9	4.3	4.4	5.7	3.8	
8715	5.4	4.3	4.5	4.0	5.1	4.2	3.2	
8697	5.1	5.3	6.2	5.3	5.8	3.8	3.4	
MEAN	5.7	4.7	5.5	4.6	5.4	4.5	3.6	
SD	0.66	0.61	0.56	0.48	0.64	0.82	0.40	
N	8	8	8	8	8	4	4	

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Inorganic Phosphorus

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193

UNITS: mg/dL

ABBR: IP								UNITS	mg/dL
			Week -1					Week 26	
		:0.3 mg base/							
8692			4.3	4.7	4.8	5.1			
8718	3	7.0	5.6	5.1	5.3	6.0		• •	
870	5	5.7	5.4	5.9	4.8	5.7			
8714	4	7.1		5.2	5.3	5.9			
870	1	5.7	5.0	5.1	4.3	5.3	3.5	2.7	
870	2	5.5	4.7	4.4	4.2	4.6	3.7	3.7	
8720)	6.8	5.4	5.4	5.3	6.1	4.6	4.4	
8704	4	6.5	5.2	5.1	5.0	5.2	4.5	4.3	
MEA!	٧	6.3	5.1	5.1	4.9	5.5	4.1	3.8	
SI		0.67	0.42	0.45	0.44	0.52	0.56	0.78	
1	N	8	8	8	8	8	4	4	
GROU	JP: 4-F:	1.0 mg base/	kg/day					•••••	
	5		4.7	4.6	5.2	6.3			
8719			5.4	5.4	6.1	6.0			
871				4.8	4.9	5.7			
8716		5.7	5.5	5.3	4.4	5.5			
872		5.8	6.5	5.6	4.9	5.4	3.7	3.8	
870		5.7	5.9	5.5	4.4	5.4	3.8	4.7	
8689		6.8	4.5	4.7	5.3	5.2	5.0	4.6	
872		6.1	4.1	5.0	5.2	5.8	3.9	4.1	
MEA	N	6.2	5.2	5.1	5.1	5.7	4.1	4.3	
St		0.41	0.78	0.39	0.55	0.36	0.61	0.42	
1	V	8	8	8	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Glucose

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: GLU

UNITS: mg/dL

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,									
			Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
		:0 mg base/kg		************					
	8721	114	107	106	100	108			
	8712	103	107	94	101	101			
	8710	118	113	107	104	119			
	8723	110	106	120	108	122			
	8705	116	109	94	102	108	100	107	
	8700	114	105	94	97	111	103	92	
	8699	116	112	102	101	120	102	97	
	8690	102	88	98	100	104	94	107	
	MEAN	112	106	102	102	112	100	101	
	SD	6.1	7.8	9.0	3.2	7.8	4.0	7.5	
	N	8	8	8	8	8	4	4	
	GROUP: 2-F	:0.1 mg base/	'kg/day						
	8717	111	103	105	96	125			
	8703	123	117	97	108	112			
	8713	117	101	107	106	120			
	8693	123	110	111	101	113			
	8695	97	91	92	89	95	97	98	
	8709	143	122	95	95	105	94	98	
	8715	109	102	100	101	105	104	104	
	8697	109	98	109	100	107	100	104	
	MEAN	117	106	102	100	110	99	101	
	SD	13.7	10.2	7.0	6.1	9.4	4.3	3.5	
	N	8	8	8 .	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Glucose

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: GLU

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
 GROUP: 3-F	0.3 mg base/	kg/day						
8692	107	95	99	102	102			
8718	113	102	111	98	104			
8706	102	95	99	86	107			
8714	103	97	82	86	99			
8701	118	107	98	97	102	109	106	
8702	108	102	95	100	98	103	106	
8720	129	110	108	118	116	108	109	
8704	120	121	112	114	123	113	123	
MEAN	113	104	101	100	106	108	111	
SD	9.3	8.9	9.9	11.5	8.8	4.1	8.1	
N	8	8	8	8	8	4	4	
 GROUP: 4-F:	:1.0 mg base/	kg/day						
8696	105	89	93	82	107	• •		
8719	113	94	91	96	109			
8711	121	104	96	104	101			
8716	104	105	89	91	92			
8725	137	122	111	105	108	101	115	
8707	136	105	101	100	103	108	109	
8689	110	104	87	108	112	95	116	
8722	120	110	98	107	102	101	122	
MEAN	118	104	96	99	104	101	116	
SD	12.8	9.9	7.7	9.0	6.2	5.3	5.3	
N	8	8	8 .	8	8	4	4	



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Haptoglobin

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193

ABBR: HAPT							UNITS: m	g/dL
Animal II	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26	
CPOLID+ 1-	-F:0 mg base/kg	/day						
	41.7	•	B	B	B			
8712		B						
8710		B		B	B	• •		
8723	36.3	43.5	90.2	22.6	47.4			
8705	B	B	B	118.0	39.4	B	40.4	
8700	B	B	B	B	B	B	B	
8699	B	17.2	B	B	28.5	27.6	B	
8690	B	100.4	17.6	88.8	30.5	68.6	31.9	
MEAN	39.0	46.7	46.0	76.5	36.5	48.1	36.2	
SD	3.82	37.48	38.77	48.88	8.70	28.99	6.01	
N	2	4	3	3	4	2	2	
00010. 3	5.0.1 mm book	La faint					•••••	•••••
	-F:0.1 mg base/		10.0	D	B			
8717	23.1				B			
8703	B	17.6		B				
8713 8693	70.8		169.5	_	_			
8695		16.6					B	
8709	B	B	B		B		B	
	22.4		_	B	27.3		_	
8715	B		B	_	B			
8697	В	11.3	В	•• В	В	6	- В	
MEAN	32.8	45.2	71.8	40.0	43.8	62.1	25.5	
SD		39.75			25.09		NA	
N	5	6	3 .	2	3	2	1	

(--) - Data Unavailable

B - Below Linearity

NA - Not Applicable



IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP TEST: Haptoglobin

STUDY ID: UIC-18A

SEX: FEMALE

STUDY NO: 193 ABBR: HAPT

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP. 3-	F:0.3 mg base/	ka/dav	******	• • • • • • • • • • • •			
	84.8		89.6	27.0	B		
8718		68.4					
8706		54.9					
8714	B		76.6		77.6		
8701	35.1	64.6	37.9	22.7	30.2	24.4	B
8702	26.8	B	B	B	B	B	B
8720	63.9	61.6	93.3	68.5	75.5	98.4	41.3
8704	23.0	21.4	27.5	16.6	20.0	44.3	B
MEAN	48.8	52.6	74.3	44.7	52.8	55.7	41.3
SD	22.29	17.41	35.43	32.04	32.16	38.29	NA
N	7	6	6	5	6	3	1
CPOLID+ A-	F:1.0 mg base/	kn/dav		••••••	••••••		•••••
		23.3	60.4	83.8	45 6	••	••
8719	B		193.3				••
8711	_	23.0			40.0		
8716	36.6		304.2		123.6		
8725	18.4		216.3		B		B
8707		18.4			B		B
8689	_	23.3			_	105.5	_
8722	37.2		244.8		B	B	B
MEAN	28.1	31.7	182.4	57.1	63.0	105.5	18.6
SD	8.43	16.64	77.86	23.03	36.74		NA
N	6	7	8 .	7	5	1	1

(--) - Data Unavailable

B - Below Linearity

NA - Not Applicable